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Abstract 
 
Many patients with Behcet’s disease (BD) have disease that is severe and do not 
respond to the conventional treatment of systemic corticosteroids and 
immunosuppressive agents.  Recently, IFN-α therapy has shown promise as an 
effective treatment that may also improve long-term outcome.  This study aims to 
provide an insight into the mechanisms of action and disease-modifying ability of 
IFN-α by focussing on the impact on T cell subsets. 
 
In this study, I describe my investigation into the effects of an additional 6-month course 
of IFN-α therapy in modulating T cell subsets and their cytokine expression in BD 
patients ex vivo over the first 12 months.  Investigation of T cell responses confirms 
previous findings on Th1 and Th2 cells and their associated cytokines following IFN-
α treatment.  Analysis of Th17 cells shows these cells are downregulated by IFN-α 
therapy in peripheral blood.  On the other hand, Foxp3+ T cells are upregulated by 
IFN-α therapy which is a novel mechanism that may contribute substantially towards 
the disease-modifying ability of IFN-α treatment.  Notably, most effects of IFN-α on T 
cells, including Th17 and Treg cells, persist even after cessation of treatment. 
 
Also, I report in details the responses of CD4+, CD8+ and γδ T cell subsets in vitro 
following treatment of healthy donor PBMCs with IFN-α.  The findings are largely in 
agreement with the ex vivo study.  Fopx3-expressing and IFN-γ-, IL-10-, and TGF-β- 
producing CD4+ and CD8+ T cells are all increased by IFN-α treatment.  Whereas, 
IL-17-producing CD4+, CD8+ and γδ T cell are decreased following treatment with 
IFN-α. 
 
Our data may provide new inroads into elucidating the immunomodulatory 
mechanisms involved in the disease-modifying ability of IFN-α therapy.  Which of the 
above mechanisms plays the most important role in the observed beneficial effects 
of IFN-α in the treatment of BD remains to be elucidated. 
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Chapter 1 
Introduction 
 
 
1.1  Overview of the immune system 
 
The immune system is an elaborate and dynamic network of cells, tissues, and 
organs that work together to defend the body against a myriad of ever-evolving 
pathogens, including bacteria, viruses, and parasites, as well as disease.  One 
critical feature of the immune system is its ability to distinguish self from non-self.  It 
detects a wide variety of harmful stimuli and through a series of steps called immune 
response, the immune system seeks out and destroys disease-causing organisms or 
substance.  In most cases, it does a great job of launching attacks that eliminate 
invading microbes, infected cells, and tumours while ignoring healthy tissues 
(Janeway et al. 2005).  Importantly, the immune system normally does not mount a 
strong immune response against self antigens, a phenomenon called self-tolerance.  
When the immune system recognises a self antigen and mounts a strong response 
against it, autoimmune disease develops and may result in a serious threat to health.  
Therefore, it is imperative proper balance has to be maintained between preserving 
immune competence and preventing self-harm and autoimmunity (Jager & Kuchroo 
2010). 
 
The immune system is composed of two major subdivisions, the innate and the 
adaptive immune systems, and protects individuals with layered defences of 
increasing specificity.  Both innate and adaptive immunity depend on the ability of 
the immune system to distinguish between self and non-self molecules, and 
achieving appropriate immune response against harmful stimuli requires 
coordination between the two types of immunity (Janeway et al. 2005).  Although 
autoimmune diseases are mediated by the actions of adaptive immune cells 
targeting self-antigen in tissues, the innate immune system plays a key role in the 
initiation and propagation of tissue inflammation (Codarri, Fontana, & Becher 2010). 
 
The innate immunity system is what we are born with and it is non-specific; all 
antigens are attacked pretty much equally.  It is genetically based and we pass it on 
  
19 
 
to our offspring. This system does not confer long-standing immunity against a 
pathogen.  It consists of external physical barriers such as the skin and mucous 
membranes and also cells like phagocytes (macrophages, neutrophils, and dendritic 
cells), mast cells, eosinophils, basophils and natural killer cells.  The complement 
system participates in innate immunity as well.  Once activated complement can lead 
to increased vascular permeability, recruitment of phagocytic cells, and lysis and 
opsonisation of pathogens.  Innate immune responses are controlled by the 
recognition of conserved features of pathogens using invariant pattern recognition 
receptors such as toll-like receptors (TLRs) expressed mainly on antigen-presenting 
cells (APCs).  However, this early phase of defence can be overcome by many 
pathogens (Janeway et al. 2005). 
 
When an innate response fails to eliminate a pathogen, the more versatile adaptive 
immunity is initiated by the activation of T and B lymphocytes in secondary lymphoid 
tissues, where dendritic cells carry antigens collected in the periphery.  Innate 
immunity is an essential prerequisite for the adaptive immune response, because the 
antigen-specific lymphocytes of the adaptive immune response are activated by co-
stimulatory molecules that are induced on cells of the innate immune system during 
their interaction with foreign organisms or substance.  The cytokines produced 
during these early phases also play a key role in stimulating the subsequent adaptive 
immune response and shaping its development (Janeway et al. 2005). 
 
The adaptive immune system is mediated by two main cell types, T and B 
lymphocytes, and the response is closely regulated.  B cells are produced in the 
stem cells of the bone marrow; they produce highly specific soluble receptors termed 
antibodies (Ab) and oversee humoral immunity.  T cells are nonantibody-producing 
lymphocytes which are also produced in the bone marrow but sensitised in the 
thymus and constitute the basis of cell-mediated immunity.  Many T cell effector 
functions are achieved through the production of pro-inflammatory, anti-inflammatory 
or regulatory cytokines, which help to amplify or modulate the immune response 
(Janeway et al. 2005). 
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1.2 B and T Lymphocytes 
 
Lymphocytes comprise approximately 20-30% of leucocytes in the circulation.  
However, the relative proportion of cells populations in whole blood can vary greatly 
between individuals and with states of health and disease, and in response to stimuli.  
Within the lymphocyte subset, the relative proportion of T lymphocytes and B 
lymphocytes in healthy adults has been reported to range from 61-85% and 7-23% 
respectively (Junqueira, Carneiro, & Kelley 1992;Palmer et al. 2006).  Each 
lymphocyte expresses cell surface receptors of a single specificity, generated by the 
random recombination of variable receptor gene segments and the pairing of distinct 
variable chains.  The process enables lymphocytes to deal with virtually any antigens 
(Janeway et al.2005). 
 
There are three sets of molecules responsible for the specificity of acquired immune 
response based on their capacity to bind foreign antigen.  Lymphocyte antigen 
receptors, in the form of immunoglobulins (Ig) on B cells and T cell receptors (TCR) 
on T cells, are the means by which lymphocytes recognise antigens.  Ig exist in both 
membrane-bound forms (B-cell receptors) and secreted forms (antibodies).  On the 
other hand, TCR are membrane-bound proteins that are able to recognise short 
protein sequences (peptides) that are presented by APC.  Major histocompatibility 
complex (MHC) molecules constitute a third class of antigen-binding molecules and 
consist of two types: class I and class II (Janeway et al. 2005). 
 
In the early stages of Ig and TCR production, a mechanism of genetic recombination, 
known as VDJ recombination or somatic recombination, takes place.  Antigen 
receptor gene rearrangement of variable (V), diversity (D) and joining (J) gene 
segments generates enormous repertoire of antigen receptors with different antibody 
specificities, providing the versatility that is essential to normal immune functioning.  
Also, antigen-dependent immunoglobulin gene diversification, via somatic 
hypermutation (SHM), and class-switch recombination (CSR) occur in mature B cells 
during the humoral immune response.  SHM generates point mutations in the 
variable domains of the immunoglobulin heavy and light chains and CSR generates 
different antibody isotypes by recombination (Janeway et al. 2005). 
 
  
21 
 
In contrast to those of Ig and TCR, the binding groove of MHC is not a product of 
gene rearrangement.  The function of MHC molecules is to present products of self 
or foreign proteins to T cells.  The peptides that bind to class I molecules commonly 
derive from proteins synthesised intracellularly, whereas class II molecules usually 
bind peptides derived from proteins synthesised extracellularly.  The two classes of 
MHC molecule are different in their structure and expression pattern on tissues of 
the body.  Besides engagement by TCR, the two types of MHC molecules are 
recognised by different co-receptor molecules, CD8 and CD4, during antigen 
recognition and the binding is necessary for the T cell to make an effective response 
(Janeway et al. 2005). 
 
For both B and T cells, signalling through antigen receptors of lymphocytes induces 
clonal expansion and differentiation of antigen-specific lymphocytes, provided that 
they receive a co-stimulatory signal.  Antigens that stimulate B cells can be either in 
solution or fixed to a solid matrix and bind to membrane Ig.  Whereas, T cells are 
generally stimulated by small peptides and TCR do not bind antigen in solution.  
After priming and clonal selection of T lymphocytes bearing antigen-specific 
receptors, activated T cells leave the lymphoid tissues and travel to the inflammation 
site, where they exert specific effector functions.  To provide enhanced protection 
against reinfection, a subset of these proliferating lymphocytes differentiates into 
memory cells (Janeway et al. 2005).  Priming, expansion and memory formation are 
controlled by APCs and evidence reveals that chemokine ligands and receptors 
control or modulate various phases of the adaptive immune response (Viola, 
Contento, & Molon 2006). 
 
 
1.3  T cell development 
 
   1.3.1 Thymocytes and stages of their development 
 
The earliest progenitors of T cells are produced in the bone marrow.  T, in T cell, 
stands for thymus, since this is the principal organ responsible for the T cell’s 
maturation.  The thymus can be divided into an outer cortex and inner medulla.  
Within the thymus, T cell precursors develop into thymocytes and progress through a 
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series of phenotypically distinct stages.  Immature thymocytes are present in the 
outer cortex of the thymus, and mature thymocytes are present in the inner medulla 
of the thymus.  Distinct maturational phases are marked by changes in the status of 
T cell receptor genes and in the expression of the T cell receptor, and by changes in 
expression of cell surface proteins such as the CD3 complex and the co-receptor 
proteins CD4 and CD8.  Particular combinations of cell surface proteins can thus be 
used as markers for T cells at different stages of differentiation.  Thymocytes are 
subdivided roughly as being double negative (DN), double positive (DP), or single 
positive (SP), based on the expression of the CD4 and CD8 coreceptors (Janeway et 
al. 2005). 
 
When precursor cells first enter the thymus from the bone marrow, they do not 
express TCR and lack most of the surface molecules characteristic of mature T cells 
such as CD4 and CD8.  Such cells are called DN thymocytes.  The DN stage is 
heterogeneous and can be subdivided into four distinct subsets in mice (DN I-IV) 
based on the expression of CD44 and CD25.  On the other hand, immature 
thymocytes do not express the same surface markers in humans.  The 
corresponding human DN subpopulations are characterised by the differential 
expression of CD34, CD38, and CD1a.  Three distinct DN stages can be recognised: 
a CD34+CD38-CD1a- stage that represents the most immature thymic subset, 
followed by the CD34+CD38+CD1a-, and CD34+CD38+CD1a+ stages (Dik et al. 2005). 
 
Following the acquisition of CD1a expression, human thymocytes mature via a CD4 
immature single positive (ISP) intermediate in between the DN and DP stages.  With 
regards to DP thymocytes, there are two discrete stages of development before 
surface expression of CD3.  Firstly, the early DP (EDP) stage is characterised by the 
expression of CD8α, resulting in cells that are CD3-CD4+CD8α+β-.  Secondly, the DP 
blast stage results from the upregulation of CD8β, producing CD3-CD4+CD8α+β+ 
cells.  The next stage in maturation is the single positive stage, where cells lose 
expression of either CD4 or CD8, leaving them either CD4+CD8- or CD4-CD8+.  
Single positive thymocytes migrate to the medulla of the thymus and remain there for 
1-2 weeks.  They are tested for interactions with self-MHC molecules and undergo 
final maturational changes before release to peripheral tissues (Joachims et al. 
2006).  
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   1.3.2 αβ and γδ lineage commitment 
 
The thymus is able to generate distinct types of mature T cells that are differentiated 
for specific TCR recognition and effector functions.  Multipotent precursor 
thymocytes rearrange and express the genes encoding TCR during development 
and mature as either αβ or γδ lineage T cells.  αβ T cells represent the majority of 
thymocytes in the thymus and T cells in the periphery.  On the other hand, γδ T cells 
have been reported to be prominent during embryonic thymic development, and 
represent a small minority population of T cells in the peripheral blood but a major 
subset in other anatomical locations.  The development of γδ T cells may involve 
also extrathymic sites (Kreslavsky et al. 2010).  Since αβ and γδ cells derive from a 
common precursor, the issue of when the two lineages diverge during development 
is of considerable interest. 
 
Previous reports have indicated that human thymocytes first rearrange their TCRδ 
locus, followed closely by TCRγ locus.  Progenitors that productively rearrange 
TCRγ and TCRδ loci express functional TCRγδ at the cell surface (Dik et al. 2005).  
Most that are successful early in development never attempt TCRβ gene 
rearrangements, and the majority of them become functionally mature without 
progression through the DP stage and egress to the periphery with a CD4-CD8- (or, 
more rarely, with CD4-CD8+ or CD4+CD8-) phenotype (Janeway et al. 2005).  
However, γδ developmental potential persists into the later phases of human 
thymocyte development until at least the CD3-CD4+CD8α+β- (EDP) stage.  Even 
though the majority of EDP cells express intracellular TCRβ (TCRβic), a small 
percentage of these cells still have the capacity to yield γδ cells.  Nevertheless, the 
γδ potential in the next developmental stage (DP blasts) is drastically diminished.  
Thus, it is likely that γδ potential correlates inversely with the expression of TCRβ ic in 
thymocyte populations (Joachims et al. 2006) (Fig 1.1). 
 
The percentage of TCRβic+ cells continue to increase as the cells mature and reach 
a plateau at the EDP and DP blast stages (Joachims et al. 2006) (Fig 1.1).  The 
process in which the TCRβ chain pairs with the pre-TCRα protein to produce a pre-
TCR complex that signals survival, expansion, and allelic exclusion is referred to as 
β-selection.  Expression of pre-TCR complex leads to a burst of proliferation, 
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upregulation of both CD4 and CD8 coreceptors, silencing of TCRγ expression, and 
initiation of TCRα rearrangement (which leads to the deletion of TCRδ found within 
TCRα locus) (Joachims et al. 2006).  Hence, β-selection results in the expression of 
a complete TCRαβ.  However, the point of β-selection in human thymocyte 
development is still controversial.  Though one study indicated that β-selection 
occurs at the EDP to DP blast transition (Carrasco et al. 1999), other studies 
suggested it begins as early as the CD34+CD38+CD1a+ (Dik et al. 2005) or CD4 ISP 
stages (Blom et al. 1999). 
 
Over time it has become clear that correspondence between the type of TCR 
expressed and the developmental history of a cell is not always perfect.  Therefore, it 
is of major interest to study whether the types of TCR play a role in αβ versus γδ 
lineage determination or only in the progression of already committed precursors.  It 
has been reported that the majority of γδ thymocytes have variable gene segments 
of TCRβ in germline configuration, and a small percentage of γδ thymocytes have 
complete rearrangements in the TCRβ locus.  However, the few complete TCRβ 
rearrangements are predominately out-of-frame.  As a result, whether the few γδ 
cells with complete in-frame TCRβ rearrangements die by apoptosis or are diverted 
to the αβ lineage remains to be clarified (Joachims et al. 2006). 
 
In addition, the majority of αβ thymocytes have been reported to have both their γ 
alleles rearranged, and one-third of the TCRγ rearrangements in αβ thymocytes are 
in-frame.  The potential for a significant proportion of αβ cells to express a functional 
TCRγδ, therefore, could not be ruled out.  However, data have demonstrated that αβ 
thymocytes are depleted of in-frame δ rearrangements, and productive TCRγ and 
TCRδ rearrangements are rare in αβ cells.  Consequently, it has been suggested 
that vast majority of cells that develop into αβ thymocytes are those that could not 
express a functional TCRγδ (Joachims et al. 2006). 
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Fig 1.1: Human αβ and γδ thymocyte development 
αβ and γδ thymocytes develop from a common precursor.  γδ developmental potential 
decreases with increasing maturation, but is retained until at least the EDP stage.  
Decreasing γδ potential is paralleled by increasing proportions of cells expressing TCRβic. 
Thus, cells undergo β-selection and commitment to the αβ lineage as they progress through 
several phenotypic stages (adapted from Joachims et al. 2006).  TCRβS exp, surface 
expression of TCRβ. 
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Although human αβ vs γδ development is primarily influenced by the timing of TCR 
gene rearrangements and expression of functional TCR, other cellular factors and 
signalling pathways that regulate the accessibility of TCR loci and gene 
recombination can play a key role in lineage decisions.  This is supported by reports 
that sustained Notch signalling efficiently skew the development of earliest thymic 
progenitors toward a γδ cell fate (De Smedt et al. 2002;Garcia-Peydro, de Yebenes, 
& Toribio 2003). 
 
Intriguingly, in various murine transgenic and knockout systems, the TCR per se 
does not play a deterministic role in the lineage decision, leading to the development 
of γδ lineage cells driven by TCRαβ and vice versa.  These puzzling observations 
were recently explained by the demonstration that TCR signal strength, rather than 
TCR type per se, instructs lineage fate, with stronger TCR signal favoring γδ and 
weaker signal favoring αβ lineage fates (Kreslavsky, Gleimer, & von Boehmer 2010).  
The potential relevance of the signal strength model of αβ/γδ lineage choice in 
humans is currently unknown and will require clarification by further investigation. 
 
Collectively, development of thymocytes is a flexible and dynamic process during 
which CD4 and CD8 are successively upregulated.  Also, αβ and γδ T cells share a 
large portion of their developmental paths and there is a prolonged window of 
development through which β-selection and γδ lineage commitment can occur 
simultaneously.  As the development progresses through stages, the frequency of β-
selected cells increases and γδ potential diminishes.  Cells that survive the rigorous 
selective processes that operate in the central lymphoid organs are exported to the 
peripheral lymphoid organs before emerging as immunocompetent cells in the 
peripheral circulation.  Upon entry to the peripheral bloodstream, the cells are 
considered mature T cells.  With regards to effector functions, there are no major 
differences between γδ T cells and αβ T cells (Kreslavsky et al. 2010). 
 
 
1.4 CD4+ and CD8+ T cells 
 
Two different functional classes of αβ T cells are distinguished by the type of 
glycoprotein co-receptor (CD4 or CD8) expressed on the cell surface.  CD4+ and 
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CD8+ T cells have distinct effector functions and recognise different class of MHC 
molecules.  After engaging MHC class II molecules, CD4+ T cells function to activate 
other effector cells of the immune system.  MHC class II molecules are normally 
found on specialised APCs such as B lymphocytes, dendritic cells, and 
macrophages (Janeway et al.2005).  When CD4+ T cells recognise peptides bound 
to MHC class II molecules on B cells, they stimulate B cells to produce antibodies.  
In the absence of CD4+ T cell help, although B cell responses can be initiated, the 
somatic hypermutation, isotype switching, and clonal selection necessary for 
production of high-affinity immunoglobulins are restricted (Castellino & Germain 
2006).  Moreover, CD4+ T cells recognising peptides bound to MHC class II 
molecules on macrophages activate these cells to destroy foreign organisms or 
substances in their vesicles (Janeway et al. 2005). 
 
By contrast, CD8+ T cells predominantly recognise peptides presented by MHC class 
I molecules, which are expressed by almost all nucleated cells.  CD8+ T cells 
contribute to host defense during acute and chronic infection with viruses, 
intracellular bacteria, or single-cell as well as multi-cellular parasites, and they also 
participate in the elimination of transformed cells (Janeway et al. 2005).  The 
differentiation of CD8+ T cells is characterised by the acquisition of effector functions 
as well as modifications in adhesion molecule and chemokine receptor expression 
on the surface of the CD8+ T cells.  In comparison with CD4+ T cells, the time 
required of antigen exposure to initiate proliferation is less for naive CD8+ T cells, 
and they also divide sooner and more frequently (Seder & Ahmed 2003).  Help by 
CD4+ T cells is crucial in inducing CD8+ memory, and a lack of CD4+ T cell help will 
allow an acute but not a sustained CD8+ T cell response (Castellino & Germain 
2006). 
 
In the course of immune responses, both MHC class I and MHC class II molecule 
expression is regulated by cytokines, in particular interferons.  In the case of IFN-γ, it 
upregulates the expression of MHC class I and MHC class II molecules, and can 
promote the expression of MHC class II molecules on certain types of cells that do 
not normally express them.  Interferons also augment the antigen presenting function 
of MHC class I molecules by facilitating the expression of intracellular components 
that allow peptides to be loaded onto MHC molecules (Janeway et al. 2005). 
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Ligation of the TCR and co-receptor is not enough to stimulate naive T cells to 
acquire effector capacity and proliferate.  Co-stimulatory signal, delivered by the 
same APC is required as well.  CD8+ T cells have been suggested to need a 
stronger co-stimulatory signal than CD4+ T cells.  The two B7 glycoproteins, 
B7.1(CD80) and B7.2(CD86), are the best studied co-stimulatory molecules.  CD28, 
a member of the immunoglobulin family, is the receptor for B7 molecules on the T 
cell.  Ligation of CD28 by B7 molecules or by anti-CD28 antibodies is an absolute 
requirement for clonal expansion of naive T cells.  After activation, naive T cells 
express an array of proteins that sustain or modify the co-stimulatory signal.  One 
example is CD40 ligand (CD154), which transmits activating signals to the T cell and 
activates APCs to express B7 molecules after binding to CD40 on APCs.  This 
enables further T cell proliferation as a result (Janeway et al. 2005). 
 
 
1.5 Cytokines and chemokines 
 
   1.5.1 Cytokines 
 
Cytokines are a family of pleiotropic host derived signalling proteins and peptides 
that provide a fundamental mechanism for cell-cell communication.  They mediate 
and regulate immunity, inflammation, and haematopoiesis and link cells of the 
immune system to those in surrounding tissues.  Actions of cytokines can contribute 
to clinical manifestations of diseases and complex interactions exist between 
cytokines, inflammation and the adaptive responses in maintaining homeostasis, 
health, and well-being (Elenkov et al. 2005).  The names of the various cytokines 
reflect the context of their discovery, rather than a systematic naming strategy.  For 
example, the term ‘interleukins’ was initially used as a naming system for proteins 
with the ability to act as communication signals between different populations of 
leucocytes, however, it then became recognised that the spectrum of action of 
interleukins was not confined to leucocytes (Janeway et al. 2005). 
 
It is well appreciated that cytokines are produced by immunologically competent cells 
during host response to infection, invasion and inflammation.  During development, 
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after injury or in tumour growth, cytokines can convey destructive or reparative 
signals to other cells (Stow et al. 2009).  Notably, cytokines influence the quantitative, 
as well as the qualitative outcome of the immune response, i.e. they regulate the 
intensity of the inflammatory and specific immune reaction; and they determine 
whether the exposure to a given antigen will result in a state of specific tolerance.  In 
addition, certain cytokines upregulate the effector function of self-aggressive cells, 
others participate in the suppression of such cells.  Hence, cytokines are relevant to 
the regulation of self-tolerance (Janeway et al. 2005). 
 
It is common for different cell types to secrete the same cytokine or for a single 
cytokine to produce multiple biologic effects on a variety of cells and tissues 
(pleiotropy).  Cytokines are redundant in their activity, meaning similar functions can 
be stimulated by different cytokines.  Cytokines can promote either induction or 
inhibition of the synthesis of other cytokines by their synergistic or antagonistic 
effects.  They operate in both an autocrine and paracrine fashion to control the 
proliferation, differentiation, and activity of immune cells.  Of note, significant quantity 
can be detected within the systemic circulation.  This makes initiation of functional 
changes at tissue locations distant from the original site of synthesis possible, and 
thus, potentially all tissues are likely to be influenced by cytokines (Stow et al. 2009). 
 
Cytokines typically act in cascades or networks and stimulate metabolic and 
biochemical changes in responding cells when present at low concentrations.  They 
usually have a short duration of action and act over short distances, although some, 
such as colony stimulating factors, act at distant sites.  Communication between 
cells can be mediated by cytokines through binding to specific cell surface receptors 
directly and activating intracellular second-messenger systems.  Subsequent 
activation of protein kinases or phosphatases, in turn, regulates the activity of 
transcription factors that recognise specific sequences in the promoters of a variety 
of genes, including genes encoding message for cytokines. (Stow et al. 2009). 
 
Depending on the cytokine, its extracellular abundance, the presence and availability 
of the matching receptor on the cell surface, and downstream signals activated by 
receptor binding, the effect of a particular cytokine on a given cell can vary.  
Responses to cytokines include increasing or decreasing expression of membrane 
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proteins (including cytokine receptors), proliferation, and secretion of effector 
molecules.  Cytokine activity can be blocked by antagonists, molecules which bind 
cytokines or their receptors.  Interestingly, a number of membrane-bound cytokine 
receptors also exist in a soluble form.  Soluble cytokine receptors usually function as 
natural antagonists for the biological actions of the respective cytokines (Zidek, 
Anzenbacher, & Kmonickova 2009). 
 
 
   1.5.2 Chemokines 
 
A special class of more than 50 cytokines has the generic term chemokines (derived 
from chemotactic cytokines) because they have a broad range of actions on the 
recruitment and function of specific populations of leukocytes at the sites of infection 
and inflammation.  These proteins target many cell types and exert their biological 
effects by interacting with G protein-linked transmembrane receptors called 
chemokine receptors.  Some chemokines are considered pro-inflammatory and can 
be induced during an immune response to recruit cells of the immune system to a 
site of infection, while others are considered homeostatic and are involved in 
controlling the migration of cells during normal processes of tissue maintenance or 
development (Janeway et al. 2005). 
 
Chemokines are classified into four groups, depending on the relative position of the 
first N-terminal cystein residues. In the CC family (β-chemokines), the first two 
cysteins are adjacent; in the CXC family (α-chemokines), they are intervened by one 
amino acid.  In the CX3C family (δ-chemokines), the first two cysteins are separated 
by three amino acids.  The C family (γ-chemokines) contains only two of the four 
conserved cysteins.  Chemokines are released by many different cell types and 
serve to guide cells of both innate immune system and adaptive immune system 
(Zidek, Anzenbacher, & Kmonickova 2009). 
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1.6  Helper T cells 
 
The importance of distinct subsets of CD4+ T lymphocytes in the aetiology of a 
variety of immune-mediated diseases has become clear in the last 20 years.  They 
play a central role in immune protection and orchestrate diverse immune responses 
through production of cytokines and chemokines.  CD4+ helper T cells are important 
regulators of both humoral and cellular immunity, and can be differentiated from 
naive CD4+ T cells upon antigen stimulation by professional APCs and the 
contextual micro-environment provided by the innate immune system (Murphy & 
Reiner 2002).  Each subset of CD4+ T lymphocytes expresses unique transcription 
factors which confer subset-specific expression profiles of cytokine production and 
effector function.  CD4+ T cells are capable of augmenting responses of CD8+ T cells, 
helping B cells make antibodies, enhancing microbicidal activity in macrophages and 
recruiting neutrophils, eosinophils and basophils to sites of inflammation.  Also, CD4+ 
T cells are important mediators of immunologic memory (Zhu & Paul 2008). 
 
 
   1.6.1 Th1 and Th2 cells 
 
In 1986, Mosmann and Coffman showed that the functional heterogeneity of murine 
CD4+ T cells was due to their different profile of cytokine production and identified 2 
main subsets of activated CD4+ T cells, Th1 cells and Th2 cells (Mosmann et al. 
1986).  Th1 cells secrete interleukin IL-2, IFN-γ, and TNF-β, whereas Th2 cells 
secrete IL-4, IL-5, IL-6, and IL-10.  Human CD4+ T cell clones have similar, but not 
identical, restricted cytokine profiles.  Human Th1 and Th2 subsets are usually 
defined according to IFN-γ/IL-4 production because the synthesis of IL-2, IL-6, and 
IL-10 is not stringently restricted to a single subset (Vukmanovic-Stejic et al. 2000). 
 
Th1 cells are responsible for both phagocyte activation and the production of 
opsonising and complement-fixing antibodies, thus playing an important role in 
mediating immune responses against intracellular pathogens (Annunziato & 
Romagnani 2009).  The principal cytokine products of Th1 cells include IFN-γ, 
lymphotoxin-α (TNF-β), and IL-2 (Wan 2010), and Th1 cells predominantly express 
chemokine receptors CXCR3 and CCR5 (Yamamoto et al. 2000).  IL-12 has been 
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shown to play a central role in the differentiation of Th1 cells, and it is appreciated 
that IFN-γ also contribute to the induction of Th1 cells (Zhu, Yamane, & Paul 2010).  
Furthermore, stimulation of differentiated Th1 cells with IL-18 plus IL-12 induces 
TCR-independent IFN-γ production (Annunziato & Romagnani 2009). 
 
IL-12, which is produced by activated APCs, activates the transcription factor, Stat4.  
In conjunction with TCR-dependent signals, Stat4-dependent signalling induces the 
expression of the transcription factor T-bet, also known as Tbx21 (Szabo et al. 2003).  
In addition, activation of Stat1 by IFN-γ has been shown to be important for the 
induction of T-bet during Th1 differentiation in vitro (Afkarian et al. 2002;Lighvani et 
al. 2001).  Collectively, the outcomes of IFN-γ and IL-12 signalling are to solidify their 
Th1 function through promoting the expression of T-bet.  T-bet belongs to the T-box 
family of transcription factors and is the only known T-box gene specifically 
expressed in the lymphoid system.  It is rapidly and specifically induced in 
developing Th1 cells and is critical for initiating Th1 development.  Thus, T-bet is 
recognised as a master regulator of Th1 differentiation (Szabo et al. 2000).  T-bet 
also synergises with Stat4 to induce many Th1-specific genes, including IFN-γ, IL-
12Rβ2, and IL-18R1 (Zhu, Yamane, & Paul 2010). 
 
Conversely, Th2 cells mediate host defence against extracellular parasites including 
helminths and play an important role in the induction and persistence of allergic 
inflammatory diseases.  The cytokines produced by Th2 cells include IL-4, IL-5, IL-9, 
IL-13, and IL-25 (Zhu & Paul 2008), and Th2 cells express chemokine receptors 
CCR3, CCR4, and CCR8 (Yamamoto et al. 2000).  IL-4, produced by activated T 
cells and some innate immune cells, provides positive feedback for Th2 cell 
differentiation and activates Stat6, which upregulates the expression of the 
transcription factors GATA-3 and c-maf (Murphy & Reiner 2002).  GATA-3 alone, 
however, is not sufficient to induce IL-4 production. 
 
IL-2 is also important for initial IL-4 production, and Stat5 activation by IL-2 is critical 
for Th2 development (Annunziato & Romagnani 2009).  Activated human basophils, 
eosinophils and mast cells express IL-25, which can upregulate GATA-3 expression 
in human memory Th2 cells (Wang et al. 2007).  In addition, thymic stromal 
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lymphopoietin (TSLP) could induce naive CD4+ T cells to differentiate into Th2 cells 
in the presence of allogeneic myeloid DCs (Lu et al. 2009). 
 
Of note, T cells expressing both Th1 and Th2 cytokine patterns are designated Th0 
and may be Th1/Th2 precursors (Miner & Croft 1998).  There is a mutual regulation 
of Th1 and Th2 polarisation induced not only by IL-4 and IFN-γ, respectively, but 
also by the Th1-specific and Th2-specific transcription factors.  GATA-3 has been 
revealed to downregulate Stat4 (Usui et al. 2003), and strong Stat5 activation 
suppresses T-bet expression (Zhu et al. 2003).  In addition, T-bet can inhibit GATA-3 
expression (Usui et al. 2006). 
 
 
   1.6.2 New fates of Helper T cells 
 
In recent years, new fates of CD4+ T cells have emerged.  Each subset specialises 
in regulating different aspects of immunity and each has their own distinct cytokine 
products and biological functions.  Some of these, such as naturally occurring 
regulatory T cells (nTreg) and natural killer T cells (NKT), are already distinct 
lineages when they leave the thymus.  However, other than Th1 and Th2, naive 
CD4+ T cells could differentiate into other distinct subsets including Th17, follicular 
helper T cells (Tfh), and ones that produce IL-9 (Th9) and IL-22 (Th22) only 
(Veldhoen 2009;Zhu & Paul 2008) (Fig 1.2). 
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Figure 1.2: An overview of the main populations of CD4+ effector T cells 
When the naive CD4+ T helper cell recognises a given antigen on the surface of the antigen 
presenting cell, the cytokines present in the microenvironment created by the response of 
the innate immunity play a critical role in dictating the type of effector cell that is 
subsequently induced (adapted from Annunziato & Romagnani 2009).  DTH, delayed type 
hypersensitivity.  EAE, experimental autoimmune encephalomyelitis.  EAU, experimental 
autoimmune uveitis.  PIA, peptoglycan-induced arthritis.  CIA, collagen-induced arthritis. 
  
c 
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Described since 2005, Th17 cells are characterised by IL-17 production and may 
have evolved for protection against microbes that Th1 or Th2 cells are not suited for 
(Harrington et al. 2005;Park et al. 2005).  Although Th17 cells have been recognised 
as a unique subset only recently, IL-17 has been discovered for much longer.  On 
the other hand, CD4+ Tregs were originally identified by their constitutive expression 
of CD25 (IL-2 receptor-α) and have been referred to as CD4+CD25+ Tregs for many 
years (Sakaguchi et al. 1995).  In 2003, forkhead box protein 3 (Foxp3) was reported 
to be the master transcriptional regulator for nTregs (Fontenot, Gavin, & Rudensky 
2003;Hori, Nomura, & Sakaguchi 2003).  As there have been substantial amount of 
discoveries on both Th17 and Treg due to intense interests recently, their 
development, function and molecular characterisation are described in more details 
in the following sections. 
 
Th9 cells were proposed in 2008.  TGF-β was shown to reprogram Th2 cells to lose 
their characteristic profile and switch to IL-9 secretion.  Differentiation of these cells 
was able to be promoted in the presence of TGF-β and IL-4.  They have not been 
shown to express any transcription factors related to other CD4+ T cell subsets like 
T-bet, GATA3, RORγt and Foxp3, emphasising that Th9 cells are distinct from Th1, 
Th2, Th17 and Foxp3+ iTreg populations (Veldhoen et al. 2008b). 
 
Th22 cells became the latest addition to the CD4+ T helper cell subsets in 2009 and 
they were hypothesised to be important in skin homeostasis and pathology.  This 
distinct subset of human memory T cells was identified to express chemokine 
receptor CCR6, skin-homing receptors CCR4, and CCR10 and high levels of IL-22.  
Little IL-17 and IFN-γ were produced by these cells.  Th22 cells could be induced by 
stimulation of naive T cells in the presence of IL-6 and TNF or by the presence of 
plasmacytoid dendritic cells.  Compared with Th17 cells, they were less dependent 
on transcription factor, retinoic acid-related orphan receptor-γt (RORγt) for IL-22 
production.  Additionally, aryl hydrocarbon receptor (AHR) agonists were shown to 
promote Th22 cell differentiation and Th22 cells could be generated in vitro in the 
presence of IL-6 and TNF from naive CD4+ T cells (Duhen et al. 2009;Trifari et al. 
2009). 
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The term Tfh has been suggested for a subpopulation of B helper T cells that 
specifically localise to B cell areas of lymph nodes and spleen, and express CXCR5.  
The absence of a transcriptional master switch has long prevented the recognition of 
Tfh as a separate subset (Breitfeld et al. 2000;Schaerli et al. 2000).  Tfh cells play a 
crucial role in orchestrating T cell-dependent B cell responses and can be regarded 
as a subset linking innate immunity and subsequent B cell responses (Reinhardt, 
Liang, & Locksley 2009).  In peripheral blood, they were demonstrated to coexpress 
CD45RO and CCR7.  However, CCR7 expression is lost in secondary lymphoid 
organs, which allows these cells to home to B-cell follicles and germinal centers 
where they express high levels of CD40 ligand and inducible T cell co-stimulator 
(ICOS).  Tfh cells are also defined by enhanced expression of programmed cell 
death 1 (PD1), the transcriptional repressor B cell lymphoma 6 (Bcl-6) and cytokines 
IL-21 and IL-4, which stimulate B cell differentiation and antibody production (King 
2009).  Although the cytokine profile of these cells have been found to be 
heterogeneous, two cytokines are important in the development of Tfh: IL-6 and IL-
21 (Vogelzang et al. 2008). 
 
 
1.7  T helper 17 and IL-17-producing T cells 
 
   1.7.1 T helper 17 cells and associated cytokines 
 
CD4+ T cells are the best-characterised source of IL-17 during adaptive immune 
responses and perhaps during chronic inflammatory responses, but other cells such 
as neutrophils, CD8+ T cells, invariant NKT cells and γδ T cells all were reported to 
express IL-17 (Ferretti et al. 2003;Lockhart, Green, & Flynn 2006;Michel et al. 
2007;Shin et al. 1999).  Human Th17 cells mediate immune responses against 
extracellular bacteria and fungi (Weaver et al. 2006) and produce IL-17A, IL-17F, IL-
6, IL-21, IL-22, IL-26 and TNF-α, but not IFN-γ or IL-4 (Crome, Wang, & Levings 
2010).  IL-17A is now recognised as the founding member of a family of pro-
inflammatory cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25) 
and IL-17F (Kolls & Linden 2004).  IL-17 has been known to play a role in inducing 
the activation of macrophages, fibroblasts, epithelial and endothelial cells and 
promoting the production of various inflammatory cytokines such as TNF-α, IL-1β, 
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and IL-6 as well as enhancing proliferation, maturation and recruitment of neutrophils 
(Kolls & Linden 2004;Witowski, Ksiazek, & Jorres 2004). 
 
The inflammatory responses by IL-17 involve NF-κB and mitogen-activated protein 
kinase (MAPK) pathways (Schwandner, Yamaguchi, & Cao 2000;Shalom-Barak, 
Quach, & Lotz 1998), and most cells can potentially respond to this cytokine as the 
IL-17 receptor is expressed ubiquitously.  Table 1.1 shows representative target cell 
types and the influence of cytokine IL-17.  The target cell types best analysed are of 
non-immune origin, particularly epithelial and mesenchymal cells within diseased or 
inflamed tissues.  IL-17-dependent activities have been revealed in immune cells as 
well, particularly B lymphocytes and APCs (Onishi & Gaffen 2010). 
 
The receptor for IL-17 is a heterodimer made up of IL-17RA and IL-17RC.  In contrast 
to IL-17RC, IL-17RA is expressed at particularly high levels in haematopoietic tissues.  
Both IL-17A and IL-17F use the IL-17RA chain for their signalling, but IL-17A binds 
to IL-17RA with much higher affinity.  IL-17A and IL-17F are within close proximity on 
the chromosome and have a co-ordinated expression pattern, implying they have 
very similar functions and are likely to be regulated by similar mechanisms (Crome, 
Wang, & Levings 2010;Hymowitz et al. 2001).  IL-21 promotes Th17 differentiation in 
an autocrine fashion (Nurieva et al. 2007) and serves as a positive feedback 
amplifier.  IL-22, a member of the IL-10 family, is a multifunctional cytokine that has 
both pro-inflammatory and anti-inflammatory roles and can induce the expression of 
anti-microbial peptides (Hirota, Martin, & Veldhoen 2010).  The expression of IL-22 is 
inhibited by TGF-β (McGeachy et al. 2007). 
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Table 1.1: Target cells and genes of IL-17. 
IL-17 acts on a variety of cells due to its ubiquitous receptor.  Shown are 
representative target cell types, the role of IL-17 (adverse or beneficial) and key 
target genes (Onishi & Gaffen 2010). 
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   1.7.2 Chemokine and other surface receptors for T helper 17 cells 
 
Several studies have examined the pattern of chemokine and cytokine receptor 
expression on Th17 cells.  CCR6 identifies almost all IL-17-producing T cells in 
human peripheral blood and CD45RO+CCR6+ peripheral blood T cells secrete 100-
fold more IL-17 protein than do CCR6- T cells (Singh et al. 2008).  However, CCR6+ 
IL-17-secreting population is not homogeneous (Acosta-Rodriguez et al. 2007).  
Expression of CCR6 and CCR4 together identifies a homogeneous population of IL-
17-secreting peripheral blood memory T cells.  Whereas, CCR6 and CXCR3 
together detects Th1 cells secreting IFN-γ only and CD4+ T cells secreting both IFN-
γ and IL-17.  It is now generally accepted that Th17 cells express IL-23R in humans.  
Most recently, CD161, a C-type lectin, has been demonstrated to be a novel surface 
marker for human Th17 cells as well.  It was observed that not only do human Th17 
cells express CD161 during their life, but they also exclusively originate from a 
CD161+ naive CD4+ T cell precursor (Cosmi et al. 2008).  AHR, a receptor which 
interacts with environmental toxins such as dioxin, is abundantly expressed in Th17 
cells and is important in IL-22 expression (Veldhoen et al. 2008a).  It remains to be 
determined whether human AHR polymorphisms exist that would link environmental 
pollutants with a genetic predisposition to the development of autoimmunity. 
 
 
   1.7.3 Transcription factors related to T helper 17 cells and associated 
cytokines 
 
Stat3, the major signal transducer for IL-6, IL-21 and IL-23, is indispensable for IL-17 
production and deletion of Stat3 results in the loss of IL-17 producing cells (Harris et 
al. 2007;Laurence et al. 2007;Mathur et al. 2007).  Stat3 is also responsible for the 
induction of IL-23R and Foxp3 is upregulated in its absence.  Like other T cell 
subsets, Th17 also have a lineage-specific transcription factor, namely retinoic acid-
related orphan receptor gamma-t (RORγt) in mice or retinoic acid-related orphan 
receptor C isoform 2 (RORc2) in human (Ivanov et al. 2006).  Cells deficient in these 
factors produce very little IL-17.  Furthermore, over-expression of RORc2 induces 
many aspects of the Th17 cell phenotype, including expression of CCR6, CCR4, CD161 
and induction of a Th17-associated cytokine profile (Crome et al. 2009).  Another closely 
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related transcription factor, RORα, can also play a role in controlling IL-17A and IL-
17F production (Yang et al. 2008c).  Runx1 also interacts with RORγt and induces 
optimal RORγt expression and IL-17 production in Th17 cells (Zhang, Meng, & 
Strober 2008). 
 
 
   1.7.4 Positive and negative regulations of T helper 17 cells 
 
The combination of cytokines that induce the differentiation of human Th17 cells is a 
subject of much debate.  It is not easy to compare the results of experiments designed to 
investigate how human Th17 cells develop in vitro, because several different 
activation conditions, types of culture media and experimental readouts have been 
reported.  Culturing human naive CD4+ T cells from cord blood in serum-free medium 
revealed a need of TGF-β for Th17 differentiation (Manel, Unutmaz, & Littman 2008), 
but TGF-β appears to have dual effects on human Th17 differentiation in a dose-
dependent manner. 
 
While TGF-β is required for the expression of RORγt, it can inhibit the function of 
RORγt at high doses and favour inducible regulatory T cell differentiation (Manel, 
Unutmaz, & Littman 2008).  However, inflammatory cytokines (IL-1β, IL-6, and IL-21 
or IL-23) relieve the latter effect of TGF-β (Manel, Unutmaz, & Littman 2008).  
Therefore, inducible regulatory T cells and Th17 cells are reciprocally regulated 
during differentiation.  A recent study has further explored the role of TGF-β in the 
development of human Th17 cells in vitro, and found the requirement of TGF-β is indirect, 
and related to suppression of Th1 development (Santarlasci et al. 2009).  By using 
serum-free medium, it has been clarified that the optimum conditions for human 
Th17 differentiation are TGF-β, IL-1β, and IL-2 in combination with IL-6, and IL-21 or 
IL-23 (Amadi-Obi et al. 2007;Annunziato et al. 2007;Volpe et al. 2008;Yang et al. 
2008a).  Of the latter cytokines, IL-23 have been suggested to be the most effective 
(Chen et al. 2007b;Janeway et al. 2005;Manel, Unutmaz, & Littman 2008;Volpe et al. 
2008;Wilson et al. 2007). 
 
A key aspect of the control of Th17 proliferation is the regulation of IL-23R (Chen et 
al. 2007b).  Although naive CD4+ T cells express low levels of this receptor, the 
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combination of TGF-β, IL-1β, and IL-23 can induce IL-23R effectively (Chen et al. 
2007b;Manel, Unutmaz, & Littman 2008).  Thus, IL-23 promotes expression of its 
own receptor, enabling it to become an effective inducer of IL-17.  In addition to 
cytokine-driven Th17 lineage commitment, it has been shown that exposure of memory 
CD4+ T cells to prostaglandin E2 (PGE2), a mediator of tissue inflammation, results in 
populations that are enriched for IL-17-producing cells.  PGE2, acting via the 
prostaglandin receptor EP2-mediated and EP4-mediated signalling and cAMP 
pathways, also induces upregulation of IL-23 and IL-1 receptor expression in human 
T cells (Boniface et al. 2009).  Conversely, reduced IFN-γ production by freshly 
isolated memory T cells in the presence of PGE2 was observed.  Therefore, PGE2 
may affect the balance between the highly inflammatory cytokine IL-17 and the 
negative feedback loop exerted by IFN-γ considerably in chronically inflamed tissues 
(Napolitani et al. 2009). 
 
Because of their potential for inducing immune-mediated damage to the host, it is 
perhaps not surprising that multiple mechanisms exist to inhibit Th17 production as 
demonstrated in murine studies.  Both Th1-related IFN-γ and Th2-related IL-4 have 
been shown to downregulate Th17 differentiation (Harrington et al. 2005;Park et al. 
2005).  Recent studies have shown that IL-27, an IL-12 related cytokine, is able to 
inhibit Th17 development as well as induce IL-10 production from T cells (Yoshida, 
Nakaya, & Miyazaki 2009). 
 
 
   1.7.5 Co-expression of IL-17 and IFN-γ 
 
Cells that co-express IFN-γ and IL-17 have been described in various papers and 
named Th17/Th1 (Acosta-Rodriguez et al. 2007; Annunziato et al. 2007).  It is 
intriguing to note that both Th17 cells and these double-producer cells have been 
reported to co-express the lineage-specific transcription factors T-bet and RORC and 
express not only IL-23R but also IL-12Rβ2 chain.  Stimulation of human Th17 clones 
in the presence of IL-12 can downregulate RORC and upregulate T-bet and enable 
these cells to produce IFN-γ in addition to IL-17A (Annunziato, Cosmi, & Romagnani 
2010).  Also, it has recently been demonstrated that human Th1 clones that express 
the Th17-associated molecule CD161, can express the transcription factor RORC 
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(Cosmi et al. 2010).  Similar to cells that expressed IL-17 alone, these Th17/Th1 
cells have been observed to be resistant to suppression of proliferation by regulatory 
T cells (Annunziato et al. 2007).  These CD4+ T cells that co-express IL-17 and IFN-γ 
may support the synergism between IL-17 and IFN-γ in producing tissue damage.  
Whether the cells producing both IL-17 and IFN-γ represent a stable population or a 
transitional phenotype is currently still unclear. 
 
 
1.8  Regulatory T cells 
 
Tregs play a key role in maintaining self-tolerance and in preventing immune 
pathologies by suppressing the strength and/or nature of the immune response to 
non-self antigens (Sakaguchi 2004;Shevach 2000). Treg cells were reported to 
represent ~5-10% of the peripheral CD4+ T cells in humans (Dieckmann et al. 2001).  
In humans, several different types of Tregs have been described and these include 
specialised subsets of CD4+, CD8+, double-negative CD3+CD4-CD8-, γδ T cells, and 
NKT cells (Allan et al. 2008b).  It is likely that these Tregs interact with each other in 
a synergistic manner to maintain immune homeostasis and therapeutic research is 
most advanced for two main types of CD4+ Tregs: Foxp3+ and IL-10 producing type 
1 T regulatory (Tr1) cells. 
 
 
   1.8.1 Mechanisms of action 
 
The mechanisms of action of Tregs are complex and not well defined.  These have 
included cell contact-mediated suppression and secretion of suppressor cytokines 
(IL-10, TGF-β, IL-35) (Brusko, Putnam, & Bluestone 2008;Collison et al. 2010).  Treg 
cell-mediated suppression affects the function of APC as well.  The interaction of 
CTLA-4 on Treg cells with CD80 and CD86 on DCs is an important pathway and 
inhibition of CD80 and CD86 expression by Treg cells limits the capacity of the DCs 
to stimulate naive T cells through CD28 resulting in immune suppression (Shevach 
2009).  Interactions between CTLA-4 and CD80 and CD86 can also lead to the 
expression of the regulatory molecule indoleamine 2,3-dioxygenase (IDO) which 
induces the catabolism of tryptophan into pro-apoptotic metabolites that result in the 
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suppression of effector T cell activation.  IDO induction was found to depend on high 
expression of CTLA-4 on the Treg cells (Grohmann et al. 2002). 
 
Another cell surface antigen that may play a role in Treg cell suppression of DC 
function is lymphocyte activation gene-3 (LAG-3), a CD4 homolog that binds MHC 
class II molecules with very high affinity.  Binding of LAG-3 to MHC class II 
molecules expressed by immature DCs induces inhibition on DC maturation and 
immunostimulatory capacity.  Due to capability of activated human T cells to express 
MHC class II molecules, Treg cell-mediated ligation of LAG-3 on effector cells might 
also result in suppression (Liang et al. 2008).  One other anti-inflammatory 
mechanism that may be used by Treg cells is the catalytic inactivation of 
extracellular ATP by CD39.  This allows Treg cells to quench ATP-driven pro-
inflammatory processes on multiple cell types, particularly DCs (Borsellino et al. 
2007). 
 
Treg-mediated suppression can involve apoptosis and cytolysis of target cells by a 
variety of means.  It has been reported that Treg cells can upregulate Fas and FasL 
expression following activation and suppress the proliferation of CD8+CD25- cells by 
inducing Fas-mediated apoptosis (Strauss, Bergmann, & Whiteside 2009).  Also, 
Human CD4+CD25+Foxp3+ Treg cells can be activated by a combination of 
antibodies to CD3 and CD46 to express granzyme A and kill activated CD4+ and 
CD8+ T cells and other cell types in a perforin-dependent, Fas-FasL-independent 
manner (Grossman et al. 2004).  Additionally, cytokine deprivation by Treg cells may 
contribute to their suppressive activity.  It has been suggested that nTreg cells 
suppress conventional T cell activation through competition for IL-2 consumption, 
which may result in effector T cell death due to deprivation of growth factors 
(Shevach 2009;Wan & Flavell 2008).  All these mechanisms are believed to operate 
collectively at the site of antigen presentation and a regulatory milieu that promotes 
bystander suppression and infectious tolerance is created. 
 
The phenomenon of bystander suppression results when Tregs are first activated 
through their respective TCRs to induce suppressive activity, but once activated, the 
cells with one antigen specificity can suppress effector T cells with many other 
distinct antigen specificities in a non-specific manner.  Infectious tolerance, on the 
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other hand, is a result of one population of Treg cells generating an 
immunoregulatory milieu that persists long after the removal of the eliciting cell 
population and promotes the outgrowth of a new population of Treg cells with 
antigen specificities distinct from those of the original Treg population (Tang & 
Bluestone 2008).  This could explain how such a small population of cells can 
regulate a much larger population of responder cells in vivo, and the two 
mechanisms together allow Tregs of single specificity to establish a broad and stable 
immunoregulatory effects. 
 
 
   1.8.2 CD4+CD25+/highFoxp3+ Treg cells 
 
Human Treg cells were initially defined according to their high expression of CD25, 
based on the finding that murine CD4+CD25+ T cells are highly suppressive.  In mice, 
CD4+CD25+ regulatory subset is isolated from all CD25+ T cells regardless of their 
levels of CD25 expression.  However, when similar criteria are followed to isolate 
these cells from human blood, the resulting CD25+ cells did not consistently exhibit 
an anergic phenotype or significant suppressive function.  This is likely due to the 
population being a mixture of activated effector T cells and Tregs.  Further 
investigations led to the identification of CD4+CD25high T cells which exhibited in vitro 
characteristics similar to those of the CD4+CD25+ murine regulatory cells (Baecher-
Allan et al. 2001). 
 
The CD4+CD25high cells may exist in a semi-activated state in vivo, expressing a 
number of surface Ags that are usually associated with activated T cells, and these 
Treg cells may be primed for a fast response, or constantly turned out in order to 
engage in low level regulatory activity continuously.  The suppressive function of 
these cells was reported to be cytokine-independent as the addition of blocking anti-
TGF-β or anti-IL-10 Abs had no effect on the ability of CD4+CD25high cells to 
suppress the proliferation of co-cultured CD4+CD25- cells (Baecher-Allan et al. 2001). 
 
More recently, different Treg populations have been described according to their 
origin, generation, and mechanism of actions and the Foxp3 transcription factor was 
identified as both a marker and a lineage commitment factor for CD4+CD25+ Tregs.  
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Foxp3+ Treg cells exist in at least two forms.  nTreg cells develop in the thymus and 
regulate self-reactive T cells in the periphery.  Little is known about the requirements 
for thymic Treg cell development in humans.  A second type, termed adaptive or 
induced regulatory T cells (iTreg), can differentiate from naive CD4+CD25- T cell 
precursors in peripheral lymphoid organs after antigen stimulation (Bluestone & 
Abbas 2003). 
 
It has been demonstrated that Foxp3+ Tregs of both direct thymic and peripheral origin can 
specifically recognise a wide variety of Ags due to their broad αβ TCR specificity 
(Fazilleau et al. 2007a).  nTreg and iTreg cells differ in their principal antigen 
specificities and strength of TCR stimulation needed for their generation.  While 
nTregs are primarily generated in response to self-antigens expressed in the thymus, 
environmental antigens presented by dendritic cells in peripheral lymphoid organs 
are essential for iTreg development (Jordan et al. 2001).  Compared with iTregs, the 
Foxp3 expression by nTregs are more stable, possibly due to these cells being 
continuously stimulated by self-antigens (Horwitz, Zheng, & Gray 2008). 
 
In terms of the CD25 expression level, it is high in nTreg cells, but more variable in 
iTreg cells (Bluestone & Abbas 2003).  For both types of Foxp3+ Treg cells, IL-2 has 
important, non-redundant effects on their maintenance and survival.  Evidence 
indicated that Stat5 activation, likely driven by IL-2 (and IL-15), is required for Foxp3 
differentiation in Tregs (Burchill et al. 2008).  As Tregs express little or no IL-7Rα 
(CD127), this in combination with high levels of CD25 expression was proposed as a 
way to identify Treg cells (Liu et al. 2006).  Up to 85-95% of CD4+CD25+CD127lo 
cells were reported to show Foxp3+ expression after purification.  However, like 
CD25, CD127 is not flawless as it is down-regulated early during T cell activation 
(Shevach 2006).  Although other cell surface markers such as glucocorticoid-induced 
tumor necrosis factor receptor (GITR), CTLA-4, Neuropilin-1, and PD1 have all been 
described to be present on Treg cells, none of them are unique to Tregs (Brusko, 
Putnam, & Bluestone 2008).  GITR and CTLA-4 can also be expressed on recently 
activated T cells. 
 
Foxp3+ cells in humans were recently reported to be a heterogeneous group in terms 
of their function and phenotype.  They include not only suppressive T cells but also 
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non-suppressive ones that secrete pro-inflammatory cytokines.  The main three 
subpopulations identified were CD4+CD45RA-Foxp3high activated Treg (aTreg) cells 
and CD4+CD45RA+FoxP3low resting Treg (rTreg) cells, both of which were potently 
suppressive in vitro, and non-suppressive CD4+CD45RA-Foxp3low non-Treg cells 
(Miyara et al. 2009). 
 
Most of the Foxp3high aTreg cells were shown to originate from rTreg cells and these 
appeared to be terminally differentiated Treg cells.  aTregs were indicated to be the 
main effectors of suppression which died rapidly after exertion of function.  aTreg 
cells also suppressed the proliferation of rTreg cells in a negative feedback fashion.  
On the other hand, rTreg cells were demonstrated to be highly proliferative and 
upregulate Foxp3 expression and differentiate to aTreg cells upon stimulation 
(Miyara et al. 2009).  Interestingly, activated and resting Tregs might operate on 
different suppressive mechanism as it was observed that aTreg cells were more 
active in IL-10 transcription but less active in TGF-β transcription than rTreg cells 
(Miyara et al. 2009). 
 
 
   1.8.3 The role of transcription factor Foxp3 in Treg cells 
 
Foxp3 is still the best characterised Treg-specific marker, and controls some 
distinctive features of Tregs such as promoting the expression of CD25 (IL-2 
receptor α chain), CTLA-4 and TGF-β receptor (Brusko, Putnam, & Bluestone 2008).  
The expression of Foxp3 has been demonstrated to correlate with suppressive ability 
(Yagi et al. 2004).  Importantly, it is only when human cells express Foxp3 at high 
and constitutive levels, however, that they acquire suppressor function (Allan et al. 
2008a).  Although transient Foxp3 expression is also possible in CD45RA+ cells with 
TGF-β stimulation in vitro following activation, its expression may not always 
correlate with suppressive capability (Tran, Ramsey, & Shevach 2007).  Of note, not 
all CD25+ cells are suppressive and not all Foxp3+ cells are CD25+ (Fontenot et al. 
2005). 
 
Foxp3 was originally suspected to be important for Treg functions in 2001 because 
its mutations were linked to the autoimmune scurfy mice and human 
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immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) 
(Brunkow et al. 2001;Patel 2001).  Mice that lack Foxp3, either through spontaneous 
or targeted mutation, fail to develop Treg cells and succumb to fatal autoimmune 
lymphoproliferative disease.  Mutations in the human Foxp3 gene, located on 
chromosome Xp11.23, result in IPEX syndrome, which is characterised by insulin-
dependent diabetes, thyroiditis, massive T cell infiltration into the skin and 
gastrointestinal tract, high levels of serum autoantibodies, and chronic wasting.  To 
date, about 20 different mutations in Foxp3 have been described in patients suffering 
from IPEX.  Because Foxp3 is on the X chromosome, the affected population is 
mainly boys. 
 
Foxp3 has three discernible functional domains, a carboxyl-termination forkhead 
domain (FKH; aa 338-421), a single Cys2His2 zinc finger (aa 200-223), and a 
leucine zipper-like motif (aa 240-261).  There is also a domain at the amino terminal 
region that is reasonably proline-rich (aa 1-193).  Mutations have been found 
throughout Foxp3 in IPEX patients, including in each of the domains described 
except for the zinc-finger, demonstrating that these regions of the protein are 
important for proper function (Buckner & Ziegler 2008).  Moreover, Foxp3 has been 
shown to be part of a large macromolecular complex in Tregs.  This complex 
includes both histone acetyltransferases (TIP-60) and histone deacetylaces (HDAC7 
and HDAC).  Interestingly, Foxp3 itself is also acetylated (Li et al. 2007). 
 
In contrast to the mouse, there are two isoforms of human Foxp3, differing by the 
inclusion or exclusion of exon 2 (aa71-105).  Although the expression levels of these 
two isoforms appear to be equivalent in human Treg cells, the isoform lacking exon 2, 
Foxp3B, is functionally different from the full-length one, Foxp3A, in interaction and 
suppression (Allan et al. 2005).  The interaction between full-length Foxp3 and 
RORα inhibits transcriptional activation mediated by RORα, but not in the case of the 
isoform lacking exon 2 as the region of Foxp3 involved in the interaction is encoded 
by exon 2 (Du et al. 2008).  However, either of the two isoforms can confer 
regulatory function when strongly overexpressed (Aarts-Riemens et al. 2008).   
 
Despite the obvious importance of Foxp3 in the development and function of Treg 
cells, its mechanism of action needs to be investigated further.  It has been shown so 
  
48 
 
far that Foxp3 can directly interact with NFAT, a key regulator of T cell activation and 
anergy, and the NF-κB subunit p65.  NFAT forms complexes with the AP-1 family of 
transcription factors and regulates T cell activation-associated genes (Wu et al. 
2006).  Notably, many of the genes regulated by Foxp3 are also target genes for 
NFAT, including the CD25 and CTLA-4 genes which are promoted by both NFAT 
and Foxp3 (Hori, Nomura, & Sakaguchi 2003).  Moreover, recent work has identified 
a crucial regulatory role for retinoic acid in promoting Foxp3 induction and inhibiting 
Th17 cell differentiation (Elias et al. 2008;Mucida et al. 2007). 
 
 
   1.8.4 IL-10 and IL-10-secreting Treg cells 
 
IL-10 was originally identified by Mosmann and colleagues (Fiorentino, Bond, & 
Mosmann 1989;Moore et al. 1990).  It has been known for many years that IL-10 is 
an immunosuppressive cytokine that can inhibit actions of many types of immune 
cells, suppress the progression of immune-mediated diseases and play a central role 
in maintaining tolerance (Moore et al. 2001).  Apart from its immunosuppressive 
effects, IL-10 can also act as a growth factor for mast cells, promote B cell growth 
and differentiation, and stimulate CD8+ T cell proliferation (Moore et al. 1993).  IL-10 
production can be promoted by IL-10 itself, IL-27 and TGF-β (Zhu & Paul 2008). 
 
IL-10 is secreted by monocytes, stimulated macrophages, DCs, T cells, B cells, 
eosinophils, mast cells, keratinocytes, and epithelial cells and is normally produced 
late in the immune response compared with other cytokines to dampen the response 
by suppressing inflammatory cytokines (Moore et al. 1993;Mosser & Zhang 2008).  
CD8+ T cells and all the CD4+ T cell subsets including Th1, Th2, Th17, as well as 
Treg cells are capable of producing IL-10 under certain circumstances.  In the case 
of IL-10 production by Th1 and Th17 cells, it may serve as a negative regulatory 
mechanism for limiting their own effector function to prevent host tissue damage 
(Jankovic & Trinchieri 2007).  Of note, IL-10 production was reported to be 
independent of Foxp3 in Treg cells (Gavin et al. 2007). 
 
The cytokine signals through a two-receptor complex consisting of two copies each 
of IL-10R1 and IL-10R2 (Moore et al.2001).  IL-10R1 binds IL-10 with a relatively 
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high affinity and the recruitment of IL-10R2 to the receptor complex makes only a 
marginal contribution to ligand binding (Mosser & Zhang 2008).  The binding of IL-10 
to the receptor complex activates the Janus tyrosine kinases, JAK1 and Tyk2, 
associated with IL-10R1 and IL-10R2, respectively, to phosphorylate the cytoplasmic 
tails of the receptors.  This results in the recruitment of Stat3 to the IL-10R1 
(Donnelly et al. 2004).  After homodimerisation of Stat3, the Stat homodimer is 
released from the receptor.  This is followed by translocation into the nucleus and the 
binding of Stat 3 to Stat-binding elements in the promoters of various genes.  IL-10 
gene itself is upregulated by Stat3 (Staples et al. 2007).  Stat3 also activates the 
suppressor of cytokine signaling 3 (SOCS3), which exerts negative regulatory effects 
on various cytokine genes (Murray 2007;O'shea & Murray 2008).  Moreover, the 
phosphoinositide 3-kinase (PI3K) pathway is also activated by IL-10 (Mosser & 
Zhang 2008). 
 
Most haematopoietic cells constitutively express low levels of IL-10R1, and receptor 
expression can often be considerably upregulated by various stimuli.  Non-
haematopoietic cells, such as fibroblasts and epithelial cells, can also upregulate IL-
10R1 in response to stimuli.  On the other hand, IL-10R2 is expressed on most cells, 
and thus a large number of diverse cells have the capacity to bind to and consume 
IL-10 (Mosser & Zhang 2008).  Interestingly, activated T cells have been described 
to downregulate expression of IL-10R1 to overcome the suppressive effects of IL-10, 
whereas activated monocytes upregulate this molecule and become more prone to a 
negative feedback pathway (Liu et al. 1994;Moore et al. 2001). 
 
Although many cell types produce IL-10, Tr1 cells characteristically produce high 
levels of IL-10 as well as moderate levels of IL-5, IFN-γ and TGF-β, and are one of 
the main T cell mediators of cytokine-dependent immune regulation (Roncarolo et al. 
2006).  Currently, neither a single cell surface marker nor a combination of markers 
could be used to track and purify Tr1 cells, thus it is difficult to isolate these cells ex 
vivo (Allan et al. 2008b).  However, Tr1 cells have been reported to be induced from 
naive CD4+ T cells activated by tolerogenic APCs in the periphery in the presence of IL-
10 (Roncarolo et al. 2006).  These Tr1 cells mediate suppressive effects by secreting IL-10 
and TGF-β, and promote bystander suppression once activated via the TCR (Allan et al. 
2008b).  Although Tr1 cells from humans usually produce IFN-γ, the production levels 
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of the cytokine are at least 1 log lower than those produced by Th1 cells (Levings et 
al. 2001).  Whether or not IFN-γ has any functional role remains to be determined.  
Apart from being able to regulate the responses of naive and memory T cells in vitro 
and in vivo, Tr1 cells also suppress the production of immunoglobulin by B cells 
(Kitani et al. 2000).   
 
 
   1.8.5 TGF-β and TGF-β-secreting Treg cells 
 
TGF-β is another regulatory cytokine with a pivotal role in regulating immune 
responses and it has pleiotropic effects on proliferation, differentiation, migration and 
survival in a broad range of cell lineages.  In mammals, three homologous TGF-β 
isoforms, TGF-β1, TGF-β2, TGF-β3, have been identified, and the effects of these 
three cytokines on immune cells are largely indistinguishable in vitro.  TGF-β1 is the 
predominant form expressed in the immune system as lymphoid cells produce 
mostly TGF-β1 (Li & Flavell 2008).  TGF-β is synthesised in an inactive form, pre-
pro-TGF-β precursor, and additional stimuli are required to liberate active TGF-β.  
The active form of TGF-β can function in either a cell-surface bound form or a 
soluble form (Wan & Flavell 2008).  TGF-β is operative as a surface bound protein 
on nTRegs, and blockade of cell-surface TGF-β disrupts the suppressive function of 
nTRegs (Abdulahad, Boots, & Kallenberg 2010). 
 
By binding to TGF-β type I (TGF-βRI) and type II (TGF-βRII) receptors, both of which 
are serine/threonine kinases, TGF-β exerts its functions primarily through the Smad-
dependent pathway.  In addition, TGF-β transduces signals through Smad-
independent pathways by activating phosphatidylinositol 3-kinase (PI3K) and various 
MAPKs (Li et al. 2006).  TGF-β has strong anti-proliferative effects on CD4+ T cells 
owing to its ability to inhibit IL-2 production and to upregulate cell cycle inhibitors 
(Gorelik & Flavell 2002).  TGF-β also impedes Th1 and Th2 cell differentiation by 
suppressing the transcription factors required for expression of IFN-γ (T-bet) and IL-
4 (GATA-3) respectively (Gorelik, Constant, & Flavell 2002;Heath et al. 2000).  At the 
level of APCs, TGF-β can block the activation of macrophages and their ability to 
produce pro-inflammatory cytokines.  In addition, it thwarts the maturation of DCs 
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and, like IL-10, inhibits upregulation of MHC class II surface expression (Gorelik & 
Flavell 2002). 
 
TGF-β is produced by activated macrophages, but also by a wide variety of lymphoid 
and non-lymphoid cells (Wahl, McCartney-Francis, & Mergenhagen 1989).  Foxp3+ 
Treg cells also contributes significantly as a source of TGF-β and the production of 
this cytokine plays a crucial role in controlling autoimmune diseases (Li, Sanjabi, & 
Flavell 2006).  Besides its well-known inhibitory activities on effector T cell 
differentiation and the acquisition of Th cell functions, TGF-β has an important role in 
the generation of Tregs.  It has been shown that activation of CD4+ cells in the 
presence of TGF-β promotes expression of CD25 and CTLA-4 (Zheng et al. 2002).  
Also, TGF-β activates Smad3 while TCR stimulation induces the activation of NFAT.  
Smad3 and NFAT collaborate to remodel the Foxp3 enhancer region and induce 
Foxp3 expression (Tone et al. 2008).  As TGF-β induces the Foxp3 expressing 
CD4+CD25+ Tregs, it can therefore indirectly influence T cell activation. 
 
T helper 3 (Th3) regulatory T cells, another subset of adaptive Tregs, express high 
levels of TGF-β, and are suggested to be antigen-induced regulatory T cells at the 
tissue site of inflammation (Chen et al. 1994).  Surface marker CD25 cannot 
distinguish Th3 from thymic-derived Tregs as they can display this molecule after 
activation (Zheng et al. 2002). 
 
 
   1.8.6 CD8+ regulatory T cells 
 
In recent years, CD4+ Treg function has become the object of intense study.  
Nevertheless, regulatory T cells are not strictly confined to the CD4+ T cell 
compartment.  In 1972, Gershon et al. published their landmark article about 
‘suppressor T cells’ paving the way for the concept that T cells are not only able to 
augment but also to suppress immune response (Gershon et al. 1972).  In those 
early years, the focus was in fact mainly on CD8+ T cells.  Although CD8+ Tregs also 
contribute to immunoregulation, circulating CD8+Foxp3+ T cells constitute a 
minuscule fraction of peripheral CD8+ T cells in humans.  The relatively low 
frequency of CD8+ Treg cells in the peripheral circulation in humans makes in vivo 
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identification and functional characterisation difficult.  To date, knowledge on CD8+ 
Tregs in general, remains scarce compared with CD4+ Tregs.  Research on CD8+ 
Treg cells has also received considerably less attention (Gavin et al. 2006). 
 
In parallel with naturally occurring and adaptive CD4+ Treg cells, CD8+ Treg cells 
may originate from both the thymus and the periphery, where they develop from 
naive or effector CD8+ T cells (Aandahl, Torgersen & Tasken 2008).  CD8+ Treg cells 
generally express low levels of CD25 and Foxp3 and, as for CD4+ Treg cells, no 
distinguishing marker has been identified that discriminates between naturally 
occurring and adaptive CD8+ Treg cells (Aandahl, Torgersen & Tasken 2008). 
 
Within CD8+ T cell subset, CD8+CD25+ cells have been described to share similar 
phenotypic characteristics with CD4+CD25+ thymocytes, since they may be found in 
the same areas of human thymus and constitutively express Foxp3 and GITRmRNA.  
Following stimulation, CD8+CD25+ thymocytes express CTLA-4 and TGF-β1 on their 
surface but do not produce any cytokines or express much CD127 (Cosmi et al. 
2003).  Also, CD8+ Treg cells have been reported to express TNFR2, and the 
combined expression of TNFR2 and CD25 can identify a potent subpopulation of 
CD8+ Treg cells (Ablamunits, Bisikirska, & Herold 2010).  Contact inhibition via 
CTLA-4 and TGF-β1 has been demonstrated to be the mechanism responsible for 
the suppressive capacity of CD8+CD25+ Treg cells.  It has been suggested that 
CD8+CD25+ Treg cells may be responsible for the regulation of T cell responses 
directed against viruses and transformed cells, which are usually exploited by 
cytotoxic CD8+ T lymphocytes (Cosmi et al. 2003). 
 
Furthermore, two subsets of adaptive CD8+CD28- Treg cells have been described to 
exist in humans.  Antigen-specific CD8+CD28- Treg are regulatory cells that differ 
from the non-antigen-specific CD8+CD28- Treg subset by several aspects.  In terms 
of phenotype, antigen-specific CD8+CD28- Treg cells express both CTLA-4 and 
Foxp3 (Scotto et al. 2004).  They act through cell-to-cell direct contact, promoting the 
upregulation of inhibitory ILT3 and ILT4 receptor molecules on APCs, which is 
essential to the tolerogenic phenotype acquired by APCs.  Tolerogenic APCs show 
decreased expression of costimulatory molecules and induce antigen-specific 
unresponsiveness in CD4+ T helper cells (Chang et al. 2002). 
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On the other hand, non-antigen-specific CD8+CD28- Treg cells do not express Foxp3 
and downregulate CD127 during their differentiation from circulating non-regulatory 
CD8+CD28- T lymphocytes to Tregs.  The generation process requires monocytes 
that secrete IL-10 after GM-CSF stimulation.  GITR is involved in generation 
processes as well but not in suppressor function of these cells (Fenoglio et al. 2008).  
Their suppressive function, including one on the antigen-specific cytotoxic activity of 
cytotoxic T lymphocytes, is mediated by IL-10 (Filaci et al. 2004).  Other types of 
CD8+ regulatory T cells are less well characterised. 
 
Like in CD4 T regulatory cells, CD8 Treg cells employ their suppressive function by 
releasing cytokines or by directly altering the functional status of T cells or APC.  
Secreted products and cell surface receptors facilitating suppression are only 
partially understood.  Also, CD8 Treg cells are a heterogeneous group of subsets.  
Whether all these subsets derive from a common precursor or whether different 
types of CD8 T cells can differentiate into suppressor cells is not known. 
 
 
1.9 Collaboration between transcription factors in fine-tuning T helper 
differentiation 
 
The master transcription factors and the Stat proteins are indispensable for Th cell 
fate determination and cytokine production.  Unlike the activities of master 
transcription factors which are mainly influenced by their expression levels, those of 
the Stats are controlled by cytokine-mediated post-translational modification, 
involving tyrosine and/or serine/threonine phosphorylation.  Not only do the activated 
Stat proteins, in collaboration with master transcription factors, dictate the production 
of the key cytokines by Th cells, they also play crucial roles in the induction of the 
master transcription regulators (Zhu, Yamane, & Paul 2010).  Other transcription 
factors, either constitutively expressed or induced by TCR and/or cytokine-mediated 
signalling, are also involved in attaining or modifying Th cell functions. 
 
Runx proteins have been indicated to have important roles at multiple stages of T 
cell development and in the homeostasis of mature T cells.  It was shown that Runx1 
  
54 
 
activates IL-2 and IFN-γ gene expression in conventional CD4+ T cells by binding to 
their respective promoter.  Furthermore, Runx1 interacts physically with Foxp3 
protein, and it was demonstrated that this interaction might be responsible for the 
suppression of IL-2 and IFN-γ production and upregulation of Treg cell-associated 
molecules (Ono et al. 2007).  Besides being important for Th2 cell differentiation, 
IRF4 is also indispensable for Th17 differentiation (Brustle et al. 2007).  BATF, an 
AP-1 family transcription factor, plays a critical role in Th17 cell differentiation as it is 
required for RORγt induction (Schraml et al. 2009).  Despite not being involved in 
determining T helper lineage fates, several transcription factors play a major role in 
cytokine production upon TCR and /or cytokine stimulation and these include 
members of the NFAT and Notch families. 
 
T cells express NFAT1, NFAT2, and NFAT4.  NFAT forms a complex with AP-1 and 
NFκB and regulates the expression of IL-2, IL-4, and IFN-γ in conventional T cells 
(Hu et al. 2007).  NFAT proteins play key roles in modulating Th cell differentiation 
and are indispensable for the production of effector cytokine upon TCR activation in 
differentiated Th cells.  TCR ligation increases intracellular Ca2+ concentration.  Ca2+ 
binds to calmodulin, which in turn triggers the activation of calcineurin.  Activated 
calcineurin dephosphorylates NFAT proteins, which results in the translocation of 
NFAT to the nucleus and subsequent induction of NFAT-dependent gene 
transcription (Macian 2005). 
 
On the other hand, Notch signaling has an important co-stimulatory role in controlling 
optimal T cell activation as inhibition of Notch activation decreases the division of 
both CD4+ and CD8+ T cells considerably in response to TCR stimulation (Zhu, 
Yamane, & Paul 2010).  Notch is also important in regulating differentiation of naive 
CD4+ T cells into distinct Th lineages such as iTreg and Th17 cells.  Collectively, all 
these molecules form a sophisticated transcription factor network, which is critical for 
Th cell fate determination, expansion, and function. 
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1.10  Plasticity of T helper subsets 
 
CD4+ T cell lineage commitment was considered as a unidirectional process in early 
studies.  However, the discovery of new CD4+ T cell fates and observation of cells 
with mixed phenotypes have raised the questions about the stability of CD4+ T cell 
subsets and relationship among lineages.  Recent findings suggest that CD4+ T cells 
frequently have the capacity to redirect their programs as to achieve balance 
between regulatory and effector functions.  This requires plasticity in the regulation of 
transcriptional targets and the process allows the host to shift resources as 
appropriate to eliminate offending pathogens and limit potential collateral tissue 
damage (Veldhoen 2009). 
 
Th1 and Th2 cells antagonise each other’s development and have not been 
observed to be converted into Th17 cells (Veldhoen 2009).  However, Th17 clones 
were described to express T-bet, the Th1 transcription factor, and they could be 
shifted to Th1 by the addtion of IL-12, an effect that was partially antagonised by IL-
23.  This suggested a flexibility of human Th17 cells and their possible common 
developmental origin with Th1 cells (Annunziato et al. 2007).  Also, in vitro generated 
mouse Th17 cells were able to be converted into Th2 cells in response to IL-4 
(Lexberg et al. 2008).  However, this has not been verified in humans. 
 
In addition, Foxp3+ Treg cells capable of IL-17 production have been identified and 
these cells co-express transcription factors RORc2 and Foxp3 (Koenen et al. 
2008;Voo et al. 2009).  Inflammatory cytokines including IL-21, IL-23 and especially 
IL-1β promote IL-17 production by Tregs (Koenen et al. 2008;Voo et al. 2009).  
Conversion of Tregs into IL-17-producing cells can be facilitated by the stimulation of 
APCs, especially monocytes, and IL-2 as well (Deknuydt et al. 2009;Koenen, 
Smeets, Vink, van Rijssen, Boots, & Joosten 2008).  However, the addition of TGF-β 
and IL-6 has no effect (Koenen et al. 2008).  The IL-17-producing Foxp3+ Treg cells 
preferentially express CCR6 and these cells inhibit the proliferation of CD4+ 
responder T cells in vitro, albeit to a lesser extent than freshly isolated Tregs 
(Koenen et al. 2008; Voo et al. 2009).  Notably, unlike conventional Th17 cells, these 
IL-17+FoxP3+ T cells have not been detected to express CD161, IL-22 or TNF-α 
(Ayyoub et al. 2009). 
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After incubation with low numbers of CD40-activated allogeneic B cells, naive human 
CD4+ T cells have been shown to preferentially differentiate into alloantigen-specific 
CD4highCD25high Treg cells.  These differentiated cells potently suppress effector T 
cell responses and express T-bet, IFN-γ, and CXCR3, the features of Th1 effector 
cells.  As CXCR3 confers the preferential trafficking of T cells to tissue sites of IFN-γ, 
these Th1-like Treg cells have been suggested to be useful for regulating 
pathological Th1 effector responses (Zheng et al. 2010). 
 
As yet, the functional significance of this plasticity between Th17, Th1 and Foxp3+ 
Treg cells in humans is poorly understood.  It has been suggested by promoting 
Th17 cells during the initial response, Treg-mediated suppression could be 
undermined via production of inflammatory cytokines.  On the other hand, persisting 
inflammation might drive cells into Th1-like phenotype and increase their 
susceptibility to suppression by Treg cells (O'Connor, Taams, & Anderton 2009).  
Reprogramming of T helper cell effector functions may be critical for host defense to 
specific microbial challenge. 
 
 
1.11 Subsets of CD8+ effector T cells 
 
Historically, CD8+ T cells have been regarded as a homogeneous population of 
cytotoxic cells producing a limited number of cytokines.  Indeed, some of the CD8+ T 
cells can become directly cytotoxic via perforin and granzyme B secretion (Kaech & 
Wherry 2007).  More recently, it has become clear that CD8+ T cells have the 
potential to produce a much wider array of cytokines, and the existence of distinct 
subsets of CD8+ T cells that are similar to their CD4+ counterparts has been 
established (Vukmanovic-Stejic et al.2000).  CD8+ effector T cells designated Tc1 or 
Tc2, based on their production of IFN-γ or IL-4, can be generated in vitro with the 
addition of IL-12 and IL-4 respectively (Seder & Ahmed 2003).  Tc1 clones have 
been shown to favour the development of CD4+ effectors that are Th1-biased.  
Whereas Tc2 clones not only can promote Th2 effectors but also can efficiently 
suppress the development of Th1 cells (Vukmanovic-Stejic et al. 2000).  With 
regards to in vitro cytolytic activity and the level of FasL expression, however, no 
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difference has been reported between Tc1 and Tc2 cells (Vukmanovic-Stejic et al. 
2000). 
 
Two of the best-described regulators of effector CD8+ T cell differentiation are a pair 
of highly homologous T-box transcription factors, Eomesodermin and T-bet.  Studies 
have indicated that Eomesodermin is responsible for regulating expression of 
granzyme B, perforin, and cytotoxicity (Pearce et al. 2003).  T-bet, the main 
transcription factor controlling Th1 differentiation, have been reported to be rapidly 
induced in activated CD8+ T cells downstream of TCR, IFN-γ and IL-12 signalling 
(Rutishauser & Kaech 2010).  The introduction of T-bet into polarised Tc2 cells can 
result in the conversion of these cells into Tc1 cells with production of IFN-γ and 
repression of IL-4 production (Szabo et al. 2002).  Also, GATA-3 has been 
demonstrated to be negatively correlated with the proportion of Tc1 cells and 
positively correlated with the percentage of Tc2 cells in peripheral blood 
mononuclear cells (Tan et al. 2007). 
 
Recently, IL-17 producing CD8+ T cells (Tc17) have been identified in CD27+/-
CD28+CD45RA- memory subsets and reported to differentiate from the same 
precursors as IFN-γ-producing CD8+ T cells.  These cells could produce IL-17 alone 
or in combination with IFN-γ (Kondo et al. 2009).  Tc17 cells are capable of secreting 
high levels of IL-22 and they express cytokine receptor IL-23R (Billerbeck et al. 
2010).  CD161 are a relevant marker for these human IL-17 producing cells as well.  
In terms of chemokine receptors, they have been shown to express CCR6 and a 
high level of CCR5 (Kondo et al. 2009).  Also, these cells are associated with 
transcription factors consistent with type 17 differentiation, including RORγt (RORc) 
and RORα (Billerbeck et al. 2010).  By culturing naive CD8+ T cells stimulated with 
anti-CD3 and anti-CD28 mAbs in the medium with IL-1β, IL-6, IL-23, and TGF-β, 
Tc17 cells can be induced (Kondon et al. 2009). 
 
 
1.12  γδ T cells 
 
Patients with bacterial, parasitic and viral infections often have increased numbers of 
γδ T cells in the peripheral blood and in autoimmune disease patients, γδ T cells are 
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often noted for being overrepresented among the lymphocytes that infiltrate target 
tissues (Chien, Jores, & Crowley 1996;Konigshofer & Chien 2006).  γδ T cells not 
only support regeneration of epithelium but also attract neutrophils just after tissue 
injury so as to remove necrotic epithelial cells (Kuhl et al. 2009).  Like αβ T cells, 
they develop in the thymus before entering the periphery.  They make up a minor 
part of human thymocytes and T cells in the spleen, lymph nodes, and peripheral 
blood after birth, but are greatly enriched in epithelial tissues, such as the epidermis 
and mucosa of the digestive and reproductive tracts (Bonneville, O'Brien, & Born 
2010).  They play a major role in mucosal immunity and are induced in the early 
response just after innate but well ahead of the conventional adaptive immune 
response (Deknuydt, Scotet, & Bonneville 2009).  Several γδ T cell subsets have a 
memory and pre-activated phenotype in naive individuals that can respond to a given 
challenge and enable responses to occur rapidly, without the need for prior selection 
and expansion.  In fact, antigen-naive γδ T cells are known to produce large amount 
of effector cytokines within hours upon infection (Roark et al. 2008). 
 
In support of their roles in early responses to microbial infections, studies have 
revealed that some human γδ T cells express functional TLRs such as TLR2 (Deetz 
et al. 2006;Martin et al. 2009).  Unlike αβ T cells, the detection of stress-induced 
molecules by γδ T cells is achieved by both TCR and non-TCR molecules, such as 
TLRs and NK receptors that act separately, synergistically or additively to activate 
particular γδ T cell effector functions (Bonneville, O'Brien, & Born 2010).  Of note, γδ 
T cells frequently express invariant or closely related γδ TCRs in a given tissue site, 
which differ from one tissue to another, reflecting homogeneous, but distinct, antigen 
recognition repertoires.  γδ T cells express mostly Vγ9Vδ2 (Vγ2Vδ2 in the American 
nomenclature) TCR in peripheral blood but mostly Vδ1 and Vδ3 TCR in spleen and 
gut respectively (Deknuydt, Scotet, & Bonneville 2009).  The repertoire of γδ TCRs is 
very limited but they directly recognise poorly defined polymorphic structures without 
the requirement for antigen-processing and presentation by specialised APCs.  
Unlike αβ T cells, human Vδ2+ T cells do not recognise peptides presented by 
classical or non-classical MHC molecules.  Instead Vδ2+ T cells recognise a group of 
non-peptidic prenyl pyrophosphate antigens known as phosphoantigens (Sireci et al. 
2001). 
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It has been demonstrated that γδ T cells are able to produce a range of cytokines 
similar to those of αβ T cells (Konigshofer & Chien 2006).  Apart from the production 
of soluble mediators, γδ T cells usually display potent cytotoxic effector activity.  Also, 
these cells can kill susceptible target cells by the secretory pathway through the 
production of perforin and granzymes, but can also make use of the receptor-ligand 
such as Fas/FasL pathway (Dalton et al. 2004;Narazaki et al. 2003).  Vδ2 T cells 
generally have high cytotoxic activity and display a predominant Th1-like pattern of 
cytokine production as they release massive amounts of TNF-α and IFN-γ.  However, 
certain subsets of γδ T cells, like Vδ1+ T cells, have lower cytotoxic potential and 
produce either Th1, Th2 cytokines or IL-17 (Bonneville, O'Brien, & Born 
2010;Deknuydt, Scotet, & Bonneville 2009).  In contrast to the slow adaptive Th17 
response, γδ T cells along with NKT cells are potent innate IL-17 producers which 
contribute to the initial defence against pathogens (Michel et al. 2007;Roark et al. 
2008). 
 
Several transcription factors have been described in relation to γδ T cell effector 
function.  IFN-γ production is regulated by the transcription factors T-bet and 
eomesodermin (Chen et al. 2007a), IL-4 production correlates with GATA3 
expression (Qi et al. 2009), and IL-17 production is controlled by RORγt (Fenoglio et 
al. 2009;O'Brien et al. 2010).  Besides, potent regulatory properties have been 
reported in γδ T cells as deficiency in these cells exacerbated colitis in animal 
models.  In one recent study, human γδ T cells with negative Foxp3 expression were 
shown to suppress T helper cell growth at least to the same degree as CD4+CD25+ T 
cells in an IL-2 independent manner and they responded poorly to CD3/CD28 
stimulation.  The mechanism of suppression was suggested to be related to strong 
TGF-β secretion, especially by the Vδ1 subset as they were found to be the main 
TGF-β producer compared to Vδ2 T cells (Kuhl et al. 2009).  In a separate study, 
Vδ2 Treg cells which expressed Foxp3, was induced in vitro with the combination of 
TGF-β1, IL-15 and TCR stimulation.  These Foxp3+ Vδ2 T cells displayed higher 
levels of activated phenotype (CD69+, CD25+, and HLA-DR+) and an upregulated 
expression of CTLA-4 molecules compared with the Foxp3- Vδ2 T cells.  Similar to 
nTreg cells, cell contact appeared to be central to the inhibitory activity in these cells 
(Casetti et al. 2009). 
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1.13  NKT cells 
 
NKT cells are a unique and relatively small subset of T cells that were originally 
defined to share properties of both conventional T and NK cells.  They are involved 
in immediate immune responses, tumor rejection, immune surveillance and control of 
autoimmune diseases.  They make up <0.1% of peripheral blood and are 
distinguished from NK cells by the expression of the CD3/TCR complex as well as 
NK cell markers, such as CD161c and CD56 (Hammond & Godfrey 2002).  They are 
a heterogeneous population of lymphocytes and are currently divided into three 
categories according to their TCR α-chain diversity, CD1d dependency, and 
reactivity to the glycolipid α-galactosylceramide (α-GalCer).  Type I classical 
“invariant” NKT (iNKT) cells possess invariant TCR α-chains and react to α-GalCer in 
a CD1d-dependent manner.  Type II cells show diverse TCR α-chains but are also 
CD1d dependent.  Type III cells are CD1d independent and possess diverse TCR α-
chains.  Both types II and III NKT cells do not react to α-GalCer (Rachitskaya et al. 
2008). 
 
Human iNKT cells express a Vα24-Jα18 TCR α-chain coupled with a Vβ11 β-chain 
and can be further allocated as CD4+ iNKT, CD8+ iNKT or double-negative iNKT 
cells (Gabriel, Morley, & Rogers 2009).  Due to the constitutive expression of IFN-γ 
and IL-4mRNA, iNKT cells were demonstrated to produce great amounts of both 
Th1- or Th2-type cytokines within hours of TCR stimulation (Godfrey & Kronenberg 
2004).  Interestingly, innate production of IL-17 by this group of cells was discovered 
recently in human as well.  IL-17 production was detected after purified NKT cells 
from healthy donors were stimulated with anti-CD3 Ab and IL-23 for 24 hours, 
independent of exogenous IL-6 (Rachitskaya et al. 2008).  Although NKT cells 
potentially can act as effector cells, it is likely that regulatory function reflects their 
true physiologic role which is more consistent with their small numbers.  Similar to 
CD4+CD25+ Tregs, iNKT cells have been identified to express CD25 and regulate a 
range of immune responses.  Therefore, it was suggested that some activity 
attributed to CD4+CD25+ Tregs could actually be related to CD4+CD25+ NKT cells 
(Godfrey & Kronenberg 2004).  Aberrant number and/or function of iNKT cells has 
been reported for various organ-specific and systemic autoimmune conditions such 
as RA, MS and SLE (Hammond & Godfrey 2002).  
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1.14 Central and peripheral tolerance 
 
The goal of the immune system is to protect individuals from foreign agents while 
avoiding pathology or undesirable outcomes to self during such useful responses or 
owing to undesirable reactivity to self.  The immune system relies on continuous 
generation of lymphocytes in primary lymphoid organs and hence, tolerance 
induction to self must be a continuous process throughout life.  Because the 
receptors of immune cells are generated in a random process, ones with self-
reactive receptors need to be eliminated (Daniel, Nolting, & von Boehmer 2009). 
 
Self-tolerance is achieved via multiple checkpoints operating on both precursor 
lymphocytes during their development in primary lymphoid tissues (central tolerance) 
and on mature cells in secondary lymphoid tissues as well as parenchymal sites 
(peripheral tolerance).  Self-reactive immune cells that manage to escape these 
checkpoints can pose a serious threat to health, as they can lead to the development 
of autoimmunity (Castellino & Germain 2006). 
 
To ensure the usefulness and safety of mature T cells, developing T cells within the 
thymus undergo rigorous selection.  During development, most of the thymocytes 
undergo ‘death by neglect’ as most TCRs cannot recognise any self-peptide/MHC 
molecules.  If their TCRs have low affinity for self-peptide/MHC molecules, the 
thymocytes stay alive and expand.  This positive selection ensures that mature T 
cells have the potential to recognise foreign peptide in association with self-MHC.  At 
the late stage of positive selection, CD4/CD8 lineage commitment occurs and 
thymocytes differentiate into either single CD4+ or single CD8+ T cells (Daniel, 
Nolting, & von Boehmer 2009). 
 
Positively selected CD4+ and CD8+ thymocytes test their TCRs against a broad array 
of self-MHC and self-peptide combinations for self-reactivity.  If TCRs have a high 
affinity for self-peptide/MHC molecules, negative selection (deletion) occurs as the 
cells are induced to upregulate Bim, a protein which drives cell death by apoptosis.  
Negative selection removes potentially dangerous T cells that recognise self-
peptides, and dendritic cells are important for the negative selection of T cells in the 
thymus.  However, such negative selection is not a foolproof mechanism, and some 
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T cells capable of damaging autoimmune reactivity escape to the periphery (Daniel, 
Nolting, & von Boehmer 2009).  Despite the processes of positive and negative 
selection in the thymus, all individuals still harbor a subset of cells that have TCRs 
directed toward self-antigens in peripheral tissues and organs.  Yet, most individuals 
never develop autoimmune disease. 
 
To further limit effector responses to both self as well as harmless environmental 
antigens, multiple mechanisms in the immune system function to control unwanted 
immunity.  To activate mature T lymphocytes, the dose and affinity of the antigen 
required is higher than for immature thymocytes, which leads to activation-related 
ignorance of many self-peptides presented in the periphery.  Also, T cell responses 
are regulated by requirements for simultaneous or coordinated signalling.  Antigen 
presenting cells, in particular DCs, require stimulation through innate receptors, such 
as TLRs, to be highly effective in triggering naive T cells and to induce production of 
mediators that facilitate T cell clonal expansion, viability, and development of effector 
function.  A requirement for multiple antigen-specific lymphocytes to interact, either 
directly with each other or through the intermediation of DCs, further decreases the 
risk of inappropriate responses to harmless antigens and limit the capacity of 
potentially autoaggressive cells (Castellino & Germain 2006).  Another pathway 
involved is activation-induced cell death (Bach 2002). 
 
In addition, some thymocytes are selected to become regulatory T cells, which are 
usually cells which have an intermediate affinity for self-peptide (Hogquist, Baldwin, 
& Jameson 2005).  Peripheral tolerance mechanisms involving regulatory T cells are 
essential in dealing with low-affinity, self-reactive cells and keep them in check 
(Daniel, Nolting, & von Boehmer 2009).  It is now well established that, in addition to 
central tolerance established as a result of induced apoptosis of strongly self-
reactive cells in the thymus, peripheral tolerance exists with significant contribution 
coming from Treg cell populations (Littman & Rudensky 2010). 
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1.15 Autoimmunity 
 
Many autoimmune diseases are driven by self-reactive T helper cells.  Until recently, 
organ-specific autoimmune diseases were primarily associated with Th1 cells but not 
Th2 cells. However, the discovery of a number of new effector T cell subsets, like 
Th17 and Th9 cells, and regulatory T cells, like Tregs and Tr1 cells, has changed the 
way we view and understand autoimmunity at cellular and molecular levels. In recent 
years, IL-17-producing Th17 cells have emerged as major players in autoimmunity. 
The complicated relationship between Th1 and Th17 cells, as well as the intricate 
balance between Tregs and Th17 cells, provides a basis for understanding the 
immunological mechanisms that induce and regulate autoimmunity. Here, we give an 
overview of the interplay between different effector T cell subsets and regulatory T 
cell subsets, and how they contribute to the development of autoimmunity and tissue 
inflammation (Jager & Kuchroo 2010). 
 
 
1.16  Autoimmune diseases and the roles of Th1/Th2 subsets 
 
The term ‘autoimmunity’ denotes an adaptive immune response directed against 
self-antigen.  Autoimmune diseases form a spectrum ranging from organ-specific 
conditions to systemic disorders in which the pathology is distributed throughout the 
body.  It is estimated that 5-10% of the world population is affected by autoimmune 
diseases (Shoenfeld et al. 2008).  The ability to discriminate between self and non-
self antigens is vital to the functioning of the immune system and failure in self-
tolerance can result in pathological autoimmune states.  An effector phase typified by 
chronic inflammation and tissue damage subsequent to autoimmunity against self-
antigens inevitably leads to significant morbidity and mortality.  Many autoimmune 
diseases including RA, MS and IBD are characterised by the presence of 
macrophages with an “M1” classically activated phenotype at sites of inflammation.  
These macrophages are believed to be key mediators in immunopathology through 
the production of cytokines such as TNF, IL-1, and IL-6 (Mosser & Edwards 2008). 
 
In the development of autoimmune diseases, a strong maybe deregulated Th1 
response has been implicated.  This is owing to the observations that the adoptive 
  
64 
 
transfer of Th1 clones and treatment with IL-12 induced or aggravated experimental 
autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA) 
respectively (Dardalhon et al. 2008).  Also, at the peak of EAE, Th1 cytokines such 
as IFN-γ were readily detectable in central nervous system (CNS) inflammatory 
lesions but decrease during remission (Renno et al. 1995).  However, it is now clear 
that Th1 cells are not solely responsible for driving autoimmune tissue damage in 
EAE and CIA.  This is because exacerbated disease in the absence of IFN-γ 
signalling was associated with massive neutrophil and macrophage infiltrates in the 
CNS in EAE (Ferber et al. 1996) and a reduced IFN-γ signalling resulted in more 
severe disease in CIA (Matthys et al. 1998).  These observations question the 
classic pro-inflammatory role of IFN-γ but also the Th1/Th2 paradigm as a basis for 
explaining the regulation of autoimmune diseases.  Current evidence suggests that 
IFN-γ may act as a double-edged sword in immune responses and inflammatory 
processes as it can either promote or contain autoimmunity depending on the 
specific disease and the timing, location, and intensity of IFN-γ action (Kelchtermans, 
Billiau, & Matthys 2008). 
 
Classically, IFN-γ has been treated as a pro-inflammatory cytokine as they play a 
key role in macrophage activation, inflammation and immunity.  Recently, it is 
recognised as a pleiotropic cytokine (Figure 1.3) which has physiological importance 
in controlling immune and inflammatory responses.  IFN-γ induces the production of 
cytokines, upregulates the expression of class I and II MHC antigens, Fc receptor 
and leukocyte adhesion molecules on a variety of cells.  On the one hand, it 
promotes a Th1 response, not only in the effector phase but also as one of the 
autocrine factors favouring Th1-directed differentiation.  The functional activity of 
macrophages is enhanced by the presence of IFN-γ and IFN-γ is known to influence 
isotype switching and potentiate the secretion of immunoglobulins by B cells.  
Moreover, it augments Th cell expansion and promotes T cell migration to the site of 
inflammation (Kelchtermans, Billiau, & Matthys 2008). 
 
On the other hand, the intensity of Th1-induced inflammation potentially triggers self-
regulating mechanisms in response to overt inflammation.  IFN-γ has been shown to 
reduce tissue destruction by attenuating tissue infiltration by neutrophils and 
monocytes and suppressing genes responsible for tissue-destructive enzymes such 
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as matrix metalloproteinases (MMPs), serine proteases and enzymes related to 
prostaglandin metabolism (Hu & Ivashkiv 2009).  Another important way is attributed 
to the ability of IFN-γ to downregulate IL-17 secretion (Meyers et al. 2006).  
Moreover, IFN-γ treatment was shown to promote negative feedback with 
differentiation of CD4+ Treg cells as characterised by increased expression of Foxp3, 
from CD4+CD25- T cells in a recent murine study.  These converted cells acquired 
marked regulatory properties after in vitro treatment and showed a significant 
increase in the ability to inhibit autologous T cell proliferation induced by anti-CD3 
and anti-CD28 antibodies (Wang et al. 2006). 
 
Th2 cells provide optimal help for humoral immunity, especially in B cell activation 
and immunoglobulin isotype switching and mucosal immunity, through induction of 
mast cell and eosinophil differentiation and expansion.  They evoke especially strong 
antibody responses but relatively weak cellular activity (Janeway et al. 2005).  Th2-
derived cytokines suppress several macrophage functions.  Studies have shown that 
IL-4 impedes macrophage secretion of IL-1β, TNF-α, and IL-6 (Schulze-Koops & 
Kalden 2001).  IL-10, although not an unique cytokine to Th2 cells, can also inhibit 
monocyte/macrophage function by potently suppressing the production of pro-
inflammatory cytokines, including IL-12 and TNF-α, and downregulating the surface 
expression of MHC class II, which profoundly affects the ability of APCs to activate T 
cells (Akdis & Blaser 2001;Mosser & Zhang 2008).  It has thus been suggested that 
skewing immune responses towards a Th2 phenotype could protect from or reduce 
severity of an autoimmune disease. 
 
Nevertheless, IL-4 has no known immunosuppressive effect on either naive or 
resting memory Th cells.  In fact, Th2-cytokines may participate in autoimmune 
diseases with a predominant humoral component.  Th2 cytokines are implicated in 
the development of SLE, a human autoimmune disease characterised by T cell 
abnormalities and polyclonal B cell activation, as an upregulation of Th2 cytokine 
gene expression in this disease was described (Richaud-Patin, Alcocer-Varela, & 
Llorente 1995).  In accordance with this finding, another study has reported that IL-4+ 
and IL-10+ cells are present more frequently in SLE patients than in normal subjects.  
Whereas, the proportions of IFN-γ+ and IL-2+ cells are lower in both CD4+ and CD4- 
cells in these patients.  Thus, it has been suggested that deviation of immune 
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responses towards a Th2 phenotype may have an important role in the induction of 
the polyclonal B cell activation in SLE patients (Funauchi et al. 1998). 
 
Although other cell types could trigger auto-aggressive responses independently of 
CD4+ T cells, a lack of cooperation from these cells would limit the damage to the 
host due to the reduced duration of such responses as a result.  Indeed, a sustained 
memory CD8+ T cell response and high-affinity immunoglobulin production by B cells 
are restricted without CD4+ T cell help (Castellino & Germain 2006). 
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Figure 1.3: An overview of the pro- and anti-inflammatory properties of IFN-γ. 
This figure summarises how IFN-γ can function both as an inducer and a regulator of 
immune responses. Red and green arrows represent, respectively, inhibitory and stimulatory 
actions of IFN-γ.  Please see text for more descriptions. APC, antigen-presenting cell 
(including macrophages and dendritic cells); RNI, reactive nitrogen intermediates; ROS, 
reactive oxygen species (adapted from Kelchtermans, Billiau & Matthys 2008). 
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1.17  IL-23/IL-17 axis in autoimmune and inflammatory diseases 
 
Before the discovery of Th17 subset as a distinct CD4+ effector population, it was 
considered that Th1, Th2 and B cells were the main mediators of pathology in 
autoimmunity.  Recent discoveries have forced immunologists to revisit and 
reinterpreting existing models of autoimmunity.  A more balanced role for Th1 cells 
and IFN-γ in autoimmune diseases is also emerging as autoimmune pathology has 
been demonstrated to develop in the context of either a Th17 or a Th1 effector 
response (Luger et al. 2008).  Factors that may drive the dominant effector 
phenotype could include quality/quantity of TLR and other innate signals, as well as 
the identity and diversity of cells functioning as APCs at the site of initial Ag exposure.  
Studies on IL-23p19-deficient mice and the anti-IL-23p19 antibody have revealed IL-
23, a new IL-12 family member, as the culprit in autoimmunity (Cua et al. 2003;Hue 
et al. 2006;Yen et al. 2006). 
 
IL-23 shares with IL-12 the p40 subunit - the heterodimer of IL-12 being made up of 
p40 and p35, and that of IL-23 being made up of p40 and p19 (Oppmann et al. 2000).  
Interestingly, the IL-23 receptor (IL-23R) shares with IL-12 a chain of its receptor as 
well -  the IL-12 receptor being consisted of IL-12Rβ1 and IL-12Rβ2 chains, and that 
of IL-23 being consisted of IL-12Rβ1 and IL-23R chains (Parham et al. 2002).  IL-23 
has been shown to induce the proliferation of antigen-experienced T cells, and the 
resulting IL-23R-expressing Th17 cells are highly pathogenic in causing 
autoimmunity (Langrish et al. 2005).  A not very well studied function of IL-23 is its 
role in promoting IFN-γ-producing Th1 cells.  Current published data suggest that IL-
23 affects the Th1 response, as its genetic lack or neutralisation by antibodies 
reduces not only the IL-17, but also the IFN-γ response to Ag (Luger et al. 2008).  
Therefore, IL-23 could be required to promote Th1 as well as Th17 effector 
responses.  Furthermore, IL-10 production is counter-acted by IL-23, which helps 
explain the essential role of IL-23 in mediating autoimmunity despite the fact that it is 
dispensable for Th17 differentiation (McGeachy et al. 2007).  Therefore, IL-23 is 
implicated as a crucial factor to inflammation and autoimmune diseases. 
 
As IL-17 has profound pro-inflammatory effects and induces tissue damage during 
the course of various immune-mediated diseases, Th17 cells are increasingly being 
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recognised to occupy a central position in autoimmune and inflammatory diseases.  
After stimulation by IL-23, Th17 cells produce a variety of inflammatory mediators 
such as TNF-α, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), 
CXCL1 and CCL20 (Kunz & Ibrahim 2009).  Th17 cells have been shown to be 
involved in autoimmune pathology in studies using murine models of EAE and CIA, 
two experimental autoimmune diseases that had been previously attributed to 
unchecked Th1 responses, as IL-17A-deficient mice have reduced incidence and 
severity of CIA and EAE (Koenders & van den Berg 2010).  There have been reports 
of a relationship between Th17 cells and autoimmune uveitis as well (Amadi-Obi et 
al. 2007;Chi et al. 2007).  Moreover, aberrant IL-17 expression has been described 
to be associated with human diseases including RA, IBD, SLE and psoriasis 
(Annunziato et al. 2007). 
 
Compared to Th1 disease with predominant macrophage infiltrates, Th17 cell-
mediated disease was characterised by heavy infiltrates of neutrophils (Hu & 
Ivashkiv 2009).  It is now widely believed that the interactions between 
environmental exposures and genetic predisposition contribute to the onset of 
autoimmune disease.  In genetically susceptible individuals, disease may develop 
after contact with environmental factors.  Recently, with the discovery of the AHR 
expression in Th17 cells, a link between Th17 cells and the environmental theory of 
autoimmunity has been suggested.  AHR is a transcription factor involved in direct 
recognition of aromatic hydrocarbons found in cigarette smokes, grilled food and 
industrial pollutants.  Interestingly, AHR was also found in Treg, albeit at a much 
lower level than Th17 cells (Veldhoen et al. 2008a). 
 
Autoreactive B and T cells are eliminated by apoptosis.  As a result of defects in 
apoptotic signalling, autoimmune diseases can develop from persistence of self-
reactive lymphocytes.  IL-17, alone and especially in synergy with the B cell-
activating factor (BAFF), was shown to protect B cells from apoptosis and in so doing, 
the proliferation, survival, and differentiation of B cells into plasma cells were 
promoted (Doreau et al. 2009).  Like Th1 and Th2 cells, Th17 cells were found to 
modulate B cell function and promote production of IgM, IgG and IgA, but not IgE 
(Annunziato et al. 2007).  Whether the ability of Th17 cells to modify B cell function 
directly contributes to autoimmune pathologies is to be further clarified.  While most 
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studies on IL-17 production focused on CD4+ αβ T cells, γδ T cells have also been 
shown to be a potent source of IL-17.  Studies have reported that many γδ T cells 
already exist as effector memory cells, ready to mount strong IL-17 responses 
quickly.(Peng et al. 2008;Roark et al. 2008).  In CIA, a mouse model that shares 
many hallmarks with human rheumatoid arthritis, the Vγ4Vδ4+ subset of γδ T cells 
was shown to expand and produce IL-17.  Depletion of these γδ T cells resulted in 
less severe disease (Roark et al. 2008).  All these findings make a strong case for a 
role of IL-23/IL-17 axis in human autoimmune diseases. 
 
 
1.18  Regulatory T cells and autoimmune disease 
 
Treg cells serve to restrain overactivation of effector T cells, control the reactivity of 
self-aggressive T cells not eliminated in the thymus and maintain the immune system 
in homeostatic balance.  Immune responses against pathogens must be regulated to 
prevent bystander immune pathology, and these mechanisms of regulation may also 
promote remission from autoimmune inflammatory response and prevent excessive 
tissue damage (Allan et al. 2008b). 
 
The importance of T cell regulation is highlighted by autoimmunity and massive 
immunopathology that occur in disease states in human and mouse.  In scurfy 
mutant mice, a frameshift mutation in Foxp3 transmitted by X-lined inheritance 
results in production of non-functional product and give rise to a fatal syndrome of 
extensive immune activation, oversecretion of cytokines and multi-organ 
inflammatory infiltration (Brunkow et al. 2001).  In humans, IPEX is resulted from 
mutations in Foxp3 gene located on chromosome Xp11.23 and the rare disease is 
usually fatal due to poor efficacy of immunosuppressive treatment.  Its reported 
manifestations include refractory and life-threatening diarrhoea, type1 diabetes, 
hypothyroidism, haemolytic anaemia, thrombocytopaenia and eczema (Bacchetta et 
al. 2006). 
 
To address the question of whether immune suppression by Treg cells is impaired in 
the setting of human autoimmune disease, it is crucial to understand the potential 
means by which a defect may arise.  As shown in Fig 1.4, defects in the number and 
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function of Treg cells, as well as a resistance of effector T cells to Treg cell-mediated 
suppression, could each contribute to unsuccessful T cell regulation. 
 
 
 
 
 
 
Figure 1.4: Causes of impaired Treg cell-mediated suppression in autoimmunity. 
Autoimmunity can result from a loss of regulation of autoreactive T cells.  Failures of Treg-
mediated regulation include: inadequate numbers of Treg cells; defects in Treg cell function; 
and resistance of pathogenic effector T cells to suppression by Treg cells owing to factors 
that are intrinsic to the effector cells or factors that are present in the inflammatory milieu and 
that support effector T cell resistance (adapted from Buckner J 2010).  
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The number of Treg cells found in individuals with autoimmune disease is dictated by 
Treg cell development, proliferation, and survival in the periphery and homing to the 
site of inflammation.  Genetic factors are likely to have the strongest impact on 
thymic output of Treg cells.  On the other hand, maintenance of Treg cells in the 
periphery is a dynamic process, influenced in part by conditions that promote Treg 
cell induction in the periphery and assist their proliferation and survival.  Factors that 
favour the thymic development, peripheral growth and persistence of Treg cells, 
including CD28, TGF-β, dendritic cells and the common cytokine receptor γ-chain 
cytokines (IL-2, IL-4, IL-7 and IL-15), have also been shown to have an effect on 
Foxp3 expression (Buckner 2010). 
 
Treg cell dysfunction in autoimmune disease may result from a defect in one of the 
many mechanisms through which Treg cells function.  This could happen through 
diminished expression of cell surface molecules that are known to be involved in 
contact‑dependent suppression, such as CTLA-4, CD39, lymphocyte activation gene 
3 (LAG3), granzyme A and FAS or as a result of a failure to produce soluble factors, 
including TGF-β, IL‑10 and IL‑35, that are involved in aspects of suppression.  
Underlying genetic factors may have an impact on these mechanisms.  In addition, 
the composition of the local milieu, such as the types of APCs and cytokines 
(including TNF, IL‑4, IL‑6, IL‑12, IL‑7, IL‑15 and IL‑21), can call influence Treg cell 
function (Buckner 2010). 
 
Either reduced frequency or impaired function of CD4+CD25high Treg cells has been 
reported in patients with a number of autoimmune diseases.  In SLE patients, a 
significant drop in Treg cell numbers in untreated patients and a reduction in Foxp3 
expression in patients with or without treatment were reported.  Impaired Treg 
function in SLE patients was also revealed compared to healthy donors (Lyssuk et al. 
2007).  Similarly, Treg cells from peripheral blood of patients with MS showed 
defects in Treg function and clonal expansion.  A decrease in Foxp3 levels in the 
Tregs were detected in MS patients as well and this correlated with deterioration of 
Treg function (Huan et al. 2005). 
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CD4+CD25high Treg cells derived from active RA patients, although still anergic, 
displayed compromised function as they were not able to inhibit pro-inflammatory 
cytokine secretion from effector T cells and monocytes, or convey a suppressive 
phenotype to effector CD4+CD25- T cells (Ehrenstein et al. 2004).  Interestingly, 
higher frequencies of Treg cells were found in synovial fluid than blood in patients 
and these synovial cells displayed an enhanced suppressive capacity compared with 
cells from blood (Lawson et al. 2006;van Amelsfort et al. 2004).  Diminished 
suppressor activity in both blood and target tissue Treg cells was demonstrated in 
psoriasis (Sugiyama et al. 2005).  Moreover, decreased frequency and diminished 
function of peripheral blood CD4+CD25high Treg cells were reported to be associated 
with active uveitis seen in Vogt-Koyanagi-Harada (VKH) syndrome (Chen et al. 
2008). 
 
Multiple mechanisms by which effector T cells resist Treg cells have been proposed.  
Cell‑intrinsic resistance to suppression has been reported to occur in Th17 cells 
(Annunziato et al. 2007; Crome et al. 2009).  The cytokines IL-2, IL-4, IL-7 and IL-15 
support the proliferation of effector T cells in the presence of Treg cells, indicating 
that despite the favourable roles of these cytokines in Treg cell homeostasis, the 
presence of these cytokines in the short term allows effector T cells to bypass 
suppression by Treg cells (Yates et al. 2007).  In addition, it has been suggested that 
Treg cells may not be able to suppress strongly activated responder T cells (Tresp) 
in highly inflammatory environments (Costantino, Baecher-Allan, & Hafler 2008).  
This has important implications in patients with autoimmune disease as autoreactive 
T cells are readily activated in these patients compared to healthy individuals 
(Baecher-Allan & Hafler 2006;Scholz et al. 1998).  The report of the loss of IL-6 
during autoimmune responses and the resultant significant increase in numbers of 
Foxp3 expressing regulatory T cells has given further supports to the theory (Korn et 
al. 2007). 
 
Although adoptive transfer of Tregs has been shown to be effective in preventing or 
even reversing disease in animal models, there have been no clinical studies of 
adoptive immunotherapy with Tregs in human autoimmune diseases (Brusko, 
Putnam, & Bluestone 2008).  An alternative to adoptive transfer of Tregs is the 
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promotion of de novo Treg development in vivo.  Glatiramer acetate (GA), a drug 
commonly used in MS patients, has been shown to induce generation of Foxp3+ 
Treg cells.  These Foxp3+ Tregs induced by GA either in vitro or in vivo show 
suppressive function, and GA treatment is correlated with disease improvement in 
patients with MS (Hong et al. 2005).  Another common treatment used in MS 
patients is IFN-β therapy, which, in relapsing-remitting MS patients can also lead to 
an increase in the percentage of functional Foxp3+ Tregs in the peripheral blood (de 
Andres et al. 2007).  Type 1 diabetes is a hallmark manifestation of IPEX syndrome.  
The use of rapamycin can promote expansion of functional CD4+CD25+Foxp3+ Tregs 
in type 1 diabetic patients, in whom an intrinsic defect in CD4+CD25+ Tregs has been 
reported (Monti et al. 2008). 
 
 
1.19  Behcet’s disease 
 
   1.19.1 Overview 
 
The first description of Behcet’s disease was attributed to the Turkish dermatologist 
Hulusi Behçet in 1937 who described the classical signs of the disease: oral ulcers, 
genital ulcers and uveitis (Bonfioli & Orefice 2005).  However, it was originally 
described by Hippocrates 2500 years ago.  BD is a chronic, multisystem immune-
mediated disorder that is heterogeneous in onset and has variable organ 
involvement. The underlying pathological process of BD is a systemic, immune-
mediated occlusive vasculitis involving small and large arteries and veins (George et 
al. 1997;Kalayciyan & Zouboulis 2007).  It is primarily characterised by recurrent oral 
aphthous ulcers, genital ulcers, skin lesions, and uveitis (Sakane et al. 1999).  In 
addition, BD patients may suffer from non-deforming arthritis, gastrointestinal tract 
lesions, and vascular and central nervous system problems in severe cases.  Eye 
involvement occurs in more than 50% of the patients with BD and is the presenting 
symptoms in 20% of cases (Evereklioglu 2005). 
 
The clinical course of BD is characterised by exacerbation and remission of 
unpredictable duration and frequency (Evereklioglu 2005).  The disease can result in 
considerable morbidity and increased mortality.  The prognosis of ocular involvement 
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has always been considered to be poor and it is especially true if the posterior 
segment is affected.  Despite vigorous treatment, development of recurrent, sight-
threatening ocular disease is still unpredictable, and blindness may ensue in 25% of 
BD patients (Houman & Hamzaoui 2006).  This, along with neurological involvement, 
represents one of the most devastating and, for the patient, most worrying 
manifestations of BD.  Thrombosis of the major vessels and gastrointestinal 
perforation also lead to poor prognosis (Evereklioglu 2005).  Overall, more disease 
severity is linked to male patients of younger age (Zakka et al. 2009). 
 
There are no laboratory findings specific for BD.  There may be an increase in 
inflammatory parameters, such as C-reactive protein, erythrocyte sedimentation rate, 
peripheral leukocytes and platelet counts during the active phase of the disease 
(Evereklioglu 2005).  The diagnosis of BD is based on clinical findings.  Two 
separate diagnostic systems currently exist.  One is by the International Study Group 
for Behcet’s disease in 1990 (Table 1.2) and the other is by Behcet’s Research 
Committee of Japan in 1974 (Table 1.3). 
 
 
Table 1.2: International Study Group Criteria 
(International Study Group for Behcet's Disease 1990) 
     Recurrent oral ulcers: 
           Minor aphthous, major aphthous or herpetiform ulceration observed by a  
              physician or reported reliably by the patient that is recurrent at least 3 times  
              in one 12-month period 
 
     Plus 2 of the following 
1. Recurrent genital ulcers 
   Aphthous or scarring ulceration, especially males, observed by a physician  
      or reliably reported by the patient 
2. Eye lesions 
         Anterior/posterior uveitis, cells in vitreous on slit lamp, or retinal vasculitis  
            observed by ophthalmologists 
3. Skin lesions 
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   Erythema nodosum-like lesions observed by a physician or reliably reported  
      by the patient; pseudo-folliculitis, papulopustular or acneiform nodules  
      observed by a physician in post-adolescent patients not receiving  
      corticosteroids. 
4. Positive pathergy test 
   Read by a physician at 24-48h after a prick to the forearm by a sterile  
      needle (the development of an aseptic non-specific hyperreactivity, which  
      varies from an indurated erythema to pustular formation at the prick site) 
 
 
Table 1.3: Revised diagnostic criteria proposed by the Behcet’s Disease 
Research Committee of Japan in 2003 
(Kurokawa & Suzuki 2004) 
Main Points: 
 Main symptoms: 
              Recurrent aphthous ulcers on oral mucosa 
              Skin lesions (erythema nodosum, subcutaneous thrombophlebitis, follicular  
                 papules, acneiform papules, skin hypersensitivity) 
              Ocular lesions (anterior and/or posterior uveitis) 
   Genital ulcers 
 Additional symptoms: 
              Arthritis without deformity or sclerosis 
              Epididymitis 
              Gastrointestinal lesion (Ileocecal ulceration) 
              Vascular lesions 
              Central nervous system lesions 
 Criteria for diagnosis of disease types: 
              Complete type: 
                 Four main symptoms 
              Incomplete type 
                 Three of the main symptoms, or two main symptoms and two additional  
                    symptoms 
                 Typical ocular lesion and another main symptom, or two additional  
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                    symptoms 
              BD suspected 
                 Some main symptoms appear, but the case does not meet the criteria for  
                    the incomplete type 
                 Typical additional symptom is recurrent or becomes more severe 
              Special lesions 
                 Gastrointestinal lesions (abdominal pain and occult blood) 
                 Vascular lesions (vasculitis of aorta, artery, large or small veins) 
                 Neuronal lesions (headache, paresis, lesions of brain and spinal cord,  
                    mental symptoms) 
 Laboratory data 
              Negative or positive pathergy test 
              Negative or positive prick test for vaccine for streptococci 
              Inflammatory responses (increase of erythrocyte sedimentation rate, C- 
                 reactive protein positive, neutrophilia, increase in complement activity) 
              Positive for HLA-B51 
              Pathological findings 
 
 
   1.19.2 Epidemiology 
 
BD is most commonly seen in those countries that extend from the Mediterranean to 
the Far East along the ancient trading route known as the ‘silk road’.  It has the 
highest incidence in the Middle East, the Mediterranean basin and the Far East 
regions, but it is rare in North America and Western Europe.  The prevalence is 
10/100,000 in Japan and 8–38/100,000 in Turkey.  However, there are only 
approximately 2000 patients estimated to be present in the UK (Haskard 2006).  The 
usual onset of the disease is in the third decade.  Although patients between 25 and 
35 years old were the most common, BD have been reported in all ages (Zakka, et al. 
2009).  The complete type of Behcet’s disease has been suggested to be more 
common in males, whereas there is a more equal distribution between sexes for the 
incomplete type (Zakka et al. 2009). 
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   1.19.3 Mucocutaneous manifestations 
 
Almost all patients present with recurrent aphthous ulcerations of the oral mucosa.  
This is frequently the earliest and universal sign of the disease and can precede the 
other manifestations of the syndrome by many years.  Minor aphthous ulcers (<10 
mm in diameter) are the most common type (85%); major or herpetiform ulcers are 
less frequent.  Although aphthae are usually multiple and occur more frequently in 
BD, they are indistinguishable from those of recurrent oral ulcers due to other causes 
(Yurdakul & Yazici 2008). 
 
Genital ulcers are the second most commonly observed onset manifestation.  They 
are larger and deeper than mouth lesions and have a predilection for the scrotum in 
the male, or the vulva in the female.  Furthermore, urethritis or dysuria is not a 
feature of BD, unlike Reiter’s syndrome and venereal disease.  As genital ulcers are 
usually deep and painful, they affect the quality of life.  The ulcers usually heal in 2-4 
weeks; large ulcers frequently leave a scar whereas small ulcers and those on the 
minor labia heal without leaving a mark (Mat et al. 2006). 
 
Various kinds of skin lesion occur in about 80% of patients with BD during the course 
of the disease.  Nodular lesions are observed in 50% of patients, usually confined to 
the lower limbs in the form of either erythema nodosum-like lesions or superficial 
thrombophlebitis.  Acne-like lesions or papulo-pustular lesions can also develop and 
these are mainly of cosmetic concern.  These lesions are seen frequently not only at 
the usual acne sites of the face, upper chest and upper back, but also at uncommon 
sites such as the legs and arms.  They are not considered specific for BD (Yurdakul 
& Yazici 2008). 
 
The pathergy reaction is the excessive subacute inflammatory reaction of the skin to 
non-specific trauma such as a needle prick.  In a positive reaction, a papule or 
pustule typically forms in 24-48 hours after insertion of a needle into the forearm skin 
- although whether or not pathergy occurs with formal testing depends on the size of 
needle and the number of sites tested.  The formal pathergy test involves the 
introduction of a 20-gauge needle 5mm obliquely into the patient’s flexor aspect of 
the forearm skin under sterile conditions without injection of saline.  Pathergy 
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positivity is fairly specific to BD patients; however, its sensitivity varies in different 
countries.  Whereas 60-70% of patients in Turkey and Japan have a positive 
pathergy test, it is infrequently observed in patients with BD from Northern Europe 
and North America (Yurdakul & Yazici 2008).  In the UK, it has been seen in less 
than 10% of the ‘definite’ and ‘probable’ patient groups (Pickering & Haskard 2000).  
An alternative to pathergy test is to inject monosodium urate crystals into the forearm 
skin and observe the inflammatory response, which tends to be significantly 
prolonged in patients with BD (Pickering & Haskard 2000). 
 
 
   1.19.4 Ocular manifestations 
 
Eye disease is seen in half of all patients but is more frequent and more severe 
among the male.  It typically occurs within 3 years of disease onset.  In general, 
initial exacerbations tend to be more anterior and unilateral, whereas subsequent 
attacks tend to involve the vitreous and posterior segment of the eye, becoming 
bilateral (Evereklioglu 2005).  Anterior uveitis with hypopyon, in which the 
inflammatory exudates forms a visible layer of cells in the anterior chamber, is a 
characteristic sign of ocular BD but is only observed in one-third of patients.  
Common complications of the recurrent anterior segment involvement include 
anterior and posterior synechiae, which may lead to secondary glaucoma and 
cataract formation.  Conjunctivitis, sicca syndrome, episcleritis, scleritis, keratitis with 
or without corneal ulcerations and lid lesions present rarely in BD patients (Deuter et 
al. 2008). 
 
The most common and universal posterior segment findings are persistent vitritis 
and retinal perivasculitis that usually involve the veins (periphlebitis) and less 
frequently the arteries (periarteritis).  Retinitis is another common finding.  During the 
active phase of the disease, vascular leakage with diffuse retinal or optic disc 
oedema, venous engorgement, and intraretinal haemorrhages may be present 
(Evereklioglu 2005).  Recurrent inflammation in the posterior eye segment may result 
in retinal oedema, especially macular oedema, and retinal atrophy with vascular 
occlusion, the main cause of loss of useful vision (Deuter et al. 2008).  In advanced 
cases, periphlebitis may also lead to gliotic inflammatory vessel sheathing, macular 
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degeneration with pigment epithelial changes, scarring and epiretinal membrane 
formation, optic disc swelling, neovascularisation of the iris, retina and/or optic disc 
and tractional retinal detachment (Evereklioglu 2005).  Importantly, severity and 
number of repeated inflammatory exacerbations of the posterior segment determine 
the extent of permanent ocular structural changes and, therefore, the resultant rate 
of irreversible visual loss. 
 
 
   1.19.5 Musculoskeletal manifestations 
 
Joint disease is observed in around 50% of patients in the form of synovitis, arthritis, 
and/or arthralgia.  It is mostly oligoarticular and asymmetrical.  Joint disease resolves 
in a few weeks and it seldom results in deformity and radiological erosions.  Chronic 
arthritis and osteonecrosis are seen occasionally.  Arthritis in BD affects most 
commonly the medium and large joints.  Knees are most frequently involved, 
followed in frequency by ankles, wrists, and elbows.  Involvement of the spine and 
sacro-iliac joints is uncommon, and back pain is quite rare.  Also, myositis can be 
seen in local or generalised forms (Yurdakul & Yazici 2008). 
 
 
   1.19.6 Cardiovascular manifestations 
 
Vascular involvement can involve both the venous and arterial sides and is more 
common in men than in women.  One-third of patients have thrombophlebitis of 
either the deep or the superficial veins, usually of the lower extremities.  It is 
generally migratory in nature, appearing simultaneously at several locations (Yates & 
Michelson 2006).  Importantly, BD can lead to thrombotic occlusion of the venous 
system of the upper limbs, the inferior and superior vena cava, the dural sinuses and 
the hepatic (Budd-Chiari syndrome) and renal veins (Pickering & Haskard 2000).  
Despite the high frequency of thrombophlebitis, thromboembolism is rare, most 
probably due to adherence of thrombi to the diseased veins. 
 
Arterial disease is less frequent but is a serious cause of morbidity and mortality, 
especially when it involves the pulmonary arteries.  Arterial involvement predisposes 
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to aneurysm formation or less commonly arterial thrombosis and it can involve the 
entire arterial tree.  The most frequently affected vessels, in decreasing order, are 
the pulmonary, femoral, popliteal, subclavian and carotid arteries (Al Otaibi, Porter, & 
Poate 2005).  Thrombosis has been suggested to relate to vascular inflammation 
and the resulting endothelial dysfunction (Deuter et al. 2008). 
 
Overall, cardiac involvement is rare.  However, sporadic cases have been reported 
with pericarditis, valvular lesions, myocarditis, intracardiac thrombosis, 
endomyocardial fibrosis, coronary artery involvement and ventricular aneurysms 
(Marshall 2004).  Available data currently show that atherosclerosis is probably not 
increased in BD (Yurdakul & Yazici 2008). 
 
 
   1.19.7 Central nervous system manifestations 
 
The neurological complications of BD predominantly involve the CNS, although, 
rarely, there may be involvement of muscle and peripheral nerves (Al Otaibi, Porter, 
& Poate 2005).  Headaches are common and often migrainous in nature (Pickering & 
Haskard 2000).  CNS involvement occurs in 5-10% of patients and is one of the most 
serious manifestations of BD, causing both increased morbidity and mortality 
(Sakane et al. 1999).  The natural history is extremely variable and characterised by 
fluctuations that may mimic multiple sclerosis.  The outcome varies from full recovery 
to a slowly progressive, intermittent course resulting in paralysis and death.  
Pathologic examination can show softening of both white and gray matter with foci of 
demyelination in the brain and nerves (Yates & Michelson 2006). 
 
CNS disease of BD can be divided into two categories, namely, parenchymal and 
non-parenchymal (vascular).  Most patients (80%) have parenchymal brain 
involvement, which mainly affects the brainstem, manifested by pyramidal, followed 
by cerebellar and sensory symptoms and signs, sphincter disturbances and 
behavioural changes.  Non-parenchymal disease (20%) takes the form of intracranial 
hypertension due to dural sinus thrombosis manifested by headaches and 
papilloedema. Simultaneous involvement of the dural sinuses and brain parenchyma 
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is unusual.  Dural sinus thrombosis has a relatively benign prognosis in comparison 
to parenchymal involvement (Yurdakul & Yazici 2008). 
 
Psychological disturbances can be present at some point in at least half of BD 
patients.  Changes include memory impairment, dementia, irritability, hallucination, 
delusions, anxiety, depression, and insomnia.  These disturbances sometimes lead 
to suicide attempts (Yates & Michelson 2006). 
 
 
   1.19.8 Gastrointestinal manifestations 
 
The involvement of the gastrointestinal tract is very variable in different populations 
and can be present in up to 30% of BD patients.  BD shares many of the features of 
the inflammatory bowel disease and differentiation is difficult (Deuter et al. 2008).  
The symptoms include anorexia, vomiting, dyspepsia, diarrhoea and abdominal pain.  
Mucosal ulcerations can occur at any point along the gastrointestinal tract and they 
are most commonly seen in the ileum, followed by the caecum and other parts of the 
colon.  The ileocaecal ulcers have a distinct tendency to perforate (Yurdakul & Yazici 
2008). 
 
 
   1.19.9 Renal manifestations 
 
Several renal disorders have been associated with BD and can be divided into five 
groups, namely, (1) glomerulonephritis, (2) amyloidosis, (3) renal vascular 
involvement, (4) interstitial nephritis, and (5) other problems such as complications of 
drug therapy or genitor-urinary system abnormalities (Akpolat et al. 2002). 
 
 
1.20  Aetiopathogenesis of Behcet’s disease 
 
Despite research in the last decades, the aetiology and pathogenesis of BD remains 
unclear.  A complex genetic background leading to a pro-inflammatory, innate 
immune system-derived activation, perpetuated by the adaptive immune response of 
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T cells against infectious- and/or auto-antigens has been suggested in BD 
pathogenesis (Direskeneli 2006). 
 
 
1.20.1 Autoimmune features of Behcet’s disease 
 
BD does not present like a classical autoimmune disease with anti-nuclear antibody 
(ANA) positivity, female dominance or association with other autoimmune diseases 
(Yazici 1997).  In contrast to most classical autoimmune disorders which have an 
MHC class II association, a class I antigen, HLA-B51, is associated with BD 
(Direskeneli 2001).  However, there are features that suggest BD as being 
‘autoimmune’.  A general B cell activation and autoantibodies against cell surface 
antigens such as anti-endothelial cell (AECA) and anti-lymphocyte antibodies have 
been demonstrated (Direskeneli et al. 1995;Eksioglu-Demiralp et al. 1999b).  
Interestingly, PBMC from BD patients with active disease were shown to be highly 
sensitive to spontaneous and Fas-mediated AICD after PHA activation, which 
indicate chronic in vivo activation (Frassanito et al. 1999). 
 
 
   1.20.2 Genetic background 
 
Among various genetic markers, the association of BD with HLA-B5 and its subclass 
B51 allele on chromosome 6p21, provides the strongest evidence supporting the 
involvement of genetic factors in BD pathogenesis in high prevalence countries.  The 
HLA-B51 association is most pronounced in patients from the Middle and the Far 
East (Verity et al. 1999).  Of these, HLA-B5101 and HLA-B5108 are particularly 
associated with increased risk of developing BD (Deuter et al. 2008).  Recently, the 
first genome-wide association study of BD results clearly showed a dual, 
independent contribution of two HLA alleles to BD's pathogenesis: HLA-B5101 and 
HLA-A26 (Meguro et al. 2010).  Additionally, HLA-B5701 has been identified to be 
associated with disease susceptibility in Caucasian patients in the United Kingdom, 
carrying a relative risk of disease equivalent to that of HLA-B51 (Ahmad et al. 2003).  
However, the direct role of HLA-B5 in BD development remains unclear. 
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Another important finding of the recent genome-wide association studies was 
discovery of the IL-10 gene association with BD.  One study found two single 
nucleotide polymorphisms (rs1800871 and rs1800872) in the promoter region of the 
IL-10 gene giving the strongest association result in Japanese patients (Mizuki et al. 
2010).  Another study identified an intronic polymorphism in a high linkage 
disequilibrium block of the IL-10 gene region (rs1518111).  This variation was 
associated with lower mRNA epression as well as decreased production of IL-10 
from mononuclear cells/monocytes following stimulation with LPS or muramyl 
dipeptide+PAM3Cys, respectively (Remmers et al. 2010).  The association between 
IL-10 polymorphism and BD helps at least partially explaining the 
dysregulated/exaggerated inflammatory response observed in BD patients as IL-10 
is an essential cytokine in the regulation of both innate and adaptive immune 
responses. 
 
Another shared genetic association in Turkish and Japanese BD patients was 
located within an intergenic region between the IL-23R and IL-12RB2 genes, which 
was demonstrated to be in linkage disequilibrium block of the IL-23R gene (Mizuki et 
al. 2010; Remmers et al. 2010).  IL-23 has been shown to stimulate Th17 cell 
proliferation and increase the production of inflammatory cytokines including IL-1, IL-
6, IL-17 and TNF-α (Langrish et al. 2005).  On the other hand, IL-12 plays a key role 
in Th1 responses, T-cell and NK-cell cytotoxicity, and IFN-γ production by T cells 
and NK cells (Annunziato & Romagnani 2009). 
 
Gene in linkage disequilibrium with HLA-B51, such as MHC class I chain-related 
gene A (MICA), has been indicated to contribute to pathogenesis of BD (Mizuki et al. 
2000).  The link between BD and TNF-α gene, which is closely linked to the HLA-
B51 gene, has also been investigated recently and TNF-α-1031C allele was reported 
to be associated with susceptibility to BD (Akman et al. 2008).  Moreover, IL-1, IL-12, 
IFN-γ and TGF-β1 gene polymorphisms were all found to be increased in BD 
patients and these could contribute to host susceptibility to BD (Alayli et al. 
2007;Coskun et al. 2005;Dilek et al. 2009). 
 
Similar to other complex disorders, BD is unlikely to be a single-gene disease.  
Genome-wide association studies and other approaches would help to elucidate the 
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inflammatory pathways further as well as yet unknown networks between the 
associated genes and/or pathways.  The demonstration of new loci of susceptibility 
to BD is of great significance in the pathogenesis of the disease, detecting patients 
negative to HLA-B5.  Each disease associated functional polymorphism may have a 
distinct role within the context of other associated genes, all interacting in a network 
(Gul 2011).  Their interaction with yet uncertain environmental factors may contribute 
to the complex nature of the disease. 
 
 
   1.20.3 Infectious agents 
 
Various microorganisms such as streptococci and herpes simplex virus have been 
implicated in the aetiopathogenesis of BD (Evereklioglu 2005).  No reliable animal 
model, however, has been described for BD and the model with the highest clinical 
resemblance to the human disease is that induced by inoculation with herpes 
simplex virus in which animals show several symptoms similar to BD (Deuter et al. 
2008). 
 
Due to an immune hyper-reactivity in patients, a role of streptococci in BD has been 
suggested.  KTH-1, an extract of S. sanguis SSH-83 and encoded by BES-1 gene, 
was shown to promote IL-6 and IFN-γ secretion by peripheral blood T cells in BD 
patients (Hirohata, Oka, & Mizushima 1992) and the immunogenic antigen was 
observed to upregulate γδ T cells from patients with BD, which secrete the pro-
inflammatory mediators IL-6, IL-8 and TNF-α (Mochizuki et al. 1994).  The similarities 
of the KTH-1 protein amino acid sequence encoded by BES-1 gene with human 
intraocular peptide Brn-3b have also made this protein a candidate for auto-reactive 
response in BD (Yoshikawa et al. 1998).  In addition to streptococcal antigens, 
Escherichia coli and Staphylococcus aureus have been reported to activate 
lymphocytes from BD patients to release increased amount of IL-6 and IFN-γ 
(Hirohata & Hashimoto 1998).  Therefore, these bacteria seem to participate and, at 
least, act as triggers during the course of BD. 
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Furthermore, serum titres of antibodies against Saccharomyces cerevisiae (ASCA) 
has been found to be increased in BD patients with gastrointestinal involvement 
(Fresko et al. 2005), although the clinical relevance of this finding is uncertain. 
 
 
   1.20.4 Heat shock proteins 
 
HSPs are highly conserved molecules induced by variable stress factors.  The 
presence of molecular mimicry and possible cross-reactivity between microbial and 
human HSPs have been implicated as the pathogenetic mechanism in BD 
(Direskeneli 2001).  Lymphoproliferative responses to the 65 kDa mycobacterial and 
60 kDa human HSP derived peptides were shown to be significantly higher in 
patients with BD compared to healthy controls.  Also, stimulation of peripheral blood 
lymphocytes in patients with BD by specific epitopes of human HSP60, especially 
peptide 336-351, was found to result in excess amounts of Th1 cytokine production 
(Direskeneli et al. 2000;Kaneko et al. 1997). 
 
Moreover, it was observed that the expression of HSP60 in mucocutaneous lesions 
was increased in patients with BD (Ergun et al. 2001).  For intestinal BD, HSP60 was 
expressed in peripheral blood lymphocytes and intestinal tissues of BD in the active 
state of the disease (Imamura et al. 2005).  Also, dominant infiltration of TLR-2 and 
TLR-4 expressing cells was recently revealed in the intestinal lesions of BD.  The 
TLR-2 expressing cells produced IL-12 and could contribute to the induction of Th1-
dominant immune responses in intestinal BD.  As it has been shown that HSP60/65 
is a ligand for TLR-2 and TLR-4, TLR/HSP60 interaction may be important for the 
pathogenesis and progression of intestinal inflammation of BD (Nara et al. 2008). 
 
 
   1.20.5 BD-related autoantigens 
 
A well-recognised immunological abnormality in BD is the hyperresponsiveness of T 
cells to a variety of antigens.  Attempts to identify the putative antigens have 
produced candidates such as retinal soluble antigen (S-Ag), a potent uveitic 
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autoantigen which is localised in the photoreceptor area of the retina.  S-Ag specific 
T cells, despite being at a low frequency, were found in patients with active disease.  
In response to S-Ag challenge, PBMCs from BD patients with active uveitis produced 
IFN-γ and TNF-α but not IL-2, IL-4, or IL-17 (Zhao et al. 2008).  In other studies, 
cellular proliferative response to S-Ag peptides in BD patients were described (de 
Smet et al. 2001;Yamamoto et al. 1993).  This finding is similar to the sensitisation 
against HSPs. 
 
Besides S-Ag, immune responses to interphotoreceptor retinoid binding protein 
(IRBP), another retina-specific autoantigen, has been suggested to be involved in 
the pathogenesis of human uveitis, including BD (Takeuchi et al. 2010).  It was 
reported that IRBP-stimulated IFN-γ and IL-17 production by PBMCs was 
significantly higher in BD patients than in healthy controls, indicating Th1 and Th17 
polarisation.  In particular, IFN-γ produced by IRBP-specific T cells was significantly 
increased in BD patients during the active phase of uveitis. 
 
A significant increase in lymphoproliferative response to α-tropomyosin as well as 
autoantibodies to tropomyosin have been observed in BD patients with posterior 
uveitis (Mahesh et al. 2005).  Also, α-enolase protein has been found to be the target 
protein of serum anti-endothelial cell antibodies (AECA) in BD patients (Lee et al. 
2003).  Approximately 20% of the BD patients with uveitis has been identified to be 
positive for anti-selenium-binding protein antibody and these patients have more 
frequent ocular inflammation (Okunuki et al. 2007).  Moreover, detection of serum 
kinectin autoantibody has been demonstrated in Chinese patients with BD (Lu et al. 
2005). 
 
 
   1.20.6 Immunological abnormalities 
 
In an early study, it was shown that ocular exacerbations were associated with a 
corresponding reduction in serum IgA immune complexes and an elevation in 
concentration of IgM and IgG immune complexes (Levinsky, Paganelli, & Lehner 
1979).  Although the number of total B lymphocytes was found to be normal, they 
were functionally activated during the course of BD and expressed CD13, CD33 and 
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CD80 with an increased immunoglobulin secretion.  An expansion of memory B cell 
subsets was also observed (Eksioglu-Demiralp et al. 1999). 
 
Additionally, T lymphocyte has been implicated to be the predominant cell type in the 
immunopathogenesis of BD (Zakka et al. 2009).  In patients with active disease, a 
significant increase of peripheral Th1 cells was detected compared with those in 
remission and healthy controls (Frassanito et al. 1999).  The finding of upregulated 
T-bet expression in active BD patients further substantiated the preferential skewing 
of the immune response toward the Th1 pathway (Li et al. 2003).  Surprisingly, the 
serum levels of IFN-γ in patients with BD were demonstrated to be significantly 
higher than in normal controls but the titre of IFN-γ correlated inversely with disease 
activity in an early study (Ohno et al. 1982). 
 
Various pro-inflammatory cytokines, including IL-1, IL-6, IL-8, IL-18, TNF-α, and 
soluble IL-2 receptor (sIL-2R), have been reported to be elevated in the sera of BD 
patients (Evereklioglu et al. 2002;Oztas et al. 2005;Yosipovitch et al. 1995).  
Although many immunologically active cells and neutrophils may produce these 
cytokines following stimulation, one of the major sources is monocytes and may play 
a part in the pathogenesis of chronic inflammation in this disorder.  Although NK cell 
activity in the peripheral blood of patients in the clinically active stage of Behcet's 
disease is significantly lower than that of patients in the inactive stage and normal 
controls, the actual number of NK cells is markedly increased in the peripheral blood 
of patients with active disease (Kaneko et al. 1985).  In accordance with this early 
study, an abnormal killer inhibitory receptor (KIR) expression on NK cells of BD 
patients has recently been reported (Takeno et al. 2004).  On the other hand, 
neutrophils are hyperactive in BD, with increased chemotaxis, phagocytosis, 
superoxide production and myeloperoxidase expression and produce several 
cytokines such as IL-12 (Verity et al. 2003;Zierhut et al. 2003). 
 
 
   1.20.7 γδ T cells 
 
Besides, various studies have reported the presence of elevated γδ T cells in BD 
patients.  An increased number of Vγ9Vδ2 subsets of T cells was demonstrated in 
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the intraocular fluid of BD patients with uveitis (Verjans et al. 2002).  Recently, the 
diversity of γδ T cells of BD patients in the peripheral blood and in oral mucosa was 
investigated and polyclonal activation was revealed (Freysdottir et al. 2006).  Studies 
also demonstrated a specific increase in CD8 expression by γδ T cells, and in 
absolute numbers of CD8+ γδ T cells.  Most of these CD8+ γδ T cells were revealed 
to be high IFN-γ, but poor IL-2, IL-4, IL-10, and TGF-β producing cells (Clemente et 
al. 2010;Freysdottir, Lau, & Fortune 1999). 
 
Notably, γδ T cells from inflammatory sites were reported to exhibit a higher cytotoxic 
activity (Hamzaoui et al. 1994).  In the presence of bacterial supernatants, Vδ2+ cells 
from BD patients were demonstrated to expand considerably more than normal after 
a short time in culture (Bank, Duvdevani, & Livneh 2003).  Thus, it was suggested 
that γδ T cells in BD patients had previously been primed to respond to bacterial 
antigens, and a second encounter with bacterial products or cross-reactive 
autoantigens could lead to inappropriate activation of these cells and result in an 
autoaggressive attack against host cells. 
 
 
   1.20.8 Immunohistopathology of Behcet’s disease lesions 
 
The pathology of BD varies according to the site of lesions.  The hallmark of BD 
features perivascular lymphocytic and monocytic cellular infiltrates, with or without 
fibrin deposition in the vessel wall, especially venules, swelling and surrounding 
tissue necrosis.  Also, it was reported that neutrophils and CD4+ T lymphocytes 
accumulated around the vasa vasorum and perivascular area, which expressed IL-
1α, TNF-β, IFN-γ, and IL-2 receptors (Evereklioglu 2005). 
 
A recent histopathological and immunofluorescence study of papulopustular lesions 
detected an immune complex-mediated leukocytoclastic vasculitis as compared with 
non-lesional skin in patients with BD.  The vessels of the lesional skin demonstrated 
a higher IgM deposition than non-lesional skin (Alpsoy et al. 2003).  In line with this 
finding, immunoglobulin and complement depositions were identified in the biopsies 
from mucocutaneous ulcers and papulopustular skin lesions in earlier studies (Onder 
& Gurer 1999;Onder & Gurer 2001).  Also, erythema nodosum-like lesions were 
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reported to be characterised by phleblitis and arteriolitis, demonstrating variable 
numbers of neutrophils, lymphocytes, and histiocytes with expressions of adhesion 
molecules such as E- and L-selectins (Kim & LeBoit 2000;Senturk et al. 2003). 
 
In biopsies of oral ulcers, it was found the majority of lymphocytes present in the oral 
ulcers were T cells, with no observed difference in the proportion of CD4+ or CD8+ 
cells in patients with BD.  The Th1-related cytokines IL-12, IFN-γ, and TNF-α and the 
Th1-associated chemokine receptors CCR5 and CXCR3 were increased as 
compared to normal controls.  However, low levels of the Th2 cytokine IL-4 was 
detected in oral ulcers of BD patients.  It was thus suggested that the complex 
mixture of responses in the BD patients may be due to a mixture of antigenic stimuli 
(Dalghous, Freysdottir, & Fortune 2006).  Likewise, intestinal lesions of BD 
expressed IFN-γ, TNF-α and IL-12 mRNA, and mRNA of Txk, a Tec family tyrosine 
kinase specific to Th1 cells, was also expressed in the lesions.  These indicated Th1-
dominant responses in vivo (Imamura et al. 2005). 
 
Throughout the courses of neuro-Behcet’s disease, lesions are typified by 
perivascular cuffing of T lymphocytes and monocytes (Hirohata 2008).  In the brain, 
demyelination is another common finding (Zakka, Chang, Giuliari, & Foster 2009). 
 
Ocularly, diffuse infiltration of predominantly neutrophils in the active stage, followed 
by lymphocytes and plasma cells during remission have been found in the anterior 
chamber, iris, ciliary body and choroids.  When the disease becomes chronic and 
recurrent, collagen fibres proliferate which can lead to iris atrophy, cyclitic membrane 
formation, choroidal thickening and eventually hypotonia and phthisis bulbi (Hegab & 
Al Mutawa 2000).  Retinal vasculitis, which involves veins more than arteries, is 
characterised by infiltration of leukocytes and plasma cells.  The photoreceptor 
layers in the retina are often damaged and optic neuritis, ischemia, and even atrophy 
may result in more advanced cases.  Recently, mural IgG, IgA, and C3 in both 
episcleral and choroidal vessels, along with increased serum concentrations, have 
also been observed in patients with BD (Bardak & Aridogan 2004).  Moreover, 
intraocular infiltration of CD8brightCD56+ T cells in BD patients has been reported and 
these cells are characterised as cytotoxic effector cells with functional NK receptors 
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that kill through both Fas ligand-dependent and perforin-dependent pathways (Ahn 
et al. 2005). 
 
 
1.21  Treatment in Behcet’s disease 
 
Treatment of various manifestations in BD is empirical due to the paucity of 
adequately powered, randomised controlled trials and the poor understanding of the 
aetiopathogenesis.  The conventional regimen was based on inducing severe 
immunosuppression in patients by targeting broad pathways of inflammation of the 
disease in a non-specific manner, and the regimen comprises systemic 
corticosteroids, colchicine, and immunosuppressive agents such as azathioprine, 
cyclosporine, mycophenolate mofetil and methotrexate in cases proven to be highly 
steroid dependent.  These have been tried with some success, and anti-
inflammatory drugs including NSAIDs may also prove useful. 
 
Corticosteroids produce a broad and non-selective inhibition of the immune system 
by suppressing cyclo-oxygenase and lipo-oxygenase pathways.  Therefore, the 
formation of prostaglandins, leukotrienes, and thromboxane is reduced.  Also, it 
decreases lymphocyte migration and chemotaxis, circulating monocytes, 
macrophage activity, as well as the levels of complement and interleukins.  Although 
topical and systemic corticosteroids are commonly used for the treatment of vast 
majority of BD manifestations, controlled studies are lacking and their long-term use 
is to be avoided if possible because of significant adverse effects.  Systemic 
corticosteroid treatment is started with a high dose with subsequent tapering over 
several weeks as quickly as clinical manifestations allow.  Despite successfully 
suppressing acute inflammation, corticosteroids alone often fail to prevent relapses, 
so they are frequently used in combination with other medications (Evereklioglu 
2005). 
 
Cyclosporine is a calcineurin inhibitor with more specific effects on the immune 
system than corticosteroid and cytotoxic drugs.  It is a cytostatic agent and its 
primary effect is to inhibit T cell activation and recruitment (Evereklioglu 2005).  
Because of its rapid action, cyclosporine is usually the treatment of choice for sight-
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threatening and progressive uveitis, especially with retinal vasculitis (Yurdakul & 
Yazici 2008).  However, the long-term use of cyclosporine is limited by the 
development of neurological side effects, hirtutism, hyperglycaemia, hepatotoxicity, 
nephrotoxicity and hypertension (Evereklioglu 2005). 
 
Azathioprine and methotrexate are anti-metabolite agents.  The action of 
azathioprine depends on the depletion of cellular purine stores, thus suppressing 
both DNA and RNA synthesis (Al Mutawa & Hegab 2004).  Patients on azathioprine 
should be followed for gastrointestinal disturbances and be monitored by a complete 
blood count every month for bone marrow suppression and liver function test every 
three months for hepatotoxicity (Evereklioglu 2005). 
 
Methotrexate is a cyclo-oxygenase inhibitor and suppresses the production of 
thymidylate and de novo purine synthesis.  It has multiple in vivo and in vitro effects, 
including inhibitory effects on B and T cell lymphocyte proliferation, endothelial cell 
growth, chemotaxis, neovascularisation, and generation of inflammatory mediators, 
such as lipo-oxygenase products.  Methotrexate also inhibits dihydrofolate reductase, 
which is an enzyme responsible for the reduction of folic acid.  Therefore, use of folic 
acid or folinic acid therapy can reduce toxicity without affecting the efficacy of 
methotrexate (Al Mutawa & Hegab 2004).  Patients on methotrexate should be 
monitored for gastrointestinal side effects, hepatotoxicity, renal toxicity, and bone 
marrow suppression (Evereklioglu 2005). 
 
Mycophenolate mofetil (MMF) is a relatively new immunosuppressive drug and is a 
specific inhibitor of B and T lymphocytes.  Since its efficacy has been well 
established in the management of various autoimmune diseases as well as in 
different forms of non-infectious uveitis, it may have a role to play in the treatment of 
BD (Marshall 2004).  Also, colchicine is an anti-inflammatory plant alkaloid and 
inhibits neutrophil chemotaxis by accumulating in these cells and suppressing the 
microtubule function (Evereklioglu 2005). 
 
Combined treatment is also often used in order to diminish corticosteroid dose.  Drug 
combinations are often preferred and many patients progress through various drug 
combinations with time, usually due to adverse effects.  Medications must be given 
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under expert specialist supervision and need regular monitoring to detect potential 
side effects and determine response.  Relief of symptoms, control of active 
inflammation, and prevention of recurrences and hence of irreversible end-organ 
damage and functional disability are the main goals (Evereklioglu 2005). 
 
Although the prognosis has improved with early and aggressive immunosuppressive 
treatment, many patients have refractory disease.  Over the past decade, biological 
agents that target one cytokine or inflammatory mediator have emerged as powerful 
therapies for a number of inflammatory disorders.  They are also proving to be most 
useful in BD and can result in dramatic reduction of disease burden and 
improvement of long-term outcome.  Small case series have demonstrated the value 
of biological therapies such as IFN-α and TNF-α antagonists, particularly infliximab, 
even in patients resistant to conventional treatment.  Both IFN-α and infliximab have 
proved capable of rapidly inducing remission in active disease.  If an adequate initial 
dose is used, IFN-α is capable of triggering a dramatic improvement within a few 
days (Deuter et al. 2008).  For infliximab, the benefit is usually temporary and 
infusions are required every 4-8 weeks to sustain remission (Imrie & Dick 2007); very 
few cases have been described in which treatment could be stopped without 
relapses within a few months.  In contrast, 50-60% of patients treated with IFN-α do 
not relapse one year after cessation of therapy (Deuter et al. 2008). 
 
In order to develop evidence-based recommendations for the management of BD, 
the European League Against Rheumatism (EULAR) combined current evidence 
from clinical trials with expert opinion (Hatemi et al. 2008).  Recommendations 
related to the eye, mucocutaneous disease and arthritis are mainly evidence based, 
but recommendations on vascular disease, neurological and gastrointestinal 
involvement are based largely on expert opinion and uncontrolled evidence from 
open trials and observational studies (Table 1.4). 
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Table 1.4: EULAR recommendations for treatment of BD 2008 
(Hatemi et al. 2008;Mendes et al. 2009) 
Eye disease: 
 Azathioprine and local and systemic corticosteroids 
 
Refractory eye involvement: 
 Cyclosporine A or infliximab in combination with azathioprine and 
corticosteroids 
 IFN-α alone or with corticosteroids 
 
Major vessel disease: 
 Acute deep vein thrombosis: corticosteroids, azathioprine, cyclophosphamide 
or cyclosporine A 
 Thrombosis of the vena cava and Budd-Chiari syndrome: cyclophosphamide 
 Pulmonary and peripheral arterial aneurysms: cyclophosphamide and 
corticosteroids; surgery 
 Anticoagulants, antiplatelet and antifibrinolytic agents are not recommended 
(pulmonary embolism is rare and there is the risk of major bleeding in case 
there are concomitant pulmonary aneurysms) 
 
Gastrointestinal involvement: 
 Sulfasalazine, corticosteroids, azathioprine, TNF-α antagonists or thalidomide; 
surgery 
 
Articular involvement: 
 Colchicine; IFN-α, azathioprine, TNF-α antagonists in resistant cases 
 
Neurological involvement: 
 Parenchymal disease: corticosteroids, IFN-α, azathioprine, 
cyclophosphamide, methotrexate, TNF-α antagonists 
 Dural sinus thrombosis: corticosteroids 
 Cyclosporine should be avoided in case of neurological involvement due to 
neurotoxicity 
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Mucocutaneous involvement (oral, genital and skin lesions) 
 Topical measures: corticosteroids preparations, lidocaine gel, chlorhexidine, 
sucralfate suspension 
 Erythema nodosum: colchicines 
 In resistant cases: azathioprine, IFN-α, TNF-α antagonists 
 
 
1.22  Interferon-alpha as a treatment option for Behcet’s disease 
 
IFN-α was the first cytokine identified and is of major clinical value in various 
diseases (Isaacs & Lindenmann 1957).  Interferons have well documented efficacy in 
the treatment of haematological and solid tumours, viral hepatitis, and disorders of 
presumed autoimmune aetiology (Pfeffer et al. 1998).  Upon viral infection, type I 
IFNs are the first cytokine mediators induced in huge quantities and they orchestrate 
the immediate innate response of the host toward viral infection.  In 1986, 
recombinant leukocyte IFN-α was first introduced for the treatment of BD by 
Tsambaos et al. based on the putative association between BD and viral infection 
(Tsambaos, Eichelberg, & Goos 1986).  Today, there are two different human 
recombinant IFN-αs commercially available, IFN-α2a and IFN-α2b and they differ 
only in one amino acid in position 23 (Garcia-Garcia et al. 2010).  It is of note that 
defects detected in BD patients including decreased percentage of pDCs and 
reduced serum levels of IFN-β can be corrected with recombinant IFN-α therapy 
(Pay et al. 2007). 
 
Surprisingly, however, there are reports that BD patients have higher levels of IFN-α 
compared to healthy control subjects and serum levels are more elevated in patients 
with active disease as compared to patients in remission (Kotter et al. 2005;Pay et al. 
2007).  One possible explanation for the increased production of IFN-α in BD is that 
the cytokine is not active enough to eliminate a persistent pathogen which induces 
genes encoding IFN-α.  Alternatively, there might be a diminished responsiveness to 
IFN-α signalling in BD patients, which can be rectified by exogenous IFN-α (Kotter et 
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al. 2005).  The latter explanation is supported by polymorphisms recently 
demonstrated in the receptor for the type 1 IFNs in patients with BD (Pay et al. 2009). 
 
Recent studies have focused on IFN-α2a, either used alone or in association with 
steroids and/or immunosuppressive agents.  Due to the immunomodulatory rather 
than immunosuppressive nature, it is reasoned that the use of interferons needs an 
unsuppressed immune system (Onal et al. 2009).  Therefore, the use of IFN-α 
combined with immunosuppressants remains a matter of debate and it has been 
suggested by some that concurrent use of immunosuppressives is to be avoided and 
corticosteroids should be used in low doses (Mackensen, Max, & Becker 2006).  
Treatment modalities of IFN-α vary greatly, with doses ranging from an injection of 3 
to 9 million units 3-7 times a week and treatment duration between 11 days to 64 
months.  Optimal treatment duration is not clear but intermediate to high IFN-α 
dosages were shown to be more effective than low-dose regimens.  Also, long-term 
remissions were associated with higher dosages, but no benefit was noticed with 
longer therapy in terms of efficacy or duration of induced remission (Kotter et al. 
2004a;Zouboulis & Orfanos 1998). 
 
Indeed, the risk of developing binding and neutralising antibodies increases with 
longer treatment, possibly decreasing its beneficial effects (Antonelli et al. 
1991;Zouboulis & Orfanos 1998).  Recombinant IFN-α2a induces neutralising 
antibodies in about 20% of patients, in contrast to only about 6% of those treated 
with recombinant IFN-α2b (Antonelli et al. 1991).  Autoantibodies can be detectable 
three to twelve months after initiation of IFN-α therapy and their production or 
increase in titre has been observed in up to 50% of patients treated.  Thyroid 
autoantibodies have been reported to be the most frequent.  However, 
manifestations of overt autoimmune disease have been observed in only 1-2% of 
patients.(Hauschild et al. 2008;Pellicano et al. 2005)  Overall, a meta-analysis of 144 
BD patients from 22 reports showed that despite different therapeutic regimens 
employed in individual studies, overall efficacy of IFN-α therapy was 74% for 
mucocutaneous manifestations, 93% for arthritis and 95% for uveitis (Zouboulis & 
Orfanos 1998).  Regarding time to response to IFN-α therapy, remission in ocular 
manifestations usually occurred in 2 to 4 weeks and nonocular manifestations 
remitted in 4-6 weeks (Kotter et al. 2004a). 
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The side effect profile of IFN-α is generally less severe than other systemic 
immunosuppressants.  Common side effects of IFN-α include injection site reactions, 
flu-like symptoms (fever, headache, myalgia, arthralgia, sweating and fatigue), mild 
leukopaenia and alopecia. The flu-like symptoms could be alleviated by concomitant 
administration of paracetamol and represent a good prognostic marker for a 
response to IFN-α treatment as this may indicate the absence of pre-existing anti-
IFN-α autoantibodies (Deuter et al. 2008;Mackensen, Max, & Becker 2006).  Even 
without pre-existing psychiatric disease, depression and suicidal ideations can occur 
during therapy.  An asymptomatic increase in liver enzymes has been reported, 
especially ones who receive high-dose IFN-α.  In case of an greater than five times 
elevation of liver enzymes, a therapy pause followed by a dose reduction has been 
suggested (Hauschild et al. 2008).  IFN-associated retinopathy with features such as 
cotton wool spots, arteriolar occlusions, retinal oedema and haemorrhages has been 
described in hepatitis C and melanoma patients treated with IFN-α but so far this has 
not been confirmed in BD patients.  Risk factors reported include arterial 
hypertension, diabetes mellitus and age above 45 years (Deuter et al. 2008).  
Gastrointestinal side effects such as dyspepsia, diarrhoea, loss of appetite and 
weight loss can occur, as can other less common side effects which include 
thrombocytopaenia, hypertriglyceridaemia, reduced libido, hypotension and cardiac 
disturbances (Hauschild et al. 2008). 
 
The two IFN-α isotypes have a comparable adverse effect profile, although flu-like 
symptoms and mild leukopaenia are more commonly reported with IFN-α2a 
regimens and mild alopecia more commonly with IFN-α2b treatment (Zouboulis & 
Orfanos 1998).  Fortunately, nearly all of the side effects are temporary, dose-
dependent and reversible, and discontinuation of IFN-α therapy due to adverse 
effects has been reported to be rare as a result (Deuter et al. 2008).  Of note, type 1 
diabetes occasionally develops during IFN-α treatment (Devendra & Eisenbarth 
2004).  Interestingly, disorders such as systemic lupus erythematosus, sarcoidosis, 
rheumatoid arthritis, autoimmune hepatitis, epilepsy and psoriasis may present for 
the first time during IFN-α therapy.  These conditions are contraindications for IFN-α 
treatment and treatment should be individually evaluated with the risk-benefit profile 
taken into careful consideration (Deuter et al. 2008;Hauschild et al. 2008;Selmi et al. 
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2006).  Unlike anti-TNF therapy, INF-α treatment is not associated with an increased 
risk of infection (Imrie & Dick 2007). 
 
 
1.23 Clinical trials on interferon-α in Behcet’s disease 
 
Despite a lack of data from randomised controlled trials, the results of studies 
performed so far with IFN-α therapy have been promising especially for those 
patients with disease resistant to conventional immunosuppressive treatments.  In 
particular, the clinical efficacy of IFN-α in the treatment of BD associated uveoretinitis 
appears fairly convincing. 
 
 
   1.23.1 The beneficial effects of IFN-α on ocular manifestations 
 
In one open-label, prospective series involving 50 BD patients with sight-threatening 
refractory uveitis, a 92% response rate was demonstrated with recombinant human 
IFN-α2a at initial doses of six million units subcutaneously daily.  Retinal infiltrates 
resolved after 2-3 weeks in all patients, macular oedema resolved, and visual acuity 
improved or remained stable in 97% of affected eyes (Kotter et al. 2004b).  The IFN-
α dose was subsequently adjusted according to the clinical response, and was 
discontinued whenever possible.  Importantly, 40% of patients remained in remission 
for a mean of 29.5 months after cessation of treatment.  IFN-α treatment was also 
beneficial for extraocular problems including arthritis, genital ulcers, and cutaneous 
and gastrointestinal manifestations as well, but less so for oral ulcerations. 
 
In a retrospective analysis carried out on 44 BD patients with uveitis unresponsive to 
conventional immunosuppressants, IFN-α2a was given at an initial dose of 3-6 
million units daily for a mean duration of 12.4 months and led to a partial or complete 
response in 91% of patients (Tugal-Tutkun, Guney-Tefekli, & Urgancioglu 2006).  
Visual acuity significantly improved and this benefit was preserved in 95% of patients 
throughout follow-up.  Interestingly, patients who received IFN-α treatment at the 
time of a relapse did not behave differently compared with those whose treatment 
was started during remission.  Another retrospective study by the same group found 
  
99 
 
that treatment with IFN-α2a resulted in resolution of neovascularisation of the optic 
disc, whether inflammation- or ischaemia-induced (Tugal-Tutkun et al. 2006). 
 
An open, prospective study also evaluated the intermediate-term efficacy of IFN-α2a 
in patients with active Behcet’s uveitis who failed to respond to conventional 
treatments, and 53 patients (106 eyes) were assessed.  Complete remission (no 
relapse within the first year of follow-up) was obtained in 38 patients (71.6%).  This 
was achieved even in patients with chronic inflammation associated with retinal and 
optic nerve vasculitis, neovascularisation of the optic disc, and cystoid macular 
oedema, which were unresponsive to previous conventional treatments.  The mean 
ocular attack rate of 3.6 per year decreased to 0.56 per year at one year follow-up.  
Moreover, fifteen patients (28.3%) were off treatment for all the medications and 
disease free for 28 months.  However, reinstitution of IFN-α2a treatment was 
required at a median follow-up of 65 months (Sobaci et al. 2010). 
 
Recent studies have provided valuable information concerning the beneficial effect of 
IFN-α on long-term visual prognosis in BD.  A retrospective study of 32 patients with 
severe refractory uveitis who were treated with IFN-α2a at a dose of 3-6 million units 
three times a week in combination with initial high doses of steroids demonstrated 
promising results, with uveitis being controlled in 28 patients (87.5%) and 19 patients 
(59.4%) being able to stop IFN-α after a mean treatment period of 32 months.  Of the 
28 responders, the mean follow-up period was 70.6 months.  13 patients (68%) were 
free of recurrences, and visual acuity was stabilised or improved in 87.5% of eyes 
(Gueudry et al. 2008).  In another study of 45 patients who received IFN-α for ocular 
BD, patients were followed up for a mean of 6.67 years.  Nine patients (20%) were 
able to stop IFN-α after a mean treatment period of 33 months.  Those patients 
remained relapse free for a mean of 37 months.  Importantly, 92% of the affected 
eyes showed improvement in or stabilisation of visual acuity during follow-up (Krause 
et al. 2008). 
 
These results on favourable long-term visual prognosis are supported by finding of a 
retrospective study of 53 BD patients (96 eyes) with sight-threatening uveitis.  Higher 
initial dosage of 6 million IU every day was used and visual acuity of the affected 
eyes in the series improved or remained unchanged in 91 eyes (94.8%).  IFN-α was 
  
100 
 
able to be discontinued in 47 patients (88.7%), but twenty of these 47 (42.6%) 
needed a second treatment course during a median follow-up of 6.0 years.  
Nevertheless, ocular disease remained in remission in 50% of the patients 45.9 
months after cessation of the first IFN-α course (Deuter et al. 2010). 
 
 
   1.23.2 The beneficial effects of IFN-α on non-ocular manifestations 
 
The beneficial effects of IFN-α for the non-ocular manifestations of BD have also 
been demonstrated.  A randomised, placebo-controlled, double-blind trial showed 
that both pain and duration of oral ulcers were reduced in 23 patients treated with 
IFN-α2a at a dosage of six million units subcutaneously three times a week for 3 
months (Alpsoy et al. 2002).  IFN-α decreased the frequency of both genital ulcers 
and papulopustular lesions.  Additionally, in five of six patients, the severity and 
frequency of ocular attacks was noted to improve.  However, all manifestations had 
the tendency to return to pre-treatment levels after cessation of therapy. 
 
In an open, self-controlled trial of 20 patients treated with IFN-α2b for 16 weeks and 
followed for 48 weeks, the frequency and duration of arthritic attacks has been 
demonstrated to reduce after treatment with IFN-α2b.  The mean number of 
mucocutaneous lesions also showed a tendency to decrease.  However, except for 
the duration of arthritis, the mean number and frequency of all symptoms tended to 
return to pretreatment levels in the post-treatment phase (Hamuryudan et al. 1994).  
Currently, there is little information concerning the efficacy of IFN-α therapy for 
involvement of gastrointestinal tract, central nervous system and large vessels, 
although one small study demonstrated remission in 9 of 10 patients with vascular 
disease and 4 of 4 with neurological disease after a mean duration of 22.2 months of 
IFN-α treatment (Calguneri et al. 2003). 
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   1.23.3 The combined use of azathioprine and IFN-α 
 
The efficacy of the combined use of azathioprine and IFN-α was examined in a small 
open study of ten male BD patients with retinal involvement.  For 24 weeks, they 
were treated with azathioprine and IFN-α2b five million units three times a week.  
The IFN-α was stopped after 24 weeks and the patients continued to take 
azathioprine or switched to cyclosporin A as indicated.  The mean visual acuity of 
either eye improved significantly during treatment and throughout the follow-up.  
However, frequent but reversible myelosuppression, mainly leukopaenia, was 
observed and short withdrawals of either or both drugs were necessary 
(Hamuryudan et al. 2002). 
 
In one long-term retrospective analysis, experience of IFN-α treatment on seven 
paediatric BD patients with severe uveitis was described (Guillaume-Czitrom et al. 
2007).  IFN-α2a was given at a dosage of 1.5 or 3 million units thrice a week in 
children weighing 20-30kg or 30-50kg, respectively.  The treatment was combined 
with azathioprine for two of the children.  The results are encouraging due to rapid 
steroid-sparing effect in five patients and sustained remission was achieved in four 
children.  The results, together with the above study, suggest the combination of 
IFN-α and azathioprine might be an option in the management of severe refractory 
BD uveitis. 
 
The details of these trials are summarised in Table 1.5.  
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Table 1.5: Significant clinical studies reporting the use of interferon-alpha in 
Behcet’s disease 
Reference No. of 
patients 
on IFN 
Type 
of 
IFN 
Concurrent therapy Manifestation(s) 
studied 
Study design 
Hamuryndan 
et al. (1994) 
20 2b Not reported Mucocutaneous, 
joint 
Open, self-
controlled 
Alpsoy et al. 
(2002) 
23 2a None  Mucocutaneous, 
joint, oral and genital 
ulcers, ocular 
Randomised, 
placebo-
controlled, 
double-blind 
Hamuryndan 
et al. (2002) 
10 2b Azathioprine Ocular Open 
Calguneri et 
al. (2003) 
29 NR Colchicine, 
Benzathine penicillin 
(cyclophosphamide in 
1 patient) 
Ocular, joint, 
vascular, 
neurological 
Open, 
prospective 
Kotter et al. 
(2004) 
50 (79 
eyes) 
2a Prednisolone ≤ 
10mg/day, immuno-
suppressives stopped 
Ocular, joint, 
mucocutaneous, 
oral and genital 
ulcers, vascular, 
gastrointestinal 
Open, non-
randomised, 
uncontrolled, 
prospective 
Tugal-tutkun 
et al. 
(2006a) 
44 2a Prednisolone ≤ 
10mg/day, immuno-
suppressives stopped 
Ocular Retrospective 
Tugal-tutkun 
et al. 
(2006b) 
26 (38 
eyes) 
2a Prednisolone ≤ 
10mg/day, immuno-
suppressives stopped 
Ocular (neo-
vascularisation of 
the optic disc) 
Retrospective 
Guillaume-
Czitrom et 
al. (2007) 
7 2a Corticosteroids, 
Azathioprine in 2 
Ocular Retrospective 
Gueudry et 
al. (2008) 
32 (60 
eyes) 
2a IV methyl-
prednisolone then 
prednisolone 
1mg/kg/day 
Ocular Retrospective 
Krause et al. 
(2008) 
45 (79 
eyes) 
2a Prednisolone tapered 
from 100mg/day to 
10mg/day in 2 weeks 
Ocular Retrospective 
Sobaci et al. 
(2010) 
53 (106 
eyes) 
2a Prednisolone tapered 
from 1-2mg/kg/day to 
10mg/day in 4-6 
weeks before starting 
IFN-α therapy 
Ocular Open, non-
randomised, 
uncontrolled, 
prospective 
Deuter et 
al.(2010) 
53 (96 
eyes) 
2a Prednisolone ≤ 
10mg/day, immuno-
suppressives stopped 
Ocular Retrospective 
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1.24 Pegylated interferon-alpha 
 
The clinical use of recombinant IFN-α has been restricted due to its short circulating 
half-life, which makes frequent dosing over an extended period necessary.  The 
frequently used three times weekly administration schedule of IFN-α produces peak 
drug concentration/trough concentration cycles which compromise the tolerability of 
the drug because of the high incidence of peak concentration-related adverse effects 
(Perry & Jarvis 2001).  This problem has been overcome with the introduction of 
pegylated interferons as they have a covalently attached polyethylene glycol chain 
which helps to reduce immunogenicity and clearance, and improve compliance and 
efficacy (Foster 2004).  Polyethylene glycols (PEG) are biologically inert molecules 
that can be attached to proteins to reduce their degradation and the molecular 
weight and conformation of PEG chains can have an impact on the conjugate’s 
properties (Foster 2004). 
 
Two products are now in widespread clinical use.  The 40 kDa PEG-IFN-α2a (F. 
Hoffmann-La Roche Ltd, Switzerland) is linked to a branch chain, 40 kDa PEG 
moiety and the 12 kDa PEG-IFN-α2b (Schering-Plough, USA) consists of IFN-α2b 
linked to a linear PEG chain.  The two PEG-IFN-α drugs differ in the way that the 
PEG chain is cross-linked to the IFN-α.  The PEG molecule in PEG-IFN-α2b is 
attached via a urethane bond.  This urethane linkage is unstable and susceptible to 
hydrolysis such that, once injected, native interferon-α2b is released and circulates in 
the body.  Thus, PEG-IFN-α2b is probably best regarded as a pro-drug.  On the 
other hand, the PEG polymer in PEG-IFN-α2a is attached to a lysine residue within 
the IFN-α2a molecule via a hydrolytically stable amide bond.  Consequently, the 
entire pegylated molecule circulates intact and interacts with the cell surface receptor 
(Foster 2004). 
 
Conventional IFN-α has an absorption half-life of 2.3 hours and 7 to 12 hours after 
subcutaneous administration conventional IFN-α reaches peak serum levels.  It is 
rapidly eliminated with a clearance of 6000ml/h and has an elimination half-life of 4 
to 16 hours.  Twenty-four hours after administration there is almost no measurable 
IFN in the serum (Chatelut et al. 1999;Wills 1990).  PEG-IFN-α2b has a relatively 
rapid absorption (absorption half life of 4.6h), a wide volume of distribution 
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(approximately 0.99L/kg), and reduced clearance (725ml/h) (Glue et al. 2000).  
Maximum concentrations are achieved between 15 and 44 hours post-dosing and 
are sustained for 48-72 hours (Foster 2004).  Whereas, the 40 kDa PEG-IFN-α2a is 
absorbed more slowly (absorption half life of 50h), has a more limited volume of 
distribution (8L, suggests distribution predominantly into the intravascular 
compartment), and a noticeably diminished rate of clearance (60ml/h) (Bailon et al. 
2001).  Maximum concentrations occur approximately 80 hours after dose 
administration and are sustained up to 168 hours (Foster 2004). 
 
The bioactivity of PEG-IFN-α2b has been shown to be at least comparable to that of 
the frequently used thrice weekly administration of non-pegylated IFN-α2b (Jen et al. 
2001) (Fig 1.5).  The dosage of PEG-IFN-α2b must be adjusted for body weight to 
overcome the effect of extensive tissue distribution and metabolism of the drug.  
Whereas, PEG-IFN-α2a can be given as a single fixed dose (Reddy 2004).  Of note, 
increased serum concentrations after several weeks of dosing have been reported 
for both pegylated and conventional interferons (Jen et al. 2001). 
 
PEG-IFN-α2a is cleared by both the liver and kidney and the liver plays an important 
role in the metabolism of the drug.  On the other hand, PEG-IFN-α2b releases free 
IFN-α2b soon after administration, and this is renally excreted (Foster 2010).  From 
the clinical experience, the relatively rapid absorption of PEG-IFN-α2b leads to swift 
onset of side effects and a fall in neutrophil and platelet counts could take place.  On 
the other hand, the side effects of PEG-IFN-α2a gradually increase over the first few 
weeks and neutrophil and platelet counts might not plummet until the second month 
of therapy (Foster 2004). 
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Figure 1.5: Plot of the time trend of activity for different PEG-IFN-α2b dose and 
conventional PEG-IFN-α2b groups. 
The average interferon activities were estimated to be between 19.0 and 25.2 IU/mL for 
patients treated with PEG-IFN-α2b at doses from 0.5 to 1.5 μg/kg.  The increase in the 
interferon activity was dose related.  The average interferon activity for patients treated with 
non-pegylated IFN-α2b (IFN) at 3x106 IU 3 times a week was 17.5 IU/mL, which was lower 
than that of the lowest PEG-IFN-α2b dose.  Interferon activity increased as treatment 
continued (adapted from Jen et al. 2001). 
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1.25 Biological effects of interferon-alpha and possible mechanisms of action 
 
IFN-α belongs to the type 1 interferon family and consists of at least 13 different 
isotypes in man (Table 1.6) (Pestka 1997a).  The biological significance of the 
expression of several closely similar IFN-α proteins is not known.  IFN-α proteins are 
encoded by a multigene family comprising 13 genes clustered on human 
chromosome 9 (Pestka, Krause, & Walter 2004).  The similarity between the other 
IFN-α subtypes is between 78-95% at the protein level, and 79 of the 166 amino 
acids in the IFN-α family are conserved (Kontsek 1994).  Macrophages and other 
APCs are the main cell types that contribute to the early production of IFN-α, but 
IFN-α can be produced by virtually all somatic cells after viral infection (Imrie & Dick 
2007).  Its effects are highly pleiotropic as it has antiviral, anti-proliferative, anti-
angiogenetic, and immunomodulatory properties (Pfeffer et al. 1998). 
 
 
 
 
Table 1.6: Classification of human IFNs 
IFNs have been classified in three types based on their receptor usage.  In humans, 
type I IFNs contain 13 IFN-α, 1 IFN-β, 1 IFN-ω, 1 IFN-ε and 1 IFN-κ.  Type II IFN 
includes a single IFN-γ, while type III IFNs consist of IFN-λ1, IFN-λ2, and IFN-λ3 
(Pestka 1997a) 
Type I Type II Type III 
Thirteen subtypes of IFN-α: α1, α2, α4, α5, 
α6, α7, α8, α10, α13, α14, α16, α17 and α21 
IFN-γ Three subtypes of 
IFN-λ: λ1, λ2, and λ3 
IFN-β   
IFN-κ   
IFN-ε   
IFN-ω   
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The receptor for the Type 1 IFNs consists of two chains, IFN-αR1 and IFN-αR2c 
(Pestka, Krause, & Walter 2004), which are encoded by two different genes located 
on chromosome 21q (Lutfalla et al. 1992).  The receptor is expressed by nearly all 
cell types and tissues, including immune cells (Prinz et al. 2008).  By interacting with 
their specific receptor, IFN-α activates Stat complexes which are a family of 
transcription factors that regulate the expression of certain immune system genes.  
Stat activation initiates the most well-defined cell signalling pathway for all IFNs, the 
classical Jak-Stat signalling pathway (Pestka 1997b;Stark et al. 1998).  In this 
pathway (Figure 1.6), Jaks associate with IFN receptors and, following receptor 
engagement with IFN, phosphorylate both Stat1 and Stat2.  As a result, an IFN-
stimulated gene factor 3 (ISGF3) complex forms - this contains Stat1, Stat2 and a 
transcription factor called interferon regulatory factor 9 (IRF9) - and moves into the 
cell nucleus.  Inside the nucleus, the ISGF3 complex binds to specific nucleotide 
sequences called IFN-stimulated response elements (ISRE) in the promoters of 
certain genes, known as IFN stimulated genes (ISG).  Binding of ISGF3 and other 
trasncriptional complexes induces transcription of these genes (Platanias 2005). 
In addition, Stat homodimers or heterodimers form from different combinations of 
Stat-1, -3, -4, -5, or -6 during IFN signalling; these dimers initiate gene transcription 
by binding to IFN-γ activated site (GAS) elements in gene promoters (Platanias 
2005).  The signalling by IFN-α is predominantly through Stat1 and Stat2, however, 
the pathways can involve Stat3, Stat4, Stat5, and IFN regulatory factors in various 
cells and under diverse conditions (Su & David 2000;Ziegler-Heitbrock et al. 2003).  
Type I IFNs can induce expression of genes with either ISRE or GAS elements, but 
gene induction by type II IFN can occur only in the presence of a GAS element 
(Platanias 2005). 
 
Besides the JAK-STAT pathway, IFNs can activate several other signalling 
cascades. Both type I and type II IFNs activate a member of the CRK family of 
adaptor proteins called CT10 regulator of kinase like (CRKL), a nuclear adaptor for 
Stat5 that also regulates signalling through the C3G/Rap1 pathway (Platanias 2005).  
Type I IFNs further activate p38 MAPK to induce gene transcription.  Anti-viral and 
anti-proliferative properties of IFN-α are resulted from p38 MAPK signalling 
(Platanias 2005).  Another pathway, the PI3K signalling pathway, is also regulated 
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by type I IFNs.  PI3K activates P70-S6 Kinase 1, an enzyme that increases protein 
synthesis and cell proliferation; phosphorylates of ribosomal protein s6, which is 
involved in protein synthesis; and phosphorylates a translational repressor protein 
called eukaryotic translation-initiation factor 4E-binding protein 1 (EIF4EBP1) in 
order to deactivate it (Platanias 2005). 
 
Interferons have diverse effects, influencing both innate and adaptive immune 
responses and form a network of complex interactions with other cytokines (Baccala, 
Kono, & Theofilopoulos 2005).  As well as augmenting the number of B cells and 
monocytes (Corssmit et al. 1997;Wejstal et al. 1992), IFN-α has been found to 
promote CD4+ T cells (Simon et al. 2003).  Furthermore, it was reported to enhance 
human leukocyte antigen-1(HLA-1) expression on monocytes in BD patients 
(Piazzolla et al. 1996) and improve the activity of natural killer cells and cytotoxic T 
cells (Arnaud 2002).  Under IFN-α therapy, the number of circulating NK cell, CD8+ 
γδ T cells, CD3+ γδ T cells and leukocytes, especially neutrophils were all reported to 
be substantially lowered (Simon et al. 2003;Treusch et al. 2004) 
 
By interacting with the cytokine cascade, IFN-α has displayed anti-inflammatory 
properties including abilities to inhibit IL-8 expression (Aman et al. 1993), increase 
IL-10 production (Aman et al. 1996;Kaser, Molnar, & Tilg 1998) and induce IL-1 
receptor antagonist (Tilg et al. 1993) and soluble TNFR-55 and TNFR-77 (Corssmit 
et al. 1997;Tilg, Vogel, & Dinarello 1995).  Also, it has been shown that IFN-α 
suppressed IL-1- and PMA-induced IL-1 synthesis by PBMCs (Schindler, Ghezzi, & 
Dinarello 1990).  However, the production of IL-4 was not always reported to be 
augmented by IFN-α (Brinkmann et al. 1993;Kaser, Molnar, & Tilg 1998).  On the 
other hand, the production of another Th2 cytokine, IL-5, as well as IL-13, were 
shown to be downregulated by IFN-α (Kaser, Molnar, & Tilg 1998;Schandene et al. 
1996). 
 
Surprisingly, although IFN-α was described to suppress TNF-α gene expression and 
protein synthesis in vitro and in vivo (Abu-Khabar, Armstrong, & Ho 1992;Larrea et 
al. 1996), it was demonstrated to enhance IFN-γ production by CD4+ T cells 
(Brinkmann et al. 1993;Simon et al. 2003).  However, IFN-γ has been suggested 
more recently to be not only a mediator of disease but also as a protective factor in 
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models of autoimmunity (O'shea, Ma, & Lipsky 2002).  Furthermore, it has been 
revealed that IFN-α can restore the impaired intracellular IL-2 production up to 
normal levels by promoting Th1 differentiation.  IL-2, along with B7 co-stimulators, 
has been demonstrated to promote the development of Treg cells or apoptosis of 
activated T cells.  Thus, termination of immune responses and maintenance of self 
tolerance can be achieved (Abbas 2003;Amberger et al. 2007).  Other actions 
demonstrated by IFN-α involve abilities to suppress T cell binding to endothelial cells 
and inhibit intercellular adhesion molecule-1 (ICAM-1) expression on endothelial 
cells stimulated by IFN-γ (Eguchi et al. 1992).  The capacity of IFN-α to inhibit T cell 
adhesion to endothelial cells can conceivably impede with the transmigration of 
inflammatory cells and reduce tissue injury as a result. 
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Figure 1.6: Interferon pathway. 
Interferon-α signalling takes place through an IFN receptor complex consisting of two alpha 
chains (Type I receptor) complexed with Jak1 and Tyk2.  Activation of these kinases results 
in tyrosine phosphorylation of Stat1 and Stat2; this leads to the formation of Stat1-Stat2-
IRF9 complexes, which are known as ISGF3 complexes.  These complexes translocate to 
the nucleus and bind ISREs in DNA to initiate gene transcription.  Type I IFNs also induce 
the formation of Stat1-Stat1 homodimers that translocate to the nucleus and bind GAS 
elements that are present in the promoter of certain ISGs, thereby initiating the transcription 
of these genes (modified from www.sabiosciences.com).  
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1.26 Aims of the project 
 
The overarching aim of this project is to examine further the immunomodulatory 
effects of recombinant IFN-α, with special reference to its role as a disease-
modifying therapy in Behcet’s disease, an immune-mediated disorder.  In order to 
achieve this, aspects of the influence of IFN-α will be assessed in several different 
populations of T cells.  The first major area to be studied is the conventional T helper 
subsets, Th1 and Th2, and expression of their related cytokines in response to a 6-
month course of subcutaneous IFN-α2b therapy in BD patients ex vivo.  In the first 
results chapter (Chapter 3), the influence of subcutaneous IFN-α2b therapy on the 
relative proportions of CD4+, CD8+, and TCRαβ+ T cells and pattern of cytokine 
release by CD3+ T cells, including IFN-γ, TNF-α, IL-2, and IL-4, in BD patients are 
assessed ex vivo.  The longitudinal effect of the IFN-α is of particular interest, and 
the data from before, during and after IFN-α therapy are compared. 
 
In the second results chapter (Chapter 4), this analysis is extended to Th17 and Treg 
cells, exploring the influence of a 6-month course of subcutaneous IFN-α2b therapy 
on these cell populations and the expression of IL-17, IL-10, TGF-β, and Foxp3 by T 
cells in BD patients ex vivo.  Again, the longitudinal effect of the IFN-α is of particular 
interest, as this is crucial, along with longitudinal data from Chapter 3, to help gain 
insights into the disease-modifying nature of the IFN-α therapy and its potential to 
induce long-term remission.  The effect of subcutaneous IFN-α2b therapy on the 
relative proportion of CD56+ NKT cells is examined as well. 
 
In Chapters 5-7, preliminary tests are first performed using healthy donor PBMC to 
establish in vitro models in order to test the immunomodulatory effects of IFN-α 
subsequently.  In the third results chapter (Chapter 5), the modulating action of both 
forms of recombinant IFN-α (2a and 2b) on CD4+ and CD8+ T cells producing IFN-γ 
and IL-17 cytokines are assessed.  In the fourth results chapter (Chapter 6), the 
objective is to investigate whether recombinant IFN-α2a and IFN-α2b induce 
expansion of regulatory T cell subsets and expression of immunoregulatory 
cytokines, IL-10 and TGF-β, as well as Foxp3.  In the final results chapter (Chapter 
7), the influence of a 6-month course of subcutaneous IFN-α2b therapy on the 
relative proportions of TCRγδ+ T cells in BD patients was analysed ex vivo.  This is 
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of particular interest, as γδ T cells have been implicated to play key roles in the 
pathogenesis of BD.  The ex vivo experiments are followed by assessment of the 
changes in the proportion of γδ T cell within lymphocytes and their production of 
cytokines, including IFN-γ and IL-17, under the influence of recombinant IFN-α2a 
and IFN-α2b in vitro.  Finally, the kinetics of cytokine production by T cells are 
explored by the introduction of IFN-α2a at different time-points during in vitro assays 
and the resultant changes in cytokine levels expressed by T cells are analysed for 
Foxp3 and all the cytokines examined in Chapter 5-7. 
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Chapter 2 
Materials and Methods 
 
   2.1 Materials 
 
Product Product Code Supplier 
2-Mercaptoethanol M6250 Sigma Laboratories UK 
All-trans retinoic acid 554720 Merck Chemicals UK 
Bovine serum albumin A4503 Sigma Aldrich UK 
Brefeldin A B7651 Sigma Aldrich UK 
Candida albicans 1200 Allergopharma 
Cytofix/Cytoperm 554772 BD Biosciences UK 
DMSO  038K0742 Sigma Aldrich UK 
FACS Lysing Solution 349202 Becton Dickinson 
Gentamicin 15710 Invitrogen UK 
Heat inactivated foetal calf serum 4-101-500 LabTech International UK 
Histopaque 1077 Sigma Aldrich UK 
IL-2, recombinant, human 200-02 PeproTech UK 
IMDM I3390 Sigma Aldrich UK 
Ionomycin 10634 Sigma Aldrich UK 
LPS L2630 Sigma Aldrich UK 
Non essential amino acids 11140 Invitrogen UK 
PDS-Ag (aa341-354) 800371 Biotrend 
Perm/Wash buffer 554723 BD Pharmingen UK 
PHA L8754 Sigma Aldrich UK 
PBS P4417 Sigma Aldrich UK 
PMA P1585 Sigma Aldrich UK 
Recombinant human IFN-α2a 11100-1 PBL Interferon Source 
Recombinant human IFN-α2b 11105-1 PBL Interferon Source 
RPMI-1640 Dutch Modification 22409031 Invitrogen UK 
Sodium pyruvate 11360 Invitrogen UK 
Tropomyosin T2400 Sigma Aldrich UK 
Zymosan Z4250 Sigma Aldrich UK 
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   2.2 Antibodies 
 
Table 2.1: Primary antibodies used for flow cytometry 
Antibody Clone Host Isotype Source 
Anti-human CD3,purified HIT3a Mouse IgG2a BD 
Anti-human CD3 FITC UCHT1 Mouse IgG1 BD 
Anti-human CD3 PerCP SK7 Mouse IgG1 BD 
Anti-human CD4 PE RPA-T4 Mouse IgG1 BD 
Anti-human CD4 PerCP SK3 Mouse IgG1 BD 
Anti-human CD8 FITC RPA-T8 Mouse IgG1 BD 
Anti-human CD8 PerCP SK1 Mouse IgG1 BD 
Anti-human CD25 APC 2A3 Mouse IgG1 BD 
Anti-human CD28, purified CD28.2 Mouse IgG1 BD 
Anti-human CD56 APC B159 Mouse IgG1 BD 
Anti-human Foxp3 Alexa 488 259D/C7 Mouse IgG1 BD 
Anti-human Foxp3 PE 259D/C7 Mouse IgG1 BD 
Anti-human IFN-γ FITC 25723.11 Mouse IgG2b BD 
Anti-human IFN-γ APC 25723.11 Mouse IgG2b BD 
Anti-human IgG APC G18-145 Mouse IgG1 BD 
Anti-human IgG FITC X40 Mouse IgG1 BD 
Anti-human IgG PE G18-145 Mouse IgG1 BD 
Anti-human IgG PerCP X40 Mouse IgG1 BD 
Anti-human IL-2 PE MQ1-17H12 Rat IgG2a BD 
Anti-human IL-4 FITC MP4-25D2 Rat IgG1 BD 
Anti-human IL-10 APC JES3-19F1 Rat IgG2a BD 
Anti-human IL-10 PE JES3-19F1 Rat IgG2a BD 
Anti-human IL-17 PE eBio64DEC17 Mouse IgG1 eBioscience 
Anti-human TCRαβ FITC T10B9.1A-31 Mouse IgM BD 
Anti-human TCRγδ AP B1 Mouse IgG1 BD 
Anti-human TCRγδ FITC 11F2 Mouse IgG1 BD 
Anti-human TCRγδ PE B1 Mouse IgG1 BD 
Anti-human TGF-β PE TB21 Mouse IgG1 IQ Products 
Anti-human TNF-α PE MAb11 Mouse IgG1 BD 
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   2.3 Preparation and storing of stock solutions and reagents 
 
A number of reagents were prepared, aliquoted and stored at optimum temperature 
in order to prevent degradation of the reagents as a result of multiple freeze thaw 
cycles and to protect stock solutions from contamination. 
 
 
   2.3.1 2-Mercaptoethanol 
 
2-mercaptoethanol (2ME; molecular weight 78.13) was purchased as a 14.3M stock 
solution.  14.3M 2-ME was diluted in PBS [1/14.3 vol/vol] in the laminar flow hood.  
This was then sterilised by passing through a 0.22M filter and aliquoted in 500l 
volumes and stored at -20C until use.  When 2-ME was required to be used, it was 
thawed and further diluted [1/50000 vol/vol] in culture medium to give a final 
concentration of 2x10-5 M. 
 
 
   2.3.2 All-trans retinoic acid (ATRA) 
 
A stock solution was made up to 25mg/ml by adding DMSO to stock powder.  It was 
stored at 4°C in the fridge and diluted in culture medium if necessary before use to 
achieve intended final concentrations. 
 
 
   2.3.3 Bovine serum albumin (BSA) 
 
In order to make up a stock solution of 10% BSA, 1g BSA lyophilised powder was 
added to 9ml of sterile PBS.  To make a buffer solution containing 0.1% BSA to 
dilute IFN-α2a, 100μl of 10% BSA was added to 9.9ml of sterile PBS. 
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   2.3.4 Brefeldin A (BFA) 
 
A stock solution of BFA was made up to 5mg/ml by adding 1ml of DMSO to the 
powder in the laminar flow hood.  This was aliquoted and stored at -20°C in the 
freezer until used.  During cell culture, BFA was diluted 1:10 in RPMI before 
appropriate amount was added to provide a final concentration of 10μg/ml. 
 
 
   2.3.5 Candida antigens 
 
A stock solution was made up to 2mg/ml by adding sterile PBS to stock powder.  It 
was stored at 4°C in the fridge and diluted in culture medium if necessary before use 
to achieve desired final concentrations. 
 
 
   2.3.6 FACS lysing solution 
 
This reagent was provided as a 10 x concentrate and therefore was diluted 1:10 in 
deionised water and stored at room temperature before use.  The prepared solution 
is stable for up to 1 month when stored at room temperature (20° to 25°C). 
 
 
   2.3.7 Foetal calf serum (FCS) 
 
After complete thawing of heat-inactivated FCS, it was aliquoted in 50ml volumes 
under aseptic condition.  FCS was then stored at -20C until use and thawed in a 
37C water bath when required for tissue culture. 
 
 
   2.3.8 IFN-α2a 
 
To make a stock solution of 106U/ml, each 5μl of IFN-α2a [5.4 x 107 U/ml] was 
diluted with 265μl of sterile PBS containing 0.1% BSA under sterile conditions in 
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accordance to the manufacturer’s instructions.  This was then aliquoted and stored 
at -70°C in the freezer.  When IFN-α2a was required to be used, it was thawed at 
room temperature and diluted in culture medium if necessary to achieve desired final 
concentrations. 
 
 
   2.3.9 IFN-α2b 
 
A stock solution [106U/ml] was aliquoted without dilution and stored at -70°C in the 
freezer.  When it was required to be used, it was thawed at room temperature and 
diluted in culture medium if necessary to achieve desired final concentrations. 
 
 
   2.3.10 Non-essential amino acids (NEAA) 
 
Sterile NEAA solution [100x stock] was stored at 4°C in the fridge. 
 
 
   2.3.11 Ionomycin 
 
A stock solution of 0.5mg/ml was made up by adding ethanol to ionomycin powder in 
the laminar flow hood.  This was then aliquoted and stored at -20°C in the freezer 
until use.  When it was required to be used, it was thawed at room temperature and 
diluted 1:10 in RPMI 1640 Dutch Modification.  Appropriate amount was then added 
to provide a final concentration of 1μg/ml. 
 
 
   2.3.12 L-Glutamine 
 
Glutamine stock solution [200mM] was thawed in a 37C water bath and aliquoted in 
5ml volumes under aseptic condition.  Aliquots were then refrozen and stored at -
20C in the freezer.  When it was required to be used, it was thawed in a 37C water 
bath in order to be used in tissue culture media at a final concentration of 2mM. 
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   2.3.13 Lipopolysaccharides (LPS) 
 
A stock solution of 1mg/ml was made up by adding sterile PBS to stock powder and 
aliquoted under aseptic conditions.  Aliquots were stored at -20°C in the freezer.  
When it was required to be used, it was thawed at room temperature and diluted in 
culture medium if necessary to achieve desired final concentrations. 
 
 
   2.3.14 Phosphate buffered saline (PBS) 
 
PBS was prepared following the manufacturer’s instructions.  Each PBS tablet was 
dissolved in 200ml of deionised water with a magnetic stirrer.  Sterile PBS was 
prepared in aseptic conditions by placing PBS in a 25ml syringe and filtering through 
a 0.22M filter. 
 
 
   2.3.15 PDSAg 
 
A stock solution of 1mg/ml peptide was made up by adding sterile PBS to stock 
powder and aliquoted under aseptic conditions.  Aliquots were stored at -20°C in the 
freezer.  When it was required to be used, it was thawed at room temperature and 
diluted in culture medium if necessary to achieve desired final concentrations. 
 
 
   2.3.16 Permwash buffer 
 
Concentrated Permwash buffer was diluted 1:10 in deionised water before use.  
Once diluted, the solution was stored at 4C and used within 7 days. 
  
  
119 
 
   2.3.17 Phorbol myristate acetate (PMA) 
 
A stock solution of 1mg/ml was made up by dissolving PMA powder in DMSO under 
aseptic condition.  This was then aliquoted and stored at -20°C in the freezer until 
use.  When it was required to be used, it was thawed at room temperature and 
diluted 1:1000 in RPMI 1640 Dutch Modification.  Appropriate amount was then 
added to achieve a final concentration of 25ng/ml. 
 
 
   2.3.18 Phytohemagglutinin (PHA) 
 
A stock solution was made up to 1mg/ml by adding sterile PBS to powder under 
aseptic condition and aliquoted.  Aliquots of PHA were stored at -20°C in the freezer 
until use.  When it was required to be used, it was thawed at room temperature and 
diluted 1:10 in RPMI Dutch Modification.  Appropriate amount was then added to 
provide a final concentration of 1μg/ml. 
 
 
   2.3.19 Purified mouse anti-human CD3 antibody 
 
Stock solution [0.5mg/ml] was stored at 4°C in the fridge.  During cell culture, this 
was diluted 1:1000 in RPMI 1640 Dutch Modification and appropriate amount was 
added to achieve a final concentration of 5ng/ml. 
 
 
   2.3.20 Purified mouse anti-human CD28 antibody 
 
Stock solution [0.5mg/ml] was stored at 4°C in the fridge.  During cell culture, this 
was diluted 1:10 in RPMI 1640 Dutch Modification and appropriate amount was 
added to achieve a final concentration of 1μg/ml. 
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   2.3.21 Sodium pyruvate 
 
Sterile sodium pyruvate solution was stored at 4°C in the fridge. 
 
   2.3.22 T cell medium 
 
T cell medium was prepared using RPMI 1640 Dutch Modification or in the case of 
Th1/Th17 in vitro experiments, Iscove's modified Dulbecco's medium (IMDM).  In 
aseptic conditions 67.5ml of medium was removed from a 500ml bottle of medium.  
The bottle of medium was then supplemented with FCS [10% v/v], 1% sodium 
pyruvate [1mM], 1% non-essential amino acids [1mM], L-glutamine [2mM], 
gentamicin [50g/ml] and 2-mercaptoethanol [2x10-5 M], and stored at 4°C until use.  
Once the medium was made, it was used within 14 days. 
 
 
   2.3.23 Tropomyosin 
 
A stock solution of 5mg/ml was made up by adding sterile RPMI to lyophilised 
powder under aseptic conditions and stored at 4°C in the fridge until use.  When it 
was required to be used, it was then diluted in culture medium if necessary and 
appropriate amount was added in order to achieve desired final concentrations. 
 
 
   2.3.24 Zymosan 
 
In order to make a stock solution of 1mg/ml, 5ml of ethanol was added to 50mg of 
zymosan powder in a 50ml container under aseptic conditions.  The mixture was 
vortexed to homogenise before the addition of 45mls of sterile endotoxin-free water.  
This was then stored at 4°C in the fridge until use.  When it was required to be used, 
it was then diluted in culture medium if necessary and appropriate amount was 
added in order to achieve desired final concentrations. 
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   2.4 Subjects and blood samples for ex vivo studies 
 
Patients with systemic and/or ocular features of BD, who required systemic 
treatment with steroids and a second line agent, or second line agent(s) alone, were 
recruited at several hospitals including Moorfields Eye Hospital.  The diagnosis of BD 
was based on clinical criteria of the International Study Group for BD.  On enrolment 
to the trial, all patients have consented to their blood being used for immune studies 
and this therefore provides valuable resources to investigate the mechanisms 
involved in inducing disease remission.  The trial has already completed recruitment 
and ethic’s permission was obtained for blood samples to be collected as part of the 
trial.  Only patients recruited at Moorfields Eye Hospital were included in this study. 
 
Patients were randomised to receive IFN-α2b therapy or stay on the conventional 
treatment alone.  For the treatment group, long-acting once weekly pegylated IFN-
α2b (Schering-Plough, USA) was given subcutaneously for 6 months, in addition to 
the drug regimen that would normally be used to control patients’ disease activity.  
The dosage of the IFN-α therapy is shown in Table 2.2.  Attempts were made in both 
groups to reduce systemic steroid requirement to ≤10mg daily gradually over the first 
3-6 months and to stop the second line immunosuppressive agents.  The daily 
prednisolone dosage and the combinations of immunosuppressive treatment for the 
two groups of BD patients on the IFN-α trial at baseline visits are shown in Table 2.3 
and Table 2.4. 
 
 
Table 2.2 IFN-α2b treatment dose for trial patients with Behcet’s disease 
Dosage table of weekly administration of subcutaneous pegylated IFN-α2b.  The 
dose is adjusted according to body weight. 
Patient weight (kg) Dosage of weekly pegylated IFN-α2b (μg) 
50-100 30 
101-116 35 
117-133 40 
134-149 45 
150-165 50 
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Table 2.3 Prednisolone dosage for the two groups of trial patients at baseline 
Dosage table of the daily intake of oral prednisolone for patients in the conventional 
treatment group and the IFN-α treated group. 
Treatment Standard treatment group 
Mean (range) of dosage in mg 
IFN-α therapy group 
Mean (range) of dosage in mg 
Prednisolone 11.6 (0-60) 9.9 (0-25) 
Abbreviation: mg=milligrams 
 
 
Table 2.4 Immunosuppressive treatment for the two groups of trial patients at 
baseline 
Treatment Standard treatment group 
No. (%) of patients 
IFN-α therapy group 
No. (%) of patients 
Pred + CSA + MMF 2 (9.5) 2 (9.5) 
Pred + AZA + CSA 2 (9.5) 2 (9.5) 
Pred + CSA 1 (4.8) 3 (14.3) 
Pred + MMF 4 (19.0) 3 (14.3) 
Pred + AZA 4 (19.0) 1 (4.8) 
Pred + MTX 2 (9.5) 0 
Pred 2 (9.5) 6 (28.6) 
AZT 2 (9.5) 0 
MMF 0 1 (4.8) 
Etanercept 1 (4.8) 0 
None 1 (4.8) 3 (14.3) 
Abbreviations: Pred=prednisolone; CSA = cyclosporin A; MMF=mycophenolate 
mofetil; MTX=methotrexate; AZA=azathioprine 
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Whenever ocular or systemic relapse occurred, the patients were assessed by the 
trial doctors and medications, other than IFN-α2b, were adjusted accordingly.  To 
take rapid control over the intraocular or systemic inflammation during a relapse, 
topical or systemic corticosteroids were utilised.  Following control of intraocular 
inflammation, dose of systemic corticosteroids was rapidly tapered to a maximum of 
10mg per day prednisone equivalent or discontinued.  Occasionally, introduction of 
another second line agent was required in order to contain repeated relapses, 
especially in patients on conventional treatment alone. 
 
IFN-α2b therapy was discontinued after 6 months and the follow-up period is 3 years 
for each trial patient.  The first blood samples were obtained at baseline visits and in 
the case of IFN-α2b treatment group, before the commencement of IFN-α2b therapy.  
After that, serial blood samples were taken from both groups at formal assessment 
visits at 3, 6, 12 and 24 month follow-ups.  As I am not involved in the long-term 
follow-ups of these patients, my data are focused solely on detecting the changes in 
the first 12 months. 
 
 
   2.5 Sample preparation 
 
   2.5.1 Study on patients with BD 
 
Bloods were taken from patients by venous puncture into both heparinised and non-
heparinised tubes.  Apart from using whole blood for various immunoassays, serum, 
PBMC, RNA, DNA and cell culture supernatants were collected for future studies.  
To collect serum, non-heparinised tubes containing venous blood from patients were 
centrifuged at 3000rpm for 10 minutes.  Each 500μl of serum was placed in 1.8ml 
cryotubes and stored at -70°C in the freezer.  With regards to samples in heparinised 
tubes, a small aliquot of blood was firstly spotted onto FTA Elute Cards (Whatman 
plc, UK) to store DNA for each patient.  The amount of whole blood required for 
phenotyping, intracellular cytokine staining and PCNA proliferation assays were set 
aside, and the remaining BD patient blood was processed to collect PBMC. 
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PBMCs were isolated by differential density centrifugation.  15ml of Histopaque-1077 
solution was placed in a 50ml Leucosep tube (Greiner Bio-one, Germany) and 
centrifuged for 90 seconds at 1000g to allow the histopaque to go beneath the filters 
in the tubes.  After that, the blood was diluted 1:1 with RPMI 1640 Dutch Modification 
before being added onto the filters within the Leucosep tubes under aseptic 
conditions.  These tubes were then centrifuged for 12 minutes at 1000g (Fig 2.1).  
After centrifugation, mononuclear cells were retrieved from the enriched cell fraction 
above the porous barrier by means of a Pasteur pipette.  The porous barrier is for 
avoiding recontamination with pelleted erythrocytes and granulocytes.   
 
The cells were then washed with 10ml of sterile RPMI and centrifuged twice at 400g.  
1 ml of RPMI 1640 Dutch Modification was added to the cell pellet to resuspend the 
cells before the number of cells was counted in a haemocytometer.  Cell viability was 
determined by Trypan Blue exclusion.  1x106 cells were taken from each patient visit 
and placed in a 1.5ml microcentrifuge tubes with 300μl of RNAprotect cell reagent 
(Qiagen, UK) for immediate RNA stabilisation.  These were stored at -70°C for future 
RNA studies.  Those PBMC which were not used were put in two 1.8ml cryotubes for 
each patient and pre-cooled before mixing 1:1 with DMSO buffered with 20% FCS 
under aseptic conditions.  Cryotubes were immediately wrapped in paper to insulate 
and placed in the freezer at -70°C for 1-2 days.  Afterwards, PBMC were transferred 
to liquid nitrogen tanks for long term storage. 
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Fig 2.1: Schematic figure of a density gradient centrifugation 
Anticoagulated venous blood is layered onto Histopaque-1077.  During centrifugation, 
erythrocytes and granulocytes are aggregated by polysucrose and rapidly sediment; 
whereas, lymphocytes and other mononuclear cells remain at the plasma-Histopaque-1077 
interface.  Erythrocyte contamination is negligible (Sigma-Aldrich product information, 2009). 
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   2.5.2 PBMC preparation for in vitro studies 
 
PBMCs were isolated by differential density centrifugation.  15ml of Histopaque-1077 
solution was placed in 50ml Leucosep tubes and centrifuged for 90 seconds at 
1000g.  Buffy coats obtained from normal healthy adult donors (North London Blood 
Transfusion Service) were diluted 1:5 with RPMI 1640 Dutch Modification under 
sterile conditions.  After that, diluted buffy coats were added directly onto the filters 
within the Leucosep tubes.  These tubes were then centrifuged for 12 minutes at 
1000g.  After centrifugation, mononuclear cells were retrieved from the enriched cell 
fraction above the porous barrier by means of a Pasteur pipette. 
 
The cells were then washed with 10ml of sterile RPMI 1640 Dutch Modification and 
centrifuged twice at 400g.  10ml of RPMI 1640 Dutch Modification was added to the 
cell pellet to resuspend the cells before the number of cells was counted in a 
haemocytometer.  Cell viability was determined by Trypan Blue exclusion.  In each 
1.8ml cryotube, 1x107 pre-cooled cells suspended in 500μl of RPMI 1640 Dutch 
Modification were mixed 1:1 with DMSO buffered with 20% FCS.  Cryotubes were 
immediately wrapped in paper to insulate and placed in the freezer at -70°C for 1-2 
days.  Afterwards, PBMCs were transferred and stored at -196ºC in liquid nitrogen 
tanks.  Healthy donor PBMCs obtained this way were used in all in vitro experiments, 
except in some preliminary experiments testing the polarising effects of tropomyosin 
and PDSAg, where PBMCs from BD patients were used instead. 
 
 
   2.5.3 Thawing of PBMCs 
 
20ml of RPMI 1640 Dutch Modification with 10% FCS was prepared for each tube of 
cryo-preserved PBMCs and the medium was warmed in a 37°C water bath until use.  
Sufficient amount of cryotubes containing cryo-preserved PBMCs required for 
experiments were taken out of storage in liquid nitrogen tank and thawed quickly in a 
37°C water bath.  The tubes were swirled around to facilitate thawing of cells.  As 
soon as PBMCs were defrosted, they were added drop-wise into the warm medium 
under aseptic conditions.  These were then centrifuged for 10 minutes at 400g.  
Supernatants were decanted and pellets of cells were resuspended.  Cells were 
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washed again with warm RPMI 1640 Dutch Modification containing 10% FCS to 
remove DMSO.  Cells were counted in a haemocytometer and viable cells were 
determined by Trypan Blue exclusion.  Appropriate amount of T cell medium, either 
RPMI 1640 Dutch Modification- or IMDM-based, was then added to achieve 1 x 106 
live PBMC in each 750μl of medium.  During in vitro experiments, these were further 
diluted with the addition of various reagents and T cell medium to reach a final 
concentration of 1 x 106 cells/ml. 
 
 
   2.6 Experimental assays 
 
   2.6.1 Cell surface phenotyping in patients with BD ex vivo 
 
Whole blood studies were performed so that drugs were still present in the blood.  
Changes in cell surface phenotype were evaluated using fluorochrome-conjugated 
antibodies and flow cytometry.  100µl aliquots of whole blood were placed in 1.5ml 
microcentrifuge tubes and stained with 5µl of anti-surface marker antibodies and the 
surface markers examined included CD3, CD4, CD8, CD25, CD56, TCRαβ and 
TCRγδ.  These were left in the dark at room temperature for 30 minutes before red 
cell lysis was carried out with the addition of 1ml 1x FACS lysing solution according 
to manufacturer’s instructions and left in the dark for 10 minutes.  Afterwards, 
samples were centrifuged at 4000rpm for 4 minutes.  Supernatants were decanted 
and washing was carried out using 1ml of PBS.  These samples were stored in 300μl 
of PBS at 4ºC until ready for flow cytometry. 
 
In addition, intracellular expression of Foxp3 was examined in these experiments.  
After red cell lysis and decanting of supernatants, cells were fixed and permeabilised 
with 100μl of Cytofix/Cytoperm in keeping with manufacturer’s instructions for 20 
minutes at 4°C.  1ml of Permwash was then added to microcentrifuge tubes to keep 
cells permeabilised and to serve as an antibody diluent and cell wash buffer.  
Subsequently, samples were incubated with 5μl of anti-Foxp3 antibodies for 30 
minutes at 4°C.  1ml of Permwash was applied again before finally keeping the cells 
in 200µl of PBS at 4ºC until ready for flow cytometry.  
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   2.6.2 Intracellular cytokine staining in patients with BD 
 
Whole blood was diluted 1:1 with RPMI 1640 Dutch Modification medium and 
aliquoted, 200µl/well, in 96 well flat bottom cell culture plates.  Cell cultures were 
unstimulated, stimulated with anti-CD3 [5ng/ml] and anti-CD28 [1μg/ml] monoclonal 
Abs, or a combination of PMA [25ng] and ionomycin [1μg/ml] for 24 hours.  BFA 
[10μg/ml] was added to all cell cultures to prevent protein secretion and allow 
accumulation of cytokines within cells.  After incubating overnight (approximately 22 
hours) at 37°C in a humidified 5% CO2 atmosphere, cells were transferred to 1.5ml 
microcentrifuge tubes before staining.  Staining of surface markers was performed 
with 5μl of fluorochrome-conjugated anti-CD3, CD4 and CD25 Abs or matched 
isotype control mAbs for 30 minutes at room temperature in the dark.  Red cell lysis 
was carried out with 1ml 1x FACS lysing solution as described in Section 2.6.1.  
Subsequently, cells were fixed and permeabilised with 100μl of Cytofix/Cytoperm 
and incubated at 4°C for 20 minutes. 
 
Cells in each tube were washed with 1ml 1x Permwash before staining with 
fluorochrome-conjugated anti-cytokine antibodies including IFN-γFITC (5μl), IL-2PE 
(5μl), IL-4FITC (50μl of 1:150 dilution with 1x Permwash) , IL-10PE (50μl of 1:50 
dilution with 1x Permwash), IL-10APC (25μl of 1:250 dilution with 1x Permwash), TNF-
α (5μl), IL-17 (5μl), and TGF-β1 (5μl), as well as anti-Foxp3 Ab (5μl) and matched 
isotype controls (5μl of 1:50 dilution with 1x Permwash) for 30 minutes.  Incubations 
were carried out in the dark in order to prevent fluorochrome from photobleaching.  
Finally, washing in Permwash was carried out and samples were stored in 200µl of 
PBS at 4ºC until acquisition of data with flow cytometry. 
 
 
   2.6.3 PCNA proliferation assay in patients with BD 
 
Whole blood was diluted 1:5 with RPMI 1640 Dutch Modification and aliquoted, 
250μl/well, in 24 well flat bottom cell culture plates.  Cells were stimulated with anti-
CD3 [5ng/ml] and anti-CD28 [1μg/ml] mAbs, PHA [1μg/ml], and a selection of 
antigens, including recall Ag tuberculin purified protein [0.1, 0.5, 1, 5, and 10μg/ml] 
(Statens Seruminstitut, Denmark), and putative Behcet’s Ags such as PDSAg [0.5, 1, 
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2.5, and 5μg/ml], α-tropomyosin [0.01, 0.1, 1, 10μg/ml], and heat shock protein 60 [5, 
10, 50μg/ml] (HSP60, aa336-351; Biotrend, Germany).  In each well, the volume was 
made up to 500μl/well with RPMI 1640 Dutch Modification and the plates were then 
incubated in an incubator with 5% CO2 at 37°C for 5 days.  Aliquots of supernatants 
from these cultures were taken at 24hours under aseptic conditions and stored at -
70ºC for future studies as well. 
 
After 5 days, content of the wells was transferred to 5ml polystyrene round bottom 
test tubes and red cell lysis was performed with 3.5ml 1x FACS lysing solution.  After 
10 minutes in the dark at room temperature, cells were washed with 4ml of PBS and 
centrifuged at 300rcf for 5 minutes.  Supernatants were decanted and 1ml of 
methanol was added to each tube.  The content of each tube was mixed well by 
vortexing gently and cells were then incubated at 4°C for 30 minutes.  Afterwards, 
each tube of cells were washed with 3ml of PBS before adding 100μl of 
Cytofix/Cytoperm.  Again, cells were incubated at 4°C for 30 minutes.  Subsequently, 
cells were washed wtih 1x Permwash followed by adding 2.5μl of PCNAFITC (Abd 
Serotec, UK) to each tube.  The tubes were incubated overnight at 4°C.  On final day, 
each tube of cells were washed with 2ml 1x Permwash before adding 200μl to 
resuspend the cells.  Immediately before aquisition of data with flow cytometry, 2μl 
propidium iodide [1mg/ml] (Sigma-Aldrich, UK) was added to each tube. 
 
Although I have performed these proliferation assays and acquired some of the data 
in collaboration with my colleagues, this area was not the focus of my research and 
therefore I did not carry out analysis of data obtained from these assays. 
 
 
   2.6.4 Preliminary tests in vitro 
 
   2.6.4.1 PBMC stimulation with antigens and polyclonal stimuli 
 
In order to establish in vitro models to investigate the effects of IFN-α on T cells, 
required amount of frozen PBMCs were thawed as described in Section 2.5.3.  300μl 
(4x105 cells) of healthy donor PBMCs were placed in each well of 48 well flat bottom 
culture plates and these cells were untreated or stimulated with polyclonal stimuli, 
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including anti-CD3 [5ng/ml] and anti-CD28 [1μg/ml] Abs, and PMA [25ng/ml] and 
ionomycin [1μg/ml], or with Ags such as LPS; zymosan, Candida albicans, and 
ATRA.  In the case of BD-related antigens, such as PDSAg and α-tropomyosin, 
PBMCs from BD patients were used as a trial instead of healthy donor cells.  
Appropriate amount of T cell medium was then added to make up to 400μl for each 
well.  Cells were cultured in an incubator with 5% CO2 at 37°C for either 24 or 39 
hours.  BFA was added straight after the introduction of stimuli in cultures incubated 
over 24 hours.  In the case of 39 hour cultures, BFA was added after 15 hours of 
incubation.  At the end of cell culture, intracellular cytokine staining was carried out 
as described in Section 2.6.7.  Staining and data analysis were performed to 
examine IFN-γ and IL-17 producing CD4+ and γδ T cells, as well as CD4+ T cells 
expressing IL-10 and Foxp3. 
 
 
   2.6.4.2 Tests of the influence of 1 day resting on PBMC cultures in vitro 
 
It was examined whether resting frozen healthy donor PBMCs for one day in culture 
medium in the presence or absence of IL-2 after thawing could alter cytokine 
production by these cells.  On day 1, required amount of frozen healthy donor 
PBMCs were thawed as described in Section 2.5.3, and resuspended in IMDM-
based T cell medium.  600μl (8x105 cells) of PBMCs were placed in wells of 24 well 
flat bottom culture plates under aseptic conditions, except the wells designated for 
tests without resting the cells.  For half of these wells, suboptimal IL-2 [0.5U/ml] was 
added before T cell medium was added to make up to 800μl per well.  After 24 hours 
of incubation with 5% CO2 at 37°C, 600μl (8x10
5 cells) of freshly thawed frozen 
healthy donor PBMC were placed in the wells earmarked for tests without resting. 
 
Straight after, cells defrosted on both day 1 and day 2 were activated with polyclonal 
stimuli, including anti-CD3 [5ng/ml] and anti-CD28 [1μg/ml] Abs, and PMA [25ng/ml] 
and ionomycin [1μg/ml], or left untreated.  PHA [1μg/ml] was used as a trial stimulus 
as well.  BFA was added 2 hours after the introduction of stimuli to all wells, and cells 
were further incubated for 22 hours in an incubator with 5% CO2 at 37°C.  At the end 
of culture on day 3, intracellular cytokine staining was performed as described in 
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Section 2.6.7.  Staining and data analysis were carried out to examine IFN-γ and IL-
17 producing CD4+ and γδ T cell populations only. 
 
 
   2.6.4.3 Tests of the effects of medium choice on PBMC cultures in vitro 
 
On day 1, required amount of frozen healthy donor PBMCs were thawed as 
described in Section 2.5.3, and resuspended in either RPMI 1640 Dutch 
Modification- or IMDM-based T cell medium.  600μl (8x105 cells) of healthy donor 
PBMCs were placed in wells of 24 well flat bottom culture plates under aseptic 
conditions.  After that, cells were activated with polyclonal stimuli, including anti-CD3 
[5ng/ml] and anti-CD28 [1μg/ml] Abs, and PMA [25ng/ml] and ionomycin [1μg/ml], or 
left untreated.  T cell medium was then added to make up to 800μl per well.  BFA 
was added 2 hours after the introduction of stimuli to all wells, and cells were further 
incubated for 22 hours in an incubator with 5% CO2 at 37°C.  At the end of culture on 
day 2, intracellular cytokine staining was performed as described in Section 2.6.7.  
Staining and data analysis were carried out to examine IFN-γ and IL-17 producing 
CD4+ and γδ T cell populations only. 
 
 
   2.6.4.4 Tests of the influence of longer incubation time on PBMC cultures in 
vitro 
 
On day 1, required amount of frozen healthy donor PBMCs were thawed as 
described in Section 2.5.3, and resuspended in IMDM-based T cell medium.  600μl 
(8x105 cells) of healthy donor PBMCs were placed in wells of 24 well flat bottom 
culture plates under aseptic conditions.  After that, cells were activated with 
polyclonal stimuli, including anti-CD3 [5ng/ml] and anti-CD28 [1μg/ml] Abs, and PMA 
[25ng/ml] and ionomycin [1μg/ml], or left untreated.  T cell medium was then added 
to make up to 800μl per well.  Cells were incubated for 24 and 39 hours in an 
incubator with 5% CO2 at 37°C, and BFA was added in the last 22 hours of 
incubation for all wells.  At the end of culture, intracellular cytokine staining was 
performed as described in Section 2.6.7.  Staining and data analysis were carried 
out to examine IFN-γ and IL-17 producing CD4+ and γδ T cell populations only. 
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   2.6.5 Tests of the effects of recombinant IFN-α on PBMC cultures in vitro 
 
Required amount of frozen healthy donor PBMCs were thawed as described in 
Section 2.5.3, and resuspended in T cell medium.  600μl (8x105 cells) of healthy 
donor PBMCs were placed in wells of 24 well flat bottom culture plates under aseptic 
conditions.  After that, cells were treated with IFN-α2a (101-105 U/ml) or IFN-α2b 
(101-104 U/ml), or left untreated.  This was then followed by activation with polyclonal 
stimuli, including anti-CD3 [5ng/ml] and anti-CD28 [1μg/ml] Abs, and PMA [25ng/ml] 
and ionomycin [1μg/ml], or left alone without stimulation.  T cell medium was then 
added to make up to 800μl per well.  Cells were incubated for 24 hours, and in some 
earlier experiments 39 hours, in an incubator with 5% CO2 at 37°C, and BFA was 
added in the last 22 hours of incubation for all wells.  At the end of culture, 
intracellular cytokine staining was performed as described in Section 2.6.7. 
 
 
   2.6.6 Kinetics of the influence of IFN-α on PBMC cultures in vitro 
 
On day 1, required amount of frozen healthy donor PBMCs were thawed as 
described in Section 2.5.3, and resuspended in T cell medium.  600μl (8x105 cells) of 
healthy donor PBMCs were placed in wells of 24 well flat bottom culture plates under 
aseptic conditions.  One-fifth of the wells were treated with 104 U/ml IFN-α2a straight 
away before incubation in an incubator with 5% CO2 at 37°C.  24 hours later on day 
2, half of the wells were stimulated with PMA [25ng/ml] in combination with 
ionomycin [1μg/ml], and the other half was left alone without stimulation.  In addition, 
104 U/ml IFN-α2a was added to one-fifth of the wells for each of the 3 time-points at 
4 hours before, the same time as, or 4 hours after, the introduction of 
PMA/ionomycin on day 2.  T cell medium was added to make up to 800μl per well, 
and BFA was added in the last 22 hours of incubation for all wells.  At the end of 
culture, intracellular cytokine staining was performed as described in Section 2.6.7. 
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   2.6.7 Intracellular cytokine staining for in vitro cell cultures 
 
At the end of cell culture at 37°C in a humidified 5% CO2 atmosphere, cells were 
transferred from cell culture plates to 1.5ml microcentrifuge tubes.  Samples were 
centrifuged at 4000rpm for 4 minutes in order to take off supernatants.  Dispersed 
cells were then stained for surface markers with 5μl of fluorochrome-conjugated anti-
CD3, CD4, CD8, CD25 and TCRγδ antibodies (BD Biosciences) or matched isotype 
control mAb and cells were incubated in the dark for 30 minutes at room temperature.  
After that, each tube of cells was washed with 1ml of PBS and then fixed and 
permeabilised with 100μl of Cytofix/Cytoperm according to manufacturer’s 
instructions.  After 20 minutes of incubation at 4°C, each tube of cells was washed 
with 1ml 1x Permwash.  Subsequently,  intracellular staining was carried out with 
fluorochrome-conjugated anti-cytokine antibodies including IFN-γFITC (5μl), IFN-γAPC 
(5μl), IL-10PE (50μl of 1:50 dilution with 1x Permwash), IL-10APC (25μl of 1:250 
dilution with 1x Permwash), IL-17PE (5μl), and TGF-β1
PE (5μl), as well as anti-
Foxp3AlexaFluor488 (5μl), anti-Foxp3PE (5μl) and matched isotype controls (5μl of 1:50 
dilution with 1x Permwash) for 30 minutes at 4°C.  Cells were washed once more 
with 1x Permwash before 200μl PBS was added to each tube.  Samples were stored 
at 4ºC until ready for acquisition with flow cytometry. 
 
 
   2.7 Flow cytometry and analysis 
 
To quantify the populations of T cell subsets, acquisition was carried out using four-
colour FACSCalibur and CellQuest software (BD Biosciences).  Data analysis was 
performed using Winlist Version 3.0 (Verity Software House, USA).  At least 10,000 
events were acquired for all experiments in ex vivo studies, and in the case of 
samples stained with Foxp3, at least 25,000 events were attained.  For in vitro 
studies, at least 25,000 events were acquired for all samples except for preliminary 
experiments.  Viable lymphocytes were gated according to forward and side scatters, 
and careful attention was paid to avoid inclusion of debris and dead cells from 
analysis.  Flow cytometric determination of cytokines in the cytoplasm of peripheral 
CD3+, CD4+ and CD8+ T cells was performed.  Cytokine-positive T cells were 
defined by setting regions with the lower-limits for cytokine positivity determined from 
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unstimulated cultures.  Results were expressed as the percentages of cytokine-
producing cells in CD3+, CD4+ or CD8+ T cell populations.  For Treg cell analysis, 
CD4+CD25high T cells were defined by selecting those CD4+ lymphocytes whose 
CD25 expression exceeded the level of CD25 positivity seen on the CD4- population 
(usually more than 102 of fluorescence intensity) (Fig 4.2).  Also, unreactive isotype-
matched Abs were used as negative controls and to verify the amount of background 
staining, and as a guide for setting markers to delineate “positive” and “negative” 
populations. 
 
For data analysis in Chapters 3 and 4, data from follow-up assessment visits were 
compared to data from initial visits for BD patients.  The aims are to identify changes 
in immune cell and cytokine profile in IFN-α treated patients throughout the 12 month 
observation period and whether these alterations are distinct features when 
compared to those receiving conventional immunosuppressive therapy alone.  
Patients were analysed only when paired data were available.  That is, patients were 
not included in the analysis if either baseline or follow-up visits were missing.  Due to 
this same reason, 12 month visits were examined separately from 3 and 6 month 
ones as not all patients who have been through 3 and 6 months visits have data from 
12 month assessment visits.  This way, maximal numbers of patients could be 
included in the analysis of the 3 and 6 month data, and the disease modifying ability 
of IFN-α, even when patients were off treatment, could be examined separately.  
Also, some samples were omitted from the ex vivo experiments due to insufficient 
cell numbers, and these data were not included in the analysis.  In addition, less 
patient numbers were available for Th17 cell analysis in ex vivo intracellular cytokine 
staining experiments as these staining combinations were included after half way 
through the trial and baseline data were not available for more than half of BD 
patients. 
 
 
   2.8 Statistical analysis 
 
Statistical calculations were performed using Prism 5 (Graphpad Software, Inc, USA) 
for ex vivo BD patient data and Excel 2007 (Microsoft Corporation, USA) for in vitro 
data.  Wilcoxon signed-rank test and Student’s t-test were used for statistical 
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analysis of ex vivo and in vitro data respectively.  A p-value of <0.05 was taken to be 
significant and marked with ‘*’ on the figures (‘**’ if p-value was <0.01), unless 
otherwise stated in the figures.  Boxplots show the median and interquartile range 
(IQR) and the ends of the whiskers illustrate the minimum and maximum of all the 
data for individual variables. 
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Chapter 3 
Immunomodulatory effects of subcutaneous interferon-alpha 2b on 
conventional T helper subsets and their cytokines in patients with Behcet’s 
disease ex vivo 
 
 
   3.1 Introduction 
 
T helper (Th) cells are a heterogeneous population of lymphocytes that are involved 
in activating and directing other immune cells.  Mature Th cells are described to 
always express the surface protein CD4 (Zhu & Paul 2008).  Th cells play a central 
role in immune protection and orchestrate the magnitude and persistence of diverse 
immune responses through production of cytokines and chemokines (Zhu & Paul 
2008).  They are essential in helping B cells to produce antibodies in the primary 
response, in the activation and growth of cytotoxic T cells, and in maximising 
bactericidal activity of phagocytes such as macrophages.  Th cells are neither 
phagocytic nor cytotoxic (Zhu, Yamane, & Paul 2010). 
 
The reason for the heterogeneity of Th cells is mainly related to their protective 
function, because it enables the best type of response to combat pathogens and 
maintain immune homeostasis.  It is the diversity in function and their role in 
influencing other cells that gives T helper cells their name (Annunziato & Romagnani 
2009).  CD4+ T cells are generally treated as having a pre-defined role as helper T 
cells within the immune system, although there are known rare exceptions. For 
example, there are sub-groups of regulatory T cells, natural killer T cells, and 
cytotoxic T cells that are known to express CD4 (although cytotoxic examples have 
been observed in extremely low numbers in specific disease states, they are usually 
considered non-existent) (Gabriel, Morley, & Rogers 2009;van de Berg et al. 2008). 
All of the latter CD4+ T cell groups are not considered T helper cells. 
 
The initial understanding of the existence of distinctive populations of differentiated 
CD4+ T cells came from the analysis of mouse CD4+ T cell clones that were shown 
to be divisible into two major groups, designated Th1 and Th2 cells by Mosmann & 
Coffman (Mosmann & Coffman 1989).  Subsequently, distinct subpopulations of Th 
  
137 
 
cells similar to those first identified by Mosmann et al in mice are found also in 
humans (Del Prete et al. 1991).  Th1 and Th2 clones could be distinguished mainly 
by the cytokines produced by the cells, and through the expression of different 
patterns of cell surface molecules.  Establishment of a Th1/Th2 balance plays an 
important regulatory role in the immune system and imbalances of cytokine 
production contribute to immunopathologic conditions (Jager & Kuchroo 2010). 
 
With regard to cytokine expression, Th1 cells make IFN-γ as their signature cytokine 
and also uniquely produce lymphotoxin (TNF-β).  Th1 cells tend to be good IL-2 
producers, and many make TNF-α as well.  The most important function of Th1 cells 
is to promote cell-mediated immunity as they are crucial for activating macrophages 
and induce proliferation of cytotoxic CD8+ T cells.  Over-exuberant pro-inflammatory 
activities of Th1 cells can cause tissue damage and elicit unwanted inflammatory 
response.  By contrast, Th2 cells fail to produce IFN-γ or lymphotoxin.  Their 
signature cytokines are IL-4, IL-5, and IL-13. They also make TNF-α, and some 
produce IL-9.  Although initially thought to be unable to make IL-2, later results 
indicated that Th2 cells could often produce relatively modest amounts of IL-2 (Zhu, 
Yamane, & Paul 2010).  Th2 cells promote allergic reactions, and were viewed as 
the primary helpers of B cell responses and, therefore, autoantibody production 
(Palmer & Weaver 2010).  Both Th1 and Th2 cells also produce IL-10 (O'Garra & 
Vieira 2007). 
 
Behcet’s disease is a chronic, relapsing vasculitis of uncertain aetiology and 
immunopathogenesis which may produce distressing symptoms with the 
combinations of variable systemic involvements (Yates & Michelson 2006).  It is 
characterised by exacerbations and remissions with varying healing time among 
patients (Evereklioglu 2005).  There is strong evidence for generalized aberrant T 
cell responses in BD.  The percentage of CD4+ cells has been reported to be 
significantly lower in patients with BD as compared to healthy controls.  This is 
especially in the CD4+CD45RA+ subset and when patients are in the active phase of 
the disease.  On the other hand, increase in CD8+ cells have been observed among 
BD patients (Kahan, Hamzaoui, & Ayed 1992). 
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The examination of mucocutaneous biopsies of BD patients has revealed enhanced 
levels of IL-8, IL-10, monocyte chemoattractant protein 1 (MCP-1), IFN-γ and IL-12 
mRNA.  The parallel increase in IL-12 and IFN-γ expression within mucocutaneous 
lesions, associated with the absence of Th2-related cytokines IL-4 and IL-13, points 
to a strong polarised Th1 immune response (Ben Ahmed et al. 2004).  Observation 
of increased serum IL-18, a factor capable of inducing IFN-γ production (Gracie, 
Robertson, & McInnes 2003), and TNF-α levels in BD patients further supports Th1 
predominance (Oztas et al. 2005).  As IL-8 is a strong activator of neutrophil function, 
the upregulation of its level may support the implication of polynuclear cell 
hyperfunction in the pathogenesis of BD lesions (Ben Ahmed et al. 2004). 
 
BD patients on immunosuppressive treatment were recruited at various sites but 
blood samples were only collected from Moorfields Eye Hospital patients (more 
details in Chapter 2).  Patients were randomised into two groups with one group 
receiving additional 6 months of IFN-α therapy.  As Th1 predominance has been 
reported in BD patients and IFN-α treatment has been suggested to induce Th1-
related cytokines, especially IFN-γ (Simon et al. 2003;Takaoka et al. 2000).  The 
influence of subcutaneous IFN-α2b therapy was examined first on conventional αβ T 
cell subsets and related cytokines.  Given the significant role of γδ T cells in BD, its 
response following IFN-α treatment was examined as well and results were shown in 
a separate chapter (Chapter 7). 
 
 
   3.2 Aims 
 
IFN-α is known to exert pleiotropic effects and we aim to verify whether previously 
reported effects of IFN-α including the induction of Th1-related cytokines can be 
demonstrated following IFN-α treatment in BD patients.  More specifically, the 
influence of a 6-month course of subcutaneous pegylated IFN-α2b therapy on 
modulating conventional Th1 and Th2 subsets and the production of IFN-γ, TNF-α, 
IL-2 and IL-4 by peripheral blood lymphocytes before, during and after cessation of 
therapy are examined. 
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Another aim is to investigate the effect of pegylated IFN-α2b therapy on surface 
phenotype of T cells, such as CD4, CD8 and TCRαβ expression, in whole blood 
samples of BD patients. 
 
 
   3.3 Results 
 
The experiments presented here were performed in conjunction with Mr A 
Nouraeinejad and Ms G Galatowicz.  Approximately 70% of the samples used for 
data analysis in this section were processed by me, and all data analysis is my own 
work. 
 
 
   3.3.1 IFN-α therapy does not induce any changes in the surface CD4, CD8, 
and TCRαβ expression in T lymphocytes in BD patients 
 
To examine the influence of IFN-α therapy on CD4 and CD8 expression by 
peripheral blood T lymphocytes in BD patients and the proportions of TCRαβ-
expressing subpopulations within the CD4+ and CD8+ subsets, serial whole blood 
samples from BD patients receiving conventional immunosuppressive therapy with 
or without recombinant IFN-α2b treatment were phenotyped.  The CD4/CD8 
phenotyping results were obtained after gating on the CD3+ lymphocytes during 
analysis.  As shown in Figure 3.1, there was no significant alteration of the levels of 
either CD4 or CD8 surface expression on peripheral blood T lymphocytes in BD 
patients whether they were on IFN-α or not. 
 
As for the assessment of TCRαβ expression, presence of CD8 surface protein was 
used to discriminate between CD4+ and CD8+ T cell population after gating on 
lymphocytes.  Like the individuals on conventional immunosuppressive treatment, no 
significant effect on the TCRαβ expression was consistently displayed by the 
patients on IFN-α therapy (Figure 3.2). 
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Fig 3.1: IFN-α therapy does not change the percentage of CD4+ or CD8+ lymphocytes 
Whole blood from BD patients receiving either the conventional treatment alone (n=16) or 
with IFN-α2b therapy (n=15) were obtained at 0, 3, 6 and 12 month assessment visits.  
These samples were stained with anti-CD3, anti-CD4, and anti-CD8 antibodies.  (a), The 
graph shows percentages of the CD4+ fraction.  (b), The graph displays the proportions of 
CD8+ T cells.  The results are presented as boxplots. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.2: IFN-α therapy does not change the percentage of TCRαβ expression in either 
CD4+ or CD8+ lymphocytes 
Whole blood from BD patients receiving either the conventional treatment alone (n=13) or 
with IFN-α2b therapy (n=12) were obtained at 0, 3, 6 and 12 month assessment visits.  
These samples were stained with anti-CD8, and anti-TCRαβ antibodies.  (a), The graph 
shows percentages of the TCRαβ expression in the CD4 T cells.  (b), The graph displays the 
proportions of the TCRαβ expression in the CD8 T cells.  The results are presented as 
boxplots. 
(a)
0 3 6 12 0 3 6 12
0
20
40
60
80
100
*
Conventional
treatment alone
IFN- therapy in
the first 6 months
(n=16)      Months      (n=15)
%
 o
f 
C
D
4
+
 e
x
p
re
s
s
io
n
 
(b) 
0 3 6 12 0 3 6 12
0
20
40
60
80
100 Conventional
treatment alone
IFN- therapy in
the first 6 months
(n=16)      Months      (n=15)
%
 o
f 
C
D
8
+
 e
x
p
re
s
s
io
n
 
(a) 
0 3 6 12 0 3 6 12
0
20
40
60
80
100
Conventional
treatment alone
IFN- therapy in
the first 6 months
(n=13)      Months      (n=12)
%
 o
f 
C
D
8
-
T
C
R


+
 e
x
p
re
s
s
io
n
 
(b) 
0 3 6 12 0 3 6 12
0
20
40
60
80
100 Conventional
treatment alone
IFN- therapy in
the first 6 months
(n=13)      Months      (n=12)
%
 o
f 
C
D
8
+
T
C
R


+
 e
x
p
re
s
s
io
n
 
   
 
 
   
  
141 
 
   3.3.2 IFN-α2b therapy upregulates IFN-γ expression by T cells in BD patients 
 
To investigate the effects of IFN-α on signature Th1 cytokine, IFN-γ, serial whole 
blood samples from BD patients on conventional immunosuppressive therapy with or 
without additional IFN-α2b treatment were studied using intracellular cytokine 
staining method and flow cytometry.  Cell cultures were either untreated or treated 
with anti-CD3/CD28 Abs or PMA/ionomycin for 24 hours before staining.  Cytokine 
production was analysed by gating on either CD3+ or CD4+ lymphocyte populations. 
 
In terms of IFN-γ+ production by CD3+ T cells in untreated cultures (Fig 3.3a), a 
significant increase was detected in the IFN-α2b-treated group at 3 months after 
initiation of therapy (median 0.7% and IQR 0.5-1.3%; p<0.05) as compared to data 
from baseline visits (median 0.4% and IQR 0.3-0.7%).  This upregulation of IFN-γ 
level was maintained at 6 month visits (median 0.7% and IQR 0.4-0.9%; p<0.05) and 
even after cessation of therapy at 12 months (median 1.0% and IQR 0.6-1.5%; 
p<0.01) in the IFN-α treated patients.  In cultures stimulated with PMA/ionomycin 
(Fig 3.3b), such enhancement of IFN-γ-expressing cells was only observed at 12 
month follow-ups (median 9.0% and IQR 6.5-11.0%; p<0.05) as compared to initial 
visits (median 4.6% and IQR 3.3-7.9%).  In CD3/CD28 stimulated cultures, no 
significant change in levels was detected in either group of BD patients (data not 
shown).  Similarly, a tendency to increase in IFN-γ expression was evident in CD4+ T 
cells (Fig 3.4) from patients with IFN-α treatment, however, none of the results was 
statistically significant. 
 
No change in IFN-γ production by either CD3+ or CD4+ T cells was identified in the 
individuals on conventional immunosuppressants alone.  However, a significantly 
decreased expression by CD4+ T cells was found in 12 month visit samples after 
activation with PMA/ionomycin (median 6.8% and IQR 3.3-10.4%; p<0.05) as 
compared to baseline visit ones (median 4.0% and IQR 1.4-6.7%) (Fig 3.4b). 
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Fig 3.3: Upregulation of IFN-γ expression with IFN-α therapy in CD3+ T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months.  These were stained with anti-CD3 surface antibodies before 
intracellularly with anti-IFN-γ antibodies.  The data are shown as percentages of IFN-γ+ cells 
among CD3+ lymphocytes.  Of the patients presented here, 17 (14) BD patients were on 
conventional treatment alone and 15 (14) were on IFN-α2b therapy as well.  The number in 
brackets denotes the number of patients represented in the 12 month data.  In (a), results 
were from untreated cell cultures; in (b), results were from cell cultures stimulated with PMA 
and ionomycin.  All results are presented as boxplots. 
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Fig 3.4: Tendency of IFN-γ expression to upregulate with IFN-α therapy in CD4+ T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months.  These were stained with anti-CD4 surface antibodies before 
intracellularly with anti-IFN-γ antibodies.  The data are shown as percentages of IFN-γ+ cells 
among CD4+ lymphocytes.  Of the patients presented here, 9 (7) BD patients were on 
conventional treatment alone and 6 (6) were on IFN-α2b therapy as well.  The number in 
brackets denotes the number of patients represented in the 12 month data.  In (a), results 
were from untreated cell cultures; in (b), results were from cell cultures stimulated with PMA 
and ionomycin.  All results are presented as boxplots.  ns=not significant. 
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   3.3.3 IFN-α2b therapy enhances TNF-α expression by T cells in BD patients 
 
Using intracellular cytokine staining method as described in Materials and Methods, 
the influence of IFN-α on TNF-α expression in T cells were examined.  Cell cultures 
were either untreated or activated with anti-CD3/CD28 Abs or PMA/ionomycin for 24 
hours before staining.  Cytokine expression was analysed by gating on CD3+ 
lymphocytes. 
 
Overall, no significant alteration in the amount of TNF-α produced by CD3+ T cells 
was demonstrated consistently in either groups of BD patients.  In the group on 
conventional treatment alone, no significant variation in TNF-α expression levels by 
CD3+ T cells was detected. 
 
In the IFN-α treatment group, there appeared to be a trend for heightened TNF-α 
levels.  In CD3/CD28 stimulated cultures (median 1.4% and IQR 0.8-2.8%; p<0.05) 
(Fig 3.5a), an upregulation of TNF-α production was noticeable after 6 months of 
treatment, when compared to values before initiation of IFN-α therapy (median 0.8% 
and IQR 0.5-1.0%).  The trend of increased expression was also evident in the 12 
month data, as the median levels were augmented from 3.2% (IQR 1.3-5.4%) at 
baseline visits to 10.0% (IQR 6.7-13.6%; p<0.01) in cultures stimulated with 
PMA/ionomycin (Fig 3.5b).  Additionally, significant upregulation was observed in the 
12 month untreated samples (median 0.8% and IQR 0.6-1.2%; p<0.05) when 
evaluating against the numbers obtained from earliest visits (median 0.5% and IQR 
0.4-0.8%) (data not shown). 
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Fig 3.5: Enhancement of TNF-α expression with IFN-α therapy in CD3+ T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months.  These were stained with anti-CD3 surface antibodies before 
intracellularly with anti-TNF-α antibodies.  The data are shown as percentages of TNF-α+ 
cells among CD3+ lymphocytes.  Of the patients presented here, 17 (14) BD patients were 
on conventional treatment alone and 15 (14) were on IFN-α2b therapy as well.  The number 
in brackets denotes the number of patients represented in the 12 month data.  In (a), data 
were from cell cultures with CD3/CD28 stimulation; in (b), data were from cell cultures 
stimulated with PMA and ionomycin.  All results are presented as boxplots.  ns=not 
significant. 
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   3.3.4 IFN-α2b therapy increases IL-2 expression by T cells in BD patients 
 
Analysis of the effects of IFN-α on IL-2 production by CD3+ T cells was approached 
by using intracellular cytokine staining on whole blood samples as described in 
Materials and Methods.  Cell cultures were either untreated or activated with anti-
CD3/CD28 Abs or PMA/ionomycin for 24 hours before staining.  Cytokine expression 
was analysed by gating on CD3+ lymphocytes. 
 
From our data, there was a global enhancement of IL-2 production by CD3+ T cells in 
the IFN-α treatment group.  In CD3/CD28 stimulated cultures (Fig 3.6a), the levels 
were significantly increased at 3 months (median 0.6% and IQR 0.2-1.4%; p<0.05) 
and 6 months (median 0.5% and IQR 0.3-1.1%; P<0.05) when compared to the data 
from initial visits (median 0.2% and IQR 0.2-0.6%).  This upregulation was still 
evident when evaluating 12 month data (median 0.7% and IQR 0.5-1.6%; p<0.01) 
against baseline ones (median 0.3% and IQR 0.2-0.6%).  Similar results were 
observed in cultures stimulated with PMA and ionomycin as well (Fig 3.6b).  When 
compared to data from initial ones (median 1.8% and IQR 0.8-6.7%), the proportion 
of CD3+ T cells expressing IL-2 was increased as early as at 3 months (median 7.4% 
and IQR 1.3-29.9%; p<0.05) following initiation of IFN-α therapy.  Consistently, the 
median levels were enhanced from 2.2% (IQR 0.7-7.7%) before initiation of IFN-α 
therapy to 9.4% (IQR 5.1-14.3%; p<0.05) at 12 months.  Furthermore, similar results 
of IL-2 expression upregulation were found with data acquired from untreated 
samples (data not shown). 
 
In the group on conventional treatment alone, no significant alteration in the 
expression of IL-2 by CD3+ T cells was detected with the exception of a decrease 
observed in CD3/28 stimulated samples when comparing 3 month values (median 
0.6% and IQR 0.3-1.3%) with the 6 month ones (median 0.4% and IQR 0.2-0.5%; 
p<0.05) (Fig 3.6a). 
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Fig 3.6: Upregulation of IL-2 expression with IFN-α therapy in CD3+ T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months.  These were stained with anti-CD3 surface Ab before intracellularly with 
anti-IL-2 Ab.  The data are shown as percentages of IL-2+ cells among CD3+ lymphocytes.  
Of the patients presented here, 16 (15) BD patients were on conventional treatment alone 
and 14 (13) were on IFN-α2b therapy as well.  The number in brackets denotes the number 
of patients represented in the 12 month data.  In (a), data were from cell cultures with 
CD3/CD28 stimulation; in (b), data were from cell cultures stimulated with PMA and 
ionomycin.  All results are presented as boxplots. 
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   3.3.5 IFN-α2b therapy upregulates IL-4 expression by T cells in BD patients 
 
To investigate the effects of IFN-α on signature Th2 cytokine, IL-4, serial whole blood 
samples from BD patients were studied using intracellular cytokine staining method 
as described in Materials and Methods.  Cell cultures were either untreated or 
activated with anti-CD3/CD28 Abs or PMA/ionomycin for 24 hours before staining.  
Cytokine expression was analysed by gating on CD3+ lymphocytes. 
 
Similar to IL-2 data, there was a generalised upregulation of IL-4 production by CD3+ 
T cells in the IFN-α treatment group throughout the 12 month observation period.  In 
CD3/CD28 stimulated cultures (Fig 3.7a), the levels of IL-4 expression by CD3+ T 
cells were significantly elevated at 3 months (median 0.7% and IQR 0.3-1.1%; 
p<0.05) and 6 months (median 0.5% and IQR 0.4-0.9%; p<0.05) when evaluated 
against the levels at initial visits (median 0.4% and IQR 0.1-0.5%).  This 
augmentation of IL-4 expression was still evident in data obtained from the 12 month 
visit samples (median 0.7% and IQR 0.3-1.1%; p<0.05) when compared to initial 
assessment visits (median 0.4% and IQR 0.1-0.5%).  Similarly, in cultures stimulated 
with PMA and ionomycin (Fig 3.7b), the proportion of CD3+ T cells producing IL-4 
was upregulated when comparing 3 month data (median 1.3% and IQR 0.8-2.6%; 
p<0.01) with initial ones (median 0.7% and IQR 0.4-1.0%).  This increase in IL-4 
expression could still be demonstrated at 12 month assessments as the median 
levels of IL-4 were upregulated from 0.7% (IQR 0.4-0.8%) at baseline to 1.5% (IQR 
1.2-2.4%; p<0.01) at 12 months.  Consistently, augmentation of IL-4 expression was 
also observed in the untreated samples at 3, 6 and 12 months (data not shown). 
 
In the group on conventional treatment alone, no significant change in the production 
of IL-4 by CD3+ T cells was shown when comparing follow-up visit data to the initial 
visit ones.  However, in CD3/28 stimulated samples, the levels of IL-4 expression 
was downregulated at 6 months (median 0.3 and IQR 0.2-0.4%; p<0.01) when 
compared to 3 month values (median 0.6% and IQR 0.4-0.9%) (Fig 3.7a).  Likewise, 
in cultures stimulated with PMA/ionomycin, there was significant reduction of the 
proportions of CD3+ T cells-expressing IL-4 at 6 months (median 0.8% and IQR 0.4-
0.9%; p<0.01) when evaluated against 3 month data (median 1.2% and IQR 0.9-
2.8%) (Fig 3.7b). 
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Fig 3.7: Augmentation of IL-4 expression with IFN-α therapy in CD3+ T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months.  These were stained with anti-CD3 surface Ab before intracellularly with 
anti-IL-4 Ab.  The data are shown as percentages of IL-4+ cells among CD3+ lymphocytes.  
Of the patients presented here, 16 (15) BD patients were on conventional treatment alone 
and 14 (13) were on IFN-α2b therapy as well.  The number in brackets denotes the number 
of patients represented in the 12 month data.  In (a), data were from cell cultures with 
CD3/CD28 stimulation; in (b), data were from cell cultures stimulated with PMA and 
ionomycin.  All results are presented as boxplots. 
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   3.4 Discussion 
 
IFN-α has wide-ranging immunomodulatory properties and it has differential 
influences on cells of the immune system.  In an early study on the short-term effects 
of IFN-α, a single subcutaneous injection IFN-α2b induced noticeable changes in 
peripheral blood leukocyte numbers as well as activation of neutrophils and 
monocytes in healthy individuals.  IFN-α administration resulted in an increase in 
neutrophil counts and provoked sustained decrease in the number of lymphocytes, 
basophils and eosinophils (Corssmit et al. 1997). 
 
 
   3.4.1 Influence of IFN-α on peripheral blood lymphocytes 
 
IFN-α treatment was reported to induce expansion of peripheral blood lymphocytes 
and monocytes in patients with severe steroid-induced asthma.  This is in contrast to 
the number of neutrophils which was substantially reduced under the influence of 
IFN-α therapy.  Although no alteration was detected in the number of CD8+ T cells, a 
relative increase in CD4+ T cells was observed (Simon et al. 2003).  In our 
experiments, there was no significant change in the expression levels of CD4, CD8 
or TCRαβ by peripheral blood T lymphocytes in BD patients whether they were on 
IFN-α or not at any time points. 
 
 
   3.4.2.1 Biology of IFN-γ 
 
IFN-γ is a 17kD protein produced mainly by NK cells and NKT cells as part of the 
innate immune response, and by lymphocytes expressing the surface antigens CD4 
and CD8 once antigen-specific immunity develops.  Within the CD4+ T cell population, 
IFN-γ is produced predominantly by the Th1 subset (Billiau & Matthys 2009).  The 
IFN-γ receptor consists of two subunits, IFN-γ receptor 1 (IFNGR1) and IFNGR2, 
and each molecule interacts with a member of the JAK family, which are non-
receptor protein tyrosine kinases.  JAKs phosphorylate receptors and 
transcriptional coactivators known as Stats.  Thus, the binding of IFN-γ to its 
receptor activates the JAK-Stat pathway (Saha et al. 2010). 
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IFN-γ has physiological importance in regulating immune responses and 
inflammatory events and its effects include the ability to enhance the functional 
activity of macrophages, promotion of T and B cell development, and modulation of 
both class I and II MHC antigen expression on a various cell types (Billiau & 
Matthys 2009).  By induction of the transcription factor T-bet, IFN-γ enables B 
cells to undergo class switching more efficiently (Xu & Zhang 2005).  IFN-γ 
activates NK cells, enhancing their cytotoxicity and cell-mediated immune 
responses.  IFN-γ also plays an important role in chemokine-controlled processes.  
Generally, induction of neutrophil chemotactic chemokines is inhibited, but 
induction of mononuclear cell-chemotactic chemokines is stimulated by IFN-γ 
(Billiau & Matthys 2009). 
 
IFN-γ plays important roles in modulating T cell activation by two main pathways: 
by direct effects of IFN-γ on T cells or via modulation of APC function.  During 
generation of a primary Th1 response, IFN-γ acts as a positive regulator by 
selectively inducing Th1 differentiation.  Traditionally, IFN-γ was seen as a pro-
inflammatory cytokine, but it should be recognised that IFN-γ has important anti-
inflammatory potential as well.  In recent years, a more balanced role for Th1 cells 
and IFN-γ in autoimmune inflammation has become apparent.  The intensity of Th1-
induced inflammation can trigger a self-regulating mechanism in response to overt 
inflammation.  In the early stages of CD4+ T cell activation, IFN-γ regulates T cell 
proliferation by inducing caspase and ensuing apoptosis.  Once Th1 cells become 
committed, they lose their capacity to be directly affected.  However, IFN-γ counter-
regulatory circuits can still contribute by promoting Th1 cell death indirectly through 
induction of numerous factors, such as nitric oxide, indoleamine 2,3 dioxygenase 
(IDO), and TNF-α receptors (Kelchtermans, Billiau, & Matthys 2008). 
 
 
   3.4.2.2 Th1 cells, IFN-γ and Behcet’s disease 
 
An early study has indicated that BD is characterised by an increased percentage of 
peripheral IL-2- and IFN-γ-producing T cells in peripheral blood lymphocytes during 
active phase of disease, indicating a strong, polarised Th1 immune response in vivo 
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(Frassanito et al. 1999).  The disease activity in patients with BD is also correlated 
with serum IL-12 levels.  IL-12 rescues Th1 lymphocytes from spontaneous and Fas-
mediated apoptosis and initiates production of Th1 cytokine IFN-γ from Th precursor 
cells.  Moreover, IL-12 promotes differentiation of precursor cells along the Th1 
pathway and subsequent proliferation (Frassanito et al. 1999).  It is difficult at the 
present time to understand the exact biological role of IFN-γ in BD and issues, such 
as whether the increased IFN-γ is the cause or the result of developing this disease, 
need to be investigated further in order to elucidate the pro- and anti-inflammatory 
roles of IFN-γ in BD. 
 
 
   3.4.2.3 The immunomodulatory effect of IFN-α on IFN-γ 
 
From our BD patient data, an upregulation or a tendency to upregulate IFN-γ-
expressing cells was detected in both CD3+ and CD4+ T cell populations during IFN-
α2b therapy and even 6 months after the termination of treatment.  This is in contrast 
to the patients on conventional treatment alone, where even a significant 
downregulation of IFN-γ expression in CD4+ lymphocytes was sporadically observed.  
The findings are in accordance with results from another study, which showed that 
CD4+ T cells producing IFN-γ were upregulated further in BD patients under IFN-α 
treatment (Amberger et al. 2007).  Consistently, in a highly efficacious trial of IFN-α 
treatment in patients with corticosteroid-unresponsive asthma, the therapy 
dramatically increased the capacity of peripheral blood T cells to generate IFN-γ 
(Simon et al. 2003). 
 
Interestingly, it has been revealed in an very early study that the serum levels of IFN-
γ in patients with BD were significantly higher than in normal controls but the titre of 
IFN-γ correlated inversely with disease activity (Ohno et al. 1982).  Although IFN-γ 
can mediate disease, its anti-inflammatory properties can serve as a protective factor 
in models of autoimmunity (Kelchtermans, Billiau, & Matthys 2008).  Hence, 
enhancement of CD4+ T cells producing IFN-γ are not necessarily counterintuitive to 
the effectiveness of IFN-α as a treatment for BD.  It has been suggested that type I 
IFNs, IFN-α/β, augment IFN-γ signalling via association of type I and type II IFN 
receptor subunits (Takaoka et al. 2000).  Also, the type of adaptive immune 
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response is conditioned by the type of preceding innate immunity.  IFN-α produced 
by dendritic cells and/or IFN-γ released by NK cells upon stimulation by IL-12 
activate Stat1 in the naive CD4+ T cells.  Activated Stat1 upregulates T-bet 
expression in T cells and subsequently promotes early T cell IFN-γ production and 
IL-12Rβ2 expression.  T cells with IL-12Rβ2 expression can then respond to IL-12 
directly and induce high IFN-γ production and sustain the expression of IL-12Rβ2 
through activation of Stat4 (Szabo et al. 1997).  These interactions could offer one 
explanation why Th1 polarisation was observed in our patients after treatment with 
exogenous IFN-α.  Moreover, it has been reported that IFN-α2a induces phenotypic 
maturation of dendritic cells and enhances their capacity to stimulate T cells.  In 
CD40-stimulated DCs, IFN-α2a augments the production of IL-12, which contributes 
to Th1 polarisation and IFN-γ secretion (Tamir et al. 2005). 
 
 
   3.4.3.1 Biology of TNF-α 
 
TNF-α, a 17 kD peptide, is a multi-functional inflammatory cytokine, which plays a 
fundamental role in the establishment and maintenance of the inflammatory 
response.  It is produced predominantly as a secreted protein by several types of 
cells including T and B lymphocytes, mast cells, NK cells, neutrophils, endothelial 
cells, smooth and cardiac muscle cells, fibroblasts and osteoclasts, but especially by 
activated macrophages (Bradley 2008).  Cells expressing CD4 secrete TNF-α while 
CD8+ cells secrete little or no TNF-α. 
 
The effects of TNF-α are mediated by binding of TNF-α to distinct TNF receptor type 
1 (TNFR1) and type 2 (TNFR2).  The two TNF-α receptors have similar affinities, and 
they are found on many cell types, including activated T and B cells, macrophages, 
and neutrophils (Benveniste & Benos 1995).  Apart from mediating cell survival and 
pro-inflammatory signals through NF-κB and AP-1, TNFR1 can initiate cell death 
signalling pathways.  Ligation of TNFR1 is both necessary and sufficient to induce 
cytotoxic and pro-inflammatory TNF-α responses.  However, the signalling pathways 
initiated by TNFR2 are less clearly defined, and TNFR2 appears to signal both 
shared and opposing effects to TNFR1.  TNFR2 may promote cell activation, 
migration or proliferation (Bradley 2008). 
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TNF-α is produced early and rapidly during inflammation and its release stimulates 
numerous other pro-inflammatory mediators such as IL-1, IL-6, IL-8, and TNF-α itself, 
which can further influence the course and outcome of an inflammatory response 
and subsequent pathologic consequences (Duzgun et al. 2005).  At sites of 
inflammation, chronic TNF-α signals can contribute to the survival of effector T cells 
(Clark et al. 2005).  The cytokine has been described to modulate immunological 
responses by enhancing the expression of MHC class I and class II molecules (Ma 
2001).  Also, TNF-α is a major inducer of endothelial adhesion molecules and 
chemokines.  Hence, the upregulation of TNF-α may have a major effect on the 
recruitment of leukocytes to active inflammatory sites (Duzgun et al. 2005). 
 
TNF-α possesses immunosuppressive effects as well.  In an early murine study, it 
has been demonstrated that chronic exposure to TNF-α suppresses the response of 
both Th1 and Th2 subsets and attenuates T cell receptor signaling in vivo (Cope et al. 
1997).  Upon macrophage activation, TNF-α signalling can selectively inhibit IL-12 
gene expression as part of the scheme of cytokine feedback and self-limiting 
modulations (Ma et al. 2000).  Moreover, TNF-α can promote lymphoid T cell 
apoptosis, inhibit dendritic cell co-stimulation and induce other cytokines that can 
inhibit cell-mediated immunity (O'shea, Ma, & Lipsky 2002).  Recently, it was reported 
that the suppressive function of Treg cells was regulated by TNF-α through its 
receptor TNFR2, constitutively expressed on human Tregs and particularly at higher 
levels in the CD45RA- subset.  TNF-α/TNFR2 signalling was demonstrated to inhibit 
the suppressive function of CD4+CD25high Tregs via activation of the NF-κB cascade 
(Nagar et al. 2010) and pre-treatment (up to 48 hours) of Treg cells with TNF-α 
caused a marked downregulation of Foxp3 mRNA and protein expression (Valencia 
et al. 2006). 
 
Interesting findings on Treg cells were demonstrated in RA patients treated with an 
anti-TNF-α agent, infliximab, as well.  CD4+CD25high T cells isolated from patients 
with active RA showed inability to suppress pro-inflammatory cytokines released by 
effector T cells and monocytes.  After treatment with infliximab, the capacity of Treg 
cells to suppress cytokine production was restored to the level found in healthy 
individuals, and a regulatory phenotype was able to be conveyed to effector T cells 
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(Ehrenstein et al. 2004).  A subsequent study by the same group revealed that the 
restoration of function of the CD4+CD25high population after infliximab therapy was 
most likely to be due to the suppressive effects of the newly differentiated 
Foxp3+CD25highCD62L- Treg cells which suppressed via TGF-β- and IL-10-
dependent mechanisms.  Of note, the natural CD62L+ Treg cells remained defective 
in infliximab-treated patients (Nadkarni, Mauri, & Ehrenstein 2007). 
 
These findings suggest a mechanism by which TNF-α can modulate Treg cells.  It 
has been postulated that at the start of an inflammatory process, intense TNF-α 
production may debilitate the activity of Treg cells and support induction of immune 
reactivity and the effector phase of lymphocyte responses.  During recovery, a 
reduction in TNF-α level may lead to enhanced Treg function that keeps immune 
reactivity in check and avoids triggering immune responses to autologous tissue 
antigens revealed during inflammation (Valencia et al. 2006). 
 
 
   3.4.3.2 TNF-α and Behcet’s disease 
 
TNF-α has been considered to be associated with the pathogenesis and activity of 
BD as higher levels of TNF-α have been found in the aqueous humour and serum of 
BD patients with uveitis (Dilek et al. 2009;Santos et al. 2001).  This is in accordance 
with another study which showed a significant increase of both serum IL-18 and 
TNF-α in BD patients with active disease when compared with healthy volunteers 
(Oztas et al. 2005).  Increased levels of IL-18 may support Th1 predominance in 
Behcet’s disease.  In addition, the number of TNF-α producing cells was reported to 
be increased in the active phases of the disease (Misumi et al. 2003). 
 
TNF-blocking agents such as infliximab and etanercept have been reported to 
induce rapid and effective suppression of almost all manifestations of systemic and 
ocular BD, at least in the short term (Sfikakis et al. 2007).  The most commonly used 
anti-TNF agent has been infliximab, and it has been shown to promote a complete 
and rapid remission of sight-threatening ocular inflammation and improvements of 
visual acuities (Sfikakis et al. 2004).  A single infusion of infliximab (5 mg/kg) can 
lead to complete response of vitritis and retinitis in about half of the cases.  Cystoid 
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macular oedema, the most-therapy resistant manifestation of ocular BD, resolve in 
90% of patients by day 28.  The initial response is fast, e.g. within 24 hours, but 
relapses can necessitate continuous treatment.  The recent recommendations are to 
include it as an add-on immunosuppressive therapy for selected patients with BD, 
who are refractory or intolerant to traditional immunosuppressives (Sfikakis et al. 
2007).  Moreover, in the only placebo-controlled study of any anti-TNF agent in BD, 
etanercept was demonstrated to significantly reduce the mean numbers of oral 
ulcers, nodular and papulopustular lesions (Melikoglu et al. 2005). 
 
 
   3.4.3.3 The immunomodulatory effect of IFN-α on TNF-α 
 
With the exception of data analysed using 6 month CD3/CD28 stimulated samples, 
our data did not reveal any meaningful upregulation in the proportion of CD3+TNF-α+ 
T cells in BD patients in the first 6 months while they were on IFN-α2b therapy.  
However, after 6 months of IFN-α2b treatment and especially after cessation of 
therapy, significantly elevated TNF-α expression levels were sporadically observed 
in the blood samples of these patients.  On the other hand, increased TNF-α 
production was not detected in the group of patients on conventional treatment alone. 
 
In a previous study, a significant increase in TNF-α level, reflecting activation of 
macrophages, in the serum of BD patients during treatment with IFN-α2a was 
reported (Kotter et al. 2005).  This is in line with an early study which demonstrated 
IFN-γ augmentation in IL-2-, mitogen-, or PMA-induced production of both TNF-α 
and TNF-β by PBMCs (Nedwin et al. 1985).  Therefore, the observed upregulation of 
IFN-γ in our experiments could contribute to the sporadic increase in TNF-α 
production levels. 
 
The proportions of CD3+ T cells producing TNF-α were low in our experiments on BD 
patients as the mean levels were less than 2% with CD3/CD28 stimulation and less 
than 10% with PMA/ionomycin stimulation.  The data is comparable to an early study 
where healthy donor PBMCs were stimulated with PMA/ionomycin for 24 hours.  The 
proportion of CD3+ cells producing TNF-α was found to be less than 5% (Mascher, 
Schlenke, & Seyfarth 1999).  
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   3.4.4.1 Biology of IL-2 
 
IL-2, a 15kD cytokine, is historically known as T cell growth factor.  It is a cytokine 
that is produced primarily by newly activated CD4+ T cells, although CD8+ T cells, B 
cells, NK cells, NKT cells, and dendritic cells activated by microbial stimuli have also 
been reported to produce IL-2 in low levels (Gaffen 2001;Letourneau et al. 2009).  
Three distinct receptor chains have been identified as components of the IL-2 
receptor (IL-2R): the common γ chain (γc) or CD132, which is shared by the 
common γ chain cytokine family, comprising IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21; 
the β chain or CD122, which is shared by both IL-2R and the IL-15 receptor; and the 
α chain or CD25 (Kovanen & Leonard 2004;Letourneau et al. 2009). 
 
Two functional IL-2 receptor forms have been described: the dimeric low-affinity 
receptor, which is composed solely of CD122 and γc, and the trimeric high-affinity 
receptor, which is composed of CD25, CD122, and γc.  The low-affinity receptor is 
found at low levels on naive CD4+ T cells, at intermediate levels on naive CD8+ T 
cells and memory CD4+ T cells, and at high levels on memory CD8+ T cells and NK 
cells.  In contrast, the high-affinity receptor is essentially expressed on 
CD4+CD25+Foxp3+ Treg cells and activated T cells (Letourneau et al. 2009). 
 
Early in an immune response, IL-2 maintains T cell survival and supports the growth 
and expansion of T cells.  If the response is enduring, as in the case of self-antigens, 
the prolonged IL-2 exposure makes T cells sensitive to Fas-mediated apoptosis and 
terminates the response (Abbas 2003).  IL-2 has initially been reported to inhibit the 
differentiation of Th17 cells (Laurence et al. 2007).  However, this effect is abolished 
in the presence of IL-1β (Kryczek et al. 2007) and under these conditions, IL-2 has 
instead a positive effect on IL-17 production by human CD4+ T cells (Manel, 
Unutmaz, & Littman 2008). 
 
Recent studies demonstrated that IL-2, along with B7 co-stimulators, promoted the 
development of Treg cells.  Thus, along with the effect on apoptosis of activated T 
cells, termination of immune responses and maintenance of self tolerance can be 
achieved (Abbas 2003;Amberger et al. 2007).  IL-2 is indispensable for the induction 
of Tregs as IL-2 signalling is required for thymic development, peripheral expansion 
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and suppressive activity of Treg cells (Shevach et al. 2006).  In line with previous 
studies, treatment of cancer patients with exogenous IL-2 has been correlated with an 
increase in the frequency of Foxp3+ Tregs.  These cells generated by IL-2 therapy 
expressed similar levels of Foxp3 and had similar potency for suppression compared 
to Treg cells present in healthy controls (Ahmadzadeh & Rosenberg 2006;Zhang et 
al. 2005).  Although regulatory CD4+CD25high cells express high levels of IL-2 
receptors, the suppressive ability of these cells is inhibited with the addition of 
exogenous IL-2 to co-cultures of CD4+CD25high cells and CD4+CD25- responder cells 
in vitro.  It has thus been suggested that suppression by Treg cells at the initiation of 
significant inflammatory responses in vivo would be kept in check by the secretion of 
IL-2 by Ag-responsive T cells (Baecher-Allan et al. 2001). 
 
 
   3.4.4.2 IL-2 and Behcet’s disease 
 
Early studies revealed that serum level of IL-2 in BD patients is comparable to 
healthy controls (Kosar et al. 1999;Sayinalp et al. 1996).  However, a more recent 
study showed that the fraction of CD3+ and CD4+ T cells producing IL 2 was 
substantially lower in untreated BD patients compared to healthy controls.  On the 
other hand, there was no difference for the CD8+ subsets between patients with BD 
and healthy individuals (Amberger et al. 2007). 
 
 
   3.4.4.3 The immunomodulatory effect of IFN-α on IL-2 
 
From our data, there was an upregulated expression of IL-2 by CD3+ T cells noted in 
BD patients who received IFN-α2b therapy.  This augmentation effect was observed 
even after cessation of IFN-α2b therapy.  This result is supported by previous 
findings that IFN-α2a therapy enhanced CD3+ T cells producing IL-2 in BD patients, 
which may be explained by the promotion of Th1 differentiation (Amberger et al. 
2007).  Increased IL-2 levels in myeloma patients treated with IFN-α2a have been 
demonstrated as well (Sonmez et al. 2004).  It is possible that the upregulation of IL-
2 may impede autoimmune inflammatory responses through induction of Treg cells.  
By this means, patients may regain self-tolerance and clinical remission is seen.  
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   3.4.5.1 Biology of IL-4 
 
IL-4, a 20kD glycoprotein, is a pleiotropic common gamma chain cytokine best 
known for its ability to direct antigen-activated T cells to differentiate into Th2 and 
Tc2 effectors and its action on activated B cells to undergo IgE isotype switch 
(Annunziato & Romagnani 2009).  Apart from T cells, numerous sources of IL-4 have 
been identified, including γδ T cells, eosinophils, basophils, NKT cells and mast cells 
(Min 2010).  Stat5 activation induced by IL-2 is crucial for Th2 cell differentiation in 
vitro (Paul & Zhu 2010).  IL-4 exerts its biological effects by binding to the IL-4 
receptor α-chain, a component of both the type 1 and type 2 IL-4 receptors (IL-4R).  
In the type 2 IL-4R, IL-4Rα is paired with IL-13Rα1 rather than the common γ chain, 
which also binds IL-13 (Nelms et al. 1999).  These receptors are widely expressed 
throughout the body.  IL-4 modulates T cell activation, mast cell proliferation, and 
haematopoiesis.  It is an important growth factor for T and B cells and increases the 
survival of cultured human lymphocytes.  Overproduction of IL-4 has been 
associated with elevated IgE production and allergic diseases in vivo (Schulze-
Koops & Kalden 2001). 
 
Of importance in regulating immune responses is the ability of IL-4 to downregulate 
the activation and the inflammatory functions of monocytes and macrophages.  IL-4 
enhances the expression of MHC class II molecules and of several cytokine 
inhibitors such as IL-1 receptor antagonist (IL-1Ra), soluble IL-1 receptor type II and 
TNF receptors while inhibiting the secretion of pro-inflammatory cytokines, including 
IL-1β, TNF-α, IL-6, IL-8 and IL-12 (Schulze-Koops & Kalden 2001).  The ability of 
Th2 effectors to control Th1-mediated inflammatory responses has been attributed 
largely to these anti-inflammatory effects of IL-4.  Consequently, IL-4 has been used 
in vivo as a successful treatment for a number of experimental autoimmune diseases 
that are caused by activated Th1 cells in animals, such as experimental allergic 
encephalomyelitis.  Moreover, IL-4 downregulates metalloproteinase production in 
vitro and stimulates tissue inhibitor of metalloproteinases 1 (TIMP1) production, 
suggesting a protective effect of IL-4 towards extracellular matrix degradation 
(Schulze-Koops & Kalden 2001).  In mice, IL-4 has also been shown to 
downregulate Th17 differentiation (Harrington et al. 2005;Park et al. 2005). 
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More recently, IL-4 was demonstrated to induce the development of CD4+CD25+ T 
cells with regulatory capacity from peripheral naive CD4+CD25- precursor cells.  The 
IL-4-induced generation of peripheral Tregs was independent of the presence of 
TGF-β or IL-10, but was dependent on Ag-specific stimulation and B7 costimulation.  
Also, endogenous IL-2 was demonstrated to have a role as a growth factor for 
CD25+ Treg cells.  IL-4-induced CD25+ Tregs phenotypically and functionally 
resembled naturally occurring CD25+ Treg cells.  IL-13, the other IL-4R α-chain-
binding cytokine, was identified to have similar effects on the induction of CD25+ 
Treg cells (Skapenko et al. 2005).  Interestingly, it has been shown in a recent 
murine study that Treg cells with attenuated Foxp3 expression preferentially convert 
into IL-4-producing Th2 effector cells even in a Th1-polarising environment (Wan & 
Flavell 2007). 
 
 
   3.4.5.2 IL-4 and Behcet’s disease 
 
Like in healthy control subjects, it has been described that the amount of IL-4-
producing cells is low in patients with BD.  Previous studies showed that there was 
no significant difference in the frequency of IL-4-producing CD3+, CD4+ and CD8+ 
cells in patients with active BD, BD patients in complete remission, and healthy 
control subjects (Frassanito et al. 1999;Sugi-Ikai et al. 1998).  These findings 
suggested that resolution of active BD did not involve a Th2 immune response. 
 
 
   3.4.5.3 The immunomodulatory effect of IFN-α on IL-4 
 
Analysing our data, IL-4 upregulation was detected in T cells as early as 3 months 
after initiation of IFN-α therapy in BD patients and this trend was evident at 6 month 
assessments as well.  At 12 months, this increase in CD3+ T cells expressing IL-4 
was still maintained despite cessation of IFN-α therapy in the treatment group.  In 
accordance to our observation, it was demonstrated that at the protein level, IFN-α 
increased IL-4 synthesis dose-dependently in PBMCs from healthy donors, 
especially after stimulation with Concanavalin A or anti-CD28/PMA (Kaser, Molnar, & 
Tilg 1998).  Also, in the presence of IFN-α, CD4+ T cells stimulated with PMA and 
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anti-CD28 Ab were shown to increase in IL-4 mRNA accumulation after 24 hours of 
culture (Schandene et al. 1996). 
 
As IL-2 has been shown to be necessary for T cells to acquire IL-4 producing 
capacity (Paul & Zhu 2010), the enhanced amounts of IL-2 expression detected in 
our experiments could contribute to IL-4 augmentation.  This is further supported by 
the finding in a murine study which have shown that CD25 (IL-2Rα) expression is 
higher in developing Th2 cells than in developing Th1 cells, possibly due to the 
action of transcription factor c-Maf.  Hyperresponsiveness of IL-2 may be conferred 
as a result of such higher expression of CD25 (Hwang, White, & Ho 2002). 
 
Nevertheless, the production of IL-4 has not always been reported to be augmented 
by IFN-α.  In a study on freshly isolated, purified human CD4+ and CD8+ T cells 
stimulated for 24 hours via TCR/CD3 complex, it was demonstrated that IFN-α did 
not increase the frequency of IL-4-producing cells and it antagonised the 
suppressive effect of IL-4 on IFN-γ production (Brinkmann et al. 1993).  The 
molecular basis for these variable effects of IFN-α on IL-4 production remains to be 
specified. 
 
In our experiments on BD patients, the mean proportions of CD3+ T cells producing 
IL-4 were up to 2% after cells were stimulated with PMA/ionomycin overnight.  These 
levels are similar to a study on healthy subjects where the mean percentages of 
CD3+ T cells and subpopulations of CD4+ T cells producing IL-4 after 6 hours of 
stimulation with PMA/ionomycin were shown to be 2.1% and 5.1% respectively 
(Baran et al. 2001).  In another study, the proportions of IL-4 producing CD4+ T cells 
from patients with BD and normal subjects were shown to be around 5% after 
PBMCs were cultured with Concanavalin A (ConA) followed by PMA/ionomycin 
(Koarada et al. 2004). 
 
 
   3.4.6 The potential influence of systemic steroids and immunosuppressants 
 
The findings from experiments were not always consistent with previous studies, and 
this could be explained in part because patient blood samples were collected in 
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different disease phases and in part due to ongoing immunosuppressive therapies.  
Unfortunately, the influence of subcutaneous IFN-α therapy could not be tested in 
the absence of some degree of immunosuppression in our patients.  As a result, the 
variability observed in phenotype and cytokine profile could partly be explained by 
individual treatment history of each patient. 
 
Glucocorticoids (GCs), such as prednisolone, are among the most potent 
immunosuppressive and anti-inflammatory drugs available and widely used as 
therapeutics for inflammatory and autoimmune disorders.  GCs were shown to 
suppress the production by APCs of IL-12, the main inducer of Th1 responses.  
Since IL-12 is extremely potent in enhancing IFN-γ and inhibiting IL-4 synthesis by T 
cells, the effect on IL-12 was found to be associated with decreased IFN-γ but 
increased production of IL-4 by T cells.  GCs were also reported to have a direct 
effect on Th2 cells by upregulating their IL-4 and IL-13 production (Elenkov 2004).  In 
a recent study on MS patients, TNF-α production by peripheral blood cells was 
observed to be suppressed following a short course of IV methylprednisolone.  The 
inhibitory effect of dexamethasone on LPS-stimulated TNF-α production by 
peripheral blood cells in vitro was demonstrated as well (van Winsen et al. 2010).  
With regards to IL-2, GCs were shown to block its signaling via the Jak-Stat pathway 
(Bianchi, Meng, & Ivashkiv 2000). 
 
Cyclosporine A was found to significantly block IFN-γ production by polyclonally 
stimulated PBMCs as well as CD4+ and CD8+ T cells from both BD patients and 
normal controls.  The ex vivo production of IFN-γ by PBMCs was also significantly 
inhibited in BD patients with active uveitis after 1 and 3 months of cyclosporine A 
treatment in ELISA experiments (Chi et al. 2010).  With regards to TNF-α, 
cyclosporine A was shown to inhibit its production in 24 hour co-cultures of activated 
peripheral blood lymphocytes and THP-1 cells from a monocytic leukaemia cell line 
(Gonzalez-Alvaro et al. 2009).  In terms of IL-2 protein secretion, it was 
demonstrated to be significantly inhibited in anti-CD3/CD28 stimulated whole blood 
cultures in vitro when cyclosporine A was added (Hartel et al. 2003). 
 
It was shown that methotrexate inhibited anti-CD3/CD28 stimulated IFN-γ, TNF-α 
and IL-4 cytokine production by whole blood, PBMCs and T cells from healthy 
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donors in vitro, and oral intake of 10 mg methotrexate by rheumatoid arthritis 
patients led to marked inhibition of cytokine production in blood drawn after 2 hours 
(Gerards et al. 2003).  In the presence of mycophenolic acid throughout the culture 
period, the production of IL-2 by polyclonally activated peripheral blood lymphocytes 
was elevated after 24 hours and the mechanism was indicated to be a decrease in 
IL-2 consumption due to blocking of the T cell proliferation.  In the same system, 
however, the production of IFN-γ was suppressed (Izeradjene et al. 2001).  Also, it 
was shown that mycophenolic acid did not have any influence on the production of 
TNF-α (Gonzalez-Alvaro et al. 2009). 
 
Due to these findings on the influence of immunosuppressants, it was considered to 
divide the patients into smaller subgroups to examine our results further according to 
patients’ individual treatment in order to minimise biases.  However, this approach 
would have required a much larger sample size before meaningful results could be 
achieved. 
 
 
   3.5 Summary of findings 
 
We did not detect any dissimilarity in terms of the number of CD4+, CD8+ and αβ T 
cells before and after the initiation of IFN-α2b therapy.  Six months of subcutaneous 
pegylated IFN-α2b therapy showed the tendency to enhance T cell production of 
IFN-γ but not TNF-α on a regular basis in BD patients.  Under the influence of IFN-
α2b therapy, upregulation of IL-2 and IL-4 expression by CD3+ T cells was also 
consistently observed.  All the positive effects of IFN-α described here were clearly 
enduring as they were evident even after the termination of IFN-α2b treatment.  One 
must be aware that although Th1 and Th2 cells are the major sources of their 
respective cytokines such as IFN-γ and IL-4, many others cells within and outside 
the immune system also produce these.  However, it wasn’t in the scope of this 
study to explore this further. 
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Chapter 4 
The effects of subcutaneous interferon-alpha 2b on Th17 and regulatory T 
cells and their cytokines in patients with Behcet’s disease ex vivo 
 
 
   4.1 Introduction 
 
Th17 cells are currently defined as CD4+ cells that produce IL-17A and F, but not 
IFN-γ or IL-4 (Crome, Wang, & Levings 2010).  IL-17 has been known to promote the 
production of various pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 as 
well as enhancing proliferation, maturation and recruitment of neutrophils.  Based on 
evidence that Th17 cells can mediate inflammation and tissue destruction, there has 
been intense interest in defining their origins, functions and developing strategies to 
block their pathological effects (Kolls & Linden 2004;Witowski, Ksiazek, & Jorres 
2004). 
 
In BD patients, apart from the previously known pathogenic cytokines, increased 
serum IL-17 levels have been demonstrated as compared to that of healthy controls 
(Hamzaoui et al. 2002).  It was also reported that IL-17 serum levels in active BD 
patients were enhanced to a higher degree than that of patients in remission, and a 
possible role of IL-17 in the pathogenesis of BD was thus suggested.  A recent study 
investigated the role of IL-23 and IL-17 in BD and identified increased expression of 
IL-23 and IL-17 in patients with active uveitis compared to normal controls and 
patients in remission (Chi et al. 2008).  It was shown that IL-17 was predominantly 
produced by CD45RO+ memory T cells and the percentage of CD4+ T cells 
producing IL-17 was significantly higher than CD8+ T cells producing IL-17.  In 
addition, it has been revealed that IL-17A has an important role in acute attacks of 
not only eye disease but also oral ulcers, genital ulcers, and articular manifestations 
in BD patients (Ekinci et al. 2010).  Moreover, it has been reported that IL-17 gene 
single nucleotide polymorphisms (SNPs) may influence the susceptibility of BD (Jang 
et al. 2008). 
 
Treg subsets and their associated cytokines, including IL-10 and TGF-β, play a 
crucial role in maintaining self-tolerance and in preventing immune pathologies by 
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regulating the strength and/or nature of the immune response to non-self antigens 
(Sakaguchi 2004;Shevach 2000).  It was reported recently that although the 
percentages of CD4+CD25high Treg cells among CD4+ T cells in BD patients with 
inactive disease were normal, the levels decreased significantly before ocular 
attacks (Nanke et al. 2008).  This is in contrast to an earlier report that the frequency 
of Tregs increased significantly in a transient fashion during inflammatory 
manifestations and recovered to normal values during the remission phase 
(Hamzaoui, Hamzaoui, & Houman 2006). 
 
In addition, in vitro experiments have demonstrated that the suppressive capacity of 
CD4+CD25high Treg cells in BD patients with active disease may be reduced, 
comparing with Treg cells from healthy controls.  Also, it is possible that the most 
potent CD4+CD25high T cells are not found in the peripheral blood but exert their 
suppressive activity in the target organs (Shevach 2004).  In CSF, CD25high and 
Foxp3-expressing CD4 cells have been demonstrated to be significantly increased in 
BD patients when compared with non-inflammatory neurological control patients 
(Hamzaoui, Houman, & Hamzaoui 2007). 
 
Surprisingly, the serum levels of IL-10 were found to be significantly higher in BD 
patients compared to healthy controls and it may elevate even further during active 
disease (Hamzaoui et al. 2002).  Regarding the serum levels of TGF-β in BD 
patients, they were demonstrated to be comparable to those in both rheumatoid 
arthritis and osteoarthritis patients (Ertenli et al. 2001).  Unfortunately, the serum 
TGF-β levels were not compared to the ones in healthy individuals in the study. 
 
 
   4.2 Aims 
 
Having observed the positive influence of IFN-α on Th1 and Th2 cytokines, the aim 
of this chapter is to investigate the effect of a 6-month course of subcutaneous IFN-
α2b therapy on modulating the non-conventional T cell subsets associated with 
immune-mediated disorders.  In particular, changes to the proportions of peripheral 
blood Th17 and Foxp3+ Treg subsets and their cytokine profile before, during and 
after cessation of therapy are examined. 
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Another aim is to study the effect of pegylated IFN-α2b therapy on the relative 
amount of CD3+CD56+ NK T cells in whole blood samples of BD patients by 
phenotyping, as these cells have been shown to have the capacity to secrete IL-17 
or exhibit regulatory function. 
 
 
   4.3 Results 
 
The experiments presented here were performed in conjunction with Mr A 
Nouraeinejad and Ms G Galatowicz.  Approximately 70% of the samples used for 
data analysis in this section were processed by me, and all data analysis is my own 
work. 
 
 
   4.3.1 IFN-α2b therapy suppresses IL-17 expression by CD4+ T cells in BD 
patients 
 
To investigate the effects of IFN-α on Th17 cell population, serial whole blood 
samples from BD patients on conventional immunosuppressive therapy with or 
without IFN-α2b treatment were studied using intracellular cytokine staining method 
and flow cytometry.  Cell cultures were either untreated or treated with anti-
CD3/CD28 Abs or PMA/ionomycin for 24 hours before staining.  Cytokine expression 
was analysed by gating on either CD4+ lymphocyte populations. 
 
Although, no significant change was detected in the proportions of Th17 cells in the 
untreated cultures and cultures with CD3/CD28 stimulation (data not shown), a 
significant downregulation of Th17 cells was found in the IFN-α2b-treated group over 
the 12 month observation period in cultures stimulated with PMA/ionomycin (Fig 
4.1a).  As early as 3 months after initiation of IFN-α therapy, the percentage of IL-17+ 
expression by CD4+ T cells in our patients was observed to be reduced (median 
0.8% and IQR 0.3-1.9%; p<0.05) compared to the initial values from baseline visits 
(median 2.0% and IQR 1.7-2.7%).  Although no further decrease was seen at follow-
ups afterwards, the levels of Th17 cells remained low at 6 months (median 0.8% and 
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IQR 0.7-1.2%; p<0.05) with IFN-α therapy and even after the end of treamtent period 
(median 1.0% and IQR 0.7-1.8%; p<0.05).  The suppressive effect of IFN-α 
treatment on Th17 was not detected in the individuals on conventional treatment 
alone. 
 
As CD4+ T cells producing both IL-17 and IFN-γ has been reported (Annunziato et al. 
2007), this cell population was included in our data analysis as well.  Unlike patients 
treated with IFN-α, there was a significant decrease in the levels of CD4+ T cells 
expressing both IL-17 and IFN-γ comparing 12 month values (median 0.1% and IQR 
0.0-0.2%; p<0.05) with the ones from initial visits (median 0.4% and IQR 0.4-0.8%) in 
individuals on conventional treatment alone (Fig 4.1b).  This was only demonstrated 
in data with PMA/ionomycin.  Thus, this is unlikely to be a consistent trend as it was 
not observed in other culture conditions or at other time points. 
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Fig 4.1: Downregulation of IL-17 expression with IFN-α therapy in CD4+ T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months.  These were stained with anti-CD4 surface antibodies before 
intracellularly with anti-IFN-γ and anti-IL-17 antibodies.  The data are shown as percentages 
of IL-17+ and IL-17+IFN-γ+ cells among CD4+ lymphocytes.  Of the patients presented here, 9 
(7) BD patients were on conventional treatment alone and 6 (6) were on IFN-α2b therapy as 
well.  The number in brackets denotes the number of patients represented in the 12 month 
data.  In (a), results showed the changes in the IL-17+ cells; in (b), results showed the 
changes in the IL-17+IFN-γ+ cells.  All data were obtained from cultures stimulated with PMA 
and ionomycin.  The results are presented as boxplots. 
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   4.3.2 IFN-α2b therapy potently enhances Foxp3 expression by CD4+ T cells in 
BD patients 
 
To examine the influence of IFN-α administration on cell populations positive for 
Foxp3, the marker’s expression levels in the peripheral blood of each BD patient 
treated with or without IFN-α2b therapy were established using intracellular cytokine 
staining method and flow cytometric analysis.  Cell cultures were either untreated or 
treated with anti-CD3/CD28 Abs or PMA/ionomycin for 24 hours before staining.  
Foxp3 expression pattern was analysed by gating on either CD4+, CD4+CD25+, or 
CD4+CD25high lymphocyte populations.  An example of the gates for lymphocytes, 
CD4+CD25+, and CD4+CD25high cell populations is shown in Fig 4.2.  In Fig 4.3, 
representative flow cytometry data on CD4+ T cells expressing Foxp3 from a BD 
patient who was treated with a 6 month course of IFN-α2b therapy are displayed.  In 
Fig 4.4, the influence of IFN-α on Foxp3 expression is further illustrated in both 
CD25+ and CD25- cell populations. 
 
With regards to the Foxp3 expression within CD4+ T cells, it was clear that an 
upregulation of Foxp3-expressing cells could be seen in all 3 culture conditions in the 
group on IFN-α therapy.  In unstimulated cultures (Fig 4.5a), the proportions of 
Foxp3+ cells were observed to be increased at 3 months (median 5.7% and IQR 2.5-
6.8%; p<0.01) and at 6 months (median 5.0% and IQR 3.2-8.7%; p<0.01) from 
baseline levels (median 2.4% and IQR 1.5-3.4%).  At 12 months, this enhancement 
was maintained (median 5.0% and IQR 3.5-7.4%; p<0.01) when compared to initial 
visits (median 2.3% and IQR 1.5-3.5%).  In cultures stimulated with PMA/ionomycin 
(Fig 4.5b), similar augmentation of Foxp3 expression could be observed as the 
levels were raised comparing follow-up visits at 3 months (median 12.0% and IQR 
6.8-14.3%; p<0.01) and 6 months (median 9.4% and 5.7-14.0%; P<0.05) to the ones 
before initiation of treatment (median 6.3% and IQR 3.9-7.8%).  The data from 12 
month visits were found to be in agreement as well (median 9.8% and IQR 8.0-
12.0%; p<0.01).  In addition, enhancement of Foxp3 expression was consistently 
identified when examining results from cultures activated with anti-CD3/CD28 Abs 
over the 12 month assessment. 
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Human Treg cells were initially defined according to their high expression of CD25, 
based on the finding that murine CD4+CD25+ T cells are highly suppressive 
(Baecher-Allan et al. 2001;Sakaguchi et al. 1995).  Therefore, Foxp3-expressing 
cells within the CD4+CD25+ and CD4+CD25high cell populations were explored.  
Within CD4+CD25high cell populations, the percentage of Foxp3+ cells was 
upregulated under all 3 cultures conditions.  Without cell activation (Fig 4.7a), the 
proportion of Foxp3 expression was enhanced at 3 (median 34.6% and IQR 22.9-
58.8%; p<0.01) and 6 months (median 44.2% and IQR 17.0-63.7%; p<0.01) after 
commencing IFN-α treatment when evaluated against initial levels (median 14.0% 
and IQR 9.1-33.6%).  Similarly, the percentage was augmented from baseline values 
(median 25.0% and IQR 18.8-42.2%) to heightened levels at 3 (median 48.6% and 
IQR 33.3-67.7%; p<0.01) and 6 months (median 59.0% and IQR 30.5-66.7%; p<0.01) 
with PMA/ionomycin stimulation (Fig 4.7b).  Reliably, the levels were upregulated at 
12 months with both forms of polyclonal stimulation, and this change was evident in 
the cultures stimulated witih anti-CD3/CD28 Abs as well (data not shown). 
 
CD4+CD25+ T cells expressing Foxp3 were studied as well and their relative 
percentage was found to be increased at follow-ups in the IFN-α treatment group.  
The trend was observed on data obtained from unstimulated cultures (Fig 4.6a) as 
the levels were upregulated at 3 months (median 9.8% and IQR 5.0-12.8%; p<0.01) 
and at 6 month visits (median 7.5% and IQR 5.3-14.1%; p<0.01) when compared to 
the numbers before treatment (median 4.1% and IQR 2.8-5.9%).  After the cessation 
of therapy, the proportion of Foxp3-expressing cells was still high (median 7.6% and 
IQR 6.4-11.9%; p<0.01) relative to initial values (median 4.1% and IQR 2.8-5.2%).  
With PMA/ionomycin stimulation (Fig 4.6b), tendency of Foxp3 augmentation was 
apparent as well.  After 3 months of IFN-α therapy, the proportions of T cells 
expressing Foxp3 was raised (median 15.9% and IQR 9.9-21.1%; p<0.01) in 
comparison to baseline (median 8.6% and IQR 6.6-8.8%).  At 12 months, the levels 
are still maintained (median 15.2% and IQR11.9-18.7%; p<0.01). 
 
The results on the individuals receiving conventional treatment alone, in contrast, did 
not show any upregulation of Foxp3 expression.  In some cases, even a significant 
downregulation was revealed.  In CD4+ T cells, the proportion of Foxp3-expressing 
cells was decreased in data obtained from cultures activated with PMA/ionomycin at 
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6 month assessment (median 4.3% and IQR 3.2-7.2%; p<0.05) relative to baseline 
values (median 6.8% and IQR 4.7-9.2%) (Fig 4.5b).  Likewise, with PMA/ionomycin 
stimulation, the percentage of CD4+CD25+ T cells expressing Foxp3 were 
downregulated at 6 months (median 9.2% and IQR 6.1-10.4%; p<0.05) from baseline 
results (median 10.2% and IQR 8.4-13.1%) (Fig 4.6b).  Similar trends were observed 
at 12 months visits as well. 
 
To verify the results from intracellular cytokine staining experiments, whole blood 
samples from BD patients were phenotyped without cells being activated or cultured 
to investigate the influence of IFN-α2b therapy on Foxp3 expression by peripheral 
blood CD4+ T lymphocytes.  Within CD4+ T cells (Fig 4.8a), there were certainly 
increases after starting IFN-α therapy at 3 (median 4.3% and IQR 3.1-7.0%; p<0.01), 
6 (median 5.2% and IQR 3.4-7.7%; p<0.01), and 12 month (median 3.5% and IQR 
3.0-6.2%; p<0.01) follow-up visits, when evaluated against initial visit data (median 
2.1% and IQR 1.2-3.2%).  Within CD4+CD25+ T cells (Fig 4.8b), there was 
enhancement of Foxp3 levels with IFN-α therapy at 3 (median 5.9% and IQR 5.1-
10.8%; p<0.01), 6 (median 8.0% and IQR 5.2-12.4%; p<0.01), and 12 month 
(median 6.3% and IQR 4.2-8.7%; p<0.01) assessments, when compared to baseline 
values (median 3.1% and IQR 2.1-5.0%).  Likewise, impressive results were 
obtained from data on CD4+CD25high T cells (Fig 4.8c) as the levels were raised from 
low levels before IFN-α treatment (median 16.6% and IQR 8.1-19.5%) to 
substantially elevated ones at 3 (median 34.0% and IQR 18.8-58.6%; p<0.01), 6 
(median 31.8% and IQR 21.0-60.6%; p<0.01) and 12 (median 33.3% and IQR 22.7-
45.3%; p<0.01) month assessments. 
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(a)         Lymphocytes 
 
 
 
 
 
 
 
 
 
 
 
(b)  CD4+CD25+ T cells   (c)  CD4+CD25high T cells 
 
Fig 4.2: Flow cytometry: CD25 gating for identifying Treg subsets 
Flow cytometric gating strategies to identify Treg cells in patients with BD.  (a) Dot plot of 
forward scatter (FSC) versus side scatter (SSC) for all events showing all peripheral blood 
cell populations and G1 gate indicates lymphocyte population.  (b) Lymphocytes were 
analysed on the basis of surface markers CD4 and CD25; the G2 gate identifies the 
percentage of CD4+CD25+ T cells.  (c) The G3 gate identifies the percentage of 
CD4+CD25high T cells. 
  
G2 
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(a)   0 months  (b)   3 months 
 
(c)   6 months  (d)   12 months 
 
Fig 4.3: CD4+ T cells expressing Foxp3 in a BD patient on IFN-α2b therapy 
Whole blood samples were prepared using intracellular cytokine staining method.  
Lymphocytes were selected according to forward- and side-scatter properties and CD4+ T 
cells were gated on.  The graphs show representative data on the expression of Foxp3 
within CD4+ T cells in a patient who was on IFN-α2b therapy.  The data are from (a) the 
baseline visit, (b) 3 month assessment visit, (c) 6 month assessment visit, and (d) 12 month 
assessment visit.  The numbers in the histograms indicate the percentages of cells positive 
for Foxp3.  All samples shown were from unstimulated cultures.  
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(a)   0 months  (b)   12 months 
 
Fig 4.4: The influence of IFN-α2b therapy on the expression of CD25 and Foxp3 
Whole blood samples were prepared using intracellular cytokine staining method.  
Lymphocytes were selected according to forward- and side-scatter properties and 
CD4+ T cells were gated on.  The graphs show representative data on the Foxp3 
expression within either the CD25+ or CD25- T cell populations in a patient who was 
on IFN-α2b therapy.  The data are from (a) the baseline visit, and (b) 12 month 
assessment visit.  The numbers in the histograms indicate the percentages of cells 
positive for Foxp3.  Samples shown were from unstimulated cultures.  
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Fig 4.5: Upregulation of Foxp3 expression with IFN-α therapy in CD4+ T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months and prepared using intracellular cytokine staining method.  Cells were 
stained with anti-CD4 surface antibodies before intracellularly with anti-Foxp3 antibodies.  
The data are shown as percentages of Foxp3+ cells among CD4+ lymphocytes.  Of the 
patients presented here, 16 (14) BD patients were on conventional treatment alone and 13 
(12) were on IFN-α2b therapy as well.  The number in brackets denotes the number of 
patients represented in the 12 month data.  In (a), data were from untreated cell cultures; in 
(b), data were from cell cultures stimulated with PMA and ionomycin.  The results are 
presented as boxplots. 
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Fig 4.6: Upregulation of Foxp3 expression with IFN-α therapy in CD4+CD25+ T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months and prepared using intracellular cytokine staining method.  Cells were 
stained with anti-CD4 and anti-CD25 surface antibodies before intracellularly with anti-Foxp3 
antibodies.  The data are shown as percentages of Foxp3+ cells among CD4+CD25+ 
lymphocytes.  Of the patients presented here, 16 (14) BD patients were on conventional 
treatment alone and 13 (12) were on IFN-α2b therapy as well.  The number in brackets 
denotes the number of patients represented in the 12 month data.  In (a), data were from 
untreated cell cultures; in (b), data were from cell cultures stimulated with PMA and 
ionomycin.  The results are presented as boxplots. 
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Fig 4.7: Upregulation of Foxp3 expression with IFN-α therapy in CD4+CD25high T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months and prepared using intracellular cytokine staining method.  Cells were 
stained with anti-CD4 and anti-CD25 surface antibodies before intracellularly with anti-Foxp3 
antibodies.  The data are shown as percentages of Foxp3+ cells among CD4+CD25high 
lymphocytes.  Of the patients presented here, 16 (14) BD patients were on conventional 
treatment alone and 13 (12) were on IFN-α2b therapy as well.  The number in brackets 
denotes the number of patients represented in the 12 month data.  In (a), data were from 
untreated cell cultures; in (b), data were from cell cultures stimulated with PMA and 
ionomycin.  The results are presented as boxplots. 
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Fig 4.8: Phenotyping experiments showing augmentation of Foxp3 expression with 
IFN-α therapy in CD4+ T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months.  Cells were stained with anti-CD4 and anti-CD25 surface antibodies 
before with anti-Foxp3 antibodies.  The data are shown as percentages of Foxp3+ cells 
among subpopulations of CD4+ lymphocytes.  Of the patients presented here, 17 BD 
patients were on conventional treatment alone and 16 were on IFN-α2b therapy as well.  In 
(a), results were from all CD4+ T cells; in (b), results were from CD4+CD25+ T cells.  In (b), 
results were from CD4+CD25high T cells.  The results are presented as boxplots.  ns=not 
significant. 
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   4.3.3 IFN-α2b therapy shows a tendency to increase IL-10 expression by T 
cells in BD patients 
 
Analysis of the effects of IFN-α on IL-10 expression by T cells was approached using 
intracellular cytokine staining on whole blood samples as described in Materials and 
Methods.  Cell cultures were either untreated or activated with anti-CD3/CD28 Abs 
or PMA/ionomycin for 24 hours before staining.  Cytokine expression was analysed 
by gating on CD3+ or CD4+ lymphocytes.  Within the CD4+IL-10+ cells, Foxp3 
positivity was studied as well. 
 
To start with, the CD3+ T cells were examined.  In untreated cultures (Fig 4.9a), an 
upregulation of IL-10 levels was noticed at 6 months (median 0.4% and IQR 0.2-
0.6%; p<0.05) when compared to initial visits (median 0.2% and IQR 0.1-0.3%) in the 
IFN-α treated group.  In CD3/CD28 stimulated cultures (Fig 4.9b), a significantly 
heightened proportion of IL-10 expressing cells was shown at follow-up visits at 6 
(median 0.3% and IQR 0.2-0.6%; p<0.05) and 12 months (median 0.4% and IQR 
0.2-0.7%; p<0.05) when evaluated against baseline values(median 0.2% and IQR 
0.1-0.3%) in the IFN-α treated group.  Significant changes were not evident in 
cultures stimulated with PMA/ionomycin (data not shown).  No meaningful alteration 
in the IL-10 expression level was noticed in the group on conventional treatment 
alone except an increase noticed at 3 months (median 0.4% and IQR 0.2-0.5%; 
p<0.05) from baseline values (median 0.2% and IQR 0.1-0.3%). 
 
Afterwards, the CD4+ T cell populations were analysed.  In untreated cultures (Fig 
4.10a), a raised level of IL-10 expression was found at 3 (median 0.3% and IQR 0.1-
0.7%; p<0.05), 6 (median 0.3% and IQR 0.2-0.7%; p<0.05), and 12 month (median 
0.3% and IQR 0.1-0.7%; p<0.01) follow-ups relative to the results from initial visits 
(median 0.1% and IQR 0.1-0.2%) in the IFN-α treated patients.  These IL-10+ cells 
were found to be mostly Foxp3- and hence an upregulation of this subpopulation was 
noted as well.  The relative proportions of CD4+IL-10+Foxp3- (Fig 4.10b) were shown 
to be elevated at 3 (median 0.2% and IQR 0.1-0.5%; p<0.05), 6 (median 0.2% and 
IQR 0.1-0.6%; p<0.05), and 12 months (median 0.3% and IQR 0.1-0.6%; p<0.05) 
when compared to results from initial visits (median 0.1% and IQR 0.1-0.2%).  In 
contrast, there was no significant alterations of cells with either IL-10+ or IL-
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10+Foxp3- expression in the group on conventional treatment alone.  Also, no 
change in the CD4+IL-10+Foxp3+ subpopulation was revealed in our patients whether 
they received IFN-α treatment or not (data not shown). 
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Fig 4.9: Upregulation of IL-10 expression with IFN-α therapy in CD3+ T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months and prepared using intracellular cytokine staining method.  Cells were 
stained with anti-CD3 surface antibodies before intracellularly with anti-IL-10 antibodies.  
The data are shown as percentages of IL-10+ cells among CD3+ lymphocytes.  Of the 
patients presented here, 18 (15) BD patients were on conventional treatment alone and 15 
(13) were on IFN-α2b therapy as well.  The number in brackets denotes the number of 
patients represented in the 12 month data.  In (a), data were from untreated cell cultures; in 
(b), data were from CD3/CD28 stimulated cell cultures.  The results are presented as 
boxplots. 
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Fig 4.10: Upregulation of IL-10+ and IL-10+Foxp3- expression with IFN-α therapy in 
CD4+ T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months and prepared using intracellular cytokine staining method.  Cells were 
stained with anti-CD4 surface antibodies before intracellularly with anti-IL-10 and anti-Foxp3 
antibodies.  The data are shown as percentages of positive cells among CD4+ lymphocytes.  
Of the patients presented here, 16 (14) BD patients were on conventional treatment alone 
and 10 (12) were on IFN-α2b therapy as well.  The number in brackets denotes the number 
of patients represented in the 12 month data.  In (a), data were from cells with IL-10+ 
expression; in (b), data were from cells with IL-10+Foxp3- expression.  All cultures were 
untreated and the results are presented as boxplots. 
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   4.3.4 IFN-α2b therapy shows the tendency to increase TGF-β expression by T 
cells in BD patients 
 
Using intracellular cytokine staining method as described in Materials and Methods, 
the influence of IFN-α on TGF-β expression by T cells were examined.  Cell cultures 
were either untreated or activated with anti-CD3/CD28 Abs or PMA/ionomycin for 24 
hours before staining.  Cytokine expression was analysed by gating on CD3+ 
lymphocytes. 
 
In the IFN-α treatment group, there was no significant alteration of the amounts of 
TGF-β-expressing CD3+ T cells with PMA/ionomycin stimulation (Fig 4.11b).  
However, in untreated cultures (Fig 4.11a), the enhancement of TNF-α expression 
was clearly shown at 3 (median 1.2% and IQR 0.6-2.5%; p<0.05), 6 (median 1.0% 
and IQR 0.6-1.9%; p<0.01), and 12 month (median 1.2% and IQR 0.7-1.8%; p<0.01) 
follow-ups when evaluated against the baseline visit data (median 0.7% and IQR 
0.3-1.0%).  Similarly, in CD3/CD28 stimulated cultures, the median levels of TGF-β 
expression was raised from 1.1% (IQR 0.6-1.6%) initially to 1.4% (IQR 0.7-2.5%; 
p<0.05) at 3 months (data not shown).  Despite being statistically insignificant 
(p=0.08), an tendency to upregulate of the TGF-β expression was seen at 12 months 
as well (data not shown). 
 
On the other hand, no consistent alteration was noted in patients on conventional 
treatment alone whether cells were cultured with or without CD3/CD28 stimulation 
(Fig 4.11a).  However, in cultures stimulated with PMA/ionomycin (Fig 4.11b), the 
proportion of CD3+ T cells expressing TGF-β was downregulated at 3 (median 2.1% 
and IQR 1.4-4.3%; p<0.01) and 6 months (median 1.6% and IQR 1.1-2.9%; p<0.01) 
when compared to the baseline visit data (median 3.8% and IQR 2.5-6.7%).  At 12 
months (median 1.7% and IQR 1.4-3.3%; p<0.01), the trend continued when 
evaluated against initial assessment results (median 4.7% and IQR 3.0-8.9%).  
 
The proportion of CD3+ T cells expressing both IL-10 and TGF-β was investigated as 
well, and their levels were found to be very low.  No significant change was found in 
either group of BD patients whether they were on IFN-α or not (data not shown). 
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Fig 4.11: The effects of IFN-α therapy on TGF-β expression by CD3+ T cells 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months and prepared using intracellular cytokine staining method.  Cells were 
stained with anti-CD3 surface antibodies before intracellularly with anti-TGF-β antibodies.  
The data are shown as percentages of TGF-β+ cells among CD3+ lymphocytes.  Of the 
patients presented here, 18 (15) BD patients were on conventional treatment alone and 18 
(16) were on IFN-α2b therapy as well.  The number in brackets denotes the number of 
patients represented in the 12 month data.  In (a), data were from untreated cell cultures; in 
(b), data were from PMA/ionomycin stimulated cell cultures.  The results are presented as 
boxplots. 
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   4.3.5 IFN-α2b therapy does not increase CD56+ expression by T cells in BD 
patients 
 
To examine the influence of IFN-α therapy on NKT cells in BD patients, serial whole 
blood samples from BD patients receiving conventional immunosuppressive therapy 
with or without recombinant IFN-α2b treatment were phenotyped.  The phenotyping 
results were obtained by analysing CD56+ cells after gating on the CD3+ 
lymphocytes. 
 
As shown in Figure 4.12, there was no significant change in the levels of CD56 
expression within the CD3+ T lymphocyte populations in BD patients whether they 
were on IFN-α or not.  The only exception found was an increased percentage of the 
CD3+CD56+ T cells in the group on conventional treatment alone when 3 month 
levels (median 6.0% and IQR 4.3-10.2%; p<0.01) were compared to the baseline 
ones (median 3.3% and IQR 2.4-6.1%). 
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Fig 4.12: Phenotyping experiments showing CD56 expression by CD3+ T cells in BD 
patients 
Whole blood samples from BD patients were obtained at baseline visits and follow-ups at 3, 
6, and 12 months.  Cells were stained with anti-CD3 and anti-CD56 surface antibodies.  The 
data are shown as percentages of CD56+ cells within CD3+ lymphocytes.  Of the patients 
presented here, 16 BD patients were on conventional treatment alone and 15 were on IFN-
α2b therapy as well.  The results are presented as boxplots. 
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   4.4 Discussion 
 
Inflammation is characterised by a complex interaction of pro- and anti-inflammatory 
mediators. A favourable balance leads to a recovery of homeostasis while an 
unfavourable balance, associated with an exacerbated release of pro-inflammatory 
cytokines, leads to damaging effects. Individual background seems to govern this 
equilibrium, and it is known that a great heterogeneity exists between individuals. 
 
 
   4.4.1.1 Biology of IL-17 
 
IL-17 has assorted biological functions, but the most notable role of IL-17 is its 
involvement in inducing and mediating pro-inflammatory responses.  As well as 
promoting neutrophil recruitment and macrophage activation and survival, IL-17 
stimulates the production of many other pro-inflammatory cytokines, chemokines and 
prostaglandins from a variety of immune and non-immune cells (Crome, Wang, & 
Levings 2010).  Recently it was described that IL-17 itself can also function as a 
chemokine, acting directly on the IL-17RA and IL-17RC of monocytes to induce their 
migration (Shahrara et al. 2009).  Due to these roles, the IL-17 family has been linked to 
many immune/autoimmune related diseases. 
 
 
   4.4.1.2 The immunomodulatory effect of IFN-α on IL-17 
 
From our data, a downregulation of IL-17 expression was seen after cells cultures 
were activated with PMA/ionomycin in the IFN-α2b-treated group compared to 
patients on conventional treatment alone.  This was evident at all follow-up visits up 
to 12 months compared to the data before initiation of treatment.  This is in 
accordance to a recent study which found that IFN-α significantly decreased IL-17 
production by anti-CD3/CD28 stimulated PBMCs in cell culture supernatants from 
BD patients (Liu et al. 2011).  These findings are supported by other studies on 
inflammatory conditions.  In ulcerative colitis patients, treatment with pegylated IFN-
α2b therapy was reported to result in a significant decrease of colonic IL-17A mRNA 
expression after 4 weeks and the downregulation of IL-17A expression in colonic 
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tissue was associated with clinical remission (Moschen et al. 2008).  Similarly, direct 
IFN-β1a treatment of CD4+CD45RA+ naive T cells cultured in Th17-polarising 
conditions demonstrated decrease in RORc, IL-17A, IL-23R and CCR6 levels in both 
MS patients and healthy controls (Ramgolam et al. 2009). 
 
 
   4.4.1.3 Mechanisms leading to the inhibitory effects of IFN-α on IL-17 
 
Like IFN-γ, IFN-α mediates its signal through phosphorylation of Stat1 resulting in 
induction of T-bet, which is critical for Th1 cell development, and subsequent 
inhibition of Th17 responses (Harrington et al. 2005).  In addition to the direct 
inhibitory effect of IFN-α on Th17 development, IFN-α binds to the type 1 IFN 
receptor on DCs, macrophages and microglia cells within the CNS.  In these cells, 
IFN-α-mediated signalling inhibits the activation of an intracellular isoform of 
osteopontin, followed by the induction of IL-27 (Guo, Chang, & Cheng 2008).  
Although IL-27 induces Th1 differentiation, the same cytokine has 
immunosuppressive properties which depend on IL-2 suppression, induction of IL-10 
production as well as inhibition of Th17 differentiation (Yoshida, Nakaya, & Miyazaki 
2009). 
 
IFN-γ plays an important role in Th17 cell biology.  The development of Th17 cells 
from naive precursor cells is strongly suppressed by IFN-γ both in vitro and in vivo 
(Harrington et al. 2005;Meyers et al. 2006;Park et al. 2005).  Anti-IFN-γ added during 
in vitro Th17 differentiation leads to upregulated IL-17 expression, and increased 
expression of the IL-23R is displayed by the treated cells as well.  Therefore, it was 
proposed that IFN-γ signaling might exert its inhibitory effect on pathogenic Th17 
cells by thwarting IL-23R expression (Harrington et al. 2005).  It has been observed 
that both IL-4 and IFN-γ suppress RORC2 by upregulating GATA-3 and T-bet, 
respectively, thereby inhibiting Th17 differentiation.  However, IL-17 does not 
significantly alter expression of IL-4 or IFN-γ but does induce IL-2 expression in 
CD4+ T cells, suggesting that this cytokine may promote T cell proliferation and survival 
(Crome, Wang, & Levings 2010).  All these mechanisms, by which autoreactive 
Th17 cells can be regulated, may explain the molecular basis of IFN-α therapy for 
Behcet’s disease.  As described in Chapter 3, we have observed upregulation of 
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both IFN-γ and IL-4 expression by T cells, and this could help explain why a 
suppression of Th17 cells was found in patients treated with recombinant IFN-α. 
 
 
   4.4.1.4 T cells co-expressing IL-17 and IFN-γ 
 
Although Th17 lineage development is independent of that of Th1, they can often be 
found side-by-side, suggesting that the interplay between Th17 and Th1 is likely to 
be important for our understanding of autoimmune disorders (Annunziato et al. 2007).  
In our experiments, the so-called Th1/Th17 cells were detected only in very low 
amount and IFN-α2b therapy did not seem to have any influence on this cell 
population.  In the future it will be important to determine if these Th1/Th17 cells are a 
distinct and stable lineage of CD4+ T effector cells, or whether they are an intermediate 
state destined to become true Th1 or Th17 cells. 
 
 
   4.4.2.1 Biology of regulatory T cells 
 
Treg cells are pivotal for the maintenance of peripheral self-tolerance and 
imbalances in this T cell compartment have been shown to contribute to various 
autoimmune diseases (Allan et al. 2008b).  Foxp3+ Tregs regulate a wide variety of 
different immune cells including naive and memory CD4+ and CD8+ T effector cells, B 
cells, NK cells, monocytes, and DCs in vitro and in vivo (Grossman et al. 2004;Lim et al. 
2005).  Currently, it is not clear whether Foxp3+ Tregs of direct thymic origin differ in 
phenotype or function from those of peripheral origin.  What is clear is that cells of both 
types can specifically recognise a wide variety of Ags (Fazilleau et al. 2007b). 
 
In peripheral blood, roughly 50% of lymphocytes are CD4+ and the CD4+CD25high T 
cell subset comprises 1-2% of circulating CD4+ T cells in humans.  nTreg cells 
mainly reside within the CD4+CD25high cell population (Baecher-Allan et al. 2001).  In 
adult human peripheral blood, CD4+CD25high Treg cell compartment contains not 
only antigen-experienced, CD45RA- memory cells, but also a subpopulation of 
CD45RA+ naive recent thymic emigrants without previous exposure to extrathymic 
self or foreign antigens (Seddiki et al. 2006).  Analysis of naive Treg cell prevalence in 
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peripheral blood indicates that their proportion among CD4+ T cells declines with age, 
starting from a range of 4-10% in cord blood and decreasing to 1-4% in young adults 
and to 0.5-1.5% in healthy elderly donors.  However, the prevalence of CD45RA- Treg 
cells slightly increases with age starting from a range of 0-0.5% in cord blood and 
increasing to 1-2.5% in young adults and to 1-4% in elderly health donors (Miyara et al. 
2009; Sakaguchi et al. 2010). 
 
 
   4.4.2.2 CD25 expression and its relationship with Foxp3+ Treg cells 
 
Although there is not one particular cell surface marker that defines Treg cells, the 
CD25 surface molecule is at least expressed on the vast majority of cells that 
express the Foxp3 transcription factor (Apostolou et al. 2008).  Given that the 
expression levels of CD25 and Foxp3 are usually proportional in human Foxp3+ T 
cells, one shortcoming of examining T cells expressing high levels of CD25 is the 
exclusion of CD25intFoxp3low naive Treg cells (Miyara et al. 2009).  Therefore, in our 
experiments, CD4+CD25+ T cells were examined as well as CD4+CD25high T cells in 
order to cover the effects of IFN-α2b on these naive Treg populations.  However, one 
must be aware that CD4+ T cells with intermediate CD25 expression (CD25int) are 
made up mainly of recently activated non-regulatory effector T cells, with only 5 to 
15 % Foxp3+ Treg cells (Hoffmann et al. 2006). 
 
In addition, it has been reported that non-regulatory CD45RO+Foxp3low T cells that 
produce pro-inflammatory cytokines may constitute 30-50% of the CD4+Foxp3+ T 
cells, which contain the CD4+CD25-Foxp3+ cell population (Sakaguchi et al. 2010).  
Committed regulatory T cells with the CD25- phenotype are present in the periphery 
as a minor fraction of CD4+ T cells but they may become CD25+ upon activation.  
Data have shown that CD4+CD25- cells exhibit an approximately 60-fold lower level 
of Foxp3 mRNA expression than CD4+CD25+ cells as measured by real-time 
quantitative RT-PCR (Yagi et al. 2004). 
 
In accordance to these findings, our data consistently demonstrated that Foxp3+ 
expression levels were much lower in either CD4+ or CD4+CD25+ cell subpopulations 
compared to CD4+CD25high cell population.  One important point to bear in mind 
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though is that there is no firm criterion suggested from previous studies as to where 
the boundary lies between intermediate and high CD25 expression. This vague 
boundary has complicated the reproducibility of clinical data analysing the number 
and function of Treg cells, particularly under inflammatory conditions in which 
activated T cells express CD25. 
 
In order to reduce populations with transient expression of Foxp3 and determine the 
true fraction of stable Foxp3+ Tregs among CD25high cells, it may be an idea to 
incorporate steps to rest cells obtained from patients with inflammatory disorders 
during experiments.  Alternatively, analysis of CD69 expression on Treg subsets has 
been suggested in order to determine whether these cells are contaminated with 
recently activated CD4+ T cells as these would be mainly CD69+ (Valencia et al. 
2006). 
 
 
   4.4.2.3 Foxp3 expression levels in CD4+CD25high T cells 
 
Approximately 60% to 90% of CD25high cells are Foxp3+ (Tang & Bluestone 2006).  It 
was reported that CD45RA+CD4+CD25high T cells homogeneously maintained their 
Treg cell phenotype and function even after long-term culture (up to 3 weeks).  In 
contrast to CD45RA+CD4+CD25high Treg cells, CD4+ T cells selected solely for 
CD25high expression, were highly variable with respect to Foxp3 expression (50.5 to 
72.8% Foxp3+ cells) after long-term in vitro expansion (Hoffmann et al. 2006).  This 
was despite that more than 90% of the sorted cells expressed Foxp3 after isolation. 
 
In our experiments the percentages of Foxp3+ cells in CD25high cells were observed to 
be substantially lower.  This was evident whether whole blood samples were cultured 
over 24 hours or not as shown in the phenotyping and intracellular cytokine staining 
experiments.  One possible explanation could be the presence of non-regulatory 
effector T cells that preferentially expand in culture over time.  Another explanation 
could be the presence of a substantial number of ‘‘induced’’ Tregs that only 
transiently express Foxp3 after recent in vivo stimulation and revert to effector T cells 
during culture or before phenotyping could be performed (Tran, Ramsey, & Shevach 
2007;Walker et al. 2003).  The BD patient blood samples used in our experiments 
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were not usually processed on the day of collection.  They were stored at room 
temperature and processed in the morning the following day.  One other possible 
factor to consider could be that our BD patients had lower basal levels of 
CD25highFoxp3+ cells to begin with. 
 
Additional contributing factor leading to the observed lower Foxp3+ expression has 
been provided by recent findings that Foxp3 mRNA and protein expression in cell 
lines derived from CD45RA-CD4+CD25high Treg cells is particularly prone to be lost 
after 2 to 3 weeks in culture upon repetitive polyclonal TCR and CD28 co-receptor-
mediated stimulation.  After long-term culture, there can be parallel increase in 
cytokine-secreting cells within this cell population, even in the absence of a pro-
inflammatory milieu (Hoffmann et al. 2009).  Despite gaining the ability to secrete 
inflammatory cytokines (IL-2, IFN-γ, or both), these cytokine-secreting cells do not 
convert completely to effector T cells, as they also produce substantial amounts of 
IL-10.  Thus, such cells may still be regulatory but mediate their effects via cytokines 
rather than cell-contact-dependent mechanisms.  Of note, these data have been 
obtained using cell cultures with high-dose exogenous IL-2 present.  As IL-2 has 
been demonstrated to have important, non-redundant effects on the maintenance 
and survival of Foxp3+ Treg cells (Burchill et al. 2008), the loss of Foxp3+ expression 
in our experiments could be greater and over shorter period of time as a result of 
absence of exogenous IL-2 in cultures. 
 
 
   4.4.2.4 Upregulation of Foxp3 expression in BD patients treated with IFN-α 
 
Our data from phenotyping and intracellular cytokine staining experiments showed a 
significant upregulation of Foxp3 expression in CD4+CD25high T cell subsets as early as 
after 3 months of subcutaneous IFN-α2b therapy.  The enhanced expression of Foxp3 in 
BD patients was also observed in the CD4+ and CD4+CD25+ T cell populations.  
Importantly, these positive findings were observed consistently in both phenotyping 
experiments and unstimulated cultures where no cell activation was involved.  
Consequently, expansion of recently activated non-regulatory CD45RO+Foxp3low T 
cells was unlikely to be a major contributor to these results.  Collectively, these 
results are likely to signify that Treg cell populations were promoted in BD patients 
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treated with IFN-α2b.  In BD patients receiving conventional treatment alone, however, 
no change or even a decrease in the proportion of Foxp3 expressing cells were 
detected.  This may indicate that the augmentation of Foxp3 expression in IFN-α2b-
treated patients was not associated with the influence of systemic prednisolone or 
other immunosuppressants. 
 
It remains to be determined how stable the enhanced expression of Foxp3 is and 
whether the status can be sustained even after stopping the IFN-α2b therapy.  
Encouragingly, Foxp3 expression levels were significantly elevated in our IFN-α2b-
treated BD patients at 6 month assessments and these changes were still evident at 
12 month visits, 6 months after ending the treatment. 
 
Our findings of Foxp3 upregulation in peripheral blood lymphocytes by IFN-α2b 
therapy are in contrast to a recent study on melanoma patients receiving 4 weeks of 
IFN-α2b treatment where no statistically significant change in Foxp3+ Treg level was 
detected (Ascierto et al. 2010).  This could be explained in part by different patient 
characteristics at recruitment as Behcet’s disease patients may have normal or even 
decreased levels of CD4+CD25high Treg cells in peripheral blood to start with (Nanke 
et al. 2008) compared to increased levels in melanoma patients (Ascierto et al. 2010).  
Also, the treatment duration for our patients on IFN-α2b therapy was for 6 months, 
which was substantially longer. 
 
In accordance to our results, an upregulation of Foxp3+ Treg cells, associated with 
increase of Stat5 but downregulation of Stat3, was demonstrated in lymph node 
biopsies of melanoma patients with nodal metastasis after a course of high-dose 
IFN-α2b therapy over 48 weeks (Wang et al. 2008).  Similarly, in a study on MS 
patients, treatment with IFN-β increased the expression of Foxp3 mRNA in PBMCs 
significantly after 6 months but not Foxp3 protein on CD4+CD25+ T cells 
(Vandenbark et al. 2009).  Although a significant reduction was demonstrated in the 
capability of patients’ plasmacytoid dendritic cells (pDCs), known inducers of Tregs, 
to produce IFN-α in a group of heterogeneous uveitis patients including BD (Plskova 
et al. 2006), it was suggested that the deficiency could be overcome with the 
administration of exogenous IFN-α. 
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   4.4.2.5 Foxp3 and Treg function 
 
Hypoproliferative (‘anergic’) and immune suppressive activities are two defining 
properties for Foxp3 expressing Treg cells.  Intriguingly, Foxp3low expressing T cells 
were demonstrated to remain anergic upon TCR stimulation in vitro, but their 
immunosuppressive activities were greatly impaired (Wan & Flavell 2007).  Thus, 
anergy and immune suppression are two separable properties of Treg cells that are 
affected differentially by the expression levels of Foxp3.  While Foxp3 does not seem 
to control the entire Treg transcriptome, it is clearly essential for Treg differentiation 
and/or function, as its absence leads to a lack of Tregs and fatal autoimmune 
disease (Buckner & Ziegler 2008).  Notably, previous studies have shown that 
transfection of human Foxp3 into naive CD4+ T cells can induce Treg functions 
(Oswald-Richter et al. 2004;Yagi et al. 2004). 
 
Foxp3 is expressed by both activated and regulatory T cells in the peripheral blood 
as are other known Treg cell biomarkers such as CD25.  Virtually all activated CD4+ 
and CD8+ T cells have been shown to transiently upregulate Foxp3 and acquire 
suppressive properties (Pillai et al. 2007).  However, it has been indicated that only 
those cells with sustained, high level Foxp3 expression go on to differentiate into 
Treg cells (Buckner & Ziegler 2008).  In one study, it was noted that not all CD25+ T 
cells in typical activation cultures had regulatory function and the great majority of 
these cells became CD25- after 10 days.  Only those T cells that remained CD25+ 10 
days after activation were Foxp3+ and showed suppressive function (Walker et al. 
2005).  Data from another group suggested that the human cells, unlike mouse cells, 
need more time to become fully differentiated CD4+CD25+Foxp3+ suppressor cells.  
It was observed that upon repeated stimulation, the cells became anergic, some then 
expressed membrane TGF-β, and T cell proliferation was strongly suppressed 
subsequently (Horwitz et al. 2008). 
 
Activated T cells possibly require additional factors, as well as the functional and 
phenotypic changes generated by Foxp3 expression, to acquire full suppressive 
activity.  It has been reported that the maintenance of intrinsic Treg stability likely 
involves the epigenetic modification of the Foxp3 locus, especially the two highly 
conserved CpG-rich regions located in the Foxp3 first intron and up-stream Foxp3 
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promoter.  The methylation status of these two regions is tightly associated with 
stable gene expression of Foxp3 (Miyara et al. 2009).  In Foxp3+ Tregs with 
suppressive activity, CpGs in these regions are fully demethylated, whereas the 
CpG's of Foxp3low non-regulatory T cells are incompletely demethylated.  More 
recently, the expression of Helios, a member of the Ikaros transcription factor family, 
has been shown to be unique in thymus-derived CD4+CD25+Foxp3+ Treg cells and 
this enables nTreg to be distinguished from iTreg cells and, most importantly, 
recently activated cells (Thornton et al. 2010). 
 
Interaction of Foxp3 with other transcription factors has also been suggested to be 
critical to its action.  Foxp3 has been demonstrated to directly interact with NFAT, a 
key regulator of T cell activation and anergy, and the NF-κB subunit p65.  Several 
residues in the forkhead domain of Foxp3 interact with NFAT directly, and 
mutagenesis of these residues result in a decrease in the ability of Foxp3 to inhibit 
IL-2 production (Buckner & Ziegler 2008).  Therefore, at least one mechanism of 
Foxp3-mediated transcriptional repression involves direct contact with NFAT and 
subsequent inhibition. 
 
Requirement of other transcription factors, such as Runx, has been described.  
There are three putative Runx binding sites in the proximal Foxp3 promoter.  It has 
been suggested that these binding sites have partially redundant functions, but 
binding to at least two sites seems to be necessary for full promoter activation.  In 
suppression experiments, reduced suppressive activity has been shown to be 
caused by reduced Foxp3 expression in CD4+CD25+Foxp3+ iTreg cells by small 
interfering RNA (siRNA) inhibition of Runx1 and Runx3.  These results demonstrate 
the important role of Runx1 and Runx3 not only for the induction of Foxp3, but also 
for the suppressive capacity of Treg cells (Klunker et al. 2009). 
 
It remains to be determined whether the induced Foxp3+ T cells in our experiments 
are functionally competent suppressive cells.  Maintenance of sustained Foxp3 
expression as T cell activation wanes may be key for acquisition of suppressor 
function and development of peripherally induced Tregs.  Nevertheless, we can 
speculate that a small subset of effector T cells with activation induced Foxp3 may 
not downregulate Foxp3 and therefore ultimately develop into functional Treg cells.  
  
196 
 
   4.4.3.1 Biology of IL-10 
 
IL-10 is a multi-functional regulatory cytokine first described as a molecule secreted 
by Th2 cells that could inhibit cytokine synthesis by Th1 cells (Zhu & Paul 2008).  All 
the CD4+ T cell subsets including Th1, Th2, Th17, as well as Treg cells are capable 
of producing IL-10 under certain conditions (Anderson et al. 2007;Jankovic et al. 
2007;McGeachy et al. 2007).  The principal role of IL-10 seems to be keeping 
immune responses in check and preventing the detrimental effects of excessive 
inflammatory reactions. 
 
IL-10 is a potent inhibitor of antigen presentation, and its main biological function 
appears to be exerted on DCs and macrophages.  It inhibits MHC class II expression 
as well as the upregulation of costimulatory molecules CD80 (B7-1) and CD86 (B7-
2), which profoundly affects the ability of APCs to activate T cells.  IL-10 inhibits the 
maturation of DCs and differentiation of DCs from monocyte precursors.  Thus, many 
of the immuno-inhibitory characteristics of IL-10 can be attributed to their effect on 
APCs to downregulate the production of the Th1-associated cytokines IL-2 and IFN-γ, 
and also the Th2-associated cytokines IL-4 and IL-5.  Thus, the original description 
of IL-10 as a crossregulator of Th1/Th2 immunity is probably no longer applicable.  
The other profound effect of IL-10 is to suppress the production of pro-inflammatory 
cytokines and mediators from macrophages and DCs, including IL-1, IL-6, IL-12, 
TNF-α.  IL-10 can further inhibit inflammation by increasing the release of IL-1 
receptor antagonist by macrophages (Akdis & Blaser 2001;Mosser & Zhang 2008). 
 
IL-10 can target naive CD4+ T cells, possibly via an inhibition of CD28 signalling 
pathway.  It has little or no direct effects on activated or memory T cells due to the 
reduction of IL-10R upon T cell activation (Akdis & Blaser 2001).  Inflammatory 
chemokines of both the CC and CXC type are suppressed by IL-10, as is the 
production of macrophage matrix metalloproteases.  Then again, it is important to 
note that the biologic functions of IL-10 are not solely restricted to suppression of the 
immune system.  IL-10 can augment B cell proliferation, prolong B cell survival, and 
contribute to class switching in B cells.  It can also costimulate NK cell proliferation 
and cytokine production.  IL-10 can act as a growth factor to stimulate the 
proliferation of certain subsets of CD8+ T cells (Mosser & Zhang 2008).  Furthermore, 
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T cells are protected from apoptotic death by IL-10 through upregulation of Bcl-2, a 
protooncogene (Cohen et al. 1997). 
 
 
   4.4.3.2 The immunomodulatory effect of IFN-α on IL-10 
 
Analysing our data, a tendency to upregulate IL-10 production by CD3+ and CD4+ T 
cells was observed.  The finding is in line with a recent study which showed that IFN-
α significantly increased IL-10 production by anti-CD3/CD28 stimulated PBMCs in 
cell culture supernatants from BD patients (Liu et al. 2011).  Our results are also in 
agreement with earlier studies.  In patients with uveitis, IL-10 production by 
CD3+/CD4+ T cells was reduced but was restored to normal after IFN-α therapy (Ito 
et al. 2001;Plskova et al. 2006).  In patients with corticosteroids-resistant asthma, the 
observation of increased IL-10 expression in venous blood T cells and monocytes as 
a consequence of IFN-α therapy has been described (Simon et al. 2003).  In addition, 
IFN-α was found to induce mild upregulation of IL-10 production by CD4+CD3- Th2-
like clones isolated from peripheral blood of patients with hypereosinophilic 
syndrome (Schandene et al. 1996).  Stimulation of DCs with LPS induced mainly 
production of IL-10 that was further amplified by IFN-α (Tamir et al. 2005). 
 
 
   4.4.3.3 Biology of Tr1 cells 
 
For the systemic control of autoreactive T effector cells in a multi-system 
inflammatory disease, apart from Foxp3+ Treg subsets that function mainly via 
contact-dependent mechanism, distinct induced Tr1 cells that lack Foxp3 expression 
also regulate T cell functions.  Recent evidence suggests that, like in the case of 
human effector T cells, Tr1 cells can express Foxp3 upon activation, albeit 
transiently (Roncarolo & Gregori 2008).  Human Tr1 cells generated in vitro do not 
constitutively express Foxp3, but upon activation can upregulate this transcription 
factor to levels similar to those observed in activated effector T cells.  Interestingly, 
functional suppressor Tr1 cells can be differentiated in vitro from naive T cells of 
IPEX patients lacking Foxp3 (Roncarolo & Gregori 2008).  It has been indicated that 
one of the mechanisms of action of Foxp3+ Treg cells may relate to the induction of Tr1 
  
198 
 
cells in vivo, as there is evidence that Foxp3+ Treg cells induce the development of Tr1 
cells in vitro (Dieckmann et al. 2002). 
 
Through the capacity to secrete IL-10 by Tr1 cells, infectious tolerance can be mediated 
effectively.  Also, Tr1 cells may enhance the function of Foxp3+ Treg cells by inhibiting 
production of pro-inflammatory cytokines such as TNF-α, as the presence of these 
cytokines may compromise the suppressive capacity of Foxp3+ Tregs (Thunberg et al. 
2007).  Currently, there are no known specific cell-surface markers for Tr1 cells, and 
it is therefore difficult to identify and track these cells.  Although many cell types 
produce IL-10, Tr1 cells characteristically produce high levels of IL-10 as well as 
lower levels of TGF-β (Roncarolo et al. 2006).  In addition to their cytokine production 
profile, Tr1 cells are functionally characterised by their intrinsic low proliferative 
capacity (Levings et al. 2001).  Tr1 cells are found in vivo in the chronic presence of 
low levels of antigen.  Although Tr1 cells must encounter their antigen to exert these 
regulatory effects, once activated, they seem to suppress in an antigen non-specific 
manner and bystander inhibition by cytokines such as IL-10 (Groux et al. 
1997;Roncarolo, Levings, & Traversari 2001).  Furthermore, Tr1 cells can be 
induced from naive CD4+ T cells activated by tolerogenic APCs in the periphery in the 
presence of IL-10 (Roncarolo et al. 2006). 
 
 
   4.4.3.4 The immunomodulatory effect of IFN-α on Tr1 cells 
 
From our experiments, a tendency to enhance IL-10 production by CD3+ and CD4+ T 
cells was detected.  This is likely to support induction of a larger population of Tr1 
cells.  Notably, the increase in the CD4+IL-10+ T cell populations was mostly 
accounted for by the CD4+IL-10+Foxp3- cells, some of which were likely to be Tr1 
cells.  Not surprisingly, an upregulation of CD4+IL-10+Foxp3- T cells themselves were 
also observed. 
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   4.4.4.1 Biology of TGF-β 
 
Previous studies revealed that TGF-β plays a key role in inducing tolerance and 
maintaining T cell homeostasis.  It can target proliferation and differentiation 
programs in T cells independently.  TGF-β has been found to inhibit T cell 
proliferation via multiple pathways, including blocking IL-2 expression (Wan & Flavell 
2008).  However, inclusion of IL-2 in T cell cultures relieves TGF-β inhibition of T cell 
proliferation.  Of note, TGF-β-mediated inhibition of Th cell differentiation can still 
take place in the presence of IL-2 despite the fact that T cell proliferation is 
encouraged (Sad & Mosmann 1994;Wan & Flavell 2008).  This indicates that TGF-β 
can inhibit T cell proliferation through yet to be defined IL-2-independent 
mechanisms. 
 
TGF-β is a powerful regulator of effector T cell differentiation, and it generally 
impedes the acquisition of Th cell functions (Gorelik & Flavell 2002).  TGF-β has 
been shown to inhibit both Th1 and Th2 differentiation, possibly through 
downregulation of Th1 and Th2 master regulators, T-bet, and GATA3 (Gorelik, 
Constant, & Flavell 2002;Gorelik, Fields, & Flavell 2000;Park, Letterio, & Gorham 
2007).  However, the activity of TGF-β is influenced by the environmental milieu.  
Also, TGF-β is intimately associated with the survival and function of Treg cells (Li et 
al. 2006).  Nevertheless, it is now generally accepted that whereas TGF-β alone 
induces Foxp3 and inhibits Th17 differentiation, if inflammatory cytokines such as IL-6 
are present, TGF-β-induced Foxp3 is suppressed and the expression of Th17-defining 
transcription factors is favoured (Yang et al. 2008b). 
 
 
   4.4.4.2 The immunomodulatory effect of IFN-α on TGF-β 
 
Our ex vivo data showed the tendency to upregulate TGF-β by CD3+ T cell 
populations as early as 3 months after starting IFN-α therapy and the trend was still 
evident at 12 month visits.  This is in contrast to patients on conventional treatment 
alone as no change or even a downregulation of TGF-β expression by T cells was 
observed.  The positive effects of IFN-α therapy on TGF-β levels have not been 
reported previously. 
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In a study on myeloma patients treated with 2 weeks of low dose IFN-α2a, no 
significant change in TGF-β level was detected with IFN-α administration (Sonmez et 
al. 2004).  Also, there was no significant effect observed on the levels of TGF-β in 
patients with melanoma treated with 4 weeks of IFN-α2b either (Ascierto et al. 2010).  
The difference could be related to the dosage of IFN-α administered and the shorter 
period of IFN-α therapy compared to our study.  Importantly, the production and 
action of IL-10 and TGF-β are interrelated and likely involve a positive feedback loop 
in which IL-10 enhances expression of TGF-β and vice versa.  IL-10 not only 
enhances production of TGF-β, but it can also modulate the ability of cells to respond 
to TGF-β.  This involves the IL-10-mediated restoration of TGF-βR2 expression on 
recently activated T cells, which typically downregulate this molecule and become 
resistant to the inhibitory effects of TGF-β (Cottrez & Groux 2001).  Therefore, the 
production and function of IL-10 and TGF-β may be interdependent, and the 
enhancement of one cytokine may also lead to the augmentation of the other as 
observed in our data.  
 
 
   4.4.5 Relationships between Th17 and Treg cells 
 
The developmental relationship between Treg and Th17 subsets is complex and has 
not been completely elucidated.  Previous studies have suggested the existence of 
not only a functional antagonism between the two subsets, but also of a dichotomy, 
mutually exclusive, in their generation.  During development, both Treg and Th17 
cells require TGF-β for differentiation, albeit at different levels (Manel, Unutmaz, & 
Littman 2008).  Also of note is that aTreg cells specifically expressed high amounts 
of AHR repressor transcripts and the ensuing constraint on Th17 cell development 
might play an important part in promoting Treg cell differentiation (Miyara et al. 2009).  
In the presence of IL-1β, IL-2, IL-21 and IL-23, CD4+CD25hiFoxp3+ Tregs were found 
to differentiate into IL-17-producing cells, when stimulated by allogeneic APCs 
(Koenen, Smeets, Vink, van Rijssen, Boots, & Joosten 2008).  In agreement, another 
study reported that Treg cells converted to Th17 cells when cultured in the presence 
of monocyte-derived IL-1β and IL-2 and lost their suppressive abilities (Deknuydt et 
al. 2009). 
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Interestingly, memory Tregs (CD25+CD127lowCD45RA−Foxp3+) display more a 
tendency to be converted to Th17 cells than conventional memory CD4+ T cells.  In 
addition, memory Tregs demonstrate a more pronounced proficiency to give rise to 
Th17 cells than natural naive Tregs (CD25+CD127lowCD45RA+Foxp3+) (Deknuydt et 
al. 2009).  In the peripheral blood, up to 3% of Foxp3+ Tregs cells in peripheral blood 
are capable of producing IL-17 upon activation and these cells co-express 
transcription factors RORc2 and Foxp3 (Voo et al. 2009).  These cells are suggested 
to be generated in the periphery.  Intriguingly, these IL-17+Foxp3+ Treg cells are 
reported to function as both effector and Tregs cells and are capable of suppressing 
the proliferation of CD4+ responder cells in vitro.  Compared to Foxp3+IL-17- cells, 
the levels of Foxp3 expression in the Foxp3+IL-17+ cells are significantly lower (Voo 
et al. 2009).  It is likely CD4+ T cells positive for IL-17 in our experiments contain 
some cells with Foxp3+IL-17+ phenotype as a large part of our experiments involved 
some kinds of polyclonal activation.  Further evaluation will need to be carried out in 
the future in order to clarify the roles of this subset of cells in relation to our findings. 
 
A disputable question is whether Th17 cells are susceptible to the suppressive effects of 
Tregs.  As exacerbation of Behcet’s disease may be linked to Th17 cells, it is crucial to 
understand whether an upregulation of Treg cells would ameliorate this aspect of 
inflammation.  Consistent data from human studies show that Th17 cells are resistant to 
Treg-mediated suppression at the level of proliferation, as well as cytokine production 
(Annunziato et al. 2007;Evans et al. 2007;Lohr et al. 2006).  Further examination 
revealed that although Treg cells could limit TNF-α and IL-6 produced by RORc2-
transduced T cells, they failed to suppress IL-17 (Crome et al. 2009).  IL-17 has been 
shown to induce effector T cell proliferation and also impede the ability of Treg cells to 
regulate this proliferation.  Also, the fact that IL-17 could stimulate IL-2 production by effector 
T cells all may help explain the resistance of Th17 cells to suppression by Treg cells 
(Crome et al. 2009). 
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   4.4.6.1 Biology of NKT cells 
 
NKT cells are a special kind of lymphocyte that bridges the adaptive immune system 
with the innate immune system.  Once activated, these cells can perform functions 
ascribed to both Th and Tc cells, including cytokine production and release of 
cytolytic molecules (Godfrey & Kronenberg 2004;Kawano et al. 1999).  NKT cells 
may promote the functions of CD4+CD25high T cells by secreting cytokines, including 
IL-2 and TGF-β, and modulate both Th1 and Th2-associated immunity (Godfrey et al. 
2000;La Cava, Van Kaer, & Fu 2006).  Similar to CD4+CD25+ Tregs, iNKT cells have 
been identified to express CD25 and regulate a range of immune responses 
(Godfrey & Kronenberg 2004).  Innate production of IL-17 by this group of cells was 
discovered recently in human as well (Rachitskaya et al. 2008). 
 
 
   4.4.6.2 NKT cells and Behcet’s disease 
 
In BD, a decreased frequency of NKT cells in the peripheral circulation was observed 
in patients with neurological manifestations, contrasting with a high percentage of 
these cells within the CSF mononuclear cells.  The difference was considered due to 
migration of unimpaired NKT cells toward the inflammatory sites to exert their 
regulatory function.  These NKT cells were found to be biased towards a Th1 
phenotype (Hamzaoui et al. 2006).  However, in a separate study, CD3+CD56+ cells, 
especially the CD8+CD56+ subset, were reported to increase significantly in both the 
aqueous humor and peripheral blood of BD patients with uveitis compared with 
healthy controls and patients with idiopathic anterior uveitis (Yu et al. 2004).  Similar 
increase of CD4+CD56+ T cells in the peripheral blood of BD patients  were 
described as well (Eksioglu-Demiralp et al. 1999a).  Therefore, these cells may play 
a role in the pathogenesis of BD, but their precise role remains to be clarified. 
 
Analysing our data, no significant influence on NKT cell populations by IFN-α therapy 
was detected. 
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   4.4.7 The potential influence of systemic steroids and immunosuppressants 
 
As the majority of our BD patients were still taking various combinations of steroids 
and other immunosuppressants.  Their potential effects on Th17 and Treg cells are 
discussed in this section. 
 
 
   4.4.7.1 The immunomodulatory effects on IL-17 
 
In one report, methylprednisolone (MP), a synthetic glucocorticoid, was shown to 
partially block PMA/ionomycin-triggered IL-17 production by lymphocytes from 
healthy donors in vitro (Ziolkowska et al. 2000).  Interestingly, IL-17 production was 
reported to be less sensitive than IFN-γ production to the influence of MP 
(Momcilovic et al. 2008).  Also, it was recently demonstrated that intravenous MP 
enhanced Treg cells and their expression of functional molecules including IL-10 in 
patients with MS two days after treatment.  However, the levels returned to baseline 
values by 6 weeks post-treatment (Braitch et al. 2008). 
 
Cyclosporine A was shown to significantly block IL-17 production by polyclonally 
stimulated PBMCs as well as CD4+ and CD8+ T cells from both BD patients and 
normal controls.  The ex vivo production of IL-17 by PBMCs was also significantly 
inhibited in BD patients with active uveitis after 1 and 3 months of cyclosporine A 
treatment in ELISA experiments (Chi et al. 2010).  Compared to corticosteroids, 
cyclosporine A was found to have even greater inhibitory action on IL-17.  
Furthermore, the presence of cyclosporine A in cell cultures was observed to 
significantly downregulate IL-17 production by memory Th17 cells at both protein 
and mRNA levels in healthy individuals and RA patients (Zhang et al. 2008). 
 
Mycophenolic acid was shown to inhibit IL-17 production induced by IL-15 in 
peripheral blood lymphocytes.  Methotrexate, however, did not exhibit any effect on 
the production of IL-17 (Gonzalez-Alvaro et al. 2009). 
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   4.4.7.2 The immunomodulatory effects on Treg cells 
 
It was reported that steroid treatment resulted in a significant increase in Foxp3 and 
IL-10 mRNA expression by freshly isolated and unstimulated CD4+ T cells in patients 
with moderate to severe asthma.  In vitro, 6 and 24 hours of dexamethasone 
treatment of healthy donor CD4+ T cells also led to an upregulation in Foxp3 mRNA 
expression (Karagiannidis et al. 2004). 
 
On the other hand, calcineurin inhibitors such as cyclosporine were found to be 
damaging to Foxp3+ Tregs as high blood levels of these correlated with lower Foxp3+ 
Treg frequency in liver transplant patients (San Segundo et al. 2007). 
 
Conversion of immunosuppressive treatment from calcineurin inhibitors to 
mycophenolate mofetil in liver transplant recipients, however, resulted in the 
enrichment of CD25+Foxp3+ T cells in peripheral blood after 6 months (Demirkiran et 
al. 2009). 
 
 
   4.5 Summary of findings 
 
We demonstrated that 6 months of subcutaneous IFN-α2b therapy can result in 
lower amount of peripheral blood Th17 cells in BD patients.  On the other hand, 
CD4+Foxp3+ Treg cell populations, especially CD4+CD25high T cells, were augmented 
following IFN-α2b treatment in these patients.  Notably, both of these effects were 
enduring as they were observed even after cessation of IFN-α therapy.  Also, a 
tendency to upregulate the production levels of IL-10 and TGF-β by T cells was 
detected after treatment with IFN-α.  This increase in immunoregulatory cytokine levels 
could assist in the regulation of Th cells and promote the number and function of Treg 
subsets.  Regarding NKT cells, however, no significant result was able to be observed. 
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Chapter 5 
The in vitro effects of interferon-alpha 2a & 2b on IFN-γ and IL-17 expression 
by CD4+ and CD8+ T cells in healthy donors 
 
 
   5.1 Introduction 
 
Before the discovery of Th17 subset as a distinct CD4+ effector population, Th1 cells 
were long considered to be the major effectors in multiple autoimmune and immune-
mediated diseases.  Preferential skewing of the immune response toward the Th1 
pathway was also demonstrated in BD patients (Li et al. 2003).  As IL-17 has 
profound pro-inflammatory effects and induces tissue damage during the course of 
various immune-mediated diseases, Th17 cells are increasingly being recognised to 
have a key role in autoimmune and inflammatory diseases (Kunz & Ibrahim 2009). 
 
IL-17A and IL-17F can form homo- or hetero-dimers.  This can give rise to three 
forms of IL-17: IL-17A/A, IL-17A/F and IL-17F/F, with potentially different biological 
activities. A study on mouse Th17 cells showed that IL-17A/A appears to have the 
strongest function in tissue inflammation, followed by IL-17A/F.  However, polarised 
Th17 cells express IL-17F/A in higher amounts than either homodimer (Liang et al. 
2007).  IL-17 (A and F) induces production of a broad range of pro-inflammatory 
cytokines and chemokines, including IL-6, colony-stimulating factors, CXC 
chemokines, human β-defensin-2 and metalloproteinases, by a variety of cells 
(Weaver et al. 2007).  Dysregulated IL-17 has been implicated to cause severe 
pathogenic consequences.  Recently, increased expression of IL-17 and IL-23 has 
been identified in BD patients with active uveitis compared to normal controls and 
patients in remission (Chi et al. 2008). 
 
As a result, when investigating the immunomodulatory effects of IFN-α treatment, 
analysing changes in T cell subsets producing IFN-γ and IL-17 became one of our 
main focus.  In Chapter 3, we have shown that subcutaneous IFN-α2b therapy has 
the tendency to augment IFN-γ levels in T cells and suppress Th17 cells in BD 
patients in vivo.  In this chapter, we concentrate on exploring the in vitro effects of 
exogenous IFN-α on IL-17- and IFN-γ-producing T cells.  In order to establish 
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adequate amount of Th17 cells to test the effects of exogenous IFN-α, various stimuli, 
including LPS, zymosan, Candida albicans, alpha-tropomyosin, PDS-Ag, and all-
trans retinoic acid (ATRA) were used in an attempt to induce healthy donor PBMCs 
to produce IL-17 in the preliminary tests.  These stimuli were chosen based on 
previously reported links with Th17 or Behcet’s disease.  The only exception is ATRA, 
which is expected to have a suppressive rather than augmentation effect on Th17 
cells.  Polyclonal stimulation using anti-CD3/CD28 Ab and PMA/ionomycin was 
evaluated as well. 
 
LPS is the major component of the outer membrane of Gram-negative bacteria, and 
activates TLR4.  It promotes the secretion of pro-inflammatory cytokines in many cell 
types.  Low titre of antibodies against LPS have been found in BD patients' sera 
(Cuchacovich et al. 2005), and LPS-stimulated production of TNF-α, IL-1, IL-6 and 
IL-8 has been observed to be significantly increased in patients with BD (Mege et al. 
1993).  LPS-conditioned medium was found to exhibit strong IL-17 inducing activity 
in naive human CD4+ T cells after 5 days in culture with CD3/CD28 polyclonal 
activation.  Conditioned medium was derived from supernatants of PBMCs cultured 
for 72 hours with LPS, and IL-17 concentrations were measured by ELISA (Kattah et 
al. 2008).  Similarly, stimulation of healthy donor PBMCs with 1mg/ml LPS has been 
shown to induce increased concentration of IL-17 in supernatants collected after 24 
hours of culture as measured by ELISA (Moschen et al. 2008). 
 
Zymosan, a yeast cell-wall component, binds to TLR2 and human dectin-1 (β-glucan 
receptor) (Dillon et al. 2006).  It was demonstrated that the supernatants of 
zymosan-stimulated DCs contained IL-1β and IL-23 and induced production of IL-17 
and IL-22 in naive human CD4+ T cells stimulated with anti-CD3 and anti-CD28.  In 
the experiments, naive cells were initially stimulated with anti-CD3 and anti-CD28 Ab 
and were washed and stimulated again with anti-CD3 Ab and 10ng/ml PMA after 5 
days.  Supernatants were collected another 18 hours later (Gerosa et al. 2008). 
 
C. albicans is a dimorphic organism that can take either a yeast form (spherical 
morphology) or hyphal form (rod morphology).  In the presence of heat-killed C. 
albicans yeast or hyphae, ELISA measurements of IFN-γ and IL-17 concentrations in 
5 day culture supernatants of naive CD4+ T cells stimulated with autologous 
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monocytes and anti-CD3 were performed.  C. albicans in the yeast form induced the 
differentiation of IFN-γ-producing cells, whereas C. albicans in the hyphal form 
primed naive T cell differentiation toward Th17 cells.  Also, the yeast form of this 
fungus induced monocyte-derived DCs to produce IL-12 and at high concentrations, 
IL-23, as revealed in 48 hour culture supernatants.  On the other hand, C. albicans 
hyphae selectively triggered IL-23 production (Acosta-Rodriguez et al. 2007). 
 
Retinal-S antigen (S-Ag) is a candidate autoantigen in BD.  The protein is found 
mainly in the retina, and an immune mediated response to this antigen can only 
occur after eye damage due to uveitis.  T cell responses against S-Ag are present in 
various types of human uveitis, including BD.  Among the immunodominant epitopes 
of S-Ag, an epitope named PDS-Ag (aa 342–355) is found to share homology with 
HLA-B51 and HLA-B27, which are linked to uveitis in BD (Direskeneli 2001). 
 
Tropomyosins are a family of proteins expressed in muscle as well as in non-muscle 
cells including epithelial cells, fibroblasts, and platelets.  A significantly increased 
lymphoproliferative response to alpha-tropomyosin as well as autoantibodies to 
tropomyosin have been reported in BD patients with posterior uveitis (Mahesh et al. 
2005).  These abnormalities support a possible role for alpha-tropomyosin as a self-
antigen in patients with BD. 
 
A crucial regulatory role for retinoic acid in promoting Foxp3 induction and inhibiting 
Th17 cell differentiation has been identified (Elias et al. 2008;Mucida et al. 2007).  
This is in accordance to a recent report that IL-17 secretion by naive human CD4+ T 
cells was partially inhibited by addition of exogenous retinoic acid after 5 days in 
culture with polyclonal activation in the presence of Th17 polarising mileu  (TGF-β, 
IL-1β, IL-6 and IL-23) (Kattah et al. 2008). 
 
 
   5.2 Aims 
 
Having established the capacity of subcutaneous IFN-α2b to upregulate T cells 
producing IFN-γ and suppress Th17 cells in vivo in Chapters 3 and 4, the aim of this 
chapter is to investigate the in vitro immunomodulatory effects of IFN-α on CD4+ as 
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well as CD8+ T cells producing IFN-γ and IL-17.  As the effect of IFN-α on Th1-type 
cytokines is more established, the focus is therefore more on T cells producing IL-17 
in this chapter.  Assays are set up using healthy donor PBMCs to test the influence 
of various concentrations of IFN-α2a and IFN-α2b on T cells and the kinetics of the 
interactions. 
 
 
   5.3 Results 
 
   5.3.1 Preliminary experiments to establish Th1/Th17 test models with 
antigens and polyclonal stimulation 
 
In order to develop in vitro models with adequate amount of Th17 cells to test the 
effects of IFN-α on these cells, healthy donor PBMCs were either activated with 
various concentrations of antigens or stimulated with polyclonal stimuli for 24 hours 
before intracellular cytokine staining and preparation for flow cytometry.  Untreated 
cultures were included as part of the experiments as well.  Cytokine expression was 
analysed by gating on CD4+ lymphocyte populations. 
 
It was found that antigens, including LPS, zymosan and candida, promoted very low 
levels of IFN-γ (Fig 5.1a) and IL-17 (Fig 5.1b) expression in CD4+ T cells regardless 
of the concentrations of antigens used, and as expected the levels were even lower 
in the case of ATRA.  Subsequently, extra 15 hours of incubation was tested for cell 
cultures with LPS and candida yeast extract so there would be more time for 
interactions between cells and antigens.  However, the increase in production levels 
of IFN-γ and IL-17 achieved was far from satisfactory.  Concurrent use of LPS and 
CD3/CD28 stimulation was evaluated as well, but the effect was no more than using 
anti-CD3/CD28 Ab alone. 
 
Thus, it was decided to test BD patient PBMCs with BD-related antigens, such as 
alpha-tropomyosin and PDS-Ag as a trial.  However, similar results were observed 
and IFN-γ and IL-17 production levels achieved were no better than using LPS on 
healthy donor PBMCs.  Originally, HSP60 was going to be tested as well if the trials 
on alpha-tropomyosin and PDS-Ag were successful.  Because of the very low 
  
209 
 
production levels achieved, it was decided not to use up any more of the precious 
BD patient PBMCs to test the immunomodulatory ability of HSP60 and other BD-
related antigens. 
 
Fortunately, substantially higher production levels of both IFN-γ and IL-17 were able 
to be induced in CD4+ T cells consistently with polyclonal stimulation such as anti-
CD3/CD28 Ab and especially PMA/ionomycin (Fig 5.1a and Fig 5.1b).  These results 
were repeatable as shown by the data in nine separate experiments each for Th1 
and Th17 cells despite the fact that the experiments were performed in singles. 
 
As a result, healthy donor PBMCs activated with anti-CD3/CD28 Ab and/or 
PMA/ionomycin were chosen as the basis for test models in subsequent in vitro 
experiments and further preliminary experiments with antigens were not carried out. 
  
  
210 
 
 
 
Fig 5.1: The effect of a selection of stimuli on the levels of Th1 and Th17 cells in 
healthy donors 
Healthy donor PBMCs were untreated, activated with anti-CD3 (5ng/ml) & anti-CD28 
(1μg/ml), activated with PMA (25ng/ml) & ionomycin (1μg/ml) or stimulated with various 
stimuli including LPS, zymosan, candida, and all-trans retinoic acid for 24 hours or 39 hours.  
In one experiment, both LPS and CD3/CD28 stimulation were administered.  Also, in 2 of the 
experiments, PBMCs from BD patients were used instead and stimulated with either 
polyclonal stimuli or α-tropopmyosin or PDS-Ag for 24 hours.  Results are shown as 
proportion of CD4+ T cells expressing cytokines.  In (a), percentage of IFN-γ+ cells and in (b), 
percentage of IL-17+ cells are shown.  Each colour represent a separate experiment and all 
experiments were done only once in singles.  1 is the lowest antigen concentration used and 
7 is the highest.  The actual concentrations of stimuli are shown inside the brackets in the 
legend. 
(b) 
(a) 
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   5.3.2 Preliminary experiments to establish the needs to rest cells in the 
medium after thawing and the effects of adding suboptimal IL-2 
 
Next, it was examined whether resting healthy donor PBMCs for one day in culture 
medium with or without addition of suboptimal amount of IL-2 after thawing could 
lead to recovery of functional ability by “stunned” cells and thus enhance the 
proportions of T cells producing cytokines. 
 
In terms of IFN-γ production by CD4+ T cells (Fig 5.2a), a small upregulation of 
cytokine levels was evident in PHA stimulated cultures with one day resting and 
presence of IL-2 (p<0.01).  In PMA/ionomycin stimulated cultures, an increase in the 
proportion of CD4+ T cells expressing IFN-γ was observed with one day resting 
whether IL-2 was added or not.  However, these results with PMA/ionomycin 
stimulation were not statistically significant.  On the other hand, in CD3/CD28 
stimulated cultures, IFN-γ production by CD4+ T cells was downregulated with 
resting, whether IL-2 was added (p<0.05) or not (p<0.01).  These inconsistent results 
may be able to be resolved with repeating experiments, but these were not carried 
out as the main focus was more on setting up reliable Th17 models using the limited 
resources available. 
 
In terms of IL-17 production by CD4+ T cells (Fig 5.2b), one day resting in culture 
medium with or without the addition of IL-2 after thawing did not have any significant 
impact on the proportion of CD4+ T cells expressing IL-17.  Anti-CD3/CD28 Ab and 
PHA were comparable in their capacity to stimulate IL-17 expression and IL-17-
enhancing effect achieved was far greater with PMA/ionomycin stimulation.  Overall, 
the findings suggest there is no advantage in resting PBMCs or adding suboptimal 
concentration of IL-2 for experiments involving Th17 cell populations. 
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Fig 5.2: The effect of resting PBMCs and suboptimal concentration of IL-2 on the 
proportion of Th1 and Th17 cells 
Healthy donor PBMCs were either stimulated straight away or rested for 1 day in culture 
medium (RPMI & supplements) ± 0.5 U/ml of IL-2 before stimulation.  Under all 3 conditions, 
PBMCs were untreated, or stimulated with anti-CD3 (5ng/ml) & anti-CD28 (1μg/ml), PMA 
(25ng/ml) & ionomycin (1μg/ml) or PHA (5μg/ml) for 24 hours.  Results are shown as 
proportion of CD4+ T cells expressing cytokines.  In (a), percentage of IFN-γ+ cells and in (b), 
percentage of IL-17+ cells are shown.  The experiment was done only once in triplicates and 
the results are shown as means ± SD. 
  
(a) 
(b) 
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   5.3.3 Preliminary experiments to establish the choice of culture medium 
 
The choice of medium was scrutinised as part of the preliminary experiments since it 
has been reported that Iscove's modified Dulbecco's medium (IMDM) can result in 
higher Th17 expansion (Veldhoen et al. 2009).  Experiments were set up to test 
healthy donor PBMCs cultured in RPMI- and IMDM-based T cell media in parallel.  In 
agreement, it was found in PMA/ionomycin stimulated cultures that the proportion of 
Th17 cells was enhanced from 1.6 ± 0.9% to 5.1 ± 3.5% (p=0.06) when the culture 
medium was switched from RPMI-based medium to IMDM-based medium (Fig 5.3b).  
However, no significant change was noticed in untreated or CD3/CD28 stimulated 
cultures. 
 
Notably, IMDM-based medium appeared to have greater influence on the levels of 
IFN-γ in CD4+ T cells (Fig 5.3a).  In comparison to cultures incubated in RPMI-based 
medium, the proportions of IFN-γ expressing CD4+ T cells were raised from 0.1 ± 
0.1% to 0.3 ± 0.2% (p<0.05) in untreated cultures and from 3.0 ± 1.6% to 13.3 ± 
1.5% (p<0.01) in PMA/ionomycin stimulated cultures by IMDM-based culture 
medium. 
 
Consequently, majority of the experiments involving investigations of Th1/Th17 were 
performed using IMDM-based culture medium. 
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Fig 5.3: The effect of different culture media on the levels of Th1 and Th17 cell 
populations 
Healthy donor PBMCs were either cultured in RPMI- or IMDM-based T cell medium.  Cell 
stimulation was provided by adding anti-CD3 (5ng/ml) & anti-CD28 (1μg/ml) or PMA 
(25ng/ml) & ionomycin (1μg/ml) for 24 hours.  Results are shown as proportion of CD4+ T 
cells expressing cytokines.  In (a), percentage of IFN-γ+ cells and in (b), percentage of IL-17+ 
cells are shown.  The histograms show means ± SD from 3 independent experiments.  One 
experiment was done in duplicates rather than triplicates and did not test cells stimulated 
with PMA/ionomycin. 
  
(a) 
(b) 
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   5.3.4 Preliminary experiments to establish incubation time with polyclonal 
stimuli 
 
The last of the preliminary experiments were carried out to investigate whether 
longer incubation with polyclonal stimuli would encourage greater expansion of Th1 
and Th17 cell populations.  Cultures of healthy donor PBMCs were performed over 
either 24 or 39 hours in these experiments. 
 
In terms of Th1 cells, longer culture time appeared to result in decreased proportion 
of IFN-γ expression by CD4+ T cells (Fig 5.4a).  This was evident in CD3/CD28 
stimulated cultures as the expression level was reduced from 23.5 ± 0.5% to 8.1 ± 
0.7% (p<0.01) with extra 15 hours of cultures.  Likewise, in cultures stimulated with 
PMA/ionomycin, the percentage of CD4+ T cells expressing IFN-γ decreased from 
66.5 ± 1.5% to 41.2 ± 10.5% (p<0.05). 
 
Regarding Th17 cell population (Fig 5.4b), longer culture showed the tendency to 
promote higher levels of IL-17 expression in CD3/CD28 stimulated culture as the 
percentage of Th17 cells was raised from 1.9 ± 0.3% to 3.6 ± 0.9% (p=ns).  However, 
in cultures stimulated with PMA/ionomycin, such increase was not evident and 
instead a slight reduction was observed with longer culture time as the levels of Th17 
cells was lowered from 8.8 ± 1.7% to 6.6 ± 2.1% (p=ns).  As there was no significant 
advantage detected with longer incubation time, a decision was made to perform 
Th1 and Th17 experiments over 24 hours. 
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Fig 5.4: The influence of length of culture time on the levels of Th1 and Th17 cell 
populations 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 (5ng/ml) & anti-CD28 
(1μg/ml) or PMA (25ng/ml) & ionomycin (1μg/ml) for 24 hours or 39 hours.  Results are 
shown as proportion of CD4+ T cells expressing cytokines.  In (a), percentage of IFN-γ+ cells 
and in (b), percentage of IL-17+ cells are shown.  The histograms show means ± SD of 
triplicate wells from one experiment.  IMDM-based culture medium was used. 
  
(a) 
(b) 
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   5.3.5 IFN-α has the tendency to promote CD4+ but inhibit CD8+ T cells 
 
To verify the findings in our ex vivo experiments and to investigate the effects of IFN-
α on T cells further, PBMCs isolated from healthy individuals were either cultured 
without stimulation or stimulated with anti-CD3 and anti-CD28 Ab or PMA and 
ionomycin for 24 hours in the presence or absence of IFN-α2a (101-105 U/ml) and 
IFN-α2b (101-104 U/ml) before staining and flow cytometry. 
 
Firstly, the influence of recombinant IFN-α2a and IFN-α2b on the amount of CD4+ 
and CD8+ T cells were examined.  Cytofluorimetric analysis of CD4 surface 
expression by lymphocytes demonstrated that the addition of IFN-α2a at higher 
concentrations upregulated the percentage of CD4+ T cells (Fig 5.5a).  With 
PMA/ionomycin stimulation, the proportion of CD4+ T cells increased from 54.9 ± 
0.4% to 55.7 ± 0.1% (means ± SEM; p<0.05) in the presence of 103 U/ml IFN-α2a.  
This level was further upregulated to 56.9 ± 0.2% (p<0.05) with 104 U/ml IFN-α2a.  
Similarly, CD4+ T cell enhancement was observed with the addition of IFN-α2b to cell 
cultures (Fig 5.5b).  With CD3/CD28 stimulation, the percentage of CD4+ T cells was 
raised from 38.1 ± 0.4% to 39.8 ± 0.2% (p<0.05) in the presence of 102 U/ml IFN-α2b. 
 
On the contrary, IFN-α was detected to have an inhibitory effect on CD8+ T cells.  In 
terms of IFN-α2a, a concentration of 104 U/ml was able to suppress the percentage 
of CD8+ T cells from 27.9 ± 0.5% to 26.3 ± 0.2% (p<0.05) (Fig 5.6a).  With 
CD3/CD28 stimulation, IFN-α2b concentrations of 102 to 104 U/ml all showed 
capacity to downregulate CD8 expression (Fig 5.6b).  The most prominent effect was 
seen with 103 U/ml IFN-α2b as the levels of CD8+ T cells were reduced from 18.1 ± 
0.5% to 17.1 ± 0.2% (p<0.05).  Likewise, IFN-α2b concentrations of 103 and 104 U/ml 
demonstrated capability to inhibit the proportions of CD8+ T cells in cultures 
stimulated with PMA/ionomycin.  The most effective IFN-α2b concentration was 
observed to be 104 U/ml as the levels were downregulated from 26.2 ± 0.1% to 24.8 
± 0.3% (p<0.05). 
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Fig 5.5: The upregulatory effect of recombinant IFN-α on CD4 expression by T cells 
PBMCs from one healthy donor were untreated, stimulated with anti-CD3 & anti-CD28 or 
PMA & ionomycin for 24 hours.  Various concentrations of exogenous IFN-α was added at 
the same time as the polyclonal stimuli to cell cultures.  Results are shown as proportion of 
lymphocytes expressing CD4 surface marker.  In (a) and (b), the effects of IFN-α2a and IFN-
α2b are shown respectively.  The histograms show means ± SEM of triplicate wells from 
three independent experiments.  Statistical analysis was performed using the Student's T-
test.  *p<0.05, **p<0.01, compared with controls without IFN-α added. 
  
(a) 
(b) 
  
219 
 
 
 
Fig 5.6: The downregulatory effect of recombinant IFN-α on CD8 expression by T cells 
PBMCs from one healthy donor were untreated, stimulated with anti-CD3 & anti-CD28 or 
PMA & ionomycin for 24 hours.  Various concentrations of exogenous IFN-α was added at 
the same time as the polyclonal stimuli to cell cultures.  Results are shown as proportion of 
lymphocytes expressing CD8 surface marker.  In (a) and (b), the effects of IFN-α2a and IFN-
α2b are shown respectively.  The histograms show means ± SEM of triplicate wells from 
three independent experiments.  Statistical analysis was performed using the Student's T-
test.  *p<0.05, compared with controls without IFN-α added. 
  
(a) 
(b) 
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   5.3.6 IFN-α induces IFN-γ production by both CD4+ and CD8+ T cells 
 
Results from Chapter 3 showed that Th1 response can be promoted by 6 months of 
subcutaneous IFN-α2b therapy.  In order to verify this finding, PBMCs isolated from 
healthy individuals were cultured without stimulation or stimulated with anti-CD3 and 
anti-CD28 Ab or PMA and ionomycin in the presence or absence of IFN-α2a (101-
105 U/ml) and IFN-α2b (101-104 U/ml) before intracellular cytokine staining and flow 
cytometry.  Cytokine expression was analysed by gating on either CD4+/CD3+CD8- 
or CD8+ lymphocyte populations to study the ability of IFN-α to induce IFN-γ 
expression in CD4+ and CD8+ T cells in vitro. 
 
The data revealed that Th1 response was consistently promoted by the presence of  
IFN-α in cultures, especially with higher concentrations.  In untreated cultures, the 
proportion of CD4+ T cells producing IFN-γ was upregulated with 105 U/ml of IFN-
α2a from 1.4 ± 0.4% to 2.3 ± 0.3% (means ± SD; p<0.05) (Fig 5.7a).  Similarly, IFN-
α2a concentrations of 103 and 104 U/ml enhanced Th1 cell percentage from 13.5 ± 
0.4% to 17.5 ± 0.9% (p<0.01) and 18.1 ± 0.7 (p<0.01) respectively with CD3/CD28 
stimulation.  With PMA/ionomycin stimulation, a dose-dependent, upregulating effect 
of IFN-α2a on Th1 cells was detected.  The peak response was seen with a IFN-α2a 
concentration of 105 U/ml, and the proportion of CD4+ T cells producing IFN-γ was 
raised from a level of 58.8 ± 0.7% to 63.9 ± 0.8% (p<0.01).  In correspondence, 
addition of IFN-α2b with concentrations of 103 and 104 U/ml to cultures increased 
Th1 cell percentage from 54.5 ± 1.0% to 57.7 ± 0.5% (p<0.01) and 60.3 ± 0.6 
(p<0.01) respectively with PMA/ionomycin stimulation (Fig 5.7b). 
 
The data also showed that CD8+ T cells producing IFN-γ were induced by 
exogenous IFN-α.  In CD3/CD28 stimulated cultures, the proportion of IFN-γ 
producing CD8+ T cells were elevated in a dose-dependent manner with IFN-α2a 
(Fig 5.8a).  In particular, a IFN-α2a concentration of 104 U/ml was demonstrated to 
increase IFN-γ producing CD8+ T cells from 12.1 ± 0.8% to 20.1 ± 1.1% (p<0.01).  
Similar trend was observed in untreated cultures and cultures activated with 
PMA/ionomycin as well, but in both cases, the highest IFN-α2a concentration tested 
of 105 U/ml was most the most potent.  In agreement, IFN-α2b was found to be 
equally effective in inducing CD8+ T cells producing IFN-γ, especially with a IFN-α2b 
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concentration of 104 U/ml (Fig 5.8b).  With addition of 104 U/ml IFN-α2b, the 
proportion of IFN-γ producing CD8+ T cells was upregulated from 0.9 ± 0.1% to 2.1 ± 
0.5% (p<0.05) in untreated cultures, from 13.9 ± 1.0% to 20.8 ± 0.5% (p<0.01) in 
CD3/CD28 stimulated cultures, and from 64.7 ± 1.1% to 69.8 ± 1.0% (p<0.01) in 
cultures stimulated with PMA/ionomycin. 
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Fig 5.7: The upregulatory effect of recombinant IFN-α on Th1 response 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD4+ T cells expressing 
IFN-γ.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  Results in 
(a) and (b) are representative of 3 independent experiments each.  PBMC were from three 
different donors for experiments on both forms of IFN-α.  One experiment each did not use 
CD3/CD28 stimulation and was incubated over 39 hours, and 101 U/ml of IFN-α (2a and 2b) 
and 105 U/ml of IFN-α2a were not tested in one experiment.  Data are means ± SD values of 
triplicate wells.  Statistical analysis was performed using the Student's T-test.  *p<0.05, 
**p<0.01, compared with controls without IFN-α added. 
  
(a) 
(b) 
  
223 
 
 
 
Fig 5.8: The enhancing effect of recombinant IFN-α on CD8+ T cells expressing IFN-γ 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD8+ T cells expressing 
IFN-γ.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  Results in 
(a) and (b) are representative of two (a) and three (b) independent experiments respectively, 
and each experiment for IFN-α2a and IFN-α2b used PBMCs from a different donor.  
CD3/CD28 stimulation was used in only one experiment for both IFN-α2a and IFN-α2b.  101 
U/ml of IFN-α (2a and 2b) and 105 U/ml of IFN-α2a were tested once in experiments.  Data 
are means ± SD values of triplicate wells.  Statistical analysis was performed using the 
Student's T-test.  *p<0.05, **p<0.01, compared with controls without IFN-α added. 
  
(a) 
(b) 
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   5.3.7 The kinetics of the upregulatory effect of IFN-α on IFN-γ production by 
T cells 
 
Although IFN-α has been observed to induce an upregulation in IFN-γ production by 
both CD4+ and CD8+ T cells in vitro, it is of interest to investigate whether pre-
treatment of PBMCs with IFN-α can exert greater influence when compared to 
adding IFN-α at the same time as cell activating agents.  Also, another question is 
whether IFN-α can still exert its impact once PBMCs are activated.  To aid in 
answering these questions, PBMCs isolated from healthy individuals were cultured 
without IFN-α treatment or with 104 U/ml IFN-α2a added 24 hours before, 4 hours 
before, at the same time as, or 4 hours after PMA/ionomycin stimulation.  The timing 
for the introduction of IFN-α to cultures was the same for both unstimulated and 
stimulated cultures, and PBMCs were incubated for 24 hours after PMA/ionomycin 
stimulation before intracellular cytokine staining and flow cytometry.  IFN-γ 
expression levels were analysed by gating on either CD4+/CD3+CD8- or CD8+ 
lymphocyte populations. 
 
Surprisingly, it was found that pre-treatment of PBMCs with IFN-α showed the least 
amount of upregulating potential.  In PMA/ionomycin stimulated cultures, IFN-α pre-
treatment did not significantly alter the proportion of either CD4+ (Fig 5.9a) or CD8+ 
(Fig 5.9b) T cells producing IFN-γ when evaluated against controls without IFN-α 
treatment.  In fact, for both CD4+ and CD8+ (Fig 5.9b) T cells, the augmenting effect 
of IFN-α on IFN-γ levels was strongest when IFN-α was introduced 4 hours after 
PMA/ionomycin stimulation. 
 
With regards to CD4+ T cells, the proportion of cells producing IFN-γ was appreciably 
raised from 57.1 ± 2.0% (means ± SEM) without IFN-α treatment to 64.3 ± 0.8% 
(p<0.01) when IFN-α was added 4 hours post PMA/ionomycin activation (Fig 5.9a).  
This elevation of IFN-γ was statistically significant even when compared to data 
influenced by 24 hours (56.4 ± 1.6%; p<0.01) and 4 hours (59.8 ± 1.8%; p<0.05) of 
IFN-α pre-treatment before polyclonal activation. 
 
Similarly, concerning CD8+ T cells, the percentage of cells producing IFN-γ was 
considerably elevated from 75.4 ± 2.7% without IFN-α to 82.2 ± 1.2% (p<0.05) when 
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IFN-α was added 4 hours post PMA/ionomycin activation (Fig 5.9b).  This increase in 
IFN-γ was still significant when evaluated against data collected from cultures with 
24 hours (74.3 ± 2.7%; p<0.05) of IFN-α pre-treatment before polyclonal activation. 
 
These trends were detected in untreated cultures as well, among both CD4+ and 
CD8+ T cells. 
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Fig 5.9: The kinetics of upregulatory effect of IFN-α on T cells expressing IFN-γ 
Healthy donor PBMCs were either treated without or with 104 U/ml IFN-α2a 24 hours before, 
4 hours before, at the same time as, or 4 hours after introduction of PMA & ionomycin to 
cultures.  The timing for the addition of IFN-α2a to cultures was the same for both 
unstimulated and stimulated cultures, and PBMCs were incubated for 24 hours after 
PMA/ionomycin stimulation before staining.  Results are shown as proportion of (a) CD4+ T 
cells and (b) CD8+ T cells expressing IFN-γ.  The histograms show means ± SEM of 
triplicate wells from three independent experiments.  All experiments used PBMCs from the 
same donor.  Statistical analysis was performed using the Student's T-test.  *p<0.05, 
**p<0.01, compared with controls without IFN-α added. †p<0.05, ††p<0.01, compared with 
data with 24-hour IFN-α pre-treatment.  ‡p<0.05, compared with data with 4-hour IFN-α pre-
treatment. 
  
(a) 
(b) 
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   5.3.8 IFN-α inhibits IL-17 production by both CD4+ and CD8+ T cells 
 
Results from Chapter 4 revealed that 6 months of subcutaneous IFN-α2b therapy 
were able to promote a downregulation of Th17 response.  Consequently, 
experiments were set up to test the influence of IFN-α on IL-17 producing CD4+ T 
cells as well as CD8+ T cells in vitro.  Again, PBMCs isolated from healthy individuals 
were either cultured without stimulation or stimulated with anti-CD3 and anti-CD28 
Ab or PMA and ionomycin in the presence or absence of IFN-α2a (101-105 U/ml) and 
IFN-α2b (101-104 U/ml) before intracellular cytokine staining and flow cytometry.  
Cytokine expression was analysed by gating on either CD4+/CD3+CD8- or CD8+ 
lymphocyte populations. 
 
As expected, data showed that Th17 response was inhibited by IFN-α consistently in 
vitro in accordance with the BD patient findings, especially with higher 
concentrations of IFN-α.  With PMA/ionomycin activation, 105 U/ml of IFN-α2a and 
104 U/ml of IFN-α2b induced a downregulation of IL-17 producing CD4+ T cells from 
2.1 ± 0.2% (means ± SD) to 1.5 ± 0.2% (p<0.01) and 1.2 ± 0.1% (p<0.01) 
respectively (Fig 5.10a and 5.10b).  Statistically significant result was evident in 
CD3/CD28 stimulated cultures as well, but only with IFN-α2b concentration of 104 
U/ml (Fig 5.10b). 
 
Likewise, IFN-α was observed to exert negative control on CD8+ T cells producing 
IL-17 in vitro.  In CD3/CD28 stimulated cultures, the proportion of IL-17 producing 
CD8+ T cells were suppressed in a dose-dependent manner with IFN-α2b (Fig 5.11b).  
In particular, a IFN-α2b concentration of 104 U/ml was able to reduce IL-17 
expressing CD8+ T cells from 0.9 ± 0.1% to 0.5 ± 0.1% (p<0.05).  In addition, similar 
trend was observed in cultures stimulated with PMA/ionomycin.  The highest IFN-α 
concentrations used in the in vitro experiments were able to promote a 
downregulation in the percentage of CD8+ T cells producing IL-17 from 0.9 ± 0.1% to 
0.6 ± 0.1% (p<0.05) in the case of IFN-α2a (Fig 5.11a) and from 0.8 ± 0.1% to 0.4 ± 
0.0% (p<0.05) in the case of IFN-α2b (Fig 5.11b). 
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Although CD4+ and CD8+ T cells producing both IFN-γ and IL-17 were detected, they 
were present in negligible amount and IFN-α2a and IFN-α2b did not have any 
significant effects on these subpopulations (data not shown). 
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Fig 5.10: The inhibitory effect of recombinant IFN-α on Th17 cell response 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD4+ T cells expressing 
IL-17.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  Results in 
(a) and (b) are representative of four independent experiments each.  PBMCs were from 
three and four different donors for IFN-α2a and IFN-α2b respectively.  CD3/CD28 stimulation, 
101 U/ml of IFN-α (2a and 2b) and 105 U/ml of IFN-α2a were used in half of the experiments.  
Also, in one experiment each for both IFN-α2a and IFN-α2b, PBMC cultures were incubated 
over 39 instead of 24 hours.  Data are means ± SD values of triplicate wells.  Statistical 
analysis was performed using the Student's T-test.  *p<0.05, **p<0.01, compared with 
controls without IFN-α added. 
  
(a) 
(b) 
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Fig 5.11: The inhibitory effect of recombinant IFN-α on CD8+ T cells expressing IL-17 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD8+ T cells expressing 
IL-17.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  Results in 
(a) and (b) are representative of two (a) and three (b) independent experiments respectively, 
and each experiment for IFN-α2a and IFN-α2b used PBMCs from a different donor.  
CD3/CD28 stimulation was used in only one experiment for either IFN-α2a or IFN-α2b.  101 
U/ml of IFN-α (2a and 2b) and 105 U/ml of IFN-α2a were tested once in experiments.  Data 
are means ± SD values of triplicate wells.  Statistical analysis was performed using the 
Student's T-test.  *p<0.05, **p<0.01, compared with controls without IFN-α added. 
  
(a) 
(b) 
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   5.3.9 The kinetics of the inhibitory effect of IFN-α on IL-17 production by T 
cells 
 
Even though IFN-α has been identified to promote an inhibition of IL-17 production 
by both CD4+ and CD8+ T cells in vitro, it is of interest to examine whether pre-
treatment of PBMCs with IFN-α can exert stronger effect when compared to adding 
IFN-α and activating stimuli concurrently.  Another question to resolve is whether 
IFN-α can still exert its influence once PBMCs are activated.  To answer these 
questions, PBMCs isolated from healthy individuals were cultured without IFN-α 
treatment or with 104 U/ml IFN-α2a added 24 hours before, 4 hours before, at the 
same time as, or 4 hours after PMA/ionomycin stimulation.  The timing for IFN-α 
addition to cultures was the same for both unstimulated and stimulated cultures, and 
PBMCs was incubated for 24 hours after PMA/ionomycin stimulation before 
intracellular cytokine staining and flow cytometry.  IL-17 expression levels were 
analysed by gating on either CD4+/CD3+CD8- or CD8+ lymphocyte populations. 
 
Although pre-treatment of PBMCs with IFN-α showed a suppression of IL-17 
production levels within both CD4+ (Fig 5.12a) and CD8+ (Fig 5.12b) T cell 
populations, the effect was stronger when IFN-α was added around the same time 
as the introduction of polyclonal stimulation by PMA/ionomycin.  More specifically, 
the maximum outcome was consistently achieved in both CD4+ and CD8+ T cells 
with simultaneous introduction of IFN-α and PMA/ionomycin to PBMC cultures. 
 
When 104 U/ml IFN-α2a and activating agents were added together, the proportion 
of CD4+ T cells producing IL-17 was downregulated considerably to 1.0 ± 0.1% 
(means ± SEM; p<0.01) from a level of 1.8 ± 0.2% in the absence of IFN-α (Fig 
5.12a).  Also, this inhibitory effect was significantly greater than one with 24-hour 
IFN-α pre-treatment (1.3 ± 0.1%; p<0.01). 
 
Similarly, concerning CD8+ T cells, the percentage of cells producing IL-17 was 
significantly reduced from 0.8 ± 0.2% without IFN-α to 0.3 ± 0.1% (p<0.05) with 
concurrent use of IFN-α and PMA/ionomycin (Fig 5.12b).  This suppressive effect 
was significantly greater than when IFN-α was added 24 hours before polyclonal 
stimulation (0.5 ± 0.1%; p<0.05). 
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Moreover, in untreated cultures, the addition of IFN-α inhibited IL-17 producing CD4+ 
and CD8+ T cells, but there was no appreciable difference adding IFN-α early or later 
during culture. 
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Fig 5.12: The kinetics of inhibitory effect of IFN-α on T cells expressing IL-17 
Healthy donor PBMCs were either treated without or with 104 U/ml IFN-α2a 24 hours before, 
4 hours before, at the same time as, or 4 hours after introduction of PMA & ionomycin to 
cultures.  The timing for the addition of IFN-α2a to cultures was the same for both 
unstimulated and stimulated cultures, and PBMCs were incubated for 24 hours after 
PMA/ionomycin stimulation before staining.  Results are shown as proportion of (a) CD4+ T 
cells and (b) CD8+ T cells expressing IL-17.  The histograms show means ± SEM of triplicate 
wells from three independent experiments.  All experiments used PBMCs from the same 
donor.  Statistical analysis was performed using the Student's T-test.  *p<0.05, **p<0.01, 
compared with controls without IFN-α added.  †p<0.05, ††p<0.01, compared with data with 
24-hour IFN-α pre-treatment. 
  
(a) 
(b) 
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   5.4 Discussion 
 
   5.4.1.1 Setting up Th1/Th17 in vitro test models using antigens and 
polyclonal stimuli 
 
It has been shown that cytokines present upon T cell activation can shape the 
differentiation of T cells.  However, there are other variables that are known to affect 
the development of T cell subsets which include the affinity of the TCR for Ag, the 
duration of the interaction between TCR and Ag, and differential co-stimulation by 
APCs (Zhu, Yamane, & Paul 2010).  In our in vitro experiments, selected antigens 
and polyclonal stimuli were used to induce expansion of Th1 and in particular, Th17 
cells in healthy donor PBMCs in order to set up test models for subsequent 
investigation of the immunomodulatory effects of exogenous IFN-α on these two cell 
populations.  Analysing our data on healthy donor PBMCs, all antigens promoted 
very low production levels of IL-17 and IFN-γ in CD4+ T cells, even with extra time in 
culture. 
 
Although LPS, zymosan and candida were previously reported to possess IL-17 
inducing activity (Acosta-Rodriguez et al. 2007;Gerosa et al. 2008; Kattah et al. 
2008), LPS was the only one which demonstrated some potential.  However, even 
the levels of Th17 cells achieved with LPS were less than one percent of 
lymphocytes.  Also, the commercial candida antigens used in the experiments were 
mainly made up of components from the yeast form rather the hyphal form, so it is 
not surprising to induce little Th17 response.  ATRA, as expected, resulted in lowest 
amount of Th17 and this is in accordance to previous report of its ability to inhibit 
Th17 cell differentiation (Elias et al. 2008;Mucida et al. 2007). 
 
Consequently, two of the BD-related antigens, PDS-Ag and alpha-tropomyosin, were 
used as a trial but they did not elicit much Th17 response by PBMCs from BD 
patients either.  Thus it was decided to conserve valuable BD patient samples and 
not to test any other BD-related antigens such as HSP60. 
 
On the other hand, polyclonal stimuli consistently showed good potential to promote 
Th17 cell populations out of all combinations used, especially in the case of PMA in 
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combination with ionomycin.  Polyclonal stimuli are quite efficient in inducing Th1 cell 
populations as well.  PMA is a mitogen which binds and activates protein kinase C, 
causing a wide range of effects in cells and tissues (Castagna et al. 1982), and 
ionomycin is a potent and selective calcium ionophore agent.  In human T cells, 
ionomycin induces hydrolysis of phosphoinositides and synergises with PMA in 
enhancing the activation of protein kinase C to mediate T cell activation (Chatila et al. 
1989). 
 
However, phorbol esters induce CD4 phosphorylation and a consequence of this is 
enhancement of CD4 internalisation and subsequent degradation of membrane CD4 
in lysosomes (Petersen et al. 1992).  As a result of this CD4 deficiency, substantial 
amount of the experiment results which involved PMA/ionomycin stimulation and 
analysed by gating on CD4 was found to be inconsistent.  Therefore, a solution of 
using CD3 and CD8 instead of CD4 to stain for CD4+ T cells was adopted in later 
experiments to resolve the problem of PMA-induced CD4 internalisation.  CD3+CD8- 
T cells were then considered as equivalent to CD4+ T cells. 
 
 
   5.4.1.2 Testing other aspects of the in vitro experimental design 
 
It has been suggested resting PBMCs overnight after thawing before testing effector 
functions would remove cells destined for death and allow “stunned” cells to recover 
functional ability (Lamoreaux, Roederer, & Koup 2006).  Therefore, instead of 
stimulating cells straight after thawing, one day resting in culture medium with or 
without suboptimal level of IL-2 was performed.  It was observed that neither resting 
nor addition of IL-2 augmented the number of Th1 or Th17 cells consistently.  This is 
in agreement with a recent study which showed overnight resting did not improve the 
CD4+ or CD8+ T cell IFN-γ responses to antigens (Owen et al. 2007).  It was thus 
concluded that it was not necessary to allow time for PBMCs to recover before 
stimulation. 
 
Concerning the choice of culture medium, it was shown recently that IMDM, a 
medium richer in aromatic amino acids, consistently resulted in higher Th17 
expansion (Veldhoen et al. 2009).  In line with the finding, IMDM did display a 
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tendency to preferentially upregulate Th17 cells as well as enhancing Th1 response 
when PMA/ionomycin stimulation was applied to cultures of healthy donor PBMC in 
our experiments, although there was no significant difference between RPMI- and 
IMDM-based media in untreated and CD3/CD28 stimulated cultures.  Consequently, 
Th17 cell experiments were carried out using IMDM-based culture medium, except 
some earlier experiments which were performed using RPMI-based culture medium. 
 
Variation of duration of cultures was experimented as well and PBMC cultures were 
performed over either 24 or 39 hours to examine whether higher proportions of Th1 
and Th17 cells could be achieved with longer culture time.  In the end, it was decided 
to perform experiments over 24 hours as there was no advantage detected with 
extra time in culture with regards to enhancing either IFN-γ or IL-17 production levels 
by CD4+ T cells. 
 
 
   5.4.2 Choosing the concentrations of IFN-α used for in vitro experiments 
 
In our BD patient trial, pegylated IFN-α2b was given according to a dosage table 
(table 2.1).  As the majority of our patients weighed between 50-100kg, 30μg of 
pegylated IFN-α2b per week was received by most patients.  The specific activity of 
pegylated IFN-α2b is approximately 7.0 x 107 IU/mg protein, compared with 2.6 x 108 
IU/mg protein for standard IFN-α2b.  As a result, each patient received an equivalent 
of approximately 2.1 million units every week for 6 months (Schering-Plough 2007).  
The actual tissue concentrations of IFN-α2b may be difficult to assess following in 
vivo administration, and further studies are required to attain the approximation for 
pegylated IFN-α2b.  However, a dose of 1-10 x 106 IU unconjugated IFN-α in vivo 
has been estimated to correlate with a concentration of 100 IU/ml at the tissue level 
(Krishnaswamy et al. 1996). 
 
It was reported that IFN-α promoted cell-cycle arrest in CD4+ T cells and the 
inhibitory effect of IFN-α on cell proliferation reached a plateau between 
concentrations of 103 and 104 U/ml.  Of note, inhibition of proliferation could be 
associated with a decrease in the production of inflammatory cytokines from cells.  
Additionally, cell viability was shown to be maintained in PBMCs and T cell clones at 
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103 U/ml of IFN-α (Krishnaswamy et al. 1996).  Nevertheless, it is currently unclear 
whether the anti-proliferative effect of IFN-α is more effective on certain subsets such 
as Th17 cells than the other ones.  Due to these early findings, a concentration of 
1000 U/ml of IFN-α was picked as the median concentration for our in vitro studies 
using healthy donor PBMCs. 
 
 
   5.4.3.1 Biology of CD8+ T cells 
 
CD8+ T cells represent an important arm of adaptive immunity and they play a role in 
the regulation of the activation and differentiation of CD4+ cells (Vukmanovic-Stejic et 
al. 2000).  Notably, dysregulated CD8+ T cells have been implicated in the 
pathogenesis of various autoimmune diseases (Liblau et al. 2002).  CD8+ T cells 
exert their effector functions through production of inflammatory cytokines such as 
IFN-γ, and induction of cytotoxic damage of target cells expressing MHC class I 
molecules and the relevant antigenic peptide via perforin/granzyme and death 
receptor pathways (Li et al. 2006).  As MHC class I molecules are found in every 
nucleated cells of the body, it is clear that there is potential for considerable amount 
of tissue damage. 
 
Compares with CD4+ T cells, naive CD8+ T cells acquire effector T cell functions 
more readily upon antigen stimulation (Seder & Ahmed 2003).  Activated CD8+ T 
cells can produce very high levels of inflammatory cytokines, including TNF-α and 
IFN-γ (Liblau et al. 2002).  All these may contribute greatly to target cell destruction 
in autoimmune diseases and therefore stringent regulation is essential for CD8+ T 
cells. 
 
 
   5.4.3.2 Influence of IFN-α on peripheral blood CD4+ and CD8+ T lymphocytes 
 
From our ex vivo experiments in Chapter 3, there was no significant alteration of the 
expression levels of CD4 or CD8 by T cells from BD patients whether they received 
IFN-α therapy or not.  Unlike our ex vivo results, there was a tendency for CD4+ T 
cell upregulation but CD8+ T cell downregulation by addition of either IFN-α2a or 
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IFN-α2b to healthy donor PBMC cultures in a dose-dependent manner, and IFN-α 
concentrations of 103 or 104 U/ml were generally found to be most powerful.  The 
difference could be related to how peripheral blood cells were treated as the in vitro 
cultures were activated with polyclonal stimulation and incubated for 24 hours. 
 
Our results are in part supported by a previous study on patients with severe steroid-
resistant asthma.  It was described that IFN-α treatment promoted a relative increase 
in CD4+ T cells but a downregulation of CD8+ T cells was not reported (Simon et al. 
2003).  In the study, 3x106 IU/day of recombinant IFN-a2a was administered on each 
patient and systemic corticosteroid treatment was maintained until a clinical 
improvement was seen and then gradually reduced.  An upregulation of CD4+ T cells 
was observed from 44.2 ± 2.8% within the lymphocyte populations before 
introduction of IFN-α therapy to 50.2 ± 2.6% two to four weeks after initiation of 
cytokine therapy. 
 
 
   5.4.4.1 The influence of IFN-α on IFN-γ production by CD4+ T cells 
 
IFN-α was reported to stimulate the production of IFN-γ by resting CD4+ T cells 
activated by PMA and anti-CD28 in a dose-dependent manner and IFN-α 
concentration of 104 IU/ml was found to be most stimulating (Schandene et al. 1997).  
Using freshly isolated human cells, it was revealed that IFN-α increased the 
expression of mRNA for IFN-γ and as a result the frequency of IFN-γ-producing 
CD4+ T cells within 24 hours of culture (Brinkmann et al. 1993).  Also, another study 
demonstrated that IFN-α augmented IL-12 priming for subsequent IFN-γ production 
and the generation of Th1 responses (Wenner et al. 1996).  These results are in line 
with our experimental findings that both IFN-α2a and IFN-α2b were proficient in 
inducing IFN-γ production by CD4+ T cells, especially at higher concentrations. 
 
 
   5.4.4.2 The influence of IFN-α on IFN-γ production by CD8+ T cells 
 
Analysing our data, it was found that CD8+ T cells producing IFN-γ were upregulated 
by the introduction of IFN-α.  This is in contrast to an early study which did not detect 
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any positive effects on the frequency of IFN-γ-producing CD8+ T cells by IFN-α.  The 
responsiveness of both purified CD4+ or CD8+ T cells to IFN-α was not altered by the 
addition of monocytes (Brinkmann et al. 1993). 
 
Of note, IFN-γ producing CD8+ T cells may have a significant role in the 
pathogenesis of BD.  It was revealed that the numbers of IFN-γ producing CD8+ T 
cells in patients with BD were increased, which resulted in a significant increase of 
the Tc1: Tc2 ratio compared with normal controls (Houman et al. 2004). 
 
 
   5.4.5.1 The influence of IFN-α on IL-17 production by CD4+ T cells 
 
From our in vitro experiments, Th17 response was found to be inhibited by IFN-α 
consistently just like in the case of the BD patient findings.  IFN-α suppresses the 
proportions of Th17 cells in a dose-dependent manner and higher concentrations of 
both IFN-α2a and IFN-α2b were particularly effective.  Notably, in accordance with 
our BD patient data, the inhibitory effect was seen only in activated cultures 
stimulated with polyclonal stimuli but not in unstimulated cultures.  Our findings are 
supported by some recent reports.  It was shown that pre-treatment with either 
recombinant IFN-α or IFN-β inhibited PBMC secretion of superantigen-induced IL-17 
and CD40 ligand-induced IL-23, which has the capacity to promote IL-17 secretion 
by memory/effector Th cells.  Similar inhibitory effects were observed with pDC TLR9 
agonist-induced type I IFN on activation-induced IL-23 and IL-17 expression (Meyers 
et al. 2006). 
 
Another study demonstrated that IFN-α potently reduced IL-17A mRNA expression 
levels in healthy donor PBMCs 8 hours after CD3/CD28 stimulation. IFN-α 
downregulated IL-17 release from PBMCs and Th17 cells in a dose-dependent 
manner and the highest IFN-α concentration used, 103 IU/ml, was found to exert 
strongest influence.  Similar to IL-17A, IL-17F mRNA expression was inhibited by 
IFN-α as well (Moschen et al. 2008).  Also, IFN-α was found to significantly reduce 
IL-17 production by either anti-CD3/CD28 stimulated PBMCs or CD4+ T cells in 
culture supernatants from healthy patients (Liu et al. 2011).  Moreover, research on 
mice reported that both IFN-αA/D and IFN-β can inhibit the differentiation of murine 
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naive Th cells into effector Th17 cells.  The αA/D molecule consists of the N-terminal 
portion of IFN-α2 and the C terminal portion of IFN-α1.  However, like IFN-γ, the 
suppressive effects were limited to the inductive phase and polarised Th17 cells 
were resistant to IFN-mediated suppression of IL-17 production as a result 
(Harrington et al. 2005). 
 
 
   5.4.5.2 The influence of IFN-α on IL-17 production by CD8+ T cells 
 
IL-17 production was initially reported within CD4+ αβ T cells and more recently IL-17 
producing cells within CD8+ αβ T cells (Tc17) was described in healthy human donor 
blood.  Tc17 cells are able to produce IL-17 alone or in combination with IFN-γ.  
They share many common differentiation patterns with Th17 cells, including key 
transcription factors, chemokine receptors, and cytokine receptors (Kondo et al. 
2009).  However, little is known about the role of IL-17 producing CD8+ lymphocytes 
in a normal immune response or in disease conditions. 
 
From our in vitro experiments, the levels of CD8+ T cells producing IL-17 was 
observed to be suppressed by IFN-α consistently as well, and like in CD4+ T cells, in 
a dose-dependent manner.  Again, higher concentrations of both IFN-α2a and IFN-
α2b had the strongest influence, and the suppressive effect was seen only in 
activated cultures stimulated with polyclonal stimuli but not in unstimulated cultures. 
 
 
   5.4.6 Cytokine levels in comparison to other studies 
 
From our data, the proportions of CD4+ T cells producing IL-17 in healthy donor 
PBMCs were around 2% even after stimulation with PMA/ionomycin for 24 hours.  
The proportions of CD8+ T cells producing IL-17 were even lower.  The levels 
achieved are similar to a recent study where purified human CD4+ T cells were 
stimulated with PMA/ionomycin and stained 6 hours later with anti-IL-17A.  The 
percentage of CD4+ T cells expressing IL-17A was shown to be around 1% in 
healthy donors (Brucklacher-Waldert et al. 2009). 
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In a study where naive CD4+ T cells were stimulated with anti-CD3/CD28 Abs and 
cultured with medium, IL-12 or IL-23 for 5 days before restimulation with 
PMA/ionomycin.  Again, the level of Th17 cells is comparable to our data and small 
changes in cell populations were described to be significant.  The mean percentage 
of IL-17 producing CD4+ cells was increased from 0.9% in cultures without IL-23 to 
1.8% in the presence of IL-23.  However, the level of Th17 cells was decreased in 
the presence of IL-12 to 0.7%.  On the other hand, measurement of the number of 
IFN-γ producing CD4+ cells showed reciprocal data, and a decrease of Th1 cells in 
the presence of IL-23 from 16.3% to 13.6% was detected when compared to cultures 
without added IL-23 (Hoeve et al. 2006). 
 
Also, in a recent study where peripheral blood samples from normal and SLE 
patients were incubated with PMA and ionomycin for 4 hours before 
immunofluorescence staining.  The levels of Th17 within CD4+ T cells were ranging 
between 1.6 ± 0.7% for normal controls and 2.0±1.2% for SLE patients with inactive 
disease.  On the other hands, the proportions of Tc17 within CD8+ T cells were 
ranging between 0.3 ± 0.1% for normal controls and 0.6 ± 0.4% for SLE patients with 
active disease.  All the levels reported are comparable to our study and the very 
small increase in active SLE patients was reported to be significant compared to 
healthy controls (Henriques et al. 2010). 
 
 
   5.4.7 The effect of IFN-α on the kinetics of IFN-γ and IL-17 production by T 
cells 
 
The kinetics of PBMC response under the influence of IFN-α was measured with 
regards to both IFN-γ and IL-17 producing CD4+ and CD8+ T cells.  This was carried 
out to obtain some indications in the potential roles of IFN-α not only as a treatment 
in chronic inflammatory diseases but possibly as a prophylaxis option in susceptible 
patients to chronic inflammatory diseases like BD. 
 
Unexpectedly, IFN-α pre-treatment of healthy donor PBMCs did not demonstrate as 
much upregulatory effect on either CD4+ or CD8+ T cells producing IFN-γ as when 
IFN-α was added later on in the cultures.  The highest level of T cells positive for 
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IFN-γ was achieved with introduction of IFN-α at the last time-point tested.  
Observations from PMA/ionomycin stimulated cultures raised the question whether 
exogenous IFN-α exerted greater control of IFN-γ production on activated PBMCs 
than unstimulated cells.  However, this wouldn’t explain the results analysed using 
untreated cultures.  Another possible explanation is that IFN-γ was produced in 
greater quantity earlier during incubation in response to IFN-α treatment and the 
results were simply a reflection of the experimental design picking up data at various 
stages of cytokine production. 
 
Similar stories were found with regards to IL-17 producing CD4+ and CD8+ T cells.  
No significant difference in terms of IL-17 production levels was observed regardless 
of when exogenous IFN-α was added to unstimulated cell cultures.  With 
PMA/ionomycin stimulation, however, IFN-α pre-treatment of healthy donor PBMCs 
was not able to produce as much inhibitory effect on either CD4+ or CD8+ T cells 
producing IL-17 as when IFN-α was added later on in the cultures.  Regarding IL-17 
production by T cells, concurrent use of IFN-α and PMA/ionomycin was detected to 
result in strongest downregulatory effect.  Again, this could be related to PBMC 
incubation time chosen before cell preparation and staining for flow cytometry.  It is 
likely that the cytokine IL-17 was produced later by T cells during cultures in 
comparison to IFN-γ. 
 
 
   5.5 Summary of findings 
 
Under the influence of higher doses of either recombinant IFN-α2a or IFN-α2b, there 
was a small tendency for CD4+ T cell upregulation but CD8+ T cell downregulation in 
healthy donor PBMCs.  Regarding impact on inflammatory cytokine production by T 
cells in vitro, IFN-α2a and IFN-α2b were demonstrated to be equally effective.  Both 
forms of IFN-α showed the tendency to upregulate IFN-γ producing CD4+ and CD8+ 
T cells and suppress CD4+ and CD8+ T cells producing IL-17.  IFN-α appeared to 
exert the strongest influence on IFN-γ producing and IL-17 producing T cells when it 
was added 20 hours before and 24 hours before intracellular cytokine staining and 
flow cytometry respectively.  Notably, IFN-α was found to be able to exert its effects 
on Th17 cells both before and after cell activation.  
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Chapter 6 
The in vitro effects of interferon-alpha 2a & 2b on CD4+ and CD8+ regulatory T 
cells and associated regulatory cytokines in healthy donors 
 
 
   6.1 Introduction 
 
The existence of self-reactive T cells in healthy individuals suggests that many self-
reactive T cells that escape clonal deletion in the thymus are subsequently released 
into the periphery, where they are capable of differentiating into potentially 
pathogenic effector cells (Bouneaud, Kourilsky, & Bousso 2000).  Thus, peripheral 
mechanisms exist in order to control immune responses and to dampen potential 
autoimmunity. 
 
It has been recognised Treg cells play prominent roles in the maintenance of 
lymphoid homeostasis, and these cells maintain tolerance to self and control 
autoimmune deviation by restraining overzealous immune responses (Allan et al. 
2008b).  Treg cells, therefore, represent an attractive target for therapeutic immune 
strategies in various clinical situations, and the interest in this field has exploded the 
past 5-10 years.  However, the increasing number and the heterogeneity of T cell 
subsets with immunosuppressive properties make it difficult to fully characterise and 
determine their importance in various clinical conditions.  The lack of knowledge of 
the mechanism of suppression by many of these Treg cell subsets further 
contributes to the complexity and hampers the development of therapeutic strategies 
that could have clinical applications. 
 
CD4+ Treg cells can be subdivided into naturally occurring Treg cells that originate 
from the thymus and adaptive Treg cells that are induced in the periphery.  Whereas 
CD4+ nTreg cells functionally require constitutive expression of the transcription 
factor Foxp3, adaptive CD4+ Treg cells are frequently Foxp3- (Allan et al. 2008a).  
Apart from CD4+CD25highFOXP3+ Treg cells, there are other T cell subsets with 
regulatory function.  Most of these cells, including IL-10-secreting Tr1 cells and TGF-
β-secreting Th3 cells, acquire regulatory functions following specific antigenic 
stimulation in particular cytokine milieus (Sakaguchi et al. 2010). 
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Nevertheless, regulatory T cells are not strictly confined to the CD4+ T cell 
compartment.  Naturally occurring CD8+ Treg cells originate from the thymus and are 
often considered to represent a separate T cell lineage.  Postnatal human thymus 
contains a defined population of CD8+ Treg cells.  They express the phenotype 
CD8+CD25+CTLA-4+GITR+Foxp3+ and suppress in a contact-dependent manner 
(Cosmi et al. 2003).  These cells should have a broad repertoire of antigenic 
specificities.  Conversely, adaptive CD8+ Treg cells originate from the postthymic T 
cell pool and are induced through a variety of in vivo or in vitro stimuli.  Adaptive 
CD8+ Treg cells can be further subclassified into those that have antigen specificity 
and those that display their immunoregulatory function in an antigen-non-specific 
fashion (Scotto et al. 2004). 
 
According to a recent study, it is relatively easy to generate non-antigen-specific 
adaptive CD8+CD28-Foxp3-CD56- Treg cells (Filaci et al. 2004).  Culturing 
CD8+CD28- T cells in a cytokine cocktail containing IL-2, IL-10 and GM-CSF is 
sufficient to expand CD8+ Treg cells; antigen recognition is not required.  Induction of 
this cell, however, is monocyte dependent, possibly reflecting the requirement for 
GM-CSF.  Antigen non-specific CD8 Treg cells are able to survive in culture for more 
than 1 month, broadening their potential therapeutic application.  Such non-antigen-
specific CD8+ Treg cells suppress APC-mediated antigen presentation, T-cell 
proliferation, and CTL-mediated cytotoxicity via IL-10 secretion, a cytokine that has 
been linked to anergy induction in activated T cells (Filaci et al. 2004; Xystraks et al. 
2004).  Likewise, adaptive alloantigen-specific CD8+ Treg cells can also be 
generated in vitro from naive CD8+ T cells and are present in human transplant 
patients (Manavalan et al. 2004). 
 
The concept that T cells are capable of downregulating immunity is now firmly 
established.  Both within the CD4 and the CD8 T cell subsets, specialised 
populations apply sophisticated mechanisms to inhibit early and late steps of 
immune responses. 
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   6.2 Aims 
 
In this chapter, we set out to explore the in vitro effects of IFN-α on regulatory T cell 
populations, expression of Foxp3, and production of immunoregulatory cytokines, 
that serve as critical gatekeepers in immune homeostasis.  The ex vivo data from 
chapter 4 demonstrated the tendency to upregulate IL-10 and TGF-β in T cells after 
6 months of IFN-α2b therapy which was preserved even at 12 month visits.  Assays 
are set up using healthy donor PBMCs to test the influence of various concentrations 
of IFN-α2a and IFN-α2b on CD4+ and CD8+ Treg subsets, production of IL-10 and 
TGF-β and the kinetics of the cytokine production. 
 
 
   6.3 Results 
 
   6.3.1 Preliminary experiments on Treg cells with antigens and polyclonal 
stimuli 
 
Having tested the influence of various antigens and polyclonal stimuli on Th1 and 
Th17 cell populations as described in chapter 5, the same panel of stimuli was 
applied to healthy donor PBMC cultures for 24 hours before intracellular cytokine 
staining to test their effects on Treg cells and IL-10 production as a comparison.  
Foxp3 expression was analysed by gating on CD4+ or CD4+CD25high T lymphocyte 
populations, whereas IL-10 expression was analysed by gating on CD4+ T 
lymphocytes only. 
 
It was found that anti-CD3/CD28 Ab and especially, PMA/ionomycin consistently 
promoted higher levels of Foxp3 (Fig 6.1) and IL-10 (Fig 6.2) expression by CD4+ T 
cells.  Also, as expected, ATRA showed the potential to induce Foxp3 expression in 
both CD4+ or CD4+CD25high T lymphocytes, and the optimal concentration of ATRA 
appreared to be 0.01μM.  However, ATRA had little effect on IL-10 expression.  At 5-
20μg/ml, LPS demonstrated the tendency to augment Foxp3 expression by 
CD4+CD25high T cells (Fig 6.1b) with longer incubation time.  Concurrent use of LPS 
and CD3/CD28 stimulation was evaluated as well, but the effect was no more than 
using anti-CD3/CD28 Ab alone.  Candida antigens were another candidate showing 
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the capacity in inducing Foxp3 expression by both CD4+ (Fig 6.1a) and 
CD4+CD25high (Fig 6.1b) T lymphocytes.  Unlike most other antigens tested, candida 
antigens, especially at lower concentrations, also showed the tendency to induce IL-
10 production by CD4+ T cells (Fig 6.2).  Furthermore, LPS, when used at a 
concentration of 5μg/ml, displayed some tendency to increase IL-10 producing CD4+ 
T cells with longer incubation time. 
 
In addition, PBMCs from BD patients were cultured with BD-related antigens, such 
as alpha-tropomyosin and PDS-Ag as a trial.  However, no significant effect on 
Foxp3 and IL-10 expression levels was noticed with either antigen on BD patient 
PBMCs, regardless of the concentrations of antigens used.  Therefore, it was 
decided not to use up any more of the precious BD patient PBMCs to test the 
immunomodulatory ability of other BD-related antigens, including HSP60.  Notably, 
Foxp3 (Fig 6.1b) and IL-10 (Fig 6.2) expression levels in PBMCs from BD patients 
were particularly low without stimulation when compared to healthy donor PBMCs, 
but the levels did increase considerably with polyclonal stimuli, especially in the case 
of PMA/ionomycin stimulation. 
 
Based on the findings in preliminary tests, PBMCs activated with anti-CD3/CD28 Ab 
and/or PMA/ionomycin were selected as the basis for our subsequent in vitro 
experiments and further preliminary experiments with antigens were not carried out.  
The positives results with polyclonal stimulation were repeatable as shown by the 
data in nine separate experiments despite the fact that the experiments were 
performed in singles. 
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Fig 6.1: The effect of a selection of stimuli on Foxp3+ expression levels in healthy 
donor PBMCs 
Healthy donor PBMCs were untreated, activated with anti-CD3 (5ng/ml) & anti-CD28 
(1μg/ml), activated with PMA (25ng/ml) & ionomycin (1μg/ml) or stimulated with various 
stimuli including LPS, zymosan, candida, and all-trans retinoic acid for 24 hours or 39 hours.  
In one experiment, both LPS and CD3/CD28 stimulation were administered.  Also, in 2 of the 
experiments, PBMCs from BD patients were used instead and stimulated with either 
polyclonal stimuli or α-tropopmyosin or PDS-Ag for 24 hours.  In (a), percentage of CD4+ T 
cells expressing Foxp3 and in (b), percentage of CD4+CD25high T cells expressing Foxp3.are 
shown.  Each colour represent a separate experiment and all experiments were done only 
once in singles.  1 is the lowest antigen concentration used and 7 is the highest.  The actual 
concentrations of stimuli are shown inside the brackets in the legend. 
(a) 
(b) 
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Fig 6.2: The effect of a selection of stimuli on IL-10+ expression by CD4+ T cells 
Healthy donor PBMCs were untreated, activated with anti-CD3 (5ng/ml) & anti-CD28 
(1μg/ml), activated with PMA (25ng/ml) & ionomycin (1μg/ml) or stimulated with various 
stimuli including LPS, zymosan, candida, and all-trans retinoic acid for 24 hours or 39 hours.  
In one experiment, both LPS and CD3/CD28 stimulation were administered.  Also, in 2 of the 
experiments, PBMCs from BD patients were used instead and stimulated with either 
polyclonal stimuli or α-tropopmyosin or PDS-Ag for 24 hours.  Percentage of CD4+ T cells 
producing IL-10 is shown.  Each colour represent a separate experiment and all experiments 
were done only once in singles.  1 is the lowest antigen concentration used and 7 is the 
highest.  The actual concentrations of stimuli are shown inside the brackets in the legend. 
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   6.3.2 IFN-α induces Foxp3 expression by CD4+ T cells 
 
The results from chapter 4 demonstrated that Foxp3 expression by CD4+ Tcells in 
patients with BD was upregulated under IFN-α2b therapy.  In order to verify these 
findings, experiments were set up with PBMCs isolated from healthy individuals to 
study the influence of IFN-α on Foxp3 expression in vitro.  PBMCs were cultured 
without stimulation or stimulated with anti-CD3 and anti-CD28 Ab or PMA and 
ionomycin in the presence or absence of IFN-α2a (101-105 U/ml) and IFN-α2b (101-
104 U/ml) before intracellular cytokine staining and flow cytometry.  Foxp3 
expression was analysed by gating on CD4+, CD4+CD25+ and CD4+CD25high 
lymphocyte populations. 
 
In agreement with data from chapter 4, consistent augmentation of Foxp3 expression 
by CD4+ T cells in a dose-dependent manner was detected.  With regards to IFN-
α2a, concentrations between 103 to 105 U/ml were demonstrated to enhance Foxp3 
expression significantly (Fig 6.3a).  In the presence of 103 U/ml IFN-α2a, the 
proportion of CD4+ T cells expressing Foxp3 was elevated from 0.8 ± 0.3% to 2.4 ± 
0.5% (means ± SD; p<0.05) with PMA/ionomycin stimulation.  Similarly, the Foxp3 
expression levels by CD4+ T cells were raised from 1.0 ± 0.3% to 2.7 ± 0.3% (p<0.01) 
in the presence of 103 U/ml IFN-α2b and PMA/ionomycin stimulation (Fig 6.3b).  
Within CD4+CD25+ T cell population, Foxp3 expression was increased by addtion of 
IFN-α as well and this was especially evident in cultures activated with 
PMA/ionmycin in the presence of 104 U/ml IFN-α.  The percentage of CD4+CD25+ T 
cells expressing Foxp3 was upregulated from 1.2 ± 0.4% to 3.0 ± 0.5% (p<0.01) with 
104 U/ml IFN-α2a (Fig 6.4a) and from 1.5 ± 0.3% to 3.0 ± 0.3% (p<0.01) with 104 
U/ml IFN-α2b (Fig 6.4b). 
 
In addition, within CD4+CD25high T cells, a population enriched in Tregs, a dose-
dependent increase in Foxp3 expression was induced by IFN-α consistently.  
Results from cultures activated with PMA/ionomycin showed that the proportion of 
CD4+CD25high T cells expressing Foxp3 was elevated from 4.7 ± 1.2% up to 8.0 ± 
0.7% (p<0.05) with 104 U/ml IFN-α2a (Fig 6.5a) and from 4.4 ± 1.2% up to 9.3 ± 
0.5% (p<0.01) with 103 U/ml IFN-α2b (Fig 6.5b).  Similar trend could be observed in 
unstimulated cultures as well. 
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Fig 6.3: IFN-α induces Foxp3 expression by CD4+ T cells 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD4+ T cells expressing 
Foxp3.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  Results 
in (a) and (b) are representative of four (a) and five (b) independent experiments.  PBMCs 
were from three different donors for experiments on both forms of IFN-α.  Two of the IFN-
α2a and IFN-α2b experiments used both CD3/CD28 and PMA/ionomycin stimulation.  Also, 
PBMCs were cultured over 39 instead of 24 hours in two experiments, and 101 U/ml of IFN-α 
(2a and 2b) and 105 U/ml of IFN-α2a were only tested twice in these experiments.  Data are 
means ± SD values of triplicate wells.  Statistical analysis was performed using the Student's 
T-test.  *p<0.05, **p<0.01, compared with controls without addition of IFN-α. 
(a) 
(b) 
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Fig 6.4: IFN-α induces an upregulation of Foxp3 expression by CD4+CD25+ T cells 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD4+CD25+ T cells 
expressing Foxp3.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  
Results in (a) and (b) are representative of four (a) and five (b) independent experiments.  
PBMCs were from three different donors for experiments on both forms of IFN-α.  Two of the 
IFN-α2a and IFN-α2b experiments used both CD3/CD28 and PMA/ionomycin stimulation.  
Also, PBMCs were cultured over 39 instead of 24 hours in two experiments, and 101 U/ml of 
IFN-α (2a and 2b) and 105 U/ml of IFN-α2a were only tested twice in these experiments.  
Data are means ± SD values of triplicate wells.  Statistical analysis was performed using the 
Student's T-test.  *p<0.05, **p<0.01, compared with controls without addition of IFN-α. 
(a) 
(b) 
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Fig 6.5: IFN-α induces an upregulation of Foxp3 expression by CD4+CD25high T cells 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD4+CD25high T cells 
expressing Foxp3.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  
Results in (a) and (b) are representative of four (a) and five (b) independent experiments.  
PBMCs were from three different donors for experiments on both forms of IFN-α.  Two of the 
IFN-α2a and IFN-α2b experiments used both CD3/CD28 and PMA/ionomycin stimulation.  
Also, PBMCs were cultured over 39 instead of 24 hours in two experiments, and 101 U/ml of  
IFN-α (2a and 2b) and 105 U/ml of IFN-α2a were only tested twice in these experiments.  
Data are means ± SD values of triplicate wells.  Statistical analysis was performed using the 
Student's T-test.  *p<0.05, **p<0.01, compared with controls without addition of IFN-α. 
(a) 
(b) 
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   6.3.3 IFN-α induces Foxp3 expression by CD8+ T cells 
 
Having established the effect of IFN-α on inducing Foxp3 expression within CD4+ T 
cells, the next goal was to explore whether similar effect was present with CD8+ T 
cells.  Again, experiments were set up with PBMCs isolated from healthy individuals, 
and cells were cultured without stimulation or stimulated with anti-CD3 and anti-
CD28 Ab or PMA and ionomycin for 24 hours in the presence or absence of IFN-α2a 
(101-105 U/ml) and IFN-α2b (101-104 U/ml) before intracellular cytokine staining and 
flow cytometry.  Foxp3 expression was analysed by gating on CD8+, CD8+CD25+ and 
CD8+CD25high lymphocyte population. 
 
From our experiments, it was revealed that although the Foxp3 expression levels by 
CD8+ T cells were very low to begin with, an upregulation was still able to be 
detected.  Following activation with PMA/ionomycin, the proportion of Foxp3 
expressing CD8+ T cells was elevated from 0.4 ± 0.1% up to 1.3 ± 0.4% (means ± 
SD; p<0.05) in the presence of 104 U/ml IFN-α2a (Fig 6.6a) and from 0.4 ± 0.2% up 
to 1.0 ± 0.3% (p<0.05) in the presence of 104 U/ml IFN-α2b (Fig 6.6b).  Similarly, 
within CD8+CD25+ cell population, Foxp3 expression levels were raised enhanced 
from 0.5 ± 0.1% up to 1.1% (p<0.01) in the presence of 105 U/ml IFN-α2a (Fig 6.7a) 
and from 0.6 ± 0.1% up to 1.5 ± 0.2% (p<0.05) in the presence of 104 U/ml IFN-α2b 
(Fig 6.7b) with PMA/ionomycin stimulation.  Similar trend of Foxp3 augmentation 
could be detected in cultures stimulated with anti-CD3/CD28 Ab as well.  Notably, 
within CD8+CD25high lymphocytes, although there appeared to be a tendency for 
inreased Foxp3 expression levels induced by IFN-α, none of the changes was 
statistically significant (Fig 6.8). 
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Fig 6.6: IFN-α induces Foxp3 expression by CD8+ T cells 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD8+ T cells expressing 
Foxp3.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  Results 
in (a) and (b) are representative of two (a) and three (b) independent experiments.  PBMCs 
were from two different donors for experiments on both forms of IFN-α.  For both forms of 
IFN-α, only one experiment used both CD3/CD28 and PMA/ionomycin stimulation.  101 U/ml 
of IFN-α (2a and 2b) and 105 U/ml of IFN-α2a were tested once in these experiments.  Data 
are means ± SD values of triplicate wells.  Statistical analysis was performed using the 
Student's T-test.  *p<0.05, **p<0.01, compared with controls without addition of IFN-α. 
(a) 
(b) 
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Fig 6.7: IFN-α induces an upregulation of Foxp3 expression by CD8+CD25+ T cells 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD8+CD25+ T cells 
expressing Foxp3.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  
Results in (a) and (b) are representative of two (a) and three (b) independent experiments.  
PBMCs were from two different donors for experiments on both forms of IFN-α.  For both 
forms of IFN-α, only one experiment used both CD3/CD28 and PMA/ionomycin stimulation.  
101 U/ml of IFN-α (2a and 2b) and 105 U/ml of IFN-α2a were tested once in these 
experiments.  Data are means ± SD values of triplicate wells.  Statistical analysis was 
performed using the Student's T-test.  *p<0.05, **p<0.01, compared with controls without 
addition of IFN-α. 
(a) 
(b) 
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Fig 6.8: IFN-α induces an upregulation of Foxp3 expression by CD8+CD25high T cells 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD8+CD25high T cells 
expressing Foxp3.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  
Results in (a) and (b) are representative of two (a) and three (b) independent experiments.  
PBMCs were from two different donors for experiments on both forms of IFN-α.  For both 
forms of IFN-α, only one experiment used both CD3/CD28 and PMA/ionomycin stimulation.  
101 U/ml of IFN-α (2a and 2b) and 105 U/ml of IFN-α2a were tested once in these 
experiments.  Data are means ± SD values of triplicate wells.  Statistical analysis was 
performed using the Student's T-test.  *p<0.05, **p<0.01, compared with controls without 
addition of IFN-α. 
  
(a) 
(b) 
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   6.3.4 The kinetics of the upregulatory effect of IFN-α on Foxp3 expression by 
T cells 
 
Although IFN-α has been observed to induce an upregulation in Foxp3 expression by 
both CD4+ and CD8+ T cells in vitro, the kinetics of this particular effect by IFN-α 
remained to be explored.  PBMCs isolated from healthy individuals were cultured 
without IFN-α treatment or with 104 U/ml IFN-α2a added 24 hours before, 4 hours 
before, at the same time as, or 4 hours after PMA/ionomycin stimulation.  The timing 
for the introduction of IFN-α to cultures was the same for both unstimulated and 
stimulated cultures, and PBMCs were incubated for 24 hours after addition of 
PMA/ionomycin before intracellular cytokine staining and flow cytometry.  Foxp3 
expression levels were analysed by gating on CD4+, CD4+CD25+, CD4+CD25high, 
CD8+, CD8+CD25+ and CD8+CD25high lymphocyte populations in turn. 
 
Clearly, adding IFN-α to PBMC cultures at all time-points tested was effective in 
inducing an upregulation of Foxp3 expression by CD4+, CD4+CD25+, and 
CD4+CD25high T cells (Fig 6.9).  Despite not being statistically significant, pre-
treatment of PBMCs with 104 U/ml IFN-α2a showed more efficacy in Foxp3 induction 
within all three cell populations than adding IFN-α2a after polyclonal activation by 
PMA/ionomycin or at the last time-point in the case of untreated cultures.  Following 
activation with PMA/ionomycin, the proportion of CD4+ T cells expressing Foxp3 was 
upregulated from 1.0 ± 0.1% up to 2.4 ± 0.2% (means ± SEM; p<0.01) with 24 hours 
of IFN-α pre-treatment and only up to 1.8 ± 0.4% (p<0.05) with 4 hours of IFN-α 
post-treatment (Fig 6.9a).  Similar results were observed within CD4+CD25+ T cells 
as well as the Foxp3 expression levels were increased from 1.6 ± 0.1% up to 3.0 ± 
0.3% (p<0.01) following 24 hours of IFN-α pre-treatment and PMA/ionomycin 
stimulation (Fig 6.9b).  In accordance, within CD4+CD25high T cells, the Foxp3 
expression levels were elevated from 4.6 ± 0.4% up to 7.6 ± 0.7% (p<0.01) with 24 
hours of IFN-α pre-treatment and activation by PMA/ionomycin (Fig 6.9c). 
 
With regards to CD8+ T cells, Foxp3 expression levels were quite low relative to 
CD4+ T cells, but they were able to be brought up with the introduction of 104 U/ml 
IFN-α2a.  Adding IFN-α at any time-points to PBMC cultures was demonstrated to be 
equally efficacious as the proportion of CD8+ T cells expressing Foxp3 was raised 
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from 0.5% to 0.8 ± 0.1% (p<0.05) following IFN-α treatment and PMA/ionomycin 
stimulation (Fig 6.10a).  However, within CD8+CD25+ T cells, pre-treatment with IFN-
α again showed the tendency to be more potent in upregulating Foxp3 expression 
than adding IFN-α later during incubation (Fig 6.10b).  With PMA/ionomycin 
stimulation, the proportion of CD8+CD25+ T cells expressing Foxp3 was enhanced 
from 0.8 ± 0.1% to 1.3 ± 0.1% (p<0.05) after 24 hours of IFN-α pre-treatment but 
only up to 1.1 ± 0.1% (p=ns) when IFN-α was added 4 hours after polyclonal 
stimulation with PMA/ionomycin.  In contrast, there was no appreciable 
augmentation of Foxp3 expression within CD8+CD25high with the introduction of IFN-
α to cell cultures, although adding IFN-α earlier in cultures showed greater potential 
than doing so later on (Fig 6.10c). 
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Fig 6.9: The kinetics of upregulatory effect of IFN-α on CD4+ T cells expressing Foxp3 
Healthy donor PBMCs were either treated without or with 104 U/ml IFN-α2a 24 hours before, 
4 hours before, at the same time as, or 4 hours after introduction of PMA & ionomycin to 
cultures.  The timing for the addition of IFN-α2a to cultures was the same for both 
unstimulated and stimulated cultures, and PBMCs were incubated for 24 hours after 
PMA/ionomycin stimulation before staining.  Results are shown as proportion of (a) CD4+, (b) 
CD4+CD25+, (c) CD4+CD25high T cells expressing Foxp3.  The histograms show means ± 
SEM of triplicate wells from three independent experiments.  All experiments used PBMCs 
from the same donor.  Statistical analysis was performed using the Student's T-test.  *p<0.05, 
**p<0.01, compared with controls without IFN-α added. 
(a) 
(b) 
(c) 
  
260 
 
 
 
 
Fig 6.10: The kinetics of upregulatory effect of IFN-α on CD8+ T cells expressing 
Foxp3 
Healthy donor PBMCs were either treated without or with 104 U/ml IFN-α2a 24 hours before, 
4 hours before, at the same time as, or 4 hours after introduction of PMA & ionomycin to 
cultures.  The timing for the addition of IFN-α2a to cultures was the same for both 
unstimulated and stimulated cultures, and PBMCs were incubated for 24 hours after 
PMA/ionomycin stimulation before staining.  Results are shown as proportion of (a) CD8+, (b) 
CD8+CD25+, (c) CD8+CD25high T cells expressing Foxp3.  The histograms show means ± 
SEM of triplicate wells from three independent experiments.  All experiments used PBMCs 
from the same donor.  Statistical analysis was performed using the Student's T-test.  *p<0.05, 
**p<0.01, compared with controls without IFN-α added. 
(a) 
(b) 
(c) 
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   6.3.5 IFN-α upregulates IL-10 production by both CD4+ and CD8+ T cells 
 
Results from chapter 4 demonstrated a tendency to upregulate the levels of IL-10 
producing T cells in BD patients who received subcutaneous IFN-α2b therapy.  In order 
to verify these findings, experiments were set up to test the influence of recombinant 
IFN-α on CD4+ T cells as well as CD8+ T cells producing IL-10 in vitro.  Healthy 
donor PBMCs were cultured without stimulation or stimulated with anti-CD3 and anti-
CD28 Ab or PMA and ionomycin in the presence or absence of IFN-α2a (101-105 
U/ml) and IFN-α2b (101-104 U/ml) before intracellular cytokine staining and flow 
cytometry.  Cytokine expression was analysed by gating on either CD4+/CD3+CD8- 
or CD8+ lymphocyte populations. 
 
Within CD4+ T cells, although proportions of IL-10 producing cells were quite low even 
after CD3/CD28 or PMA/ionomycin stimulation, the addition of IFN-α was able to induce 
an upregulation of IL-10 production in a dose-dependent manner under all three culture 
conditions.  When 105 U/ml of IFN-α2a was added to untreated PBMC cultures, the 
proportion of CD4+ T cells expressing IL-10 was increased from 0.6 ± 0.1% to 0.9 ± 
0.1% (means ± SD; p<0.05) (Fig 6.11a).  In correspondence, the percentage of IL-10 
producing CD4+ T cells was elevated from 0.9 ± 0.1% to 2.1 ± 0.6% (p<0.05) with 
CD3/CD28 stimulation and from 0.7 ± 0.1% to 1.3 ± 0.1% (p<0.01) following 
PMA/ionomycin stimulation.  Similarly, when 104 U/ml of IFN-α2b was added to 
untreated PBMC cultures, the IL-10 production levels by CD4+ T cells was raised from 
0.6% to 1.1 ± 0.2% (p<0.01) (Fig 6.11b).  Correspondingly, the proportion of IL-10 
producing CD4+ T cells was upregulated from 1.0 ± 0.2% to 1.7 ± 0.3% (p<0.05) with 
CD3/CD28 stimulation and from 0.8 ± 0.1% to 1.5 ± 0.1% (p<0.01) following 
PMA/ionomycin stimulation. 
 
Having established enhancement of IL-10 levels by CD4+ T cells, data were further 
analysed to investigate Foxp3 expression in these IL-10 producing cells.  It was 
revealed that the increase in IL-10 production levels was mainly due to Foxp3- cells.  
Following CD3/CD28 stimulation, the percentage of CD4+ T cells with IL-10+Foxp3- 
expression was augmented from 0.5 ± 0.3% up to 1.7 ± 0.6% (p<0.05) in the presence 
of 105 U/ml of IFN-α2a (Fig 6.12a) and from 0.4 ± 0.2% up to 1.3 ± 0.3% (p<0.01) in the 
presence of 104 U/ml of IFN-α2b (Fig 6.12b).  On the other hand, very low levels of 
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CD4+ T cells displayed IL-10+Foxp3+ expression and IFN-α was not observed to have 
any effects on these cells, regardless of the concentrations used (data not shown). 
 
Within CD8+ T cells, an upregulation of IL-10 production by IFN-α in a dose-dependent 
manner could be detected consistenly as well under all three culture conditions.  In the 
presence of 105 U/ml of IFN-α2a, the proportions of CD8+ T cells producing IL-10 were 
raised from 1.1 ± 0.2% up to 1.9 ± 0.1% (p<0.01) in untreated cultures, from 1.9 ± 0.3% 
up to 4.6 ± 0.4% (p<0.01) in CD3/CD28 stimulated cultures, and from 1.6 ± 0.2% up to 
2.1 ± 0.1% (p<0.05) in cultures activated with PMA/ionomycin (Fig 6.13a).  Likewise, in 
the presence of 104 U/ml of IFN-α2b, the percentages of IL-10 producing CD8+ T cells 
were elevated from 1.1 ± 0.2% up to 1.5 ± 0.1% (p<0.05) in untreated cultures, from 1.0 
± 0.2% up to 2.9 ± 0.8% (p<0.05) in CD3/CD28 stimulated cultures, and from 1.0 ± 0.1% 
up to 1.8 ± 0.3% (p<0.05) with PMA/ionomycin stimulation (Fig 6.13b). 
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Fig 6.11: IFN-α upregulates IL-10 expression by CD4+ T cells 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 or 39 hours.  Various concentrations of IFN-α was added at the same time 
as the polyclonal stimuli to cultures.  Results are shown as proportion of CD4+ T cells 
producing IL-10.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  
Results in (a) and (b) are representative of six independent experiments each.  PBMCs were 
from four different donors for both forms of IFN-α.  Only one experiment for both IFN-α2a 
and IFN-α2b used both CD3/CD28 and PMA/ionomycin stimulation.  101 U/ml of IFN-α (2a 
and 2b) and 105 U/ml of IFN-α2a were tested only in half of these experiments.  Data are 
means ± SD values of triplicate wells.  Statistical analysis was performed using the Student's 
T-test.  *p<0.05, **p<0.01, compared with controls without addition of IFN-α. 
  
(a) 
(b) 
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Fig 6.12: Upregulation of IL-10 expression by IFN-α is mainly in the Foxp3- subset in 
CD4+ T cells 
Healthy donor PBMCs were either untreated or stimulated with anti-CD3 and anti-CD28 Ab 
for 39 hours.  Various concentrations of IFN-α was added at the same time as the polyclonal 
stimuli to cultures.  Results are shown as proportion of CD4+ T cells expressing IL-10+Foxp3- 
phenotype.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  
Results in (a) and (b) are representative of three independent experiments each.  PBMCs 
were from two different donors for both forms of IFN-α.  Data are means ± SD values of 
triplicate wells.  Statistical analysis was performed using the Student's T-test.  *p<0.05, 
**p<0.01, compared with controls without addition of IFN-α. 
  
(a) 
(b) 
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Fig 6.13: IFN-α upregulates IL-10 expression by CD8+ T cells 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD8+ T cells producing IL-
10.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  Results in (a) 
and (b) are representative of three independent experiments each.  PBMCs were from two 
different donors for both forms of IFN-α.  Only one experiment for both IFN-α2a and IFN-α2b 
used both CD3/CD28 and PMA/ionomycin stimulation.  101 U/ml of IFN-α (2a and 2b) and 
105 U/ml of IFN-α2a were tested only once in these experiments.  Data are means ± SD 
values of triplicate wells.  Statistical analysis was performed using the Student's T-test.  
*p<0.05, **p<0.01, compared with controls without addition of IFN-α. 
  
(a) 
(b) 
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   6.3.6 The kinetics of the upregulatory effect of IFN-α on IL-10 production by T 
cells 
 
Having established the potential of IFN-α to induce IL-10 production by both CD4+ 
and CD8+ T cells in vitro, the next objective was to investigate the influence of IFN-α 
on kinetics of IL-10 production.  PBMCs isolated from healthy individuals were 
cultured without IFN-α treatment or with 104 U/ml IFN-α2a added 24 hours before, 4 
hours before, at the same time as, or 4 hours after PMA/ionomycin stimulation.  The 
timing for the introduction of IFN-α to cultures was the same for both unstimulated 
and stimulated cultures, and PBMCs were incubated for 24 hours after addition of 
PMA/ionomycin before intracellular cytokine staining and flow cytometry.  IL-10 
expression levels were analysed by gating on CD4+/CD3+CD8- or CD8+ lymphocyte 
populations. 
 
Evidently, the introduction of 104 U/ml IFN-α2a to PBMC cultures at all time-points 
tested showed a positive effect on IL-10 production by CD4+ T cells.  Despite not 
being statistically significant, pre-treatment of PBMCs with IFN-α demonstrated 
better capacity in IL-10 induction within CD4+ T cells than adding IFN-α after 
polyclonal activation with PMA/ionomycin or at the last time-point in the case of 
untreated cultures.  Following activation with PMA/ionomycin, the proportion of CD4+ 
T cells producing IL-10 was elevated from 1.0 ± 0.1% to 1.7 ± 0.1% (means ± SEM; 
p<0.01) with 24 hours of IFN-α pre-treatment (Fig 6.14a), and only up to 1.3 ± 0.1% 
(p<0.05) when IFN-α was added after PBMC activation.  In accordance, the IL-10 
expression levels were upregulated from 0.7 ± 0.1% up to 1.3 ± 0.1% (p<0.01) with 
24 hours of IFN-α pre-treatment in untreated cultures and only to 1.1 ± 0.1% when 
IFN-α was added at the last time-point. 
 
Similarly, IL-10 expression levels by CD8+ T cells were augmented significantly with 
the introduction of 104 U/ml IFN-α2a at any time points following PMA/ionomycin 
stimulation.  However, 24 hour of IFN-α pre-treatment was the most effective as 
proportion of CD8+ T cells producing IL-10 was raised from 1.2 ± 0.1% up to 1.9 ± 
0.2% (p<0.01) when compared to just 1.5 ± 0.1% (p<0.05) with IFN-α added at the 
last time-point (Fig 6.14b).  In untreated cultures, although an upregulation of IL-10 
levels within CD8+ T cell population was observed with IFN-α treatment at all time-
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points, the increase was only statistically significant when comparing 24 hours pre-
treatment data (1.9 ± 0.2%; p<0.05) to ones without IFN-α treatment (0.9 ± 0.2%).  In 
fact, the levels of IL-10 producing CD8+ T cells were significantly lower when IFN-α 
were added at later time-points (1.2 ± 0.2% and 1.1 ± 0.2%; p<0.05) when evaluated 
against data with 24 hours of IFN-α pre-treatment (Fig 6.14b). 
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Fig 6.14: The kinetics of upregulatory effect of IFN-α on IL-10 expression by T cells 
Healthy donor PBMCs were either treated without or with 104 U/ml IFN-α2a 24 hours before, 
4 hours before, at the same time as, or 4 hours after introduction of PMA & ionomycin to 
cultures.  The timing for the addition of IFN-α2a to cultures was the same for both 
unstimulated and stimulated cultures, and PBMCs were incubated for 24 hours after 
PMA/ionomycin stimulation before staining.  Results are shown as proportion of (a) CD4+ 
and (b) CD8+ T cells producing IL-10.  The histograms show means ± SEM of triplicate wells 
from three independent experiments.  All experiments used PBMCs from the same donor.  
Statistical analysis was performed using the Student's T-test.  *p<0.05, **p<0.01, compared 
with controls without IFN-α added. 
  
(a) 
(b) 
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   6.3.7 IFN-α upregulates TGF-β production by both CD4+ and CD8+ T cells 
 
A tendency of T cells to display a heightened TGF-β level in BD patients under 
subcutaneous IFN-α2b therapy was detected in chapter 4.  In order to verify this effect, 
in vitro experiments were performed to examine the influence of recombinant IFN-α 
on CD4+ and CD8+ T cells producing TGF-β.  Healthy donor PBMCs were cultured 
without stimulation or stimulated with anti-CD3 and anti-CD28 Ab or PMA and 
ionomycin for 24 hours in the presence or absence of IFN-α2a (101-105 U/ml) and 
IFN-α2b (101-104 U/ml) before intracellular cytokine staining and flow cytometry.  
Cytokine expression was analysed by gating on either CD4+/CD3+CD8- or CD8+ 
lymphocyte populations. 
 
Regarding CD4+ T cells, higher concentrations of IFN-α were able to induce an 
enhancement of TGF-β levels, especially after polyclonal activation.  When 105 U/ml of 
IFN-α2a was added to CD3/CD28 stimulated cultures, the proportion of CD4+ T cells 
producing TGF-β was upregulated from 1.4 ± 0.4% to 2.6 ± 0.5% (means ± SD; p<0.05) 
(Fig 6.15a).  In correspondence, the percentage of TGF-β expressing CD4+ T cells was 
elevated from 1.7 ± 0.5% to 2.9 ± 0.4% (p<0.05) with PMA/ionomycin stimulation.  
Similarly, when IFN-α2b was added to PBMC cultures stimulated with PMA/ionomycin, 
a dose-dependent increase in TGF-β expression levels by CD4+ T cells was 
consistently observed.  The most potent dose of IFN-α2b was at a concentration of 104 
U/ml and the TGF-β expression levels by CD4+ T cells was raised from 0.7 ± 0.1% 
without the influence of IFN-α to 2.0 ± 0.3% (p<0.01) (Fig 6.15b). 
 
With regards to CD8+ T cells, an upregulation of TGF-β expression by higher 
concentrations of IFN-α could be observed consistenly as well.  In the presence of 105 
U/ml of IFN-α2a, the proportion of CD8+ T cells producing TGF-β was increased from 
1.0 ± 0.6% to 2.8 ± 0.4% (p<0.01) in untreated cultures and from 3.2 ± 0.8% to 5.1 ± 
0.3% (p<0.05) in cultures activated with anti-CD3/CD28 Ab (Fig 6.16a).  Similar trend 
was detected in cultures stimulated with PMA/ionomycin as well in the presence of 
higher concentrations of IFN-α2a.  Likewise, in the presence of 104 U/ml of IFN-α2b, the 
proportion of TGF-β expressing CD8+ T cells was upregulated to 3.6 ± 0.6% (p<0.05) 
with CD3/CD28 stimulation and 2.3 ± 0.2% (p<0.05) without cell activation from 1.9 ± 
0.7% and 1.0 ± 0.5% respectively (Fig 6.16b). 
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Fig 6.15: IFN-α upregulates TGF-β expression by CD4+ T cells 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD4+ T cells producing 
TGF-β.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  Results 
in (a) and (b) are representative of three independent experiments each.  PBMCs were from 
two different donors for both forms of IFN-α.  Only one experiment for both IFN-α2a and IFN-
α2b used both CD3/CD28 and PMA/ionomycin stimulation.  101 U/ml of IFN-α (2a and 2b) 
and 105 U/ml of IFN-α2a were tested only once in these experiments.  Data are means ± SD 
values of triplicate wells.  Statistical analysis was performed using the Student's T-test.  
*p<0.05, **p<0.01, compared with controls without addition of IFN-α. 
(a) 
(b) 
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Fig 6.16: IFN-α upregulates TGF-β expression by CD8+ T cells 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportion of CD8+ T cells producing 
TGF-β.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  Results 
in (a) and (b) are representative of three independent experiments each.  PBMCs were from 
two different donors for both forms of IFN-α.  Only one experiment for both IFN-α2a and IFN-
α2b used both CD3/CD28 and PMA/ionomycin stimulation.  101 U/ml of IFN-α (2a and 2b) 
and 105 U/ml of IFN-α2a were tested only once in these experiments.  Data are means ± SD 
values of triplicate wells.  Statistical analysis was performed using the Student's T-test.  
*p<0.05, **p<0.01, compared with controls without addition of IFN-α. 
  
(a) 
(b) 
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   6.3.8 The kinetics of the upregulatory effect of IFN-α on TGF-β production by 
T cells 
 
After confirming the ability of IFN-α to promote higher TGF-β levels in both CD4+ and 
CD8+ T cells in vitro, the next goal was to explore the kinetics of the effect induced 
by IFN-α.  PBMCs isolated from healthy individuals were cultured without IFN-α 
treatment or with 104 U/ml IFN-α2a added 24 hours before, 4 hours before, at the 
same time as, or 4 hours after PMA/ionomycin stimulation.  The timing for the 
introduction of IFN-α to cultures was the same for both unstimulated and stimulated 
cultures, and PBMCs were incubated for 24 hours after addition of PMA/ionomycin 
before intracellular cytokine staining and flow cytometry.  TGF-β expression levels 
were analysed by gating on CD4+/CD3+CD8- or CD8+ lymphocyte populations. 
 
In accordance to IL-10 kinetics data, pre-treatment of PBMCs with 104 U/ml of IFN-
α2a appeared to have greater positive effect on TGF-β production by CD4+ T cells 
than treating cells with IFN-α post activation or at later time-point (Fig 6.17a).  In 
untreated cultures, the proportion of CD4+ T cells producing TGF-β was upregulated 
from 0.5% up to 1.1% (p<0.01) with IFN-α added at the earliest time-point, compared 
to only 0.9% (p<0.01) with IFN-α added at the last time-point.  With PMA/ionomycin 
stimulation, TGF-β expression levels by CD4+ T cells were raised from 1.1 ± 0.1% up 
to 1.6 ± 0.2% (means ± SEM; p<0.01) with 24 hours of IFN-α pre-treatment and only 
1.4 ± 0.2% (p=ns) with IFN-α post-treatment. 
 
With regards to CD8+ T cells, comparable amount of TGF-β expression 
enhancement was observed in untreated cultures when IFN-α was added at any 
time-points tested (Fig 6.17b).  However, with PMA/ionomycin stimulation, pre-
treatment of PBMCs with IFN-α again demonstrated better capacity in TGF-β 
induction within CD8+ T cells than adding IFN-α after polyclonal activation.  In the 
presence of PMA/ionomycin activation, the proportion of CD8+ T cells producing 
TGF-β was elevated from 0.9 ± 0.1% without IFN-α treatment up to 1.3 ± 0.1% 
(p<0.01) with 24 hours of IFN-α pre-treatment and only 1.1 ± 0.1% (p=ns) with IFN-α 
added at the last time-point. 
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Fig 6.17: The kinetics of upregulatory effect of IFN-α on TGF-β expression by T cells 
Healthy donor PBMCs were either treated without or with 104 U/ml IFN-α2a 24 hours before, 
4 hours before, at the same time as, or 4 hours after introduction of PMA & ionomycin to 
cultures.  The timing for the addition of IFN-α2a to cultures was the same for both 
unstimulated and stimulated cultures, and PBMCs were incubated for 24 hours after 
PMA/ionomycin stimulation before staining.  Results are shown as proportion of (a) CD4+ 
and (b) CD8+ T cells producing TGF-β.  The histograms show means ± SEM of triplicate 
wells from three independent experiments.  All experiments used PBMCs from the same 
donor.  Statistical analysis was performed using the Student's T-test.  *p<0.05, **p<0.01, 
compared with controls without IFN-α added.  ††p<0.01, compared with data with 24-hour 
IFN-α pre-treatment. 
  
(a) 
(b) 
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   6.4 Discussion 
 
A number of regulatory T cell subsets have been identified, and there is growing 
evidence that these cells are essential for controlling immune responses.  Although 
we have much to learn about the biology of Treg cells, it has become clear that via 
expression of inhibitory cell-surface molecules and production of cytokines such as 
IL-10 and TGF-β, Treg cells maintain peripheral tolerance to self and foreign Ags, 
and that in their absence the host may succumb to a variety of autoimmune and 
chronic inflammatory diseases (Levings et al. 2002).  Remarkably, Treg cells are 
able to suppress activated T cells in vitro at a ratio of one Treg to 20 effector cells 
(Dieckmann et al. 2001).  Therefore, a large clone size for Treg cells is less 
important than for conventional T cells, and induction of naive precursor T cells into 
Foxp3-expressing cells with regulatory capacity has become an attractive 
mechanism to dampen an overactive acute inflammation or to curtail the response to 
a chronic unresolved challenge in theory. 
 
 
  6.4.1 Setting up Treg in vitro test models using antigens and polyclonal 
stimuli 
 
Although immunosuppressive activity of Treg cells is exerted in a non-specific 
manner, the identification of few Ag recognised by Tregs in a murine study suggests 
that in vivo expansion of these cells could result from Ag-specific stimuli (Thornton & 
Shevach 2000).  Also, it has been described that Tregs express a range of TLRs, 
stimulation of which can have significant effects on the expansion and suppressive 
function of Treg cells (Allan et al. 2008b).  Tregs treated with HSP60 were reported to be 
more effective than untreated ones in suppressing CD4+CD25- or CD8+ T cells and the 
enhancing effects of HSP60 on Treg cells involved TLR2 signalling.  Besides, it was 
indicated that the HSP60-treated Tregs induced their target CD4+CD25- T cells to secrete 
IL-10 (Zanin-Zhorov et al. 2006).  Zymosan, a stimulus for TLR2 and dectin-1 (Dillon et al. 
2006), was demonstrated to promote IL-10 production by DCs at a concentration of 
200μg/ml after 18 hours of culture as tested by ELISA of culture supernatants 
(Gerosa et al. 2008). 
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In our preliminary experiments, two TLR ligands were used.  Zymosan was not found 
to induce an upregulation of either Foxp3 or IL-10 expression, even at 100μg/ml.  
LPS, on the other hand, showed the tendency to induce higher expression levels of 
Foxp3 by CD4+CD25hi T cells at 5-20μg/ml and IL-10 by CD4+ T cells at 5μg/ml with 
longer incubation time.  Another antigen made from candida extracts also displayed 
some potential in promoting Foxp3+ T cells and IL-10 cytokine.  However, of all the 
antigens used, there was none better than ATRA, at a range of concentrations, in 
enhancing Foxp3 expression.  This is consistent with reports of a crucial regulatory 
role for retinoic acid in promoting Foxp3 induction (Elias et al. 2008;Mucida et al. 
2007).  However, the presence of ATRA in PBMC cultures was not observed to 
increase IL-10 production. 
 
Due to consistent observation that polyclonal activation by anti-CD3/CD28 Ab and 
PMA/ionomycin enhanced greater amount of Foxp3 and IL-10 expression by CD4+ T 
cells, healthy donor PBMCs with or without polyclonal activation were chosen for the 
subsequent tests on the in vitro immunoregulatory effects of IFN-α. 
 
 
  6.4.2.1 CD8+ Treg cells 
 
Like in CD4+ T cells, polyclonal activation of PBMCs can lead to induction of Foxp3 
expression by human CD8+ T cells in vitro (Gavin et al. 2006;Morgan et al. 2005).  
Notably, the ability to express Foxp3 has been demonstrated to be inherent to CD8+ 
T cells, and it is independent of the mode of TCR activation yet critically dependent 
on IL-2 or IL-15 signalling (Ahmadzadeh, Antony, & Rosenberg 2007). 
 
Recently, it has been indicated that highly suppressive adaptive CD8+CD25+Foxp3+ 
T cells can be induced from CD8+CD25- T cells by continuous antigen stimulation in 
the presence of monocytes as well.  These adaptive CD8+ Treg cells express 
markers associated with a regulatory phenotype, and inhibit CD4+ and CD8+ T cell 
proliferation and cytokine production.  A contact-dependent mechanism appears to 
be the key for their suppressive activity, even though these regulatory cells express 
prostaglandin E2, IL-10, and TGF-β (Mahic et al. 2008).  An alternative way to 
induce CD8+ Treg cells is to stimulate PBMCs from primed donors with the 
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mycobacterial vaccine Bacillus Calmette Guerin (BCG) yielding 
CD8+CD25+lymphocyte-activation gene 3 (LAG-3)+Foxp3+CCL4+ cells.  The 
suppressive function of such CD8+ Treg cells was assigned to secretion of the 
chemokine CCL4 (Joosten et al. 2007). 
 
 
  6.4.2.2 The influence of IFN-α on Foxp3 expressing CD4+ and CD8+ T cells 
 
A dose-dependent upregulation of Foxp3 expression by either exogenous IFN-α2a or 
IFN-α2b was clearly evident in CD4+, CD4+CD25+, and CD4+CD25high T cells in our 
experiments.  Also, a dose-dependent enhancement of Foxp3 expression by either 
exogenous IFN-α2a or IFN-α2b was observed in CD8+, CD8+CD25+ T cells, but not 
CD8+CD25high T cells.  The difference in results with CD8+CD25high T cell population 
could be related to the much smaller number of cells detected with flow cytometry 
and hence larger variation in data as a result.  Moreover, the upregulation in the 
proportion of CD8+ T cells expressing Foxp3 observed in our data was likely 
contributed not only by the promotion of CD8+CD25+Foxp3+ T cells but also other 
Treg subsets such as the antigen-specific adaptive CD8+CD28- Tregs, which have 
been described to express both CTLA-4 and Foxp3 (Scotto et al. 2004). 
 
In support of our results, it was reported that in vitro treatment of PBMCs from MS 
patients with IFN-α could induce an increased frequency of CD4+CD25high T cells 
and a linear correlation between the CD25 mRNA and Foxp3 mRNA expression was 
also observed (Penton-Rol et al. 2008).  No study was found to describe the effect of 
in vitro IFN-α treatment on Foxp3 expressing CD8+ T cells. 
 
Of note, there are two isoforms of human Foxp3, a full-length form and a smaller 
form lacking exon 2, and they were reported to be induced equally in freshly 
activated CD4+CD25- T cells (Allan et al. 2005).  It is likely that the two isoforms are 
expressed in different Treg cell subsets.  However, further analysis of our data could 
not be performed as reagents that distinguish between the isoforms by flow 
cytometry are yet to be developed. 
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  6.4.2.3 Foxp3 levels in comparison to other studies 
 
In our experiments on healthy donor PBMCs, polyclonal stimulation with anti-
CD3/CD28 and/or PMA/ionomycin was applied for 24 hours but sometimes 39 hours 
to PBMC cultures.  Notably, a recent study demonstrated that activation with anti-
CD3/CD28-coated beads led to induction of newly expressing Foxp3+ cells as early 
as 24 hours, which peaked at 72 hours and then decreased over a period of 7-10 
days (Allan et al. 2007).  From our data, the mean proportions of T cells expressing 
Foxp3 were generally less than 3% for CD4+ T cells and less than 1.5% for CD8+ T 
cells with or without activation.  The Foxp3 expression levels achieved are 
comparable to a recent study.  It was reported that the percentages of CD4+ T cells 
expressing Foxp3 were between 3-6% depending on the types of antibodies used 
and the proportions of CD8+ T cells expressing Foxp3 were around 0.5% in normal 
subjects (Gavin et al. 2006). 
 
 
  6.4.3.1 Biology of IL-10 and Tr1 cells 
 
Suppression of specific immune response and induction of anergy in T cells are 
essential processes in regulation of immune defense. T cell anergy can be induced 
when CD4+ or CD8+ T cells are activated in the presence of IL-10 or with APCs 
which have been pre-treated with IL-10 (Groux et al. 1996;Steinbrink et al. 2002).  IL-
10, a suppressor cytokine of T cell proliferative and cytokine responses, thus plays 
an important role in peripheral T cell tolerance and contributes to the homeostasis of 
the immune system.  This effect of IL-10 is not only due to downregulation of co-
stimulatory molecules on APCs, but also dependent on direct effects on the T cells 
themselves (Moore et al. 2001). 
 
IL-10-anergised T cells become non-responsive and fail to produce cytokines.  In 
addition, these cells acquire regulatory activity and attenuate T cell responses.  This 
function is not dependent on production of immunosuppressive cytokines, but rather 
is mediated by cell-cell contact-dependent mechanisms via suppressive molecules 
expressed on the cell surface (Groux et al. 1996;Steinbrink et al. 2002)  Interestingly, 
when IL-10-anergised T cells are put through forced proliferation, and likely following 
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repetitive exposure to antigen, the cells regain some ability to proliferate and IL-10-
producing Tr1 cells are induced as a result (Allan et al. 2008b). 
 
Fully differentiated Tr1 cells may be more potent suppressor cells than anergic T 
cells in vivo, since they have been shown to inhibit both APCs and T cells, and may 
even induce the development of Tr1 cells from naive CD4+ T cells via their ability to 
produce IL-10 (Roncarolo et al. 2001).  Cultures containing Tr1 cells have been 
demonstrated to display reduced responses to alloantigens via a mechanism that 
was partially mediated by IL-10 and TGF-β.  Compared to IL-10, which has been 
considered essential for both the differentiation and effector function of Tr1 cells, 
TGF-β appeared to play little part in the enhancement of Tr1 cell development 
(Levings et al. 2001).  Of note, CD4+CD25+ Treg cells, which were observed to be 
upregulated in our experiments, may actively promote the differentiation of Tr1 cells 
as well (Levings et al. 2002). 
 
 
  6.4.3.2 The influence of IFN-α on IL-10 producing CD4+ and CD8+ T cells 
 
From our experimental data, a dose-dependent upregulation of IL-10 level was 
consistently detected in both CD4+ and CD8+ T cells with IFN-α treatment in vitro.  
These results are in line with an early study evaluating the effects of IFN-α on resting 
CD4+ cells purified from normal PBMCs and stimulated with PMA in conjunction with 
anti-CD28 Ab, which found IFN-α enhanced IL-10 production in a dose-dependent 
manner with a four-fold increase in IL-10 levels in the presence of 104 IU/ml IFN-α 
(Schandene et al. 1996).  Increased IL-10 mRNA accumulation was found in the 
system as well.  Also, another early study reported that IFN-α enhanced IL-10 
expression by unseparated PBMCs.  Upregulation of IL-10 production by either 
activated CD4+ T cells or activated monocytes were demonstrated as well, but these 
purified cells failed to express IL-10 with IFN-α treatment unless they were activated 
with appropriate stimuli.  Activation with PHA and PMA was required for purified 
CD4+ T cells and LPS was required for purified monocytes (Aman et al. 1996).  In 
contrast to IFN-α, IL-4 and IFN-γ were not observed to regulate IL-10 synthesis by 
CD3/CD28 stimulated CD4+ T cells.  Recently, IFN-α was found to significantly 
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increase IL-10 production by either anti-CD3/CD28 stimulated PBMCs or CD4+ T 
cells in culture supernatants from healthy patients (Liu et al. 2011). 
 
In accordance to our ex vivo data, the upregulation in IL-10 expression level in CD4+ 
T cells was mostly attributed to Foxp3- cells.  It has been reported that CD4+ T cells 
from cord blood or peripheral blood in the presence of IFN-α and IL-10 resulted in a 
population of cells that display a Tr1 phenotype of cytokine production: IL-10+IFN-
γ+IL-2-/lowIL-4-.  The data demonstrated that the additive effects of IL-10 and IFN-α 
acted directly on T cells to induce differentiation of Tr1 cells (Levings et al. 2001).  In 
keeping with the observation, it was reported that IL-10-producing regulatory T cells 
can be induced after priming of mature CD11c+ DCs by IFN-α (Ito et al. 2001).  
Therefore, it is likely the enhanced IL-10 production synergised with exogenous IFN-
α to promote a larger and more stable population of Tr1 cells in our experiments. 
 
Furthermore, a population of CD8+CXCR3+ cells have recently been identified and 
suggested as the counterpart of murine CD8+CD122+ Tregs.  These cells are CD28+ 
and able to produce IL-10 (Shi et al. 2009).  It is quite possible that the increased 
number of CD8+IL-10+ T cells observed in our experiments contain some cells from 
such population. 
 
 
  6.4.3.3 IL-10 levels in comparison to other studies 
 
The percentages of CD4+ or CD8+ T cells producing IL-10 were low and mostly less 
than 3% in our experiments.  These levels were comparable to a recent study using 
PBMCs stimulated with increasing concentrations of bacterial superantigens of 
Streptococcus pyogenes over 5 days.  Of note, it was indicated that IL-10 production 
appeared to occur later with a much greater proportion of CD4+ T cells producing IL-
10 at day 5 (up to 15%) than at day 1 (<2%) (Taylor & Llewelyn 2010).  Thus, it is 
likely that longer incubation time may be required to generate higher percentage of 
IL-10 producing CD4+ or CD8+ T cells. 
 
In accordance to our results, PMA/ionomycin was not shown to be very effective in 
the stimulation of significant levels of intracellular IL-10 production in an earlier study.  
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PBMCs were cultured for 48 hours in the presence of PMA/ionomycin and were 
labelled for CD3.  The proportions of IL-10 producing CD3+ T cells were upregulated 
slightly from 0.4% in culture medium alone to 1.0% in representative results from a 
healthy donor (Baran et al. 2001). 
 
In another recent study, PBMCs were cultured with anti-CD3 for 5 days and were 
labelled for CD8.  The percentages of CD8+ T cells producing IL-10 in healthy 
subjects were found to be around 2.5% and the levels increased to around 6.5% with 
6 hours of PMA/ionomycin restimulation (Ablamunits, Bisikirska, & Herold 2010). 
 
 
  6.4.4.1 Biology of TGF-β 
 
Studies of animal models and human patients have revealed the importance of TGF-
β in regulating leukocyte functions in autoimmune diseases.  Although TGF-β can 
modulate the activity of multiple cell types, it exerts the greatest impact on T 
lymphocytes.  It inhibits the production of most effector cytokines in T cells (IFN-γ, IL-
2, IL-4 and IL-10), and ectopic expression of TGF-β1 in T cells induces enhanced 
production of the anti-inflammatory cytokine IL-10.  This effect is associated with 
TGF-β activation of the IL-10 promoter via Smad4 (Kitani et al. 2003).  However, 
studies suggest that endogenous TGF-β has little contribution in the induction of 
anergy by IL-10 in human cells (Levings et al. 2002). 
 
Like in Th1 cells, the presence of TGF-β greatly attenuates IFN-γ expression in CD8+ 
T cells.  Also, TGF-β regulates cytotoxic T lymphocyte functions of CD8+ T cells by 
inhibition of perforin expression in activated CD8+ T cells (Li et al. 2006).  Of note, 
TGF-β regulation of CD8+ T cell differentiation is context dependent and is 
modulated by co-stimulatory receptor and cytokine signaling pathways (Ahmadzadeh 
& Rosenberg 2005).  Furthermore, TGF-β is a critical regulator of B lymphocyte 
activity.  TGF-β inhibits B cell proliferation, provokes apoptosis of immature or resting 
B cells, and opposes B cell activation and class switching to most isotypes except for 
IgA (Li et al. 2006). 
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  6.4.4.2 The influence of IFN-α on TGF-β producing CD4+ and CD8+ T cells 
 
In line with findings in our ex vivo experiments, our in vitro data showed that TGF-β 
expression was upregulated in both CD4+ and CD8+ T cells in the presence of IFN-α, 
especially at higher concentrations. 
 
Increased TGF-β expression by CD4+ T cells could be an indicator of expansion of 
Th3-like cells.  Th3 are a subset of antigen-induced regulatory T cells reported to be 
predominantly found at the tissue site of inflammation.  The degree to which Th3 and 
Tr1 cells come from similar precursors or are different types of regulatory T cells is 
not known (Weiner 2001).  TGF-β itself can promote the differentiation of Th3 cells, a 
process that can be enhanced by IL-4 and IL-10 (Seder et al. 1998). 
 
 
  6.4.4.3 TGF-β levels in comparison to other studies 
 
The percentages of CD4+ or CD8+ T cells producing TGF-β were low and mostly less 
than 5% in our experiments.  The levels are in keeping with a recent study where 
PBMCs were cultured with anti-CD3 for 5 days and labelled for CD8.  The 
proportions of CD8+ T cells producing TGF-β were observed to be less than 1% with 
or without PMA/ionomycin restimulation (Ablamunits, Bisikirska, & Herold 2010). 
 
 
   6.4.5 The effect of IFN-α on the kinetics of Foxp3, IL-10 and TGF-β expression 
by T cells 
 
The kinetics of PBMC response under the influence of IFN-α was measured as well 
for Foxp3, IL-10 and TGF-β levels within CD4+ and CD8+ T cell populations.  The 
idea was to obtain some indications in the potential roles of IFN-α therapy could play 
as either prophylaxis or treatment options in chronic inflammatory diseases. 
 
In terms of Foxp3, the potential for greater enhancement of its expression within 
CD4+, CD4+CD25+, CD4+CD25high and CD8+CD25+ T cell populations were observed 
with longer exposure of PBMCs to IFN-α.  With PMA/ionomycin stimulation, IFN-α 
  
282 
 
showed greater activity in upregulating Foxp3 in T cells when it was added before 
rather than after cell activation. 
 
Similar trends could also be observed in terms of IL-10 and TGF-β expression by 
both CD4+ and CD8+ T cells as higher levels were associated with adding IFN-α at 
the earlier time-points or introduction of IFN-α before cell activation by 
PMA/ionomycin.  This could imply that expression of Foxp3 and regulatory cytokines, 
including IL-10 and TGF-β, by T cells were induced to a greater degree in response 
to longer IFN-α exposure or cells required more time to respond to IFN-α treatment 
and the results were simply a reflection of the experimental design picking up data at 
different stages of cytokine production. 
 
 
   6.5 Summary of findings 
 
We were able to verify findings from BD patient data and recombinant IFN-α2a and 
IFN-α2b were found to be equally potent in their augmenting effects on 
immunoregulatory subsets and cytokines in vitro.  Both forms of IFN-α were 
efficacious in inducing Foxp3 expression by CD4+, CD4+CD25+, CD4+CD25high, CD8+, 
and CD8+CD25+ T cell populations.  IFN-α2a and IFN-α2b were also observed to 
consistently upregulate IL-10 and TGF-β levels in CD4+ and CD8+ T cells.  Moreover, 
IFN-α was able to exert its effects both before and after cell activation. 
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Chapter 7 
The immunomodulatory effects of interferon-alpha on γδ T cells 
 
 
   7.1 Introduction 
 
Although the vast majority of mature T lymphocytes express αβ TCR, a small subset 
(1-5%) of peripheral blood T cells carries the alternative γδ TCR, which is composed 
of a γ and δ chain heterodimer (Konigshofer & Chien 2006).  However, they 
constitute a major population in other anatomical localisations such as the small 
intestine and some epithelia (Hayday 2000).  The physiological roles fulfilled by γδ T 
cells are diverse and include protective immunity against extracellular and 
intracellular pathogens, tumour surveillance, modulation of innate and adaptive 
immune responses, tissue healing and epithelial cell maintenance, and regulation of 
physiological organ function (Bendelac et al. 2001;Hayday 2009).  γδ T cells are 
capable of responding to various environmental insults despite having only a limited 
amount of expressed TCR repertoire, and regulate αβ T cell activation through 
cytokine production (Kuhl et al. 2009).  The functional specialisation of γδ T cell 
subsets bestows them with a unique ability to carry out a restricted set of tasks with 
spatial and temporal features that are unmatched by other immune effectors. 
 
In Behcet’s disease, the basic aetiopathogenic mechanism consists of a 
hyperactivation of neutrophils but the primary trigger is unknown.  At present, the 
most accepted hypothesis is that a multifactorial process induces an immune 
dysregulation that results in exaggerated neutrophils activation (Mendes et al. 2009).  
γδ T lymphocytes have been suggested as one of the causes of cytokine 
dysregulation that results in neutrophils hyperactivation in BD patients.  This is 
because that an enhanced level of γδ T cells, especially CD8+ γδ T cells, in active 
lesions and peripheral blood, has consistently been demonstrated in BD patients 
(Nishida et al. 1998;Treusch et al. 2004).  Compared with healthy donors, there is 
not only neutrophil hyperactivity, but also a significant elevation of monocytes and γδ 
T cells in patients with active BD before treatment (Treusch et al. 2004).  These γδ T 
cells have been shown to express activation markers, such as CD25, CD69, and 
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CD29 and produce inflammatory cytokines including IFN-γ and TNF-α (Freysdottir, 
Lau, & Fortune 1999). 
 
There are two main γδ T cell subpopulations in humans as Vδ2+ and Vδ1+ account 
for more than 90% of the total γδ T cells (Carding & Egan 2002).  It was reported 
recently that there is a preferential activation of peripheral blood Vδ1 as compared to 
Vδ2 γδ T cells in patients with active BD (Yasuoka et al. 2008).  In supporting these 
findings and a key role of these cells in the pathogenesis of BD, increased frequency 
and number of γδ T cells, predominantly Vγ9Vδ2 T cells have been found in 
peripheral blood of BD patients (Yamashita et al. 1997) and in the intraocular fluid of 
BD patients with uveitis (Verjans et al. 2002).  Significantly, antigens that activate γδ 
T cells could play an important role in the pathogenesis of the disease.  Indeed, 
peripheral blood γδ T cells from BD patients can respond specifically to peptides 
derived from the mycobacterial HSP65 and the homologous human HSP60 (Hasan 
et al. 1996).  In addition, peripheral blood Vγ9Vδ2 T cells from patients with active 
BD were found to secrete elevated amounts of the serine protease granzyme A 
when stimulated with phosphoantigens (Accardo-Palumbo et al. 2004). 
 
 
7.2 Aims 
 
The aim of this chapter is to assess the immunomodulatory effects of 6 months of 
subcutaneous IFN-α therapy on γδ T cells in BD patients ex vivo.  In vitro assays are 
also performed to test the influence of various concentrations of IFN-α2a and IFN-
α2b on γδ T cells and their IFN-γ and IL-17 cytokine production using healthy donor 
PBMCs.  The kinetics of interactions between IFN-α and IFN-γ and IL-17 cytokine 
production by γδ T cells are to be explored as well. 
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   7.3 Results 
 
   7.3.1 IFN-α therapy helps maintain a stable population of γδ T cells in BD 
patients 
 
To examine the influence of IFN-α therapy on γδ T cells among peripheral blood T 
lymphocytes in BD patients, serial whole blood samples from BD patients receiving 
conventional immunosuppressive therapy with or without recombinant IFN-α2b 
treatment were obtained for immunofluorescence staining and flow cytometry.  
PBMCs were not incubated or activated with polyclonal stimuli.  Apart from analysing 
TCRγδ expression by gating on lymphocytes, results were analysed further using 
CD8 surface protein to acquire data on CD4+ and CD8+ T lymphocyte populations. 
 
Conspicuously, there was no significant alteration of the proportions of γδ T cells in 
BD patients under IFN-α therapy.  This is in contrast to patients on conventional 
treatment alone, who demonstrated a tendency to have elevated levels of γδ T cells.  
Among lymphocytes, the percentages of γδ T cells were raised at 6 (median 5.5% 
and IQR 3.8-8.6%; p<0.05) and 12 months (median 5.0% and IQR 2.9-7.8%; p<0.05) 
when compared to values at recruitments (median 4.9 and IQR 3.1-6.5%) (Figure 
7.1a). 
 
Within CD4+ T lymphocytes, the levels of TCRγδ+ cells were increased when 
comparing values at 6 month visits (median 3.8% and IQR 2.4-7.3%; p<0.05) with 
ones at 3 months (median 2.8% and IQR 2.0-4.9%) (Fig 7.1b).  Also, within CD8+ T 
lymphocytes, the proportions of TCRγδ+ cells were elevated at 12 month 
assessment visits (median 1.2% and IQR 0.7-2.5%; p<0.01) when evaluated against 
baseline visit values (median 0.7% and IQR 0.3-1.1%) (Fig 7.1c). 
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Fig 7.1: IFN-α therapy promotes a stable population of γδ T cells 
Whole blood from BD patients receiving either the conventional treatment alone (n=13) or 
with IFN-α2b therapy (n=12) were obtained at 0, 3, 6 and 12 month assessment visits.  
These samples were stained with anti-CD8, and anti-TCRγδ antibodies.  The graphs show 
percentages of the TCRγδ expression in (a) all lymphocytes, (b) CD4+ T cells, and (c) CD8+ 
T cells.  The results are presented as boxplots. 
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   7.3.2 Preliminary experiments to establish in vitro γδ T test models with 
antigens and polyclonal stimulation 
 
In order to set up an in vitro model to verify findings from BD patients, the same 
panel of antigens and polyclonal stimuli used in preliminary experiments in Chapter 5 
and 6 were applied to healthy donor PBMC cultures for 24 hours before intracellular 
cytokine staining and flow cytometry.  IFN-γ and IL-17 levels were analysed by 
gating on TCRγδ+ lymphocytes. 
 
Notably, none of the antigens chosen was particularly effective in inducing IFN-γ 
production by γδ T cells (Fig 7.2a).  LPS and longer incubation with candida antigens 
showed some promise in promoting IL-17 production by γδ T cells, although the 
levels achieved were less than stimulation with anti-CD3/CD28 Ab (Fig 7.2b).  
Concurrent use of LPS and CD3/CD28 stimulation was evaluated as well, but the 
effect was no more than using anti-CD3/CD28 Ab alone. 
 
In addition, PBMCs from BD patients were incubated with BD-related antigens, 
including alpha-tropomyosin and PDS-Ag, as a trial.  PDSAg, when used at 10-
50μg/ml, demonstrated some potential in augmenting IL-17 levels in γδ T cells but 
not to the same degree as stimulated by PMA/ionomycin.  All the other antigens 
tested did not encourage IL-17 production by γδ T cells.  In particular, the levels 
attained with ATRA were similar or lower than ones obtained from untimulated 
PBMC cultures. 
 
Fortunately, substantially higher production levels of both IFN-γ and IL-17 were able 
to be induced in γδ T cells consistently with polyclonal stimulation such as anti-
CD3/CD28 Ab and especially PMA/ionomycin.  These results were repeatable as 
shown by the data in nine separate experiments each for IFN-γ and IL-17 producing 
cells despite the fact that the experiments were performed in singles. 
 
As a result, healthy donor PBMCs activated with anti-CD3/CD28 Ab and/or 
PMA/ionomycin were chosen as the basis for test models in subsequent in vitro 
experiments and further preliminary experiments with antigens were not carried out. 
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Fig 7.2: The effect of a selection of stimuli on the levels of γδ cells producing IFN-γ 
and IL-17 in healthy donors 
Healthy donor PBMCs were untreated, activated with anti-CD3 (5ng/ml) & anti-CD28 
(1μg/ml), activated with PMA (25ng/ml) & ionomycin (1μg/ml) or stimulated with various 
stimuli including LPS, zymosan, candida, and all-trans retinoic acid for 24 hours or 39 hours.  
In one experiment, both LPS and CD3/CD28 stimulation were administered.  Also, in 2 of the 
experiments, PBMCs from BD patients were used instead and stimulated with either 
polyclonal stimuli or α-tropopmyosin or PDS-Ag for 24 hours.  Results are shown as 
proportion of γδ T cells expressing cytokines.  In (a), percentage of IFN-γ+ cells and in (b), 
percentage of IL-17+ cells are shown.  Each colour represent a separate experiment and all 
experiments were done only once in singles.  1 is the lowest antigen concentration used and 
7 is the highest.  The actual concentrations of stimuli are shown inside the brackets in the 
legend. 
(a) 
(b) 
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   7.3.3 Preliminary experiments to establish the needs to rest cells in the 
medium after thawing and the effects of adding suboptimal IL-2 
 
Next, it was examined whether resting healthy donor PBMCs for one day in culture 
medium with or without addition of suboptimal amount of IL-2 after thawing could 
enhance cytokine production. 
 
With regards to IFN-γ producing γδ T cells (Fig 7.3a), there was a tendency for more 
elevated levels with resting PBMCs for one day without additional IL-2 under all 4 
culture conditions, but none of these results were statistically significant. 
 
With regards to IL-17 producing γδ T cells (Fig 7.3b), there was no advantage in 
resting the cells in three out of four culture conditions and again none of the 
variations were statistically significant. 
 
Also, PHA and anti-CD3/CD28 Ab were comparable in their ability to induce either 
IFN-γ or IL-17 expression and the effects of both were not as strong as one exerted 
by PMA/ionomycin stimulation. 
 
Overall, the findings suggest there is no significant advantage in resting PBMCs or 
adding suboptimal concentration of IL-2 for experiments involving IFN-γ and IL-17 
producing γδ T cells. 
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Fig 7.3: The effect of resting PBMCs and suboptimal concentration of IL-2 on the 
proportion of IFN-γ and IL-17 producing γδ T cells 
Healthy donor PBMCs were either stimulated straight away or rested for 1 day in medium 
(RPMI & supplements) ± 0.5 U/ml of IL-2 before stimulation.  Under all 3 conditions, PBMCs 
were untreated, or stimulated with anti-CD3 (5ng/ml) & anti-CD28 (1μg/ml), PMA (25ng/ml) 
& ionomycin (1μg/ml) or PHA (5μg/ml) for 24 hours.  Results are shown as proportion of γδ T 
cells producing cytokines.  In (a), percentage of IFN-γ+ cells and in (b), percentage of IL-17+ 
cells are shown.  The experiment was done only once in triplicates and the results are 
shown as means ± SD. 
  
(a) 
(b) 
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   7.3.4 Preliminary experiments to establish the choice of culture medium 
 
The choice of medium was scrutinised as it has been reported that Iscove's modified 
Dulbecco's medium (IMDM) can result in higher Th17 expansion (Veldhoen et al. 
2009).  Experiments were set up to test healthy donor PBMCs cultured in RPMI- and 
IMDM-based T cell media in parallel. 
 
Results from these experiments demonstrated that there was no significant 
advantage with using either types of culture medium to expand IFN-γ and IL-17 
producing γδ T cell populations whether polyclonal activation was applied or not. 
 
Therefore, it was decided to perform γδ T cell experiments using IMDM-based 
culture medium in line with Th1 and Th17 experiments in Chapter 5. 
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Fig 7.4: The effect of different culture media on the levels of IFN-γ and IL-17 producing 
γδ T cell populations 
Healthy donor PBMCs were either cultured in RPMI- or IMDM-based T cell medium.  Cell 
stimulation was provided by adding anti-CD3 (5ng/ml) & anti-CD28 (1μg/ml) or PMA 
(25ng/ml) & ionomycin (1μg/ml) for 24 hours.  Results are shown as proportion of γδ T cells 
producing cytokines.  In (a), percentage of IFN-γ+ cells and in (b), percentage of IL-17+ cells 
are shown.  The histograms show means ± SD from 3 independent experiments.  One 
experiment was done in duplicates rather than triplicates and did not test cells stimulated 
with PMA/ionomycin. 
  
(a) 
(b) 
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   7.3.5 Preliminary experiments to establish incubation time with polyclonal 
stimuli 
 
PBMC cultures were performed over 24 and 39 hours to investigate whether longer 
exposure to polyclonal stimuli would promote greater expansion of γδ T cell 
population producing either IFN-γ or IL-17. 
 
With regards to γδ T cells producing IFN-γ, longer incubation time actually resulted in 
decreased levels under all three culture conditions (Fig 7.5a).  The levels were 
lowered from 3.6 ± 0.3% to 2.4 ± 0.6% (p<0.05), 7.2 ± 1.0% to 3.2 ± 0.4% (p<0.05), 
and 47.1 ± 1.1% to 25.6 ± 3.4% (p<0.01) in untreated cultures, CD3/CD28 stimulated 
cultures, and PMA/ionomycin stimulated cultures respectively. 
 
Similarly, the proportion of γδ T cells producing IL-17 was reduced with extra 15 
hours of incubation time as well (Fig 7.5b).  The levels were decreased from 2.4 ± 
0.4% to 1.4 ± 0.4% (p<0.05) and 4.1 ± 0.5% to 2.0 ± 0.8% (p<0.05) in untreated 
cultures and CD3/CD28 stimulated cultures respectively.  Such trend, however, was 
not evident in PBMC cultures activated by PMA/ionomycin. 
 
Based on the findings, a decision was made to perform γδ T cell experiments with 24 
hours of culture time. 
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Fig 7.5: The influence of length of culture time on the levels of IFN-γ and IL-17 
producing γδ T cell populations 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 (5ng/ml) & anti-CD28 
(1μg/ml) or PMA (25ng/ml) & ionomycin (1μg/ml) for 24 hours or 39 hours.  Results are 
shown as proportion of γδ T cells producing cytokines.  In (a), percentage of IFN-γ+ cells and 
in (b), percentage of IL-17+ cells are shown.  The histograms show means ± SD of triplicate 
wells from one experiment.  IMDM-based culture medium was used. 
  
(a) 
(b) 
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   7.3.6 IFN-α induces a downregulation of γδ T cells 
 
To verify the findings in our ex vivo experiments on γδ T cells, PBMCs isolated from 
healthy individuals were cultured without stimulation or stimulated with anti-CD3 and 
anti-CD28 Ab or PMA and ionomycin in the presence or absence of IFN-α2a (101-
105 U/ml) and IFN-α2b (101-104 U/ml) before staining and flow cytometry.  Data were 
obtained by examining the population of lymphocytes expressing both CD3 and 
TCRγδ surface proteins. 
 
Analysis of results revealed that recombinant IFN-α2a and IFN-α2b were equally 
effective in suppressing the amount of γδ T cells, especially at higher concentrations.  
In the presence of 105 U/ml of IFN-α2a, the proportion of CD3+TCRγδ+ T cells within 
lymphocyte population was downregulated from 1.1 ± 0.1% to 0.8 ± 0.1% (means ± 
SD; p<0.05) in CD3/CD28 stimulated cultures and from 1.2% to 1.1% (p<0.05) in 
PMA/ionomycin stimulated cultures (Fig 7.6a). 
 
Likewise, in the presence of 104 U/ml of IFN-α2b, the percentage of CD3+TCRγδ+ T 
cells within lymphocyte population was downregulated from 1.0% to 0.9% (p<0.05) in 
CD3/CD28 stimulated cultures and from 1.2% ± 0.1% to 1.0 ± 0.1% (p<0.05) in 
PMA/ionomycin stimulated cultures (Fig 7.6b). 
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Fig 7.6: The inhibitory effect of recombinant IFN-α on TCRγδ expression by CD3+ T 
cells 
PBMCs from healthy donor were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of exogenous IFN-α was added at the same 
time as the polyclonal stimuli to cell cultures.  In (a) and (b), the effects of IFN-α2a and IFN-
α2b are shown respectively.  Results in (a) and (b) are representative of 5 independent 
experiments each, and PBMCs were from four different donors for experiments on both 
forms of IFN-α.  Two of the IFN-α2a and IFN-α2b experiments used both CD3/CD28 and 
PMA/ionomycin stimulation.  Also, PBMCs were cultured over 39 instead of 24 hours in two 
experiments, and 101 U/ml of IFN-α (2a and 2b) and 105 U/ml of IFN-α2a were only tested 
twice in these experiments.  Data are means ± SD values of triplicate wells.  Statistical 
analysis was performed using the Student's T-test.  *p<0.05, compared with controls without 
IFN-α added. 
(a) 
(b) 
  
297 
 
   7.3.7 IFN-α promotes IFN-γ production by γδ T cells 
 
To study the ability of IFN-α to induce IFN-γ expression by γδ T cells in vitro, PBMCs 
isolated from healthy individuals were cultured without stimulation or stimulated with 
anti-CD3 and anti-CD28 Ab or PMA and ionomycin in the presence or absence of 
IFN-α2a (101-105 U/ml) and IFN-α2b (101-104 U/ml) before intracellular cytokine 
staining and flow cytometry.  IFN-γ expression was analysed by gating on 
CD3+TCRγδ+ lymphocyte populations. 
 
Evidently, both IFN-α2a and IFN-α2b showed that they could enhance IFN-γ 
production by γδ T cells at higher concentrations.  Following PMA/ionomycin 
activation, the IFN-γ producing γδ T cells were raised from 69.6 ± 4.9% in the 
absence of IFN-α up to 78.1 ± 0.9% (means ± SD; P<0.05) in the presence of 105 
U/ml IFN-α2a (Fig 7.7a).  Similarly, in the presence of 104 U/ml IFN-α2b, the 
proportions of γδ T cells producing IFN-γ were upregulated from 4.1 ± 0.9% up to 6.4 
± 0.2% (p<0.05) in untreated cultures and 70.1 ± 4.8% up to 78.0 ± 2.9% (p<0.05) in 
cultures stimulated with PMA/ionomycin (Fig 7.7b). 
 
A tendency for both IFN-α2a and IFN-α2b to augment IFN-γ could be detected in 
CD3/CD28 stimulated cultures as well, but the results were not statistically significant. 
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Fig 7.7: The augmenting effect of recombinant IFN-α on γδ T cells producing IFN-γ 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportions of γδ T cells producing IFN-
γ.  In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  Results in (a) 
and (b) are representative of 5 independent experiments each, and PBMCs were from four 
different donors for experiments on both forms of IFN-α.  Two of the IFN-α2a and IFN-α2b 
experiments used both CD3/CD28 and PMA/ionomycin stimulation.  Also, PBMCs were 
cultured over 39 instead of 24 hours in two experiments, and 101 U/ml of IFN-α (2a and 2b) 
and 105 U/ml of IFN-α2a were only tested twice in these experiments.  Data are means ± SD 
values of triplicate wells.  Statistical analysis was performed using the Student's T-test.  
*p<0.05, **p<0.01, compared with controls without IFN-α added. 
(a) 
(b) 
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   7.3.8 IFN-α suppresses IL-17 production by γδ T cells 
 
In order to examine the capacity of IFN-α to inhibit IL-17 production by γδ T cells in 
vitro, PBMCs isolated from healthy individuals were cultured without stimulation or 
stimulated with anti-CD3 and anti-CD28 Ab or PMA and ionomycin in the presence 
or absence of IFN-α2a (101-105 U/ml) and IFN-α2b (101-104 U/ml) before intracellular 
cytokine staining and flow cytometry.  IL-17 expression was analysed by gating on 
CD3+TCRγδ+ lymphocyte populations. 
 
The data demonstrated that both IFN-α2a and IFN-α2b could suppress IL-17 
production by γδ T cells in a dose-dependent manner.  The trend was particularly 
evident with PMA/ionomycin activation as the proportions of γδ T cells producing IL-
17 were downregulated from 16.1 ± 4.5% in the absence of IFN-α to 7.8 ± 2.5% 
(means ± SD; p<0.05) when 105 U/ml of IFN-α2a was added to PBMC cultures (Fig 
7.8a).  Likewise, the percentages of γδ T cells producing IL-17 was reduced from 
17.2 ± 2.8% in the absence of IFN-α to 11.6 ± 2.0% in the presence of 104 U/ml of 
IFN-α2b (Fig 7.8b). 
 
The tendency for IFN-α2a and IFN-α2b to inhibit IL-17 could be observed in 
untreated and CD3/CD28 stimulated cultures as well, but the results were not 
statistically significant. 
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Fig 7.8: The inhibitory effect of recombinant IFN-α on IL-17 producing γδ T cells 
Healthy donor PBMCs were untreated, stimulated with anti-CD3 & anti-CD28 or PMA & 
ionomycin for 24 hours.  Various concentrations of IFN-α was added at the same time as the 
polyclonal stimuli to cultures.  Results are shown as proportions of γδ T cells producing IL-17.  
In (a) and (b), the effects of IFN-α2a and IFN-α2b are shown respectively.  Results in (a) and 
(b) are representative of 5 independent experiments each, and PBMCs were from four 
different donors for experiments on both forms of IFN-α.  Two of the IFN-α2a and IFN-α2b 
experiments used both CD3/CD28 and PMA/ionomycin stimulation.  Also, PBMCs were 
cultured over 39 instead of 24 hours in two experiments, and 101 U/ml of IFN-α (2a and 2b) 
and 105 U/ml of IFN-α2a were only tested twice in these experiments.  Data are means ± SD 
values of triplicate wells.  Statistical analysis was performed using the Student's T-test.  
*p<0.05, **p<0.01, compared with controls without IFN-α added. 
(a) 
(b) 
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   7.3.9 The kinetics of immunomodulatory effects of IFN-α on γδ T cells 
expressing IFN-γ and IL-17 
 
Although IFN-α has been observed to enhance IFN-γ while inhibiting IL-17 
production by γδ T cells in vitro, it was not clear whether pre-treatment of PBMCs 
with IFN-α could exert greater influence when compared to adding IFN-α at the same 
time as activating agents.  Also, it was doubtful whether IFN-α could produce its 
effect once PBMCs were activated.  To aid in answering these questions, PBMCs 
isolated from healthy individuals were cultured without IFN-α treatment or with 104 
U/ml IFN-α2a added 24 hours before, 4 hours before, at the same time as, or 4 
hours after PMA/ionomycin stimulation.  The timing for the introduction of IFN-α to 
cultures was the same for both unstimulated and stimulated cultures, and PBMCs 
were incubated for 24 hours after PMA/ionomycin stimulation before intracellular 
cytokine staining and flow cytometry.  IFN-γ and IL-17 expression levels were 
analysed by gating on CD3+TCRγδ+ lymphocyte populations. 
 
In terms of IFN-γ producing γδ T cells, although upregulation was evident at all four 
time-points relative to the levels achieved without the presence of IFN-α, statistical 
significance was reached only when IFN-α was added at the second last time-point.  
In the case of untreated cultures, the proportions of IFN-γ producing γδ T cells were 
raised from 4.4 ± 0.5% in the absence of IFN-α up to 5.9 ± 0.4% (means ± SEM; 
p<0.05) at this time-point (Fig 7.9a).  Also, the concurrent introduction of IFN-α and 
PMA/ionomycin at this time-point was able to enhance the levels of IFN-γ producing 
γδ T cells from 65.4 ± 3.2% to 75.2 ± 2.1% (p<0.05). 
 
With regards to γδ T cells producing IL-17, an inhibitory effect was seen at all time-
points.  However, the strongest effect was seen when IFN-α was added at the 
second last time-point (Fig 7.9b).  In the case of untreated cultures, the proportions 
of IL-17 producing γδ T cells were downregulated from 2.8 ± 0.4% without the 
presence of IFN-α to 1.3 ± 0.1% (p<0.01) at this time-point.  The decrease was even 
significant relative to results obtained from the first (2.6 ± 0.5%; P<0.05) and second 
(2.1 ± 0.3%; p<0.05) time-points.  With PMA/ionomycin stimulation, the concurrent 
use of IFN-α reduced the levels of IL-17 producing γδ T cells from 8.3 ± 1.1% in the 
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absence of IFN-α to 5.4 ± 0.7% (p<0.05).  This result was significant even when 
evaluated against data with 24 hours of IFN-α pre-treatment (8.7 ± 0.8; p<0.01). 
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Fig 7.9: The kinetics of immunomodulatory effects of IFN-α on γδ T cells producing 
IFN-γ and IL-17 
Healthy donor PBMCs were treated without or with 104 U/ml IFN-α2a 24 hours before, 4 
hours before, at the same time as, or 4 hours after introduction of PMA & ionomycin to 
cultures.  The timing for the addition of IFN-α2a to cultures was the same for both 
unstimulated and stimulated cultures, and PBMCs were incubated for 24 hours after 
PMA/ionomycin stimulation before staining.  Results are shown as proportions of γδ T cells 
producing (a) IFN-γ and (b) IL-17.  The histograms show means ± SEM of triplicate wells 
from three independent experiments.  All experiments used PBMCs from the same donor.  
Statistical analysis was performed using the Student's T-test.  *p<0.05, **p<0.01, compared 
with controls without IFN-α added. †p<0.05, ††p<0.01, compared with data with 24-hour 
IFN-α pre-treatment.  ‡p<0.05, compared with data with 4-hour IFN-α pre-treatment. 
(a) 
(b) 
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   7.4 Discussion 
 
   7.4.1.1 γδ T cells and Behcet’s disease 
 
γδ T cells make up 1-10% of the peripheral blood T cells (Kaufmann 1996), and may 
help bridge the gap between early innate and later adaptive immune responses.  
They represent a unique subset of unconventional lymphocytes, because they 
display features of both conventional αβ T cells and NK cells (Hayday 2000).  γδ T 
cells localise in specialised areas such as the mucosal tissues and can produce 
additional cytokines with relevance for the local immune response (Bonneville, 
O'Brien, & Born 2010).  γδ T cells freshly isolated from human peripheral blood tend 
to be primed toward a Th1 phenotype (Wesch, Glatzel, & Kabelitz 2001). 
 
γδ T cells are mainly CD4-CD8- T lymphocytes characterised by their expression of 
an antigen receptor encoded by the γ and δ TCR genes.  As they do not express 
CD4 or CD8 co-receptors in most cases, activation of γδ T cells is possible without 
requirement of Ag processing and restriction by MHC molecules.  These 
characteristics might allow γδ T cells to be highly autoreactive.  However, the TCRγδ 
restriction to small compounds over-expressed after infection or cell stress, the 
restricted tissue distribution of TCR agonists as well as the short half-life of the 
effector cells all contribute to the limitation of the inherent self-reactivity of γδ T cells 
(Nedellec, Bonneville, & Scotet 2010). 
 
In Behcet’s disease, γδ T cell numbers has been observed to be significantly higher 
during active disease than in remission (Bank, Duvdevani, & Livneh 2003), 
suggesting that the increase in γδ T cells in BD is a result of disease activity, rather 
than an innately augmented level of γδ T cells in these individuals. 
 
 
   7.4.1.2 Influence of IFN-α on peripheral blood γδ T cells 
 
From our data on BD patients, escalations of both CD8- and CD8+ γδ T cell numbers 
were detected sporadically in individuals on conventional treatment alone, which 
were likely to coincide with their spontaneous relapses.  However, this tendency to 
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increase appeared to be thwarted by the addition of IFN-α therapy in the treatment 
group. 
 
Consistently, our in vitro results displayed that higher concentrations of both IFN-α2a 
and IFN-α2b could significantly downregulate the proportions of CD3+ γδ T cells in 
healthy donor PBMCs following polyclonal activation by anti-CD3/CD28 or 
PMA/ionomycin. 
 
In agreement with our results, IFN-α2a was reported to decrease the number of 
circulating CD3+ and CD8+ γδ T cells considerably after 24 weeks of treatment in BD 
patients with active ocular disease (Treusch et al. 2004).  Also, the proportions of 
CD8+ γδ T cells were observed to be reduced by IFN-α therapy in patients with 
hepatitis C in an early study (Wejstal et al. 1992). 
 
 
   7.4.2.1 Setting up IFN-γ and IL-17 producing γδ T cell in vitro test models 
using antigens and polyclonal stimuli 
 
IL-17-producing γδ T cells were reported to express TLR1 and TLR2, as well as 
dectin-1 in mice (Martin et al. 2009).  In agreement, a role for TLR2 in the 
enhancement of IL-17 production by γδ T cells was revealed in another recent 
murine study.  TLR2 activation alone was not sufficient in inducing IL-17 production 
from γδ T cells, but in combination with IL-23 induced an upregulated IL-17 
responses compared to cells treated with IL-23 alone (Reynolds et al. 2010).  As a 
result of these reports, zymosan, a stimulus for TLR2 and dectin-1 (Dillon et al. 
2006), was considered likely to have positive influence on IL-17 producing γδ T cells.  
However, such result was not observed. 
 
Analysing our data, LPS, candida antigens, and PDS-Ag were the ones which 
demonstrated some activity in the enhancement of IL-17 producing γδ T cells.  The 
tendency of LPS to promote IL-17 in CD4+ T cells was noticed in Chapter 5, and LPS 
were previously reported to possess IL-17 inducing activity (Kattah et al. 
2008;Moschen et al. 2008).  Longer cultures with candida antigens also revealed 
their potential to augment IL-17 production in γδ T cells, which was unexpected as 
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the commercial candida antigens used in the experiments were mainly made up of 
components from the yeast form rather the hyphal form.  C. albicans in the yeast 
form were reported to induce differentiation of IFN-γ producing cells rather than IL-17 
producing cells as in the case of C. albicans in hyphal form (Acosta-Rodriguez et al. 
2007).  PDS-Ag, a BD-related antigen, was another surprise as it did not elicit much 
Th17 response as depicted in Chapter 5.  ATRA, as expected, resulted in lowest IL-
17 levels in γδ T cells and this is in accordance to previous report of its ability to 
inhibit Th17 cell differentiation (Elias et al. 2008;Mucida et al. 2007). 
 
On the other hand, all antigens used in our preliminary experiments promoted very 
low levels of IFN-γ producing γδ T cells, even with extra time in culture.  Of all the 
combinations used to promote cytokine production by γδ T cells, polyclonal stimuli 
consistently showed greater potential than using antigens alone, especially in the 
case of PMA in combination with ionomycin. 
 
 
   7.4.2.2 Testing other aspects of the in vitro experimental design 
 
It has been suggested resting PBMCs overnight after thawing before testing effector 
functions would remove cells destined for death and allow “stunned” cells to recover 
functional ability (Lamoreaux, Roederer, & Koup 2006).  Therefore, instead of 
stimulating cells straight after thawing, one day resting in culture medium with or 
without suboptimal level of IL-2 was performed.  It was noted that neither resting nor 
addition of IL-2 augmented the levels of IFN-γ producing and IL-17 producing γδ T 
cells appreciably. 
 
Unlike the Th1 and Th17 experiments in Chapter 5, a significant difference between 
RPMI- and IMDM-based culture media was not found in terms of ability to induce 
IFN-γ producing and IL-17 producing γδ T cells, whether PBMC cultures were 
activated or not.  Consequently, majority of the γδ T cell experiments were carried 
out using IMDM-based culture medium in line with Th1 and Th17 experiments 
performed previously. 
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The benefit of extra time in culture was tested as well but 24 hours of culture was 
shown to be superior to 39 hours of culture with regards to achieving higher levels of 
IFN-γ and IL-17 cytokine production by γδ T cells in general.  The only exception 
was IL-17 production by γδ T cells following PMA/ionomycin stimulation where the 
levels achieved were comparable between 24 and 39 hours of culture.  Therefore, a 
decision was made to perform experiments over 24 hours without resting healthy 
donor PBMCs. 
 
 
   7.4.3 The influence of IFN-α on IFN-γ production by γδ T cells 
 
Classically, IFN-γ has been regarded as a pro-inflammatory cytokine.  In recent 
years, however, IFN-γ has been implicated not only as a mediator of disease but 
possibly as a protective factor during autoimmunity depending on factors such as the 
timing, location, and intensity of IFN-γ action (Kelchtermans, Billiau, & Matthys 
2008;O'shea, Ma, & Lipsky 2002). 
 
In Chapter 5, our data have consistently shown that both IFN-α2a and IFN-α2b could 
increase IFN-γ production by CD4+ and CD8+ T cells in vitro, especially at higher 
concentrations.  Similarly, the levels of γδ T cells producing IFN-γ were found to be 
upregulated in our experiments in the presence of increasing dose of IFN-α.  The 
possible mechanism of action has been suggested to be that type I IFNs, including 
IFN-α, promote IFN-γ signalling via association of type I and type II IFN receptor 
subunits (Takaoka et al. 2000). 
 
Of note, IFN-γ producing γδ T cells were found to lack expression of TLR2, dectin-1, 
CCR6 and AHR in comparison to IL-17+ γδ T cells in a recent murine study (Martin et 
al. 2009). 
 
 
   7.4.4.1 Biology of IL-17 producing γδ T cells 
 
It now seems that IL-17 is one of the more important villains in the pathogenesis of 
autoimmune diseases.  It is a potent inducer of autoimmunity through the promotion 
  
308 
 
of tissue inflammation and the mobilisation of the innate immune system.  The 
challenge is to keep IL-17 in check, while maintaining host defence at the same time.  
Importantly, IL-17 production is not an exclusive characteristic of CD4+ αβ T cells, 
and γδ T cells are recognised as a powerful cellular source of IL-17 as well and 
contribute to the initial defence against pathogens (Michel et al. 2007;Roark et al. 
2008). 
 
Low but significant numbers of adult human blood Vγ2Vδ2 T cells produce IL-17 or 
IL-22 ex vivo, although few produce both.  Induction of IL-17-producing cells from 
neonatal naive Vγ2Vδ2 T cells requires cytokines including IL-1β, IL-6, TGF-β, but 
not IL-23.  On the other hand, IL-23, not IL-6, is essential for maximal expansion of 
IL-17-producing memory Vγ2Vδ2 T cells in adults.  For both neonatal and adult 
Vγ2Vδ2 T cells, cells producing IL-17 have higher levels of RORγt compared with 
non-IL-17 producing cells, demonstrating the importance of RORγt in IL-17 
production (Ness-Schwickerath, Jin, & Morita 2010).  It has been observed that 
many γδ T cells already exist as effector memory cells, ready to mount strong IL-17 
responses quickly. 
 
Moreover, it was shown that some phenotypic characteristics are shared between 
Th17 and IL-17-producing γδ T cells including CCR6, RORγt, AHR, and IL-23 
receptor in a recent murine study (Martin et al. 2009). 
 
 
   7.4.4.2 The influence of IFN-α on IL-17 production by γδ T cells 
 
Our results from Chapter 4 and 5 demonstrated the capacity of recombinant IFN-α in 
the suppression of IL-17 production by CD4+ and CD8+ T cells.  It was also shown in 
a study that pre-treatment with recombinant IFN-α could inhibit human PBMC 
secretion of IL-17 and activation-induced IL-23 as measured by ELISA (Meyers et al. 
2006).  However, the subgroups of cells capable of producing IL-17, including γδ T 
cells, were not discriminated. 
 
In accordance with these findings, both IFN-α2a and IFN-α2b were observed in our 
experiments using healthy donor PBMCs to inhibit IL-17 production by γδ T cells in a 
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dose-dependent manner.  The results are particularly relevant in the understanding 
of IFN-α therapy being used as a disease-modifying treatment in immune-mediated 
diseases like BD as elevated levels of γδ T cells and IL-17 have been described to 
be associated with disease activity and implicated in the pathogenesis of BD (Bank, 
Duvdevani, & Livneh 2003;Chi et al. 2008). 
 
 
   7.4.5 The effect of IFN-α on the kinetics of IFN-γ and IL-17 production by γδ T 
cells 
 
The kinetics of PBMC response under the influence of IFN-α was measured with 
regards to IFN-γ and IL-17 production levels within γδ T cell populations.  The idea 
was to obtain some indications in the ways IFN-α therapy could contribute as either 
prophylaxis or treatment options in chronic inflammatory diseases. 
 
Unexpectedly, adding IFN-α and PMA/ionomycin simultaneously induced the largest 
increase in IFN-γ levels in γδ T cells.  On the other hand, concurrent use of IFN-α 
and PMA/ionomycin resulted in the greatest amount of IL-17 inhibition in γδ T cells.  
However, these immunomodulatory effects were not significant when IFN-α was 
added as a pre-treatment at earlier time-points.  Similar trends were also observed in 
untreated samples. 
 
A possible explanation is that IFN-γ was produced by γδ T cells in greater quantity 
relatively early during incubation in response to IFN-α treatment.  On the other hand, 
IL-17 production by γδ T cells occurred later during cultures after longer exposure of 
PBMCs to IFN-α.  The results could be simply a reflection of the experimental design 
picking up data at various stages of cytokine production. 
 
 
   7.5 Summary of findings 
 
Our data demonstrated that both IFN-α2a and IFN-α2b have the potential to 
suppress the number of γδ T cells and their production of cytokine IL-17.  On the 
other hand, IFN-γ producing γδ T cells were shown to be induced following treatment 
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with IFN-α.  Of note, IFN-α appeared to exert the strongest influence on IFN-γ 
producing and IL-17 producing γδ T cells when it was added 24 hours before 
intracellular cytokine staining and flow cytometry. 
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Chapter 8 
General discussion and future work 
 
 
  8.1 General discussion 
 
IFN-α is a leukocyte-derived cytokine with profound immunomodulatory capabilities.  
Despite its discovery more than 50 years ago (Isaacs & Lindenmann 1957), the in vivo 
operative mechanisms of actions are still not sufficiently understood.  Interferons have 
diverse effects, influencing both innate and adaptive immune responses and form a 
network of complex interactions with other cytokines (Baccala, Kono, & Theofilopoulos 
2005).  Current advances in our understanding of the development of autoimmune 
responses, including the important roles played by both recently discovered Treg and 
Th17 cell lineages, have enabled us to investigate the properties of this effective therapy 
further. 
 
 
   8.1.1 Approaches used in this study 
 
The work presented in this thesis has been directed at exploring the immunomodulatory 
effects of IFN-α on peripheral blood T cells, with a view to a potential disease-modifying 
therapy for the treatment of Behcet’s disease.  In order to achieve this goal, a number of 
approaches have been utilised.  Firstly, serial whole blood samples from BD patients 
receiving conventional immunosuppressive therapy with or without recombinant IFN-
α2b treatment were phenotyped without activation or culture.  Secondly, serial whole 
blood samples from the same group of BD patients were studied using intracellular 
cytokine staining, elucidating the influence of IFN-α on both conventional T cells and 
more recently discovered T cell subsets.  Thirdly, the phenotype of interferon treated 
healthy donor PBMCs was analysed in vitro using intracellular cytokine staining and flow 
cytometry. 
 
Human PBMCs usually contain only very low percentages of effector cells which 
produce relatively high levels of cytokines required for this kind of analysis (Vyas & 
Noble 2008).  It is therefore necessary to activate the T cells to induce rapid 
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accumulation of cytoplasmic cytokines before analysis.  In our study, cell cultures were 
either treated with anti-CD3/CD28 Abs or PMA/ionomycin for 24 or 39 hours in order to 
study cytokine production.  However, this makes it difficult to analyse the antigen 
specificity of responding T cells but will indicate the type 1/type 2/type 17 bias of the 
population, reflecting previous exposures to antigen. 
 
Intracellular cytokine staining directly analyses T cells producing a given cytokine and is 
a sensitive and convenient way of monitoring the effect of a medication longitudinally.  
Also, a unique strength of this technique is the ability to assess multiple cytokines 
simultaneously.  The human whole blood assay employed in our ex vivo experiments for 
determining IFN-α effects may resemble the in vivo situation most closely, as other 
essential factors for T lymphocyte activation are present at physiologic concentrations.  
However, our in vitro experiments gave us an indication of the influence of IFN-α in the 
absence of other immunosuppressants. 
 
 
   8.1.2 Findings from ex vivo experiments 
 
Analysing our data, six months of subcutaneous pegylated IFN-α2b therapy was not 
observed to have any impact on the proportions of CD4+, CD8+ and αβ T cells in BD 
patients.  However, the tendency of γδ T cell number to increase in BD patients was 
suppressed in those who received IFN-α therapy.  In terms of cytokine production, 
IFN-α therapy demonstrated the tendency to enhance T cell production of IFN-γ but 
not TNF-α.  Under the influence of IFN-α2b therapy, upregulation of IL-2 and IL-4 
expression by CD3+ T cells was consistently observed.  All these findings have been 
described in some earlier studies, even though the subjects of most previous studies 
were not BD patients.  Notably, all the positive effects of IFN-α detected in our work 
were enduring as they were evident even after the termination of IFN-α2b treatment.  
To our knowledge, this is the first time 12-month longitudinal data concerning BD 
patients who received IFN-α treatment was presented. 
 
CD4+ T lymphocytes play an essential role in steering immune responses and can 
contribute to autoimmunity.  These cells include effector T cells and regulatory T 
cells, which protect against effector responses to autoantigens and also against 
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responses to exogenous antigens.  Discoveries made over the past two decades 
have markedly changed the way we study immunological processes.  Not the least 
of these was the identification and cloning of several new cytokines, including IL-17.  
These discoveries provided compelling reasons to explore outside the Th1/Th2 cell 
paradigm in search of answers to explain the effector T cell responses that occur 
independently of known Th1 and Th2 cell signalling pathways.  Understanding the 
roles played by alternative T cell subsets is critical in avoiding excessive chronic 
inflammation and tissue damage. 
 
With regards to Th17 cells, it was demonstrated in our experiments that 6 months of 
subcutaneous IFN-α2b therapy could downregulate these cells in peripheral blood of 
BD patients.  This is in accordance to a very recent study which found that IFN-α 
significantly suppressed IL-17 production in PBMC culture supernatants from BD 
patients in vitro (Liu et al. 2011).  Whereas, CD4+Foxp3+ Treg cell populations, 
especially CD4+CD25high T cells, were upregulated following IFN-α2b treatment in 
BD patients.  To our knowledge, this is the first time that IFN-α treatment has been 
observed to increase the proportions of CD4+Foxp3+ T cells in PBMCs.  Importantly, 
the effects on Th17 and Treg cells were enduring as they were observed even after 
cessation of IFN-α therapy.  These findings could be pivotal in order to understand 
IFN-α as a disease-modifying treatment for BD. 
 
Furthermore, a tendency to upregulate the production levels of IL-10 and TGF-β by T 
cells was detected after treatment with IFN-α.  This increase in immunoregulatory 
cytokine levels could assist in the regulation of Th cells and promote the number and 
function of Treg subsets. 
 
 
   8.1.3 Findings from in vitro experiments 
 
In our study, in vitro experiments were carried out using healthy donor PBMCs to test 
the effects of IFN-α in the absence of the influence by corticosteroids and other 
immunosuppressants.  The other aim was to examine whether similar effects by IFN-
α on BD patients could be observed in healthy donor cells.  Additionally, the 
influence of IFN-α on different subsets of CD8+ and γδ T cells was explored further.  
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Both recombinant IFN-α2a and IFN-α2b were used and they were demonstrated to 
be equally effective in their control on the relative proportions of T cell subsets and 
inflammatory cytokine production by T cells. 
 
Higher doses of IFN-α demonstrated the tendency to upregulate CD4+ but inhibit 
CD8+ T cells.  IFN-α also showed the potential to increase IFN-γ producing CD4+ 
and CD8+ T cells and suppress CD4+ and CD8+ T cells producing IL-17.  On the 
other hand, IFN-α2a and IFN-α2b were efficacious in inducing Foxp3 expression by 
CD4+, CD4+CD25+, CD4+CD25high, CD8+, and CD8+CD25+ T cell populations.  Both 
forms of IFN-α were observed to consistently upregulate IL-10 and TGF-β levels in 
CD4+ and CD8+ T cells as well.  Notably, IFN-α was found to be able to exert its 
effects on Th17 and Treg cells both before and after cell activation.  This may imply 
that IFN-α therapy may be effective even when the disease is active.  Moreover, our 
data showed that both IFN-α2a and IFN-α2b have the potential to suppress the 
number of γδ T cells and their production of cytokine IL-17.  On the other hand, IFN-
γ producing γδ T cells were observed to be induced following treatment with IFN-α. 
 
To our knowledge, it is the first time that induction of CD4+Foxp3+ and CD8+Foxp3+ T 
cells by IFN-α has been demonstrated in vitro.  The effects of IFN-α on various CD8+ 
and γδ T cells subsets described here has not been reported in previous studies 
either. 
 
 
   8.1.4 The implications of the findings in this study 
 
In chronic inflammatory and autoimmune conditions, the entire cytokine network is in 
a long-term persistent state of activation.  In such situations, either the stimulatory or 
the counter-regulatory circuits might in the end predominate in determining the net 
global effect of cytokines (Kelchtermans, Billiau & Matthys 2008).  It is possible that 
acute flares of autoimmune diseases may be explained by a preferential 
differentiation towards pro-inflammatory lineages or enhanced survival of these 
phenotypes in the periphery.  T cell heterogeneity and plasticity open opportunities 
for targeting or redirecting specific subsets in immune-mediated diseases.  In our 
study, cytokine production by CD4+ T cells, CD8+ T cells and γδ T cells was 
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investigated.  It is likely that cooperation between different cytokine-producing T cell 
subsets needs to be regulated to achieve desired immune responses and immune 
system homeostasis. 
 
It has been suggested that the cytokines secreted by CD4+ T cells play a 
complementary function with cytokines produced by CD8+ and γδ T cells as they 
release cytokines at different phase during an inflammatory response.  Importantly, 
even though other cell types could trigger auto-aggressive responses independently 
of CD4+ T cells, a lack of cooperation from these cells would limit the damage to the 
host due to the reduced duration of such responses as a result.  Indeed, a sustained 
memory CD8+ T cell response and high-affinity immunoglobulin production by B cells 
are restricted without CD4+ T cell help (Castellino & Germain 2006). 
 
In comparison to CD4+ T cells, naive CD8+ T cells acquire effector T cell functions 
more readily upon antigen stimulation (Seder & Ahmed 2003).  Activated CD8+ T 
cells can produce very high levels of inflammatory cytokines, including IFN-γ (Liblau 
et al. 2002).  These may contribute greatly to target cell destruction in autoimmune 
diseases and therefore regulation is essential for CD8+ T cells.  Notably, it has been 
demonstrated that CD8+ T cells can direct the development of CD4+ T cells into Th1 and 
Th2 effectors.  Tc1 clones have been shown to favour the development of CD4+ 
effectors that are Th1-biased.  Whereas Tc2 clones not only can promote Th2 effectors 
but also can efficiently suppress the development of Th1 cells (Vukmanovic-Stejic et al. 
2000). 
 
γδ T cells are able to prime downstream immune events, including the production of 
pathogenic TNF-α and T helper type 1 cytokines, it is plausible that the disruption of 
γδ T cell-mediated immunostimulation could be an important mechanism of action for 
IFN-α.  Antigen-naive γδ T cells are known to produce large amount of effector 
cytokines within hours upon infection.  Also, cytokines produced by γδ T cells can 
contribute to the regulation of αβ T cell activation (Kuhl et al. 2009;Roark et al. 2008). 
 
From our data, IFN-α was shown to have the tendency to promote Th1 signature 
cytokine IFN-γ.  The proportions of IFN-γ secreting T cells, including CD4+, CD8+ 
and γδ T cells were all upregulated by IFN-α in vitro.  This could be due to the 
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augmentation of IFN-γ signalling by IFN-α via association of type I and type II IFN 
receptor subunits (Takaoka et al. 2000).  It may also be that the effects of IFN-α on 
one cell subset to secrete IFN-γ induced stimulation of other immune cells to produce 
IFN-γ in a series of positive feedback loops.  IFN-γ lowers host damage during active 
disease by lowering the recruitment of neutrophils to inflammatory sites and suppressing 
the production of highly pro-inflammatory molecules, including IL-17, and the 
development of the Th17 lineage (Kelchtermans, Billiau, & Matthys 2008).  Therefore, it 
was not unexpected that IFN-α was observed to have the capacity to downregulate IL-
17 secreting T cells including CD4+, CD8+ and γδ T cells in our experiments.  All IL-17 
producing cells may have pivotal roles in licensing T cell effector functions that result in 
inflammatory disease.  However, the relative contributions of Th17 cells versus other IL-
17 producing T cells to inflammatory responses in Behcet’s disease are not clear. 
 
The ratio of IFN-γ : IL-4 secreting cells has been reported to be higher in BD patient with 
active disease (Misumi et al. 2003).  Thus, increased disease activity in BD patients 
could be associated with higher IFN-γ : IL-4 ratio rather than higher levels of IFN-γ alone.  
It was observed in our ex vivo experiments that IL-4 production by T cells was 
appreciably augmented by IFN-α therapy, even though IFN-γ production by T cells 
showed a tendency to be upregulated by IFN-α as well.  Thus, our patients who had 
less active disease after IFN-α therapy might even have lower ratio of IFN-γ : IL-4 
secreting cells when compared to before initiation of treatment. 
 
As IL-2 has been shown to be necessary for T cells to acquire IL-4 producing capacity 
(Paul & Zhu 2010), the enhanced amounts of IL-2 expression detected in our 
experiments could contribute to IL-4 augmentation.  Early in an immune response, IL-2 
maintains T cell survival and supports the growth and expansion of T cells.  If the 
response is enduring, as in the case of self-antigens, the prolonged IL-2 exposure 
makes T cells sensitive to Fas-mediated apoptosis and terminates the response 
(Abbas 2003)  IL-2 is indispensable for the induction of Tregs as IL-2 signalling is 
required for thymic development, peripheral expansion and suppressive activity of 
Treg cells (Shevach et al. 2006).  The other common γ-chain cytokines including IL-4 
were also reported to maintain maximal regulatory function, suggesting a degree of 
redundancy of the cytokines required to maintain Treg function.  However, the 
concentrations required for IL-4 to achieve the same effect were up 50-fold higher 
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than for IL-2 in vitro, thought to reflect the high density of expression of the IL-2 αβγ 
receptor by CD4+CD25+ Tregs (Yates et al. 2007). 
 
Our results are, to our knowledge, the first demonstration of an upregulatory effect 
on T cell Foxp3 expression in PBMCs by IFN-α treatment.  It is possible that 
proliferation of Foxp3low naive natural regulatory T cells as well as induced Treg cells 
may have contributed to our findings.  Increases in Foxp3 expression can also be a 
result of activation in effector T cells, and in this case it is likely that the induced 
Foxp3 expression may provide a way to fine-tune proliferation and effector function 
of these cells.  This is based on the fact that Foxp3-transduced human naive 
CD4+CD25-CD45RA+ T cells have been demonstrated to be hyporesponsive and 
have a significantly reduced capacity to produce cytokines, including IL-2 and IFN-γ, 
upon TCR-mediated activation in comparison with controls (Allan et al. 2005).  
Moreover, Foxp3 may form transcription factor complexes with T-bet, GATA3, or 
RORγt so that the capacity of these factors to induce effector cytokines is inhibited 
(Zhu & Paul 2010).  Importantly, our findings indicate a previously unrecognised 
potential mechanism by which IFN-α therapy may provide benefit to BD patients. 
 
Tregs have the capacity to actively block immune responses, inflammation, and 
tissue destruction and have a major role in suppressing proliferation and effector 
functions of other immune cells of both the adaptive (CD4+ and CD8+ αβ T cells, and 
B cells), and the innate (NK cells, NKT cells, monocytes and dendritic cells) immune 
system (Grossman et al. 2004;Tang & Bluestone 2008).  Recently, it was also 
demonstrated that CD4+CD25highFoxp3+ T cells isolated from human blood could 
inhibit both anti-CD3 and antigen-driven activation and IFN-γ production by Vδ2+ T 
cells (Mahan et al. 2009).  Tregs were shown to suppress γδ T cell proliferation via a 
cell-cell contact-independent mechanism (Kunzmann et al. 2009).  However, it was 
reported that human Th17 cells were less sensitive to Tregs than Th1 cells.  
Likewise, CD8+IL-17+ cells showed little susceptibility to Tregs from peripheral blood 
(Annunziato et al. 2007;Ortega et al. 2009). 
 
Of note, human Treg cells probably cannot suppress pro-inflammatory cytokine 
production and proliferation in conditions in which effector T cells are strongly 
activated (Sakaguchi et al. 2010).  It is likely that the loss of suppression observed in 
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the presence of strongly activating factors is due to both an increase in effector T 
cells resistance and a decrease in Treg cell function (Koenen et al. 2008).  In 
addition, there is propensity of Tregs to convert to Th17 cells in the context of pro-
inflammatory stimuli, such as IL-1β and IL-6, in humans (Abdulahad, Boots, & 
Kallenberg 2010).  Increased Foxp3 expression induced by IFN-α in our study, 
however, could help stabilise the phenotype and function of Foxp3+ Treg cells and 
reduce their conversion to pathogenic IL-17 secreting effector T cells during active 
phase of immune-mediated disease like BD. 
 
The diversity of effector mechanisms affords versatility to a Treg-mediated 
suppression program capable of restraining diverse types of inflammatory responses 
in different tissues (Feuerer et al. 2009).  In some systems, direct cell-to-cell contact 
seems to be required; in other systems, suppression seems to involve TGF-β and IL-
10 cytokines.  Our data have suggested that IFN-α therapy has the tendency to 
upregulate IL-10 and TGF-β production by T cells.  Therefore, besides promoting 
Treg cell subsets, IFN-α may enhance negative feedback mechanisms ascribed to 
cytokines such as IL-10 and TGF-β, which limits the inflammatory reactions. 
 
Major T cell sources of IL-10 include subsets of regulatory T cells designated Tr1 as 
well as Th2, Th1, and Th17 cells.  CD8+ T cells also produce IL-10 (Mosser & Zhang 
2008).  Our results indicated that it was likely some Tr1 cells were induced by IFN-α 
treatment.  Notably, IL-10 production can be promoted by IL-10 itself, IL-27 and 
TGF-β (Zhu & Paul 2008).  As our results showed the tendency for increased TGF-β 
secretion by T cells of BD and healthy patients ex vivo and in vitro respectively 
following IFN-α treatment, it is possible that besides Tr1 cells, Th3 regulatory cells 
might also be induced by IFN-α therapy.  Different types of Treg cells have 
complementary and overlapping functions in suppression of autoimmunity and 
associated inflammation (Littman & Rudensky 2010). 
 
TGF-β suppresses immune responses through at least two ways: inhibiting the 
function of inflammatory cells and promoting the function of Treg cells (Wan & Flavell 
2008).  Although T cell specific target genes of TGF-β are largely unknown, the 
expression of genes important for T cell differentiation and function, such as GATA3, 
T-bet, STAT4, IFN-γ, and granzyme-B, are suppressed by TGF-β (Wan & Flavell 
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2008).  Although nTreg cell commitment is independent of TGF-β signalling, TGF-β 
has been suggested to promote nTreg cell survival by antagonising T cell negative 
selection and protecting nTreg cells from apoptosis (Ouyang et al. 2010). 
 
Of note, recent findings have revealed that TGF-β can also have a pro-inflammatory role 
dependent on the immunological environment.  Thus, in the presence of pro-
inflammatory cytokines, TGF-β contributes to the generation of immunopathogenic IL-17 
secreting T cells (Yang et al. 2008b).  Consequently, the prerequisite for the generation 
of Treg cells, rather than IL-17 secreting T cells, by TGF-β is the removal of pro-
inflammatory cytokines, specifically IL-6, but also TNF-α and IL-1.  IFN-α can serve this 
function well as it has been indicated in an early study to suppress the ability of IL-6, the 
critical partner for TGF-β in the production of IL-17 producing T cells, to bind to the IL-6 
receptor by downregulating IL-6 receptor expression (Anthes et al. 1995).  Also, it has 
been shown in some very early studies that IFN-α inhibits IL-1 synthesis by PBMCs 
(Schindler, Ghezzi, & Dinarello 1990), and induces IL-1 receptor antagonist (Tilg et al. 
1993). 
 
Therapy targeting Treg cell populations and immunoregulatory cytokines could be 
a powerful approach for modulating responses in immune-mediated disease like 
Behcet’s disease.  Activated Treg cells can suppress a wide range of immune 
responses through bystander suppression (Tang & Bluestone 2008), and Treg cells 
have been known to induce the development of long-lasting immunologic memory via 
modulation of APCs and de novo development of Tregs (Jonuleit et al. 2002;Roncarolo et 
al. 2006).  Thus, even though individual Treg cells have a finite lifespan, their ability to 
impart a tolerant phenotype to other cells via infectious tolerance means that their 
transient immunosuppressive signal could be maintained for a long time. 
 
In this study, we have explored the potentiation of Tregs with IFN-α treatment as evident 
by increases in Foxp3 expression and regulatory cytokine production ex vivo and in vitro.  
The resulting Foxp3+ Tregs likely serve to curb escalating effector T cell responses 
and control tissue damage.  Restoring immune homeostasis with upregulation of 
Tregs would, it is hoped, be effective as at least a short-term therapy, because it 
would then allow a tolerogenic milieu to develop and ultimately promote the recovery of 
natural regulatory responses.  It is tempting to speculate that increases in Treg cell 
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subsets after 6 months of IFN-α therapy could be responsible for the long-lived 
efficacy in patients with BD. 
 
IFN-α therapy holds the promise to replace and/or supplement indiscriminatory 
immunosuppression by drugs with potentially deadly side effects.  This is not to say 
that immunosuppressants may be completely useless.  Their transient application 
may help to set the immune system to a stage where Treg cells can be more 
effective in dealing specifically with unwanted immunity.  The data presented here 
could serve as a basis for understanding the mechanism of action of IFN-α and 
identifying strategies for effective treatment.  Our findings may provide new inroads 
into elucidating the mechanisms involved in the disease-modifying ability of IFN-α 
therapy.  Which of the above mechanisms plays the most important role in the 
observed beneficial effects of IFN-α in the treatment of BD remains to be elucidated. 
 
In conclusion, IFN-α has unique immunomodulatory properties and is a treatment 
option for BD.  This study provides molecular evidences for possible mechanisms of 
action of IFN-α in the BD treatment. 
 
 
  8.2 Limitations of this study  
 
The diverse immunosuppressive drugs received by BD patients in our study, especially 
those with active disease, may have an influence on peripheral blood T cell subsets and 
contribute to interindividual heterogeneity.  Attempts were made in both groups of BD 
patients to reduce systemic steroid requirement to ≤10mg daily gradually over the 
initial 3-6 months and to stop the second line immunosuppressive agents.  However, 
a possible implication of the concurrent use of corticosteroids and other 
immunosuppressants in our BD patients cannot be definitely ruled out.  Since similar 
effects on cytokine production were not consistently detected in patients on 
immunosuppressants alone and response of our IFN-α treated patients was 
impressive and enduring, our results suggested the observed effects were 
predominantly due to IFN-α therapy in BD patients. 
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Regrettably, larger sample size would have been more ideal as this would enable 
subgroup analysis of patients on similar immunosuppressants.  However, the 
amount of time required to recruit a much larger number of BD patients meeting the 
inclusion criteria was not practical.  Therefore, the impact of concurrent use of 
steroids and second line agents was minimised as much as we could under the 
circumstances through randomisation.  Undoubtedly, further studies on the 
influences of IFN-α monotherapy on the cytokine network in newly diagnosed yet 
untreated patients with different manifestations of BD would be useful to overcome 
the limitations of the present study.  Moreover, no age- and sex-matched healthy 
volunteer was enrolled in our study and therefore data on cytokine producing T cells 
obtained from our trial patient samples could not be evaluated against healthy 
subjects to determine whether the levels were normal to start with. 
 
It is unfortunate that an investigation of the inflammatory parameters in the active 
inflammatory sites could not be carried out as specimens other than peripheral bloods 
were not available.  As BD is a multisystem inflammatory disorder, studying peripheral 
blood samples of patients alone may not help us understand fully the extent of damages 
caused by the inflammatory response in these patients.  Also, due to omission from the 
original trial design, the in vivo effects of 6 months of IFN-α therapy on some potentially 
interesting T cell subsets such as IL-17 producing γδ and CD8+ T lymphocytes were 
not included in the investigation of our BD patients. 
 
Following the discovery that Foxp3 expression has a central role in the differentiation 
and maintenance of Treg cells, the use of flow cytometry-based analysis of Foxp3 
expression in T cells became the gold standard for defining Treg cells (Buckner 
2010).  However, it was discovered that Foxp3 can also be expressed by effector T 
cells following activation, raising the possibility that any assessment of Treg cell 
number or function may include recently activated effector T cells in the Treg cell 
populations (Pillai et al. 2007).  The lack of a cell marker that is unique to Treg cells 
and the multiplicity of Treg cell subsets complicated the task of enumerating Treg 
cells.  In our study, a phenotypical evaluation of Treg cells was the approach used to 
get an indication of their levels, but no functional assays or Treg suppression assays 
were performed to assist in the assessment of Treg levels.  Of note, as Foxp3 is a 
nuclear protein, assessment of its expression in T cells requires fixation and 
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permeabilisation of the cells, resulting in an inability to obtain viable cells for further 
functional analysis (Buckner 2010). 
 
 
  8.3 Future work 
 
Due to the fact that human effector T cells could transiently express Foxp3 following 
TCR-mediated activation (Pillai et al. 2007), performing functional assays would be 
useful to get an indication whether an upregulation of Foxp3+ expression by T cells 
following IFN-α treatment would also lead to an increase in Treg function. 
 
Studies of Treg cell function in human autoimmune diseases have examined the 
proliferation of responder cells in response to polyclonal activation in co-cultures with 
Treg cells isolated from PBMCs.  Evaluation is based on the incorporation of either 
tritiated thymidine (3H-thymidine) or on the dilution of the fluorescent label 5,6-
carboxyfluorescein diacetate succinimidyl ester (CFSE).  Measurements of cytokine 
production by the responder cells can also be performed in conjunction with these 
assays.  The classical suppression assay involves the co-culture of CD25+ Tregs 
and CD25- responder T cells over a range of suppressor : responder ratios in order 
to measure the functional activity of Tregs (Thornton & Shevach 1998). 
 
CFSE dilution is considered a superior approach for examining Treg cell-mediated 
suppression, as it shows the number of cell divisions throughout the culture period.  
On the other hand, 3H-thymidine incorporation assays only demonstrate the level of 
proliferation that occurs during the period in which the 3H-thymidine is present in the 
culture, which typically lasts for 12-16 hours.  The use of CFSE also has the 
advantage of allowing simultaneous analysis of cell surface markers and cytokines to 
better define the character of the proliferating responder cells.  However, the quantity 
of cells that is needed for CFSE assays is much greater than that required for 3H-
thymidine incorporation assays, making CFSE assays less useful when only small 
amounts of blood are available (Buckner 2010). 
 
Of note, the results of these types of studies are influenced by the way by which the 
Treg cells are isolated.  This can affect the composition of the Treg cell pool and 
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hence the degree of inhibition.  The type of selection method (bead based or flow 
cytometry based) and the stringency of selection (based on the level of CD25 
expression and the use of additional Treg cell markers) can lead to large differences 
in the percentage of isolated cells that express Foxp3 and in the level of suppression.  
The type and strength of the stimulus used should be taken into account as well 
when interpreting any of these studies (Buckner 2010). 
 
The specificity and activation status of regulatory and effector T cell populations as 
well as the cytokines present in the microenvironment and the activation status of 
antigen-presenting cells (APCs) will influence the capacity of Tregs to suppress in 
vivo.  These conditions are often not well modelled in vitro and this caveat 
represents the greatest limitation of this type of assay.  Suppressing the proliferation 
or cytokine production of highly activated polarised T cells is much more challenging.  
Tregs from the site of inflammation are more suppressive than their peripheral blood 
counterparts but, simultaneously, the activated responder T cells from the 
inflammatory foci are more resistant to suppression (de Kleer et al. 2004;van 
Amelsfort et al. 2004). 
 
To examine whether IFN-α modifies the functional features of peripheral CD4+CD25- 
T cells and CD4+CD25high T cells (which should be enriched for nTreg) , their 
proliferative capacity, cytokine production profile, and suppressive function can be 
tested in vitro.  One idea is to perform functional assays on the two T cell subsets 
purified from Behcet’s disease patients before and during IFN-α monotherapy.  
Another idea is to treat either purified Treg cells or responder cell populations from 
healthy donor PBMCs with IFN-α before performing in vitro functional assay using 
the two T cell subsets and the results can be compared to data collected from 
untreated assays.  These functional assays are likely to give some indication of the 
potential of IFN-α to enhance Treg cell function and decrease resistance of 
responder cells to suppression. 
 
As the BD patients in our study are intended to be followed up for 3 years, 
longitudinal data at two and three year assessment visits will be available for 
analysis in the near future.  This valuable information should help confirm whether 
the disease-modifying ability of IFN-α therapy persists after termination of treatment.  
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Moreover, all the clinical details and disease activity of BD patients throughout the 
trial will become available once the clinical trial has come to an end, correlation 
between clinical findings and experimental data will then be able to be examined.  It 
would also be of interest to analyse both BD patients with active and inactive disease 
and investigate whether there is a difference between the two groups in terms of 
peripheral blood T cell populations. 
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Appendix 1: Overview of the IFN-α Trial 
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Appendix 2: Fluorescent antibodies 
 
Fluorochrome Laser excitation 
line (nm) 
Maximal 
absorbance (nm) 
Maximal 
emission (nm) 
Alexa Fluor® 488 488 495 519 
FITC 488 490 525 
PE 488 490, 565 578 
PerCP 488 490 675 
APC 633, 635, 647 650 661 
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Appendix 3: Representative ex vivo FACS plots on Behcet’s disease patients 
 
(a) Representative dot plot showing the amount of CD4+ and CD8+ T cells in 
peripheral blood lymphocytes of patients. 
 
(b) Representative dot plot showing the amount of peripheral blood lymphocytes 
bearing the αβ and γδ T cell receptors. 
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(c) Representative dot plot showing the amount of CD56+ cells in peripheral blood 
CD3+ T cells. 
 
 
(d) Representative dot plots showing the influence of a 6-month course of IFN-α on 
the proportions of peripheral blood CD3+ lymphocytes producing IFN-γ and TNF-
α in one patient. 
0 months     12 months 
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(e) Representative dot plots showing the influence of a 6-month course of IFN-α 
on the proportions of peripheral blood CD3+ lymphocytes producing IL-2 and 
IL-4 in one patient. 
   0 months     12 months 
 
(f) Representative dot plots showing the influence of a 6-month course of IFN-α 
on the proportions of peripheral blood CD4+ lymphocytes producing IFN-γ and 
IL-17 in one patient. 
   0 Months     12 Months 
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(g) Representative dot plots showing the influence of a 6-month course of IFN-α on 
the proportions of peripheral blood CD3+ lymphocytes producing IL-10 and TGF-β 
in one patient. 
   0 months     12 Months 
 
(h) Representative dot plots showing the influence of a 6-month course of IFN-α on 
the proportions of peripheral blood CD4+ lymphocytes expressing IL-10 and 
Foxp3 in one patient. 
   0 months     12 months 
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Appendix 4: Representative in vitro FACS plots 
 
(a) Representative dot plots showing the effect of IFN-α (103 U/ml IFN-α2b) on 
the proportions of peripheral blood CD4+ lymphocytes producing IFN-γ and IL-
17.  Healthy donor PBMCs were stimulated with PMA and ionomycin for 24 
hours.  Similar gating strategies were applied to CD8+ and γδ T cells as well 
to examine the influence of IFN-α on these populations. 
   No IFN-α           IFN-α treated 
 
(b) Representative dot plots showing how the CD4+CD25+ and CD4+CD25hi T cells 
are gated within the T lymphocyte populations. 
   CD25+     CD25hi 
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(c) Representative dot plots showing how the CD8+CD25+ and CD8+CD25hi T cells 
are gated within the T lymphocyte populations. 
   CD25+     CD25hi 
 
(d) Representative dot plots showing the effect of IFN-α (103 U/ml IFN-α2b) on the 
proportions of peripheral blood CD4+ lymphocytes expressing Foxp3.  Healthy 
donor PBMCs were stimulated with PMA and ionomycin for 24 hours. 
   No IFN-α     IFN-α treated 
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(e) Representative dot plots showing the effect of IFN-α (103 U/ml IFN-α2b) on the 
proportions of peripheral blood CD8+ lymphocytes expressing Foxp3.  Healthy 
donor PBMCs were stimulated with PMA and ionomycin for 24 hours. 
   No IFN-α     IFN-α treated 
 
(f) Representative dot plots showing the effect of IFN-α (103 U/ml IFN-α2b) on the 
proportions of peripheral blood CD4+ lymphocytes producing IL-10 and TGF-β.  
Healthy donor PBMCs were stimulated with PMA and ionomycin for 24 hours. 
   No IFN-α     IFN-α treated 
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(g) Representative dot plots showing the effect of IFN-α (103 U/ml IFN-α2b) on the 
proportions of peripheral blood CD8+ lymphocytes producing IL-10 and TGF-β.  
Healthy donor PBMCs were stimulated with PMA and ionomycin for 24 hours. 
   No IFN-α     IFN-α treated 
 
